Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-15-378514.txt : 20151116 0001193125-15-378514.hdr.sgml : 20151116 20151116165036 ACCESSION NUMBER: 0001193125-15-378514 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151116 DATE AS OF CHANGE: 20151116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BG Medicine, Inc. CENTRAL INDEX KEY: 0001407038 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 043506204 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33827 FILM NUMBER: 151235875 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET STREET 2: SUITE 210 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-890-1199 MAIL ADDRESS: STREET 1: 880 WINTER STREET STREET 2: SUITE 210 CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 d14311d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-33827

BG MEDICINE, INC.

(Exact name of registrant as specified in its charter)


Delaware		04-3506204
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

303 Wyman Street, Suite 300 Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

(781) 890-1199

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of October 31, 2015, the registrant had 11,126,579 shares of common stock outstanding.

BG Medicine, Inc.

Index to Form 10-Q


			Page

PART I: FINANCIAL INFORMATION

	Item 1.	Financial Statements
		Unaudited Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014		3
		Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Month Periods Ended September 30, 2015 and 2014		4
		Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Month Periods Ended September 30, 2015 and 2014		5
		Notes to Unaudited Condensed Consolidated Financial Statements		6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk		26
	Item 4.	Controls and Procedures		27

PART II: OTHER INFORMATION

	Item 1.	Legal Proceedings		27
	Item 1A.	Risk Factors		27
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		28
	Item 3.	Defaults Upon Senior Securities		29
	Item 4.	Mine Safety Disclosures		29
	Item 5.	Other Information		29
	Item 6.	Exhibits		30

PART I: FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

BG Medicine, Inc. and Subsidiary

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30, 2015			December 31, 2014
	(in thousands, except share and per share data)
Assets
Current assets
Cash	$	2,642		$	4,123
Accounts receivable (net of allowances for doubtful accounts of $151 and $0, as of September 30, 2015 and December 31, 2014, respectively)		152			174
Inventory		223			400
Prepaid expenses and other current assets		139			154


Total current assets		3,156			4,851

Property and equipment, net		14			117
Intangible assets, net		92			135
Deposits and other assets		94			126


Total assets	$	3,356		$	5,229


Liabilities and Stockholders’ (Deficit) Equity
Current liabilities
Term loan		—			2,960
Accounts payable		1,332			695
Accrued expenses		562			906
Other current liabilities		48			18


Total current liabilities		1,942			4,579
Other liabilities		94			93


Total liabilities		2,036			4,672


Commitments and contingencies (Note 5)

Convertible preferred stock; $.001 par value; 5,000,000 and 0 shares authorized at September 30, 2015 and December 31, 2014, respectively; 1,474,443 and 0 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively; liquidation preference of $2,548 at September 30, 2015		2,594			—

Stockholders’ (deficit) equity

Common stock; $.001 par value; 100,000,000 shares authorized at September 30, 2015 and December 31, 2014; 11,126,579 and 8,632,810 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		11			9
Additional paid-in capital		164,118			161,550
Accumulated deficit		(165,403	)		(161,002	)


Total stockholders’ (deficit) equity		(1,274	)		557


Total liabilities and stockholders’ (deficit) equity	$	3,356		$	5,229

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BG Medicine, Inc. and Subsidiary

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
	(in thousands, except share and per share data)

Revenues:
Product revenues	$	274		$	669		$	1,160		$	2,158
Product fee revenues		60			26			116			75

Total revenues		334			695			1,276			2,233


Costs and operating expenses:
Product and product fee costs		103			234			423			764
Research and development		333			724			1,314			1,855
Selling and marketing		4			647			289			2,069
General and administrative		920			1,323			2,978			3,696


Total costs and operating expenses		1,360			2,928			5,004			8,384


Loss from operations		(1,026	)		(2,233	)		(3,728	)		(6,151	)
Interest income		—			—			—			2
Interest expense		(4	)		(165	)		(159	)		(597	)
Other income (loss)		7			1			(514	)		2


Net loss	$	(1,023	)	$	(2,397	)	$	(4,401	)	$	(6,744	)
Preferred stock dividend		(41	)		—			(41	)		—
Deemed dividend on beneficial conversion feature		(1,507	)		—			(1,507	)		—
Accretion of convertible preferred stock to liquidation value		(56	)		—			(56	)		—

Net loss attributable to common shareholders	$	(2,627	)	$	(2,397	)	$	(6,005	)	$	(6,744	)


Net loss per share attributable to common shareholders - basic and diluted	$	(0.27	)	$	(0.28	)	$	(0.66	)	$	(0.84	)


Weighted-average common shares outstanding used in computing per share amounts - basic and diluted		9,862,802			8,604,312			9,057,960			8,028,373

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BG Medicine, Inc. and Subsidiary

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	Nine Months Ended September 30,
	2015			2014
	(in thousands)
Cash flows from operating activities
Net loss	$	(4,401	)	$	(6,744	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		69			100
Stock-based compensation		630			489
Non-cash interest expense		79			164
Provision for doubtful accounts		151			—
Loss on fair value of secured convertible note		487			—
Loss on sale of property and equipment		64			—
Changes in operating assets and liabilities
Accounts receivable		(130	)		65
Inventory		177			101
Prepaid expenses and other assets		7			78
Accounts payable, accrued expenses and other liabilities		254			(1,349	)
Deferred revenue and customer deposits		63			(1	)


Net cash flows used in operating activities		(2,550	)		(7,097	)


Cash flows from investing activities
Proceeds from the sale of property and equipment		13			—


Net cash flows provided by investing activities		13			—


Cash flows from financing activities
Proceeds from public offering		2,500			9,238
Costs related to public offering		(504	)		(243	)
Payments on term loan		(2,984	)		(3,360	)
Proceeds from ESPP purchases		—			2
Proceeds from the exercise of stock options		—			22
Proceeds from secured convertible note		500			—
Proceeds from issuance of preferred stock		2,000			—
Costs related to issuance of preferred stock		(456	)		—


Net cash flows provided by financing activities		1,056			5,659


Net decrease in cash		(1,481	)		(1,438	)

Cash, beginning of period		4,123			7,751


Cash, end of period	$	2,642		$	6,313


Supplemental disclosure of cash flow information

Cash paid for interest	$	81		$	433

Supplemental schedule of non-cash financing activities

Conversion of convertible notes payable to preferred stock	$	987		$	—
Conversion of interest to preferred stock	$	7		$	—
Deemed dividend on beneficial conversion feature	$	1,507		$	—
Accretion of convertible preferred stock to liquidation value	$	56		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BG Medicine, Inc. and Subsidiary

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.	Description of Business and Basis of Presentation

Description of Business

BG Medicine, Inc. (“BG Medicine” or the “Company”) is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders.

The Company’s BGM Galectin-3^® Test is an in vitro diagnostic device that employs a manual micro-titer platform to quantitatively measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The BGM Galectin-3^® Test is cleared by the U.S. Food and Drug Administration (the “FDA”), is CE-marked and is currently available as a blood test in the United States and the European Union (“EU”).

The Company has entered into licensing agreements with leading diagnostic instrument manufacturers to develop and commercialize galectin-3 assays that will be performed on automated platforms that have been incorporated into routine practice in laboratories throughout the world. On December 23, 2014, the FDA granted 510(k) clearance for the ARCHITECT ^® Galectin-3 assay, the first FDA cleared automated blood test for Galectin-3, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure in conjunction with clinical evaluation. On July 6, 2015, the Company announced that the ARCHITECT ^® Galectin-3 assay is now available in the United States. This is the first automated test for galectin-3 to be introduced for commercial use in the United States. The ARCHITECT ^® Galectin-3 assay is performed using the Abbott ARCHITECT ^® automated immunoassay analyzer and is being commercialized through an agreement between the Company and Abbott.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. The interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position at September 30, 2015 and results of operations and cash flows for the interim periods ended September 30, 2015 and 2014.

On July 8, 2015, the Company effected a 1-for-4 reverse stock split of its common stock. All previously reported common stock share amounts in the accompanying financial statements and related notes have been retroactively adjusted to reflect the reverse stock split. As a result of the reverse stock split, the stated capital on the Company’s balance sheet attributable to its common stock, which consists of the par value per share of its common stock multiplied by the aggregate number of shares of its common stock issued and outstanding, has been reduced in proportion to the size of the reverse stock split. Correspondingly, the Company’s additional paid-in capital account, which consists of the difference between its stated capital and the aggregate amount paid to the Company upon issuance of all currently outstanding shares of its common stock, has been credited with the amount by which the stated capital is reduced.

The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates and to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these financial statements. The results for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other interim period or for any other future year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

At September 30, 2015, the Company had cash totaling $2.6 million, an outstanding balance of $0 under its secured term loan facility, which the Company repaid and which was terminated in July 2015, and stockholders’ deficit of $1.3 million. During the nine months ended September 30, 2015, the Company incurred a net loss of $4.4 million, used $2.6 million of cash in operating activities and used $3.0 million of cash for payments to extinguish the term loan facility. The Company expects to continue to incur losses and use cash in operating activities for the foreseeable future.

The Company is in the early stages of commercializing its BGM Galectin-3 Test and assisting with the commercialization of the ARCHITECT® Galectin-3 assay. Interest in the testing for galectin-3 is increasing as a result of the Company’s market development activities, although it has not yet translated into significant revenue. In order to achieve profitability, the Company will need to generate significant product revenues.

Effective January 1, 2014, the payment rate at which testing for galectin-3 is reimbursed by the Centers for Medicare and Medicaid Services (“CMS”), was increased to $30.01 from $17.80 per test. In 2015, the national limitation amount for testing for galectin-3 was reduced to $29.93 and applies across the U.S., except in Ohio and West Virginia where rates of $23.93 and $26.33, respectively, apply.

Since September 11, 2014, the Company has implemented a reduction of approximately 77% of its workforce, or 17 people (the “Restructuring”), leaving 5 employees. The Company took this step in order to reduce its operating expenses and extend its cash runway in anticipation of the commercial launch of automated versions of the Company’s galectin-3 test. The automated galectin-3 tests are being developed and commercialized by the Company’s diagnostic instrument manufacturing partners and will be performed on the partners’ automated platforms.

The Restructuring primarily eliminated the Company’s sales and marketing organization and removed certain positions in other functional areas, while preserving some senior management and other critical roles to support the clinical and commercial adoption of galectin-3 testing by providing support to the marketing and selling efforts of its automated partners, clinical research studies that have incorporated galectin-3 testing and by expanding the BGM Galectin-3 Test’s labeling indications for use through additional clinical studies and clearances by the FDA.

Employees affected by the Restructuring were provided with severance arrangements including outplacement assistance. As a result of the Restructuring, the Company has recorded total charges with respect to severance payments and benefits continuation of approximately $404,000 and $98,000 during 2014 and 2015, respectively. Of the total $404,000 charges in 2014, $128,000 was recorded in research and development, $114,000 was recorded in sales and marketing, and $162,000 was recorded in general and administrative expense. Of the $98,000 charges in 2015, $41,000 was recorded in research and development and $57,000 was recorded in sales and marketing expense. The Company paid approximately $277,000 of such expenses during the third and fourth quarters of 2014 and $225,000 during the first three quarters of 2015. As a result of the Restructuring, the Company estimates it will generate annualized expense savings of approximately $2.4 million primarily from savings in employee salaries and benefits.

In May 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Company’s principal stockholders, Pursuant to the terms and subject to the conditions contained in the Purchase Agreement, the Company issued and sold to the purchasers (the “Purchasers”) secured convertible promissory notes in an aggregate principal amount of $500,000. In addition and pursuant to the terms of the Purchase Agreement, and as approved by the Company’s stockholders at the Company’s 2015 annual meeting of stockholders (the “2015 Annual Meeting”) and the satisfaction or waiver of other closing conditions, the Company issued and sold to the purchasers $2,000,000 of shares of newly created Series A Preferred Stock, $0.001 par value per share of the Company at the second closing that was held on July 14, 2015 following the Company’s 2015 Annual Meeting.

In June 2015, the Company entered into a sublease agreement with a third party for the 880 Winter Street office space. The term of the sublease is from June 1, 2015 through December 31, 2018 covering the balance of the underlying lease term. The Company has recorded in operating costs total charges of $153,000 with respect to the net present value of the net costs that will continue to be incurred under the lease for its remaining term and the real estate brokerage commissions on the sublease. The Company has obtained office space on a short term rental basis and expects to generate annualized savings of approximately $240,000.

As further described in Note 4, the Company had a term loan facility that was secured by substantially all of the Company’s assets. On July 14, 2015 the Company paid off all of its outstanding obligations under the term loan.

In August 2015, the Company closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million.

The Company’s common stock had been listed for trading on The NASDAQ Capital Market until September 15, 2015, when it was suspended for failure to comply with The NASDAQ Capital Market continued listing standards. On September 16, 2015, the Company’s common stock began trading on the OTC Markets’ OTCQB market tier under the trading symbol “BGMD.” The

delisting of the Company’s common stock from The NASDAQ Capital Market could substantially further reduce the liquidity of the Company’s common stock and result in a corresponding material reduction in the price of the Company’s common stock. In addition, the delisting could negatively affect the Company by reducing the number of investors willing to hold or acquire the Company’s common stock, which could negatively affect the Company’s ability to raise capital, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

The Company believes that its existing cash will be sufficient to fund its operations into July 2016. For the foreseeable future and until the Company generates significant product revenues to reach cash breakeven, the Company will need to raise additional funds to finance its operations beyond July 2016. The Company may not be able to obtain adequate financing to do so when necessary, and the terms of any financings may not be advantageous to the Company and any financings may result in dilution to the Company’s stockholders.

The above circumstances along with the Company’s history, the near term forecast of incurring net losses and negative operating cash flows, the Company’s dependence on near-term revenues generated from product fees due from a single automated partner, the Company’s limited experience with the amount and timing of sales made by its automated partners and its inability to predict the timing of the market introduction of automated tests and product fees generated by the sale of automated tests by its other automated partners raise substantial doubt regarding the Company’s ability to continue as a going concern for a reasonable period of time. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

2.	Significant Accounting Policies

Product Revenues

Product revenues are recognized when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

The Company sells its products through supply agreements with laboratory testing services and diagnostic testing distributors and directly to hospitals and clinics. The Company recognizes revenue when products are received by customers, at which time both title and risk of loss have passed to the customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.

Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Freight costs billed to customers are recorded as revenue.

In the past the Company did not provide an allowance for doubtful accounts or a reserve for sales returns as the Company has not experienced any credit losses, and returns are only allowed for defects in workmanship. On June 7, 2015, Health Diagnostic Laboratory, Inc. (“HDL”), which is the Company’s largest customer of its BGM Galectin-3 ^® Test, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. In light of this filing the Company provided a provision for doubtful accounts of $151,000 in the second quarter of 2015. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016.

Product Fee Revenues

The Company recognizes product fee revenue when it receives quarterly test sales reporting and payments thereunder from its partners. The Company has entered into worldwide license, development and commercialization agreements with Abbott Laboratories, (“Abbott”), bioMérieux SA, (“bioMérieux”), Siemens Healthcare Diagnostics Inc., (“Siemens”), and Alere Inc., (“Alere”). As consideration for the rights and licenses granted by the Company to its partners, the licensees pay to the Company a product fee, as set forth in the respective agreements, for tests sold to third parties. To date, only Abbott and bioMérieux have paid product fees to the Company.

Product Fee Reclassification

Beginning in the third quarter of 2015, the Company began disclosing product fee revenue separately from product revenue. To maintain comparability, all previously reported product revenue figures in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to break out the product fee revenue recognized during those periods. Management evaluated the amount and nature of the change and concluded that it was not material to either the previously reported annual or quarterly financial statement results of operations. Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):


	As reported Three months ended September 30, 2014		As reclassified Three months ended September 30, 2014		As reported Nine months ended September 30, 2014		As reclassified Nine months ended September 30, 2014
Product Revenues	$	695	$	669	$	2,233	$	2,158
Product Fee Revenues		—		26		—		75

Total Revenues	$	695	$	695	$	2,233	$	2,233

Inventory

Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following:


(in thousands)	September 30, 2015		December 31, 2014

Raw materials	$	45	$	64
Finished goods		178		336


Total inventories	$	223	$	400

Net Loss Per Share Attributable to Common Shareholders

Basic and diluted net loss per share attributable to common shareholders is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. The Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as its convertible preferred stock, common stock, and warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common shareholders. However, the two-class method does not impact the net loss per share of common stock as the Company was in a loss position for each of the periods presented, and neither preferred shareholders nor warrant holders participate in losses.

The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
	(in thousands, except share and per share data)

Net loss	$	(1,023	)	$	(2,397	)	$	(4,401	)	$	(6,744	)
Preferred stock dividend		(41	)		—			(41	)		—
Deemed dividend on beneficial conversion feature		(1,507	)		—			(1,507	)		—
Accretion of convertible preferred stock to liquidation value		(56	)		—			(56	)		—

Net loss attributable to common shareholders	$	(2,627	)	$	(2,397	)	$	(6,005	)	$	(6,744	)
Weighted average number of shares - basic and diluted		9,862,802			8,604,312			9,057,960			8,028,373
Net loss per share attributable to common shareholders - basic and diluted	$	(0.27	)	$	(0.28	)	$	(0.66	)	$	(0.84	)

As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported:


	September 30,
	2015		2014
Options to purchase common stock		699,513		644,789
Warrants to purchase common stock		1,536,929		216,156

3.	Fair Value of Financial Instruments

At September 30, 2015, the Company’s financial instruments consisted of cash, accounts receivable, and accounts payable. The carrying amounts of accounts receivable and accounts payable are considered reasonable estimates of their fair value, due to the short maturity of these instruments.

In accordance with U.S. generally accepted accounting standards, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The table below sets forth a summary of changes in the fair value of the Company’s level 3 liability (preferred stock liability) for the three and nine months ending September 30, 2015:


	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
	(in thousands)
Beginning balance	$	31		$	—
Loss on recognition of preferred stock liability		—			79
Gain on revaluation of preferred stock liability		(31	)		(79	)

Ending balance	$	—		$	—

The resulting initial recognition and subsequent revaluation were recorded as other income (expense) in the unaudited condensed consolidated statements of operations

The table below sets forth a summary of changes in the fair value of the Company’s secured convertible notes for the three and nine months ended September 30, 2015:


	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
	(in thousands)
Beginning balance	$	929		$	—
Proceeds from secured convertible note		—			500
Loss on fair value adjustment		58			487
Conversion of secured convertible notes		(987	)		(987	)

Ending balance	$	—		$	—

The resulting fair value adjustment was recorded as other income (expense) in the unaudited condensed consolidated statements of operations.

The preferred stock liability was valued using the Black-Scholes option pricing model as of May 12, 2015, the issuance date of the secured convertible note, resulting in a fair value of $79,000. This valuation considered an underlying security price of $2.12, strike price of $2.68, risk-free interest rate of 0.02%, expected dividend yield of 0%, volatility factor of 73.8%, and expected term of 0.22 years. The preferred stock liability was revalued as of June 30, 2015 resulting in a fair value of $31,000. This valuation considered an underlying security price of $2.00, strike price of $2.68, risk-free interest rate of 0.03%, expected dividend yield of 0%, volatility factor of 73.8%, and expected term of 0.08 years. As of July 14, 2015, the mandatory conversion of the preferred stock occurred, resulting in a remaining term of zero and thereby a fair value of zero.

The secured convertible promissory notes valuation analysis was based on the probability-weighted expected return method (“PWERM”) utilizing various scenarios for the expected payout of the instrument covering the full range of the potential outcomes. The PWERM determines the value of an instrument, based upon an analysis of future values for the subject instruments, which takes into consideration the full range of the potential cash flows available to the subject instrument. The instrument value is based upon the present value of the probability of each future outcome becoming available to the instrument, and the economic rights and preferences of the instrument.

Due to the lack of relevant and market reflective Level 1 and Level 2 inputs, the Company valued the instruments using Level 3 inputs, which require significant judgment and estimates on behalf of management in developing model assumptions. The fair value model used in valuing the convertible debt instrument as of June 30, 2015 utilized the following inputs: conversion price per share, current and future stock prices, discount rate, and volatility. The following assumptions were made in the model: (1) conversion price of $2.68 per share, (2) current common stock price of $2.36 per share, (3) simulated future common stock price of $2.14 per share, (4) discount rate of 18.0%, (5) expected stock price volatility related to the current common stock price of 51.0%, and (6) expected stock price volatility related to the simulated future common stock price of 55.0%. At the conversion date of July 14, 2015, the following inputs were utilized in valuing the convertible debt instrument: (1) conversion price of $3.33 per share, (2) current common stock price of $1.54 per share, (3) discount rate of 18.0%, and (4) expected stock price volatility of 56.2%.

4.	Term Loan

On February 10, 2012, the Company entered into a secured term loan facility, and a term loan in the aggregate principal amount of $10.0 million was funded upon the closing of the transaction. On July 14, 2015, the Company paid off all of its outstanding obligations under that certain Loan and Security Agreement by and among the Company, General Electric Capital Corporation (“GECC”) as agent and the lenders and the guarantors thereto dated as of February 10, 2012, as amended (the “GECC Agreement”), and terminated the GECC Agreement. The security interest granted by the Company to GECC in its assets in connection with the GECC Agreement was also terminated at the time of the payoff. Notwithstanding the payoff, the warrants to purchase the Company’s common stock that the Company previously issued to GECC’s affiliate, GE Capital Equity Investments, Inc., and Comerica Bank in connection with the GECC Agreement, continue to remain outstanding in accordance with their terms and are not affected by the payoff.

5.	Commitments and Contingencies

From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

No amounts related to contingencies are accrued at September 30, 2015, as there are no ongoing proceedings.

6.	Follow-on Public Offerings

On April 8, 2014, the Company closed a follow-on underwritten public offering of 1,613,000 shares of its common stock, at an offering price of $6.20 per share, for gross proceeds of $10.0 million. The net offering proceeds received by the Company, after deducting underwriting discounts and commissions and expenses incurred in connection with the offering, were approximately $9.0 million.

On August 18, 2015, the Company closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering, were approximately $2.0 million.

7.	Convertible Promissory Notes and Series A Preferred Stock

On May 12, 2015, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with the Company’s principal stockholders. On May 12, 2015 (the “Initial Closing”), pursuant to the terms and subject to the conditions contained in the Series A Purchase Agreement, the Company issued and sold to the Purchasers secured convertible promissory notes in the aggregate principal amount of $0.5 million (the “Notes”). In addition, the Company agreed to issue to the Purchasers, and the Purchasers agreed to purchase from the Company, an aggregate of $2.0 million of shares of Series A Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”), at the second closing. The Company determined that the liability to issue the Series A Preferred Stock (the “Preferred Stock Liability”) at a future date was a freestanding instrument and should be accounted for as a liability. The Company remeasures the Preferred Stock Liability at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations. During the three month period ending September 30, 2015, the Company recorded other income of $31,000 upon remeasurement of the Preferred Stock Liability.

The Notes contained a compound embedded derivative that requires separate accounting from the host debt instrument. The Company elected the fair value option for the Notes as management believes recording the Notes at fair value better reflects the underlying economics of the transaction. The Company remeasures the Notes at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations.

Upon consummation of the Series A Purchase Agreement, the Company allocated the total principal proceeds of $0.5 million between the Preferred Stock Liability and the fair-valued Notes and recorded a loss of $0.5 million in other (loss) income in the unaudited condensed consolidated statements of operations.

Pursuant to the terms of the Series A Purchase Agreement, and as approved by the Company’s stockholders at the Company’s 2015 Annual Meeting, the Company issued and sold to the Purchasers $2.0 million in shares of Series A Preferred Stock at the second closing that was held on July 14, 2015 (the “Second Closing”).

Secured Convertible Promissory Notes and Related Agreements

At the Second Closing, the Notes were automatically converted pursuant to their terms into that number of shares of Series A Preferred Stock equal to the principal amount of the Notes plus all accrued but unpaid interest thereon divided by the purchase price of the Series A Preferred Stock of $1.7003 per share (the “Purchase Price”).

Contemporaneously with the execution and delivery of the Series A Purchase Agreement and the issuance of the Notes by the Company to the Purchasers, the Company and the Purchasers entered into a Security Agreement (the “Security Agreement”), dated May 12, 2015, pursuant to which the Company granted to the Purchasers a security interest in substantially all of the Company’s assets, other than the Company’s intellectual property, to secure the Company’s obligations under the Notes. Pursuant to the terms of the Security Agreement, the Company’s intellectual property would have become subject to the security interest granted by the Company to the Purchasers upon repayment of all amounts owed under that certain Loan and Security Agreement by and among the Company, General Electric Capital Corporation (“GECC”) as Agent, the Lenders and the Guarantors dated as of February 10, 2012, as amended (“the “GECC Agreement”) referred as the “Term Loan” (See Note 4). Pursuant to a Subordination and Intercreditor Agreement by and among the Company, the Purchasers and GECC, dated May 12, 2015, entered into contemporaneously with the execution and delivery of the Series A Purchase Agreement, the Company’s payment obligations under the Notes were subordinated to the Company’s payment obligations under the GECC Agreement and the security interest granted by the Company to the Purchasers to secure the Company’s obligations under the Notes was subordinated to the security interest granted by the Company to GECC to secure the Company’s obligations under the GECC Agreement. In connection with the entry into the Series A Purchase Agreement, the Company and GECC amended the GECC Agreement, dated May 12, 2015, to, among other things, permit the Company to enter into the Series A Purchase Agreement and related agreements. Upon the conversion of the Notes into shares of Series A Preferred Stock at the Second Closing, the security interest granted under the Security Agreement was terminated.

The Second Closing was subject to the approval of the Company’s stockholders at the 2015 Annual Meeting in July 2015 and the satisfaction or waiver of other closing conditions. The Company’s stockholders approved the issuance of shares of Series A Preferred Stock, shares of Series A Preferred Stock issuable upon conversion of the Notes and common stock issuable upon conversion of Series A Preferred Stock, at the 2015 Annual Meeting held on July 7, 2015.

On July 14, 2015, the Company and the Purchasers entered into the First Amendment to the Series A Purchase Agreement (the “First Amendment”) pursuant to which the Company and the Purchasers agreed to extend the period of time following the Company’s 2015 Annual Meeting for the Second Closing to occur until July 14, 2015. At the Second Closing, pursuant to the terms of the Series A Purchase Agreement, the Company issued and sold to the Purchasers 1,176,262 shares of newly designated Series A Preferred Stock of the Company at the Purchase Price of $1.7003 per share for aggregate gross cash proceeds of approximately $2.0 million. In addition, at the Second Closing, the $500,000 in aggregate principal amount of Notes, plus accrued but unpaid interest, that the Company had issued to the Purchasers in the Initial Closing, converted into 298,181 shares of Series A Preferred Stock at the Purchase Price. Following the Second Closing in July 2015, the Company had issued an aggregate of 1,474,443 shares of Series A Preferred Stock, which remain outstanding and held by the Purchasers.

The shares of Series A Preferred Stock have the rights, preferences and privileges set forth in the Restated Certificate of Designations to the Company’s Restated Certificate of Incorporation (the “Certificate of Designations”) that was filed by the Company on August 18, 2015 with the Secretary of State of the State of Delaware. The rights, preferences and privileges of the Series A Preferred Stock are as follows:

Dividends

Holders of Series A Preferred Stock will be entitled to receive, out of funds legally available for the payment of dividends under Delaware law, cumulative dividends that accrue daily at an annual rate of 8%, compounded and payable quarterly in cash or in additional shares of Series A Preferred Stock at the election of each holder. The holders of Series A Preferred Stock will also be entitled to participate in cash dividends and in-kind distributions made on shares of common stock.

The Board of Directors has not declared any dividends on common or preferred stock. At September 30, 2015, the cumulative undeclared dividends on preferred stock total $41,000, and are included as a deduction in determining net loss per share attributable to common shareholders. The carrying value of the Series A Preferred Stock was not adjusted for the cumulative undeclared dividends as the Series A Preferred Stock is not probable of becoming redeemable.

Voting Rights

Holders of Series A Preferred Stock will be entitled to vote with the holders of the common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of the common stock on the trading day immediately prior to the date its Series A Preferred Stock is issued, which was $1.40. In addition, prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of capital stock of the Company, with certain exceptions; increasing or decreasing the size of the Board of Directors of the Company (the “Board”); and certain other actions.

Conversion Rights

Each share of Series A Preferred Stock is convertible into one share of common stock at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. The conversion price will be subject to adjustment in connection with stock splits, combinations, dividends and other corporate transactions affecting the common stock. All other anti-dilution protections that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing.

A contingent beneficial conversion feature was recognized during the three months ending September 30, 2015 as a result of the conversion price being adjusted from $1.7003 to $1.00 at the time of the Second Closing. The Company recorded $1.5 million relating to the contingent beneficial conversion as a deemed dividend. The $1.5 million was included within additional paid-in capital in the condensed consolidated financial statements, and reduced the carrying value of the Series A Preferred Stock. Since the Series A Preferred Stock has no stated redemption date and is immediately convertible, the $1.5 million deemed dividend was immediately accreted, resulting in an increase in the carrying value of the Series A Preferred Stock. The deemed dividend was included as a deduction in determining net loss per share attributable to common shareholders. The conversion price adjustment feature expired following the Second Closing.

Redemption Rights

All redemption rights that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing.

Ranking

The Series A Preferred Stock will rank senior in preference and priority to the Company’s common stock and each other class or series of capital stock of the Company, except for any class or series of capital stock issued in compliance with the terms of the Restated Certificate of Designations.

Liquidation Preference

Upon liquidation, including deemed liquidations pursuant to a merger, consolidation or a sale of all or substantially all of the Company’s assets, the holders of Series A Preferred Stock will be entitled to be paid first out of any proceeds in an amount per share equal to the price at which shares of Series A Preferred Stock were sold in the Series A Preferred Stock financing, plus all accrued but unpaid dividends on each share of Series A Preferred Stock, and prior to payment of any amounts on the Company’s common stock. Thereafter, the holders of Series A Preferred Stock will also share pro rata on an as converted to common stock basis in payments made to the holders the Company’s common stock. Accordingly, the holders of the Series A Preferred Stock will be entitled to receive the proceeds out of any sale or liquidation of the Company before any such proceeds are paid to holders of the Company’s common stock and then share in any proceeds paid to holders of the Company’s common stock. As a result, only the sale or liquidation proceeds in excess of the liquidation preference plus accrued but unpaid dividends would be available for distribution to holders of the Company’s common stock.

The commissions and issuance costs associated with the Series A Preferred Stock financing were deducted from the carrying value of the Series A Preferred Stock, resulting in the carrying value of the Series A Preferred Stock being reduced below its liquidation value. The Company accretes the carrying value of the Series A Preferred Stock over the period from the date of issuance to the earliest redemption date using the effective interest method. During the nine months ending September 30, 2015, the Company recorded one month of accretion, totaling $56,000, at which point the Company ceased accretion as the Series A Preferred stock was not probable of becoming redeemable.

Board of Directors

Holders of Series A Preferred Stock will be entitled to nominate one director to the Board (the “Series A Director”). Subject to applicable law and stock exchange requirements, the Series A Director will be entitled to serve as a member of each committee of the Board. The rights to nominate a Series A Director will terminate if less than 20% of the shares of Series A Preferred Stock issued under the Securities Purchase Agreement dated May 12, 2015, as amended, by and between the Company and the Series A Holders are no longer outstanding.

Registration Rights

The Company shall comply with all federal and state laws, rules and regulations and applicable rules and regulations of the Exchange on which shares of the common are then listed. If any shares of common to be reserved for the purpose of conversion of Series A Preferred Stock require registration with or approval of any Person or group (as such term is defined in Section 13(d)(3) of the Exchange Act) under any federal or state law or the rules and regulations of the Exchange on which shares of the common stock are then listed before such shares may be validly issued or delivered upon conversion, then the Company will, as expeditiously as reasonably practicable, use commercially reasonable efforts to secure such registration or approval, as the case may be. So long as any common stock into which the of Series A Preferred Stock are then convertible is then listed on an Exchange, the Company will list and keep listed on any such Exchange, upon official notice of issuance, all shares of such common stock issuable upon conversion.

As the holders of the Series A Preferred Stock are entitled to receive liquidation preferences that other equity holders are not entitled to, the Company determined that the preferred stock should be classified as temporary equity in the condensed consolidated financial statements.

The Company reviews the rights and preferences of its equity securities for any changes in terms, rights or preferences to determine if such change is a modification or an extinguishment. The Company evaluates amendments to equity securities using a qualitative method which considers the business purpose for the amendment and whether it adds, deletes or significantly changes a substantive contractual term or the nature of the equity securities. An amendment that changes a substantive contractual term or fundamentally changes the nature of the share of preferred stock is considered an extinguishment. If considered an extinguishment, the Company accounts for the removal of the carrying value of the old securities and recognizes the new securities at their current fair value. An amendment that does not meet these criteria is a modification. If considered a modification, the Company estimates the fair value of the equity security pre- and post- modification and recognizes the incremental fair value, if any, resulting from the modified terms. During the nine months ending September 30, 2015, the Company determined that all changes to the terms of the Series A Preferred Stock resulting from amendments made to the Certificates of Designations were not substantive and should be accounted for as a modification. The amendments did not result in a material change to the fair value of the Series A Preferred Stock.

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2014. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2014, as updated from time to time in our subsequent periodic and current reports filed with the Securities and Exchange Commission.

Overview

We are developing and commercializing diagnostic products that may be used to help guide the care and management of patients who suffer from heart failure and related disorders. Our BGM Galectin-3 Test is our first U.S. Food and Drug Administration, or FDA, cleared and CE Marked diagnostic product. It is currently available as a manual or non-automated blood test in the United States and the European Union, or EU.

We have entered into licensing agreements with leading diagnostic instrument manufacturers to develop and commercialize galectin-3 assays that will be performed on automated platforms that have been incorporated into routine practice in laboratories throughout the world. On December 23, 2014, the FDA granted 510(k) clearance for the ARCHITECT ^® Galectin-3 assay, the first FDA cleared automated blood test for Galectin-3. On July 6, 2015, we issued a press release in which it announced that the ARCHITECT ^® Galectin-3 assay is now available in the United States. This is the first automated test for galectin-3 to be introduced for commercial use in the United States. The ARCHITECT ^® Galectin-3 assay is performed using the Abbott ARCHITECT ^® automated immunoassay analyzer and is being commercialized through an agreement between the Company and Abbott.

We have evolved from a research and development company to a commercial diagnostics company. Our initial transition to a commercial organization began with the FDA 510(k) clearance of our first diagnostic product, the BGM Galectin-3 Test, in November 2010. The first stage of transition was substantially completed in the first half of 2013 with the elimination of research and development activities no longer core to our commercial strategy. The second stage of transition was initiated in anticipation of the U.S. introduction of automated testing for galectin-3 and the commencement of commercialization activities by our automated partners. In order to reduce operating expenses and extend our cash runway in anticipation of the commercial launch of automated testing for galectin-3, we implemented a reduction in our workforce on September 11, 2014. In so doing, we primarily eliminated our sales and marketing organizations and removed certain positions in other function areas, while preserving some senior management and other critical roles to support the clinical and commercial adoption of galectin-3 testing by providing support to the marketing and selling efforts of our automated partners, clinical research studies that have incorporated galectin-3 testing and by expanding the BGM Galectin-3 Test’s labeling indications for use through additional clinical studies and clearances by the FDA.

Our BGM Galectin-3 Test

Our BGM Galectin-3 Test is our first FDA cleared and CE Marked diagnostic product. It is an in vitro diagnostic device that quantitatively measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay, or ELISA, on a microtiter plate platform. Heart failure patients with elevated galectin-3 levels as measured using our BGM Galectin-3 Test have been found to be at significantly greater risk of adverse outcomes, including death or hospitalization. Measurement of this protein biomarker is intended to be used in conjunction with clinical evaluation.

Galectins are a family of proteins that appear to play important roles in inflammation, immunity and cancer. Galectin-3, a member of this family of proteins, appears to be a key protein mediator of fibrosis, scarring and tissue repair and has been implicated in fibrosis in the heart, human atherosclerotic lesions, liver, kidney and lung. Elevated galectin-3 levels have been associated with adverse outcomes in heart failure, cardiovascular disease, chronic renal disease, pulmonary disease, liver disease and cancer.

In animal experiments, administration of galectin-3 to the heart led to the development of cardiac fibrosis, or stiffening, in the heart muscle, a process that is often referred to as cardiac remodeling. In these animal studies, adverse remodeling reduced the heart’s ability to pump normally, causing the animals to develop heart failure. This link between galectin-3 and cardiac remodeling is significant and suggests that galectin-3 may be a useful biomarker for adverse cardiac remodeling, an important determinant of the clinical outcome of patients suffering from heart failure.

We have obtained an exclusive worldwide license to certain galectin-3 rights that relate to the association of this protein biomarker with heart failure. We have also filed several of our own patent applications related to galectin-3.

Our BGM Galectin-3 Test is currently available as a blood test in the United States and the EU.

Automated Testing For Galectin-3

Overview

We believe that automation of our galectin-3 test will broaden its acceptance by laboratory customers and, as a result, accelerate its clinical adoption. To that end, we have entered into licensing and commercialization agreements with four leading diagnostic instrument manufacturers to develop and commercialize automated instrument versions of our galectin-3 test. We have entered into worldwide license, development and commercialization agreements with Abbott Laboratories, or Abbott, bioMérieux SA, or bioMérieux, Siemens Healthcare Diagnostics Inc., or Siemens, and Alere Inc., or Alere. These diagnostic instrument manufacturers account for a significant percentage of the automated laboratory testing instruments that are used throughout the world. The installed customer base of these automated partners reflects all major segments of the diagnostics market, including hospital laboratories, national reference laboratories, regional laboratories and others.

Progress to Date

On December 23, 2014, the FDA granted 510(k) clearance for the ARCHITECT ^® Galectin-3 assay, the first FDA cleared automated blood test for galectin-3 which is performed using the Abbott ARCHITECT ^®automated immunoassay analyzer. The clearance was obtained based on a 510(k) submission made to the FDA in February 2014, on behalf of Abbott, by Fujirebio Diagnostics, Incorporated, or Fujirebio. This is the first automated test for galectin-3 to be cleared for use in the United States. On May 8, 2015, in anticipation of the U.S. market launch of the Abbott Laboratories’ (Abbott) ARCHITECT^® Galectin-3 assay, we amended our license and development agreement with Abbott to account for market dynamic considerations since the Galectin-3 assay first began development in 2009. On July 6, 2015, we issued a press release in which we announced that the ARCHITECT ^®Galectin-3 assay is now available in the United States. On July 27, 2015, we announced that in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT^® automated immunoassay analyzer were presented at the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting in Atlanta, GA.

In January 2013, bioMérieux obtained a CE Mark for its VIDAS^® Galectin-3 assay and initiated its commercial launch in the EU. The VIDAS^® Galectin-3 assay was developed by bioMérieux for the quantitative measurement of galectin-3 levels in blood using the bioMérieux VIDAS^® automated and multiparametric immunoassay testing system. In April 2013, Abbott obtained a CE mark for its ARCHITECT^® Galectin-3 assay and initiated its commercial launch in the EU.

Recognition of Galectin-3 Testing in U.S. Guideline for the Management of Heart Failure

In June 2013, galectin-3 testing was recognized for the first time in the 2013 American College of Cardiology Foundation and the American Heart Association Guideline for the Management of Heart Failure. The ACCF/AHA Guideline is designed to assist clinicians in selecting the best management strategy for individual patients and provides expert analysis of data on prevention, diagnosis, risk stratification, and treatment. Galectin-3 testing has been assigned a Level of Evidence of ‘A’, multiple populations evaluated, and a Class of Recommendation corresponding to ‘May Be Considered’ for the purpose of additive risk stratification of acute heart failure patients, and a Level of Evidence of ‘B’, limited populations evaluated, and a Class of Recommendation of ‘May Be Considered’ for risk stratification of ambulatory heart failure patients. The guideline further notes that testing for galectin-3 is predictive of risk of adverse outcomes in heart failure, including hospitalization, and is additive to BNP and NT-proBNP testing for heart failure patient risk stratification. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice.

Reimbursement for Galectin-3 Testing

Approximately 70% of heart failure patients in the United States are of Medicare age. Therefore, reimbursement by Medicare is important to our laboratory customers. In the United States, for the 2014 calendar year, the Centers for Medicare and Medicaid Services, or CMS, published a 2014 Medicare national limitation amount for the galectin-3 blood test (analyte-specific CPT ^® Code 82777) at the amount of a crosswalked test (analyte-specific CPT ^® Code 84244) whose 2014 national limitation amount was $30.01. This national limitation replaced the galectin-3 blood test’s national limitation amount of $17.80 that was effective in 2013. In 2015, the national limitation amount for the galectin-3 blood test was reduced to $29.93 and applies across the U.S., except in Ohio and West Virginia where rates of $23.93 and $26.33, respectively, apply. In Europe, reimbursement is covered under the hospital budgeting process and typically applies to testing performed during emergency room visits and on hospital in-patients.

Our Commercial Strategy

We believe that the introduction of automated testing for galectin-3 will increase the adoption of galectin-3 testing. We believe that laboratory adoption of automated testing for galectin-3 will result in improved access to testing, shorten turn-around-time for receipt of test results, minimize objections related to the more labor intensive manual micro-titer plate testing method and, as a result, accelerate clinical adoption of galectin-3 testing.

We are commercializing the first FDA cleared automated test for galectin-3 through an agreement with Abbott whereby Abbott will promote, market, sell and distribute its automated test for galectin-3 to laboratory customers who utilize Abbott’s ARCHITECT ^® immunoassay analyzer to perform automated testing for other analytes as well. We will support Abbott’s commercialization efforts by promoting the utility of galectin-3 as a clinical biomarker. In light of Abbott’s limited experience with commercialization of an automated assay for galectin-3, the timing or extent to which Abbott will be successful in driving customer adoption of the ARCHITECT ^® Galectin-3 test is as yet uncertain.

Our Product Pipeline

New Clinical Claims and Indications for the BGM Galectin-3 Test

We believe that the clinical and commercial value of our BGM Galectin-3 Test may extend beyond its current indications for use. On March 31, 2015, we filed for premarket 510(k) notification with the FDA in order to obtain regulatory clearance to market our BGM Galectin-3 Test in the United States for a new indication for use, as an aid in the assessment of near-term risk of fatal cardiovascular events in older adults who have no prior history of coronary heart disease, cerebrovascular disease, or vascular disease. The clinical validation study submitted as part of the 510(k) notification comprised an analysis of specimens, using our BGM Galectin-3 Test, from the BioImage Study, a proprietary observational and community-based cohort of over 6,800 individuals who were followed since 2009.

Subject to obtaining substantial additional financing, we expect to pursue new clinical claims and indications for the BGM Galectin-3 Test in assessing heart failure, as well as in related disorders. Expansion of the product label to include new clinical claims and indications for use will require additional clinical studies and clearance, or approval, by regulatory bodies, such as the FDA, and inclusion in our CE Mark for use in the EU. Our ability to engage in these activities would require us to obtain substantial additional financing.

CardioSCORE™ Test

Our CardioSCORE test is a multi-analyte biomarker-based blood test that is designed as an aid in the assessment of near-term risk for significant atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. The CardioSCORE test is a proprietary in vitro diagnostic multi-analyte assay in which the levels of multiple biomarkers are measured in blood and the results are mathematically integrated to yield a single numerical score that is predictive of an individual’s near-term atherothrombotic cardiovascular risk.

In December 2012, we obtained a CE Mark for the CardioSCORE test, which allows us to market the test in Europe and other countries that recognize CE Mark. However, as a result of our decision to focus our efforts on increasing the adoption and sales of our galectin-3 test, we have decided to redirect investments from a launch of the CardioSCORE test in Europe to support our galectin-3 efforts.

In December 2011, we filed for premarket 510(k) notification with the FDA in order to obtain regulatory clearance to market the CardioSCORE test in the United States as an aid in the assessment of near-term risk for significant cardiovascular events, such as heart attack and stroke. In response to this submission, the FDA requested that we engage an independent committee of physicians to conduct a medical review and adjudication of clinical endpoints reported in the submission. Due to the time involved in responding to this request, we withdrew the 510(k) on August 8, 2012. Our medical review also included the assessment of sample stability and the evaluation of other technical issues raised by the FDA. The adjudication process, now complete, yielded results that are broadly in line with what would be expected in a U.S.-based epidemiological cohort of this composition. While we may continue to explore potential opportunities to monetize CardioSCORE, we have redirected resources to support our development and commercialization of galectin-3 testing. Currently, we are not actively engaged in development or commercialization activities related to CardioSCORE.

BioImage Study Patient Cohort and Banked Specimens

We have exclusive rights to diagnostic inventions arising from our analysis of a proprietary observational and community-based cohort of over 6,800 individuals who have been followed since 2009. Baseline blood serum, plasma, DNA, and RNA samples collected from all participants have been stored and are available for our analysis. In addition, insurance claims data, including information regarding diagnoses, procedures, and therapies related to over 1,200 non-fatal cardiovascular events that were experienced by participants in the cohort over the more than four years since follow-up was initiated is available to us for data mining. We believe that this asset provides us with a unique and proprietary platform from which we may validate and develop new diagnostic products. We are currently employing the BioImage Study Patient Cohort and banked specimens to evaluate new applications of our BGM Galectin-3 Test. Our ability to continue to engage in these activities may require us to obtain additional financing.

Recent Developments

We have been in discussions with HDL, which is the largest customer of our BGM Galectin-3 ^® Test, since its bankruptcy filing and HDL has indicated that it intends to continue operating its business, to purchase tests from us in the ordinary course and has agreed to accelerated payment terms and a limitation on amounts owed to us on such new orders. Shipments of galectin-3 test kits to HDL resumed on June 15, 2015 in volumes comparable to those that had been shipped immediately prior to the June 7, 2015 bankruptcy filing. On July 2, 2015, in accordance with the post-bankruptcy accelerated payment terms, we received timely payment from HDL for kit shipments the Company has made to HDL since June 15, 2015. Since that time, we have continued to receive timely payments from HDL, albeit on substantially smaller and less frequent orders. On September 11, 2015, True Health Diagnostics announced the

acquisition of HDL, in a court-supervised auction. HDL has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016.

On July 14, 2015, we issued and sold 1,176,262 shares of our newly designated Series A Preferred Stock, $0.001 par value per share, or our Series A Preferred Stock, in a private placement to our principal stockholders at a purchase price of $1.7003 per share for aggregate gross cash proceeds of approximately $2.0 million. In addition, the $500,000 in aggregate principal amount of our senior secured convertible promissory notes, plus accrued but unpaid interest, that we previously issued to our principal stockholders on May 12, 2015 converted into 298,181 shares of Series A Preferred Stock. Following the closing, we had issued an aggregate of 1,474,443 shares of Series A Preferred Stock and incurred issuance costs of approximately $0.5 million.

On August 18, 2015, we closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million.

Since September 16, 2015, our common stock has been quoted on the OTC Markets’ OTCQB market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter, where it trades under the trading symbol “BGMD.” As previously disclosed, our common stock had been listed for trading on The NASDAQ Capital Market until September 15, 2015. On September 14, 2015, we received a letter indicating that the NASDAQ Listing Qualifications Hearings Panel determined to delist the shares of our common stock from The NASDAQ Stock Market LLC, or NASDAQ, and suspend trading in our common stock on NASDAQ effective at the open of business on September 16, 2015 due to our continuing non-compliance with the stockholders’ equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015.

Comparison of the Three Months ended September 30, 2015 and 2014

Revenues

Our product revenues are primarily derived from sales of the BGM Galectin-3 Test. Our product revenues have tended to be concentrated with a small number of laboratory providers generating a significant percentage of our revenues in any given reporting period. As a result, the timing of orders from these customers may fluctuate significantly from month to month and quarter to quarter.

The following table summarizes our total revenues for the three months ended September 30, 2015 and 2014:


	Three Months Ended September 30,				% Increase (Decrease)
	2015		2014		% Increase (Decrease)
	(in thousands)

Product Revenues	$	274	$	669		(59	%)
Product Fee Revenues		60	$	26		131	%

Total Revenues	$	334	$	695		(52	%)

Revenues are comprised primarily of sales of our BGM Galectin-3 Test and decreased in the three months ended September 30, 2015 by $361,000, to $334,000 from $695,000 in the three months ended September 30, 2014. The decrease in product revenues resulted primarily from a 67% decline in orders from our largest customer. Product fee revenues are comprised of contractual payments as

consideration for the rights and licenses granted by us to our partners. Abbott and bioMérieux pay to us a product fee, as set forth in their respective agreements, for tests sold to third parties. Product fee revenues increased in the three months ended September 30, 2015 by $34,000, to $60,000 from $26,000 in the three months ended September 30, 2014. The increase resulted primarily from increased sales by Abbott.

Product and Product Fee Costs

Our product costs consist of expenses related to our BGM Galectin-3 Test and royalties on product fees. These expenses include the contract-manufacturing of the tests, the medical device excise tax, freight and royalty expenses payable to the licensor of certain intellectual property relating to galectin-3 based on revenues generated from the sales of the test and product fees received.

The following table provides information with respect to our product and product fee costs and product margins for the three months ended September 30, 2015 and 2014:


	Three Months Ended September 30,						% Increase (Decrease)
	2015			2014			% Increase (Decrease)
	(in thousands)

Product and product fee costs	$	103		$	234			(56	%)
Product gross margin		69	%		66	%		3	%

Product and product fee costs decreased by 56%, or $131,000, to $103,000 in the three months ended September 30, 2015 as compared to $234,000 in the three months ended September 30, 2014. The decrease in product costs associated with product revenues was commensurate with the decrease in product revenue, and the increase in gross margin relates to the increase in product fee revenues which have a higher gross margin than product revenues.

Operating Expenses

The following table summarizes our operating expenses for the three months ended September 30, 2015 and 2014:


	Three Months Ended September 30,				% Decrease
	2015		2014		% Decrease
	(in thousands)
Operating expenses
Research and development	$	333	$	724		(54	%)
Selling and marketing		4		647		(99	%)
General and administrative		920		1,323		(30	%)

Total operating expenses	$	1,257	$	2,694		(53	%)

Research and development

Historically, we have incurred research and development expenses in connection with our internal biomarker discovery and development efforts. Our research and development expenses consist primarily of direct personnel costs, fees for consultants and outside services, laboratory consumables and overhead expenses. We use consultants and outside services to provide expertise or services that we do not have.

Research and development expenses decreased by 54%, or $391,000, to $333,000 in the three months ended September 30, 2015 as compared to $724,000 in the three months ended September 30, 2014. The decrease in research and development expenses for the current period over the prior period was primarily attributable to a decrease in salaries and consultant and professional service fees, partially offset by an increase in non-cash compensation.

Selling and marketing

Selling and marketing expenses consist primarily of costs related to supporting commercialization activities associated with our BGM Galectin-3 Test.

Selling and marketing expenses decreased by 99%, or $643,000, to $4,000 in the three months ended September 30, 2015 as compared to $647,000 in the three months ended September 30, 2014. The decreased expenditures were primarily due to the elimination of our sales team in the third quarter of 2014.

General and administrative

General and administrative expenses consist primarily of personnel-related expenses, allocated occupancy costs, and expenses related to operating as a public company. These expenses include legal and regulatory costs, directors’ and officers’ insurance premiums, investor relation services, and accounting and financial reporting expenses.

General and administrative expenses decreased by 30%, or $403,000, to $920,000 in the three months ended September 30, 2015 as compared to $1.3 million in the three months ended September 30, 2014. This decrease is due primarily to decreases in salaries, corporate legal fees, public company expenses and recruitment/relocation costs.

Other income and expense

The following table summarizes other (expense) income for the three months ended September 30, 2015 and 2014:


	Three Months Ended September 30,						% Increase (Decrease)
	2015			2014			% Increase (Decrease)
	(in thousands)
Other (expense) income
Interest income/other (expense) income	$	7		$	1			600	%
Interest expense		(4	)		(165	)		(98	%)

Total other (expense) income	$	3		$	(164	)		(102	%)

Other (expense) income decreased by $167,000 primarily resulting from our repayment of the term loan with General Electric Capital Corporation and Comerica Bank in July 2015.

Results of Operations

Comparison of the Nine Months ended September 30, 2015 and 2014

Revenues

The following table summarizes our total revenues for the nine months ended September 30, 2015 and 2014:


	Nine Months Ended September 30,				% Increase (Decrease)
	2015		2014		% Increase (Decrease)
	(in thousands)

Product Revenues	$	1,160	$	2,158		(46	%)
Product Fee Revenues		116	$	75		55	%

Total Revenues	$	1,276	$	2,233		(43	%)

Product revenues are comprised primarily of sales of our BGM Galectin-3 Test and decreased in the nine months ended September 30, 2015 by $957,000, to $1.3 million, from $2.2 million in the nine months ended September 30, 2014. The decrease in product revenues resulted primarily from a 54% decline in orders from our largest customer. Product fee revenues are comprised of contractual payments as consideration for the rights and licenses granted by us to our partners. Abbott and bioMérieux pay to us a product fee, as set forth in their respective agreements, for tests sold to third parties. Product fee revenues increased in the nine months ended September 30, 2015 by $41,000, to $116,000 from $75,000 in the nine months ended September 30, 2014. The increase resulted primarily from increased sales by Abbott.

Product and Product Fee Costs

The following table provides information with respect to our product and product fee costs and product margins for the nine months ended September 30, 2015 and 2014:


	Nine Months Ended September 30,						% Increase (Decrease)
	2015			2014			% Increase (Decrease)
	(in thousands)

Product and product fee costs	$	423		$	764			(45	%)
Product gross margin		67	%		66	%		1	%

Product and product fee costs decreased by 45%, or $341,000, to $423,000 in the nine months ended September 30, 2015 as compared to $764,000 in the nine months ended September 30, 2014. The decrease in product costs associated with product revenues was commensurate with the decrease in product revenue, and the increase in gross margin relates to the increase in product fee revenues which have a higher gross margin than product revenues.

Operating Expenses

The following table summarizes our operating expenses for the nine months ended September 30, 2015 and 2014:


	Nine Months Ended September 30,				% Decrease
	2015		2014		% Decrease
	(in thousands)
Operating expenses
Research and development	$	1,314	$	1,855		(29	%)
Selling and marketing		289		2,069		(86	%)
General and administrative		2,978		3,696		(19	%)

Total operating expenses	$	4,581	$	7,620		(40	%)

Research and development

Research and development expenses decreased by 29%, or $541,000, to $1.3 million in the nine months ended September 30, 2015 as compared to $1.9 million in the nine months ended September 30, 2014. The decrease in research and development expenses for the current period over the prior period was primarily attributable to a decrease in salaries and consultant and professional service fees, partially offset by an increase in non-cash compensation.

Selling and marketing

Selling and marketing expenses consist primarily of costs related to supporting commercialization activities associated with our BGM Galectin-3 Test.

Selling and marketing expenses decreased by 86%, or $1.8 million, to $289,000 in the nine months ended September 30, 2015 as compared to $2.1 million in the nine months ended September 30, 2014. The decreased expenditures were primarily due to the elimination of our sales team in the third quarter of 2014.

General and administrative

General and administrative expenses decreased by 19%, or $718,000, to $3.0 million in the nine months ended September 30, 2015 as compared to $3.7 million in the nine months ended September 30, 2014. This decrease is due primarily to a decrease in salaries, corporate legal fees, and recruitment/relocation costs, partially offset by an increase in costs associated with the corporate office relocation and the provision for doubtful accounts.

Other income and expense

The following table summarizes other (expense) income for the nine months ended September 30, 2015 and 2014:


	Nine Months Ended September 30,						% Increase (Decrease)
	2015			2014			% Increase (Decrease)
	(in thousands)
Other (expense) income
Interest income/other (expense) income		(514	)		4			(12,950	%)
Interest expense		(159	)		(597	)		(73	%)

Total other expense	$	(673	)	$	(593	)		13	%

Other expense increased by $80,000 primarily resulting from a loss on the fair value of the secured convertible debt and a loss on the disposal of property and equipment, partially offset by less interest expense due to our repayment of the term loan with General Electric Capital Corporation and Comerica Bank in July 2015.

Liquidity and Capital Resources

Sources of Liquidity

We believe that our existing cash will be sufficient to fund our operations into July 2016. Until we generate significant product revenues to reach cash breakeven, we will need to raise additional funds to finance our operations beyond July 2016. To date, our primary sources of liquidity have included our cash balances, sales of our equity securities, our term loan, product revenue from sales of our BGM Galectin-3 Test, and service revenue from the HRP initiative. As of September 30, 2015, we had $2.6 million of cash.

Series A Preferred Stock and Secured Convertible Promissory Note Financing

On May 12, 2015, we received additional cash of $0.5 million from the sale of our secured convertible promissory notes to purchasers affiliated with Flagship Ventures in accordance with the terms of a Securities Purchase Agreement, or Series A Purchase Agreement, that we entered into on May 12, 2015. On July 14, 2015, we issued and sold 1,176,262 shares of our newly designated Series A Preferred Stock, $0.001 par value per share, or our Series A Preferred Stock, in a private placement to purchasers affiliated with Flagship Ventures at a purchase price of $1.7003 per share for aggregate gross cash proceeds of approximately $2.0 million. In addition, the $500,000 in aggregate principal amount of our secured convertible promissory notes, plus accrued but unpaid interest, that we previously issued converted into 298,181 shares of Series A Preferred Stock. Following the closing, we had issued an aggregate of 1,474,443 shares of Series A Preferred Stock.

Follow-on Underwritten Public Offerings

On August 18, 2015, we closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds that we received, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million.

On April 8, 2014, we closed a follow-on underwritten public offering of 1,613,000 shares of our common stock, at an offering price of $6.20 per share, for gross proceeds of $10.0 million. The net offering proceeds that we received, after deducting underwriting discounts and commissions and expenses incurred in connection with the offering, were approximately $9.0 million.

Strategic Alternatives

On November 13, 2014, we announced that we had retained Stifel Nicolaus & Company, Incorporated, an investment banking firm, to assist us in reviewing and evaluating strategic alternatives. We engaged in that formal process during the ten months that followed our announcement and we recently terminated our formal engagement with Stifel.

Common Stock Purchase Agreement with Aspire

On January 24, 2013, we entered into a Common Stock Purchase Agreement, or the Aspire Agreement, with Aspire Capital Fund, LLC, or Aspire, to purchase, at our option, up to an aggregate of $12.0 million of shares of our common stock over a two-year term.

The Company did not sell any shares under the Aspire Agreement, which expired in June 2015.

Secured Term Loan Facility

In February 2012, we entered into a secured term loan facility with General Electric Capital Corporation and Comerica Bank, and a term loan in the aggregate principal amount of $10.0 million was funded to us upon the closing of the transaction. The term loan accrues interest at a rate of 8% per annum plus the higher of (a) the 3-month LIBOR rate or (b) 1.25%. Interest only payments were made for the first twelve months of the loan term. Following that initial twelve month period, principal and interest payments are required to be paid on a monthly basis through maturity in August 2015.

At September 30, 2015, we had $0 outstanding under the term loan, having paid off all of our outstanding obligations under the term loan on July 14, 2015.

Quotation of Our Common Stock on the OTCQB Following NASDAQ De-listing

Our common stock had been listed on The NASDAQ Capital Market until September 15, 2015, when it was suspended for failure to comply with The NASDAQ Capital Market continued listing standards. On September 16, 2015, our common stock began trading on the OTC Markets’ OTCQB market tier under the trading symbol “BGMD.” The delisting of our common stock from The NASDAQ Capital Market could substantially further reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, the delisting could negatively affect us by reducing the number of investors willing to hold or acquire our common stock, which could negatively affect our ability to raise capital, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

Net Cash Flows

Cash (used in) provided by operating, investing and financing activities for the nine months ended September 30, 2015 and 2014 is summarized as follows:


	Nine Months Ended September 30,
Summary Cash Flow Information	2015			2014			Change
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(2,550	)	$	(7,097	)	$	4,547
Investing activities		13			—			13
Financing activities		1,056			5,659			(4,603	)

Net (decrease)/increase in cash		(1,481	)		(1,438	)		(43	)

Cash at end of period	$	2,642		$	6,313		$	(3,671	)

Nine Months Ended September 30, 2015 and 2014

Net cash used in operating activities decreased primarily due to a decrease in our net loss, an increase in non-cash charges and changes in operating assets and liabilities for the nine month period ended September 30, 2015 compared to the same period in 2014. The changes in working capital related primarily to an increase in accounts payable, accrued expenses and other current liabilities in 2015 compared to a large decrease in 2014,

Net cash provided by investing activities increased due to the proceeds received from the sale of property and equipment in the nine month period ended September 30, 2015 for which we received no similar proceeds in the nine month period ended September 30, 2014.

Net cash provided by financing activities decreased because the net proceeds from the follow-on public offering in 2014 were larger than the aggregate of the net proceeds from the 2015 public offering and the private placement of Series A Preferred Stock and secured convertible promissory notes, partially offset by a decrease in term debt payments in the nine month period ended September 30, 2015 as compared to the same period in 2014, due to the extinguishment of the term loan in July 2015.

Funding Requirements

During the nine months ended September 30, 2015, we incurred a net loss of $4.4 million and used $2.6 million of cash in operations, and expect to continue to incur losses and use cash during 2015 and beyond. At September 30, 2015, we had cash totaling $2.6 million, and an outstanding balance of $0 under our secured term loan facility having paid off all of our outstanding obligations under the secured term loan facility on July 14, 2015.

Effective January 1, 2014, the payment rate at which our BGM Galectin-3 Test is reimbursed by CMS was increased to $30.01 from $17.80 per test. In 2015, the national limitation amount for our BGM Galectin-3 Test was reduced to $29.93 and applies across the U.S., except in Ohio and West Virginia where rates of $23.93 and $26.33, respectively, apply. We are in the early stages of commercializing testing for galectin-3. Interest in the galectin-3 testing is increasing as a result of our market development activities, although it has not yet translated into significant revenue. In order to achieve profitability, we will need to generate significant product revenues.

We believe that our existing cash will be sufficient to fund our operations into July 2016. Until we generate significant product revenues to reach cash breakeven, we will need to raise additional funds to finance our operations beyond July 2016. We may not be able to obtain adequate financing to do so when necessary, and the terms of any financings may not be advantageous to us and any financings may result in dilution to our stockholders.

The above circumstances along with our history and near term forecast of incurring net losses and negative operating cash flows raise substantial doubt regarding our ability to continue as a going concern for a reasonable period of time. The accompanying condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern.

Our forecast of the period of time through which our financial resources will be adequate to support our operations and the cost to develop and commercialize our products are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in the “Risk Factors” section of this report, in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015 and in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014. We have based these estimates on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we currently expect.

Our future liquidity and capital funding requirements will depend on numerous factors, including:

•

our ability to raise additional funds to finance our operations;

•

the revenue generated by sales of our cardiovascular diagnostic tests;

•

the rate of progress and cost of our commercialization activities, including the launch of the galectin-3 test on Abbotts’ automated platform;

•

the rate of adoption by new customers of automated galectin-3 testing and the rate of migration by existing customers of manual galectin-3 testing to automated galectin-3 testing;

•

the outcome, costs and timing of seeking regulatory clearance for our product candidates and for additional indications for existing products;

•

the success of our development efforts;

•

the expenses we incur in marketing and selling our products;

•

the emergence and effect of competing or complementary products;

•

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

•

our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;

•

our need to implement additional internal systems and infrastructure, including financial and reporting systems;

•

the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;

•

the trading price of our common stock; and

•

the effect of the quotation of our common stock on the OTCQB and the delisting of our common stock from The NASDAQ Capital Market.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations and commitments set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Contractual Obligations and Commitments” in our Annual Report on Form 10-K for the year ended December 31, 2014.

Critical Accounting Policies and Significant Judgments and Estimates

A summary of our significant accounting policies is contained in the notes to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014. There have been no material changes to those policies during the nine months ended September 30, 2015.

Certain Factors That May Affect Future Results of Operations

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

•

the timing and sales ramp of new customers for Abbott’s automated galectin-3 test and the migration of our existing customers of manual galectin-3 testing to automated galectin-3 testing;

•

our ability to raise additional funds to finance our operations;

•

the commercialization by Abbott of its FDA-cleared version of the galectin-3 test on Abbott’s automated platform;

•

our ability to continue as a going concern;

•

our estimates of future performance, including the commercialization and sales of our galectin-3 test;

•

our ability to provide sufficient evidence of clinical utility for our galectin-3 test and to differentiate it from competing cardiovascular diagnostics tests;

•

our ability to obtain regulatory clearance from the FDA for our CardioSCORE test and cardiovascular risk assessment and additional indications for our galectin-3 test;

•

our ability to successfully market, commercialize and achieve widespread market penetration for our cardiovascular diagnostic tests;

•

our ability to conduct the clinical studies required for regulatory clearance or approval and to demonstrate the clinical benefits and cost-effectiveness to support commercial acceptance of our products;

•

the timing, costs and other limitations involved in obtaining regulatory clearance or approval for any of our products;

•

the potential benefits of our cardiovascular diagnostic tests over current medical practices or other diagnostics;

•

the ability of our automated partners to develop and obtain regulatory clearance of galectin-3 tests that can be performed on their automated platforms and to commercialize any such tests;

•

willingness of third-party payers to reimburse for the cost of our tests;

•

our ability to enter into collaboration and distribution agreements with respect to our cardiovascular diagnostic tests, the performance of our partners under such agreements and the potential benefits of these arrangements;

•

estimates of market sizes and anticipated uses of our cardiovascular diagnostic tests;

•

our ability to obtain and maintain intellectual property protections for our products and operate our business without infringing upon the intellectual property rights of others;

•

the expected timing, progress or success of our development and commercialization efforts;

•

our ability to successfully obtain sufficient and appropriate blood samples for our validation tests in support of our regulatory filings for our cardiovascular tests;

•

the effect of the quotation of our common stock on the OTCQB and the delisting of our common stock from The NASDAQ Capital Market;

•

our ability to enter into a strategic transaction that increases stockholder value;

•

the success of competing cardiovascular diagnostic tests that are or become available;

•

regulatory developments in the United States and other countries in which we sell or plan to sell our tests;

•

the performance of our third-party suppliers and the manufacturer of our galectin-3 tests; and

•

our estimates regarding anticipated operating losses, future revenue, expenses, capital requirements and our needs for additional financing.

Words such as “may,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to those set forth under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014 as supplemented by the risk factors discussed under “Risk Factors” in Part II, Item 1A. of this Quarterly Report on Form 10-Q and “Risk Factors” in Part II – Item 1A, of our Quarterly Report on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q or in any document incorporated herein by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to BG Medicine, Inc. or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2014, except as noted below:

Currency Exchange Rates

We have limited foreign currency exchange rate risk. The effect of an immediate 10% change in current foreign currency exchange rates would not have a material impact on our financial condition, results of operations or cash flows.

Item 4.

CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1.

LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

Item 1A.

RISK FACTORS

There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2014 and Part II – Item 1A Risk Factors in our Quarterly Report on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015, other than as set forth below:

The holders of our Series A Preferred Stock are entitled to rights and preferences that are significantly greater than the rights and preferences of the holders of our common stock, including preferential payments upon a liquidation, as well as dividend and registration rights associated with their shares.

On July 14, 2015, we issued an aggregate of 1,474,443 shares of newly designated Series A Preferred Stock, $0.001 par value per share, or Series A Preferred Stock. Holders of our Series A Preferred Stock are entitled to a number of rights and preferences which holders of our outstanding common stock do not and will not have. Among these rights and preferences is a preference on liquidation of the Company, which means that holders of the Series A Preferred Stock will be entitled to receive the proceeds out of any liquidation of the Company before any such proceeds are paid to holders of our common stock. Upon liquidation, including deemed liquidations pursuant to a merger, consolidation or a sale of all or substantially all of our assets, the holders of Series A Preferred Stock will be entitled to be paid first out of any proceeds in the amount of $1.7003 per share, which was the price at which shares of Series A Preferred Stock were sold on July 14, 2015, plus all accrued but unpaid dividends on the shares of Series A Preferred Stock, and prior to payment of any amounts on our common stock. Thereafter, the holders of Series A Preferred Stock will also share pro rata on an as converted to common stock basis in payments made to the holders of our common stock. Accordingly, the holders of the Series A Preferred Stock will be entitled to receive the proceeds out of any sale or liquidation of the Company before any such proceeds are paid to holders of our common stock and then share in any proceeds paid to holders of our common stock. As a result, only the sale or liquidation proceeds in excess of the liquidation preference plus accrued but unpaid dividends would be available for distribution to holders of our common stock.

Holders of our Series A Preferred Stock also have significant rights with respect to certain actions that the Company may wish to take from time to time. At any time prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations of the Series A Preferred Stock or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of our capital stock, with certain exceptions; increasing or decreasing the size of our board of directors; and certain other actions. As a result, we will not be able to take any of these actions without first seeking and obtaining the approval of the holders of our Series A Preferred Stock. We may not be able to obtain such approval in a timely manner or at all, even if we think that taking the action for which we seek approval is in the best interests of the Company.

On July 14, 2015, we also entered into the Fifth Amended and Restated Investor Rights Agreement, or the Investor Rights Agreement, with the holders of our Series A Preferred Stock, as well as the stockholders who hold shares of our common stock that are registrable securities our then existing Fourth Amended and Restated Investor Rights Agreement dated as of July 10, 2008. Under the terms of

the Investor Rights Agreement, we granted certain demand and piggyback registration rights with respect to the shares of common stock issuable upon conversion of the Series A Preferred Stock. Sales of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.

The holders of the Series A Preferred Stock represent a significant voting interest in the Company.

Each share of Series A Preferred Stock is convertible into one share of our common stock, at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. Assuming the full conversion of all of the shares of Series A Preferred Stock into our common stock, the holders of the Series A Preferred Stock and their affiliates would represent approximately 28.6% of our issued and outstanding capital stock as of October 31, 2015. Prior to such conversion, holders of Series A Preferred Stock will be entitled to vote with the holders of our common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of our common stock on the trading day immediately prior to the date our Series A Preferred Stock was issued, which was $1.40. Therefore, as of October 31, 2015, the holders of Series A Preferred Stock and their affiliates held approximately 17.9% of the voting power of the Company.

Our common stock is quoted on the OTCQB, which could result in a limited market for our common stock.

In pursuing our commercialization strategy for our BGM Galectin-3 Test for heart failure, we are particularly dependent upon Health Diagnostic Laboratory, Inc., or HDL, which is our largest customer and which filed for bankruptcy in June 2015.

In pursuing our commercialization strategy for our BGM Galectin-3 Test for heart failure, we are particularly dependent upon HDL, which was responsible for approximately 80% of our galectin-3 test sales in 2014 and approximately 68% of the Company’s product revenues for the fiscal quarter ended September 30, 2015. In March 2011, we entered into a supply agreement with HDL pursuant to which HDL agreed to make our microplate galectin-3 test available to physicians in the United States. Under the agreement, we agreed to provide HDL with certain clinical market development resources, programs and assistance as reasonably requested by HDL, and HDL agreed to perform certain sales, marketing and marketing education activities in support of our galectin-3 test. On June 7, 2015, HDL filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. Since HDL’s bankruptcy filing, we have received substantially smaller and less frequent orders from HDL than we had received previously. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction. HDL has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016. Accordingly, we have already experienced a substantial downturn in our revenue as a result of HDL’s bankruptcy and we may suffer significant additional lost revenues as a result of HDL’s bankruptcy or any related business interruptions experienced by HDL or if our relationship with HDL is otherwise further adversely affected. Any prolonged disruption in HDL’s operations or problems that otherwise undermine our business relationship with HDL could have a significant negative impact on our ability to execute on our commercialization strategy for our galectin-3 test in the United States and to maintain or increase the sales volume of our galectin-3 test.

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

Not applicable.

Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the quarter ended September 30, 2015.

Item 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

Item 4.

MINE SAFETY DISCLOSURES

Not applicable.

Item 5.

OTHER INFORMATION

Not applicable.

Item 6.

EXHIBITS


Exhibit Number	Exhibit Description	Filed with this Report	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number

3.1.1	Restated Certificate of Incorporation of BG Medicine, Inc.		Form 8-K (Exhibit 3.1)	2/11/11	001-33827

3.1.2	Certificate of Amendment to Restated Certificate of Incorporation of BG Medicine, Inc., dated July 8, 2015.		Form 8-K (Exhibit 3.1)	7/8/15	001-33827

3.1.3	Amended and Restated Certificate of Designations of Series A Preferred Stock of BG Medicine, Inc. filed with the Secretary of State of the State of Delaware on August 18, 2015.		Form 8-K (Exhibit 3.1)	8/18/15	001-33827

4.1	Form of Prefunded Common Stock Purchase Warrant issued to the purchasers in the 2015 public offering.		Form 8-K (Exhibit 4.1)	8/18/15	001-33827

4.2	Form of Common Stock Purchase Warrant issued to the purchasers in the 2015 public offering.		Form 8-K (Exhibit 4.2)	8/18/15	001-33827

10.1	First Amendment to Securities Purchase Agreement by and between BG Medicine, Inc. and the purchasers named therein, dated July 14, 2015		Form 8-K (Exhibit 10.1)	7/15/15	001-33827

10.2	Fifth Amended and Restated Investor Rights Agreement by and between BG Medicine, Inc. and the stockholders named therein, dated July 14, 2015.		Form 8-K (Exhibit 10.2)	7/15/15	001-33827

31.1	Certification of the Registrant’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

31.2	Certification of the Registrant’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

32	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X

101	The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Unaudited Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine month periods ended September 30, 2015 and 2014, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2015 and 2014, and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		BG MEDICINE, INC.

Date:	November 16, 2015	By:	/s/ Paul R. Sohmer
			Paul R. Sohmer, M.D.
			President and Chief Executive Officer

Date:	November 16, 2015	By:	/s/ Stephen P. Hall
			Stephen P. Hall
			Executive Vice President, Chief Financial Officer and Treasurer

EX-31.1 2 d14311dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Paul R. Sohmer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BG Medicine, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2015

/s/ Paul R. Sohmer

Paul R. Sohmer, M.D.

President and Chief Executive Officer

(principal executive officer)

EX-31.2 3 d14311dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Stephen P. Hall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BG Medicine, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2015

/s/ Stephen P. Hall

Stephen P. Hall

Executive Vice President, Chief Financial Officer

and Treasurer

(principal financial officer)

EX-32 4 d14311dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of BG Medicine, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:	November 16, 2015	/s/ Paul R. Sohmer
		Paul R. Sohmer, M.D.
		President and Chief Executive Officer
		(principal executive officer)

Dated:	November 16, 2015	/s/ Stephen P. Hall
		Stephen P. Hall
		Executive Vice President, Chief Financial Officer and Treasurer
		(principal financial officer)

EX-101.INS 5 bgmd-20150930.xml XBRL INSTANCE DOCUMENT

10000000

2.12

2.68

79000

0.001

2000000

2000000 2000000

500000

1474443

1.00

1 1 0.5 0.5

1.00

11126579

6.20

1.54

3.33

1176262

1.7003

1176262

6313000

2.36

2.14

2.00

2.68

31000

2.68

929000

1474443

0.001

100000000

11126579

1474443

0.001

11126579

5000000

1942000

562000

2036000

11000

164118000

151000

94000

-165403000

-1274000

2548000

3356000

1500000

2594000

1332000

48000

92000

178000

14000

3156000

45000

3356000

2642000

94000

139000

152000

223000

2400000

1.00

1.40

2000000

2000000 3.20

7751000

0.001

100000000

8632810

0.001

8632810

4579000

906000

2960000

4672000

9000

161550000

93000

-161002000

557000

5229000

695000

18000

135000

336000

117000

4851000

64000

5229000

4123000

126000

154000

174000

400000

0.0002

0.00

P2M19D

0.738

2000000

0.0999

184346

2315654

1613000

10000000

9000000

0.25

0.562

P0Y

0.180

298181

2000000

500000

277000

-7097000

-0.84

8028373

-6744000

2000

-6151000

-101000

2233000

-65000

2000

3360000

2158000

433000

-78000

-6744000

75000

597000

9238000

2069000

5659000

100000

164000

3696000

2000

-1349000

8384000

764000

-1438000

489000

-1000

22000

1855000

2233000

243000

644789

216156

10-Q BGMD 0001407038 2015-09-30

<div> The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center"> (in thousands, except share and per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,023</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,401</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Preferred stock dividend </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Deemed dividend on beneficial conversion feature </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accretion of convertible preferred stock to liquidation value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net loss attributable to common shareholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,627</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,005</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average number of shares - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,862,802</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,604,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,057,960</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,028,373</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common shareholders - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.66</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.84</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

Smaller Reporting Company --12-31 Q3

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Net Loss Per Share Attributable to Common Shareholders <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Basic and diluted net loss per share attributable to common shareholders is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. The Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as its convertible preferred stock, common stock, and warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common shareholders. However, the two-class method does not impact the net loss per share of common stock as the Company was in a loss position for each of the periods presented, and neither preferred shareholders nor warrant holders participate in losses. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center"> (in thousands, except share and per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,023</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,401</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Preferred stock dividend </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Deemed dividend on beneficial conversion feature </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accretion of convertible preferred stock to liquidation value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss attributable to common shareholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,627</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,005</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Weighted average number of shares - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,862,802</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,604,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,057,960</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,028,373</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common shareholders - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.66</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.84</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="92%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699,513</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644,789</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,536,929</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216,156</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> Product Revenues Product revenues are recognized when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured. The Company sells its products through supply agreements with laboratory testing services and diagnostic testing distributors and directly to hospitals and clinics. The Company recognizes revenue when products are received by customers, at which time both title and risk of loss have passed to the customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price. Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Freight costs billed to customers are recorded as revenue. In the past the Company did not provide an allowance for doubtful accounts or a reserve for sales returns as the Company has not experienced any credit losses, and returns are only allowed for defects in workmanship. On June 7, 2015, Health Diagnostic Laboratory, Inc. (“HDL”), which is the Company’s largest customer of its BGM Galectin-3 ® Test, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. In light of this filing the Company provided a provision for doubtful accounts of $151,000 in the second quarter of 2015. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016. Product Fee Revenues The Company recognizes product fee revenue when it receives quarterly test sales reporting and payments thereunder from its partners. The Company has entered into worldwide license, development and commercialization agreements with Abbott Laboratories, (“Abbott”), bioMérieux SA, (“bioMérieux”), Siemens Healthcare Diagnostics Inc., (“Siemens”), and Alere Inc., (“Alere”). As consideration for the rights and licenses granted by the Company to its partners, the licensees pay to the Company a product fee, as set forth in the respective agreements, for tests sold to third parties. To date, only Abbott and bioMérieux have paid product fees to the Company.   Product Fee Reclassification Beginning in the third quarter of 2015, the Company began disclosing product fee revenue separately from product revenue. To maintain comparability, all previously reported product revenue figures in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to break out the product fee revenue recognized during those periods. Management evaluated the amount and nature of the change and concluded that it was not material to either the previously reported annual or quarterly financial statement results of operations. Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reported Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reported Nine months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Nine months ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Product Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">669</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,158</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Product Fee Revenues </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-2550000

false

-0.66

BG MEDICINE, INC.

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Significant Accounting Policies</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Product Revenues <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Product revenues are recognized when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company sells its products through supply agreements with laboratory testing services and diagnostic testing distributors and directly to hospitals and clinics. The Company recognizes revenue when products are received by customers, at which time both title and risk of loss have passed to the customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Freight costs billed to customers are recorded as revenue. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In the past the Company did not provide an allowance for doubtful accounts or a reserve for sales returns as the Company has not experienced any credit losses, and returns are only allowed for defects in workmanship. On June 7, 2015, Health Diagnostic Laboratory, Inc. (“HDL”), which is the Company’s largest customer of its BGM Galectin-3 ® Test, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. In light of this filing the Company provided a provision for doubtful accounts of $151,000 in the second quarter of 2015. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Product Fee Revenues <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company recognizes product fee revenue when it receives quarterly test sales reporting and payments thereunder from its partners. The Company has entered into worldwide license, development and commercialization agreements with Abbott Laboratories, (“Abbott”), bioMérieux SA, (“bioMérieux”), Siemens Healthcare Diagnostics Inc., (“Siemens”), and Alere Inc., (“Alere”). As consideration for the rights and licenses granted by the Company to its partners, the licensees pay to the Company a product fee, as set forth in the respective agreements, for tests sold to third parties. To date, only Abbott and bioMérieux have paid product fees to the Company. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Product Fee Reclassification <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Beginning in the third quarter of 2015, the Company began disclosing product fee revenue separately from product revenue. To maintain comparability, all previously reported product revenue figures in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to break out the product fee revenue recognized during those periods. Management evaluated the amount and nature of the change and concluded that it was not material to either the previously reported annual or quarterly financial statement results of operations. Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As reported Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As reported Nine months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Nine months ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Product Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">669</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,158</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product Fee Revenues </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Inventory <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">(in thousands)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total inventories </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Net Loss Per Share Attributable to Common Shareholders <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Basic and diluted net loss per share attributable to common shareholders is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. The Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as its convertible preferred stock, common stock, and warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common shareholders. However, the two-class method does not impact the net loss per share of common stock as the Company was in a loss position for each of the periods presented, and neither preferred shareholders nor warrant holders participate in losses. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center"> (in thousands, except share and per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,023</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,401</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Preferred stock dividend </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Deemed dividend on beneficial conversion feature </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,507</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accretion of convertible preferred stock to liquidation value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(56</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss attributable to common shareholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,627</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,397</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,005</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,744</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Weighted average number of shares - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,862,802</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,604,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,057,960</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,028,373</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common shareholders - basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.66</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.84</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="92%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699,513</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644,789</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,536,929</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216,156</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   </div>

<div> Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reported Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Three months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reported Nine months ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As reclassified Nine months ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Product Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">669</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,158</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Product Fee Revenues </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,233</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

9057960

2015

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">5.</td> <td valign="top" align="left">Commitments and Contingencies</td> </tr> </table> From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No amounts related to contingencies are accrued at September 30, 2015, as there are no ongoing proceedings. </div>

<div> Inventory Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(in thousands)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total inventories </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

987000

-6005000

-514000

-3728000

-177000

1276000

130000

2984000

1160000

81000

-7000

-4401000

116000

-64000

159000

2500000

289000

1507000

1056000

98000

69000

79000

2000000

2978000

151000

13000

254000

500000

56000

41000

5004000

423000

-1481000

7000

630000

63000

13000

1314000

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">6.</td> <td align="left" valign="top">Follow-on Public Offerings</td> </tr> </table> On April 8, 2014, the Company closed a follow-on underwritten public offering of 1,613,000 shares of its common stock, at an offering price of $6.20 per share, for gross proceeds of $10.0 million. The net offering proceeds received by the Company, after deducting underwriting discounts and commissions and expenses incurred in connection with the offering, were approximately $9.0 million. On August 18, 2015, the Company closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million. </div> -487000 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">7.</td> <td valign="top" align="left">Convertible Promissory Notes and Series A Preferred Stock</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On May 12, 2015, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with the Company’s principal stockholders. On May 12, 2015 (the “Initial Closing”), pursuant to the terms and subject to the conditions contained in the Series A Purchase Agreement, the Company issued and sold to the Purchasers secured convertible promissory notes in the aggregate principal amount of $0.5 million (the “Notes”). In addition, the Company agreed to issue to the Purchasers, and the Purchasers agreed to purchase from the Company, an aggregate of $2.0 million of shares of Series A Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”), at the second closing. The Company determined that the liability to issue the Series A Preferred Stock (the “Preferred Stock Liability”) at a future date was a freestanding instrument and should be accounted for as a liability. The Company remeasures the Preferred Stock Liability at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations. During the three month period ending September 30, 2015, the Company recorded other income of $31,000 upon remeasurement of the Preferred Stock Liability. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Notes contained a compound embedded derivative that requires separate accounting from the host debt instrument. The Company elected the fair value option for the Notes as management believes recording the Notes at fair value better reflects the underlying economics of the transaction. The Company remeasures the Notes at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Upon consummation of the Series A Purchase Agreement, the Company allocated the total principal proceeds of $0.5 million between the Preferred Stock Liability and the fair-valued Notes and recorded a loss of $0.5 million in other (loss) income in the unaudited condensed consolidated statements of operations. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pursuant to the terms of the Series A Purchase Agreement, and as approved by the Company’s stockholders at the Company’s 2015 Annual Meeting, the Company issued and sold to the Purchasers $2.0 million in shares of Series A Preferred Stock at the second closing that was held on July 14, 2015 (the “Second Closing”). <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Secured Convertible Promissory Notes and Related Agreements <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> At the Second Closing, the Notes were automatically converted pursuant to their terms into that number of shares of Series A Preferred Stock equal to the principal amount of the Notes plus all accrued but unpaid interest thereon divided by the purchase price of the Series A Preferred Stock of $1.7003 per share (the “Purchase Price”). <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Contemporaneously with the execution and delivery of the Series A Purchase Agreement and the issuance of the Notes by the Company to the Purchasers, the Company and the Purchasers entered into a Security Agreement (the “Security Agreement”), dated May 12, 2015, pursuant to which the Company granted to the Purchasers a security interest in substantially all of the Company’s assets, other than the Company’s intellectual property, to secure the Company’s obligations under the Notes. Pursuant to the terms of the Security Agreement, the Company’s intellectual property would have become subject to the security interest granted by the Company to the Purchasers upon repayment of all amounts owed under that certain Loan and Security Agreement by and among the Company, General Electric Capital Corporation (“GECC”) as Agent, the Lenders and the Guarantors dated as of February 10, 2012, as amended (“the “GECC Agreement”) referred as the “Term Loan” (See Note 4). Pursuant to a Subordination and Intercreditor Agreement by and among the Company, the Purchasers and GECC, dated May 12, 2015, entered into contemporaneously with the execution and delivery of the Series A Purchase Agreement, the Company’s payment obligations under the Notes were subordinated to the Company’s payment obligations under the GECC Agreement and the security interest granted by the Company to the Purchasers to secure the Company’s obligations under the Notes was subordinated to the security interest granted by the Company to GECC to secure the Company’s obligations under the GECC Agreement. In connection with the entry into the Series A Purchase Agreement, the Company and GECC amended the GECC Agreement, dated May 12, 2015, to, among other things, permit the Company to enter into the Series A Purchase Agreement and related agreements. Upon the conversion of the Notes into shares of Series A Preferred Stock at the Second Closing, the security interest granted under the Security Agreement was terminated. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Second Closing was subject to the approval of the Company’s stockholders at the 2015 Annual Meeting in July 2015 and the satisfaction or waiver of other closing conditions. The Company’s stockholders approved the issuance of shares of Series A Preferred Stock, shares of Series A Preferred Stock issuable upon conversion of the Notes and common stock issuable upon conversion of Series A Preferred Stock, at the 2015 Annual Meeting held on July 7, 2015. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On July 14, 2015, the Company and the Purchasers entered into the First Amendment to the Series A Purchase Agreement (the “First Amendment”) pursuant to which the Company and the Purchasers agreed to extend the period of time following the Company’s 2015 Annual Meeting for the Second Closing to occur until July 14, 2015. At the Second Closing, pursuant to the terms of the Series A Purchase Agreement, the Company issued and sold to the Purchasers 1,176,262 shares of newly designated Series A Preferred Stock of the Company at the Purchase Price of $1.7003 per share for aggregate gross cash proceeds of approximately $2.0 million. In addition, at the Second Closing, the $500,000 in aggregate principal amount of Notes, plus accrued but unpaid interest, that the Company had issued to the Purchasers in the Initial Closing, converted into 298,181 shares of Series A Preferred Stock at the Purchase Price. Following the Second Closing in July 2015, the Company had issued an aggregate of 1,474,443 shares of Series A Preferred Stock, which remain outstanding and held by the Purchasers. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The shares of Series A Preferred Stock have the rights, preferences and privileges set forth in the Restated Certificate of Designations to the Company’s Restated Certificate of Incorporation (the “Certificate of Designations”) that was filed by the Company on August 18, 2015 with the Secretary of State of the State of Delaware. The rights, preferences and privileges of the Series A Preferred Stock are as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Dividends <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Holders of Series A Preferred Stock will be entitled to receive, out of funds legally available for the payment of dividends under Delaware law, cumulative dividends that accrue daily at an annual rate of 8%, compounded and payable quarterly in cash or in additional shares of Series A Preferred Stock at the election of each holder. The holders of Series A Preferred Stock will also be entitled to participate in cash dividends and in-kind distributions made on shares of common stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Board of Directors has not declared any dividends on common or preferred stock. At September 30, 2015, the cumulative undeclared dividends on preferred stock total $41,000, and are included as a deduction in determining net loss per share attributable to common shareholders. The carrying value of the Series A Preferred Stock was not adjusted for the cumulative undeclared dividends as the Series A Preferred Stock is not probable of becoming redeemable. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Voting Rights <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Holders of Series A Preferred Stock will be entitled to vote with the holders of the common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of the common stock on the trading day immediately prior to the date its Series A Preferred Stock is issued, which was $1.40. In addition, prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of capital stock of the Company, with certain exceptions; increasing or decreasing the size of the Board of Directors of the Company (the “Board”); and certain other actions. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Conversion Rights <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Each share of Series A Preferred Stock is convertible into one share of common stock at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. The conversion price will be subject to adjustment in connection with stock splits, combinations, dividends and other corporate transactions affecting the common stock. All other anti-dilution protections that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A contingent beneficial conversion feature was recognized during the three months ending September 30, 2015 as a result of the conversion price being adjusted from $1.7003 to $1.00 at the time of the Second Closing. The Company recorded $1.5 million relating to the contingent beneficial conversion as a deemed dividend. The $1.5 million was included within additional paid-in capital in the condensed consolidated financial statements, and reduced the carrying value of the Series A Preferred Stock. Since the Series A Preferred Stock has no stated redemption date and is immediately convertible, the $1.5 million deemed dividend was immediately accreted, resulting in an increase in the carrying value of the Series A Preferred Stock. The deemed dividend was included as a deduction in determining net loss per share attributable to common shareholders. The conversion price adjustment feature expired following the Second Closing. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Redemption Rights <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> All redemption rights that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Ranking <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Series A Preferred Stock will rank senior in preference and priority to the Company’s common stock and each other class or series of capital stock of the Company, except for any class or series of capital stock issued in compliance with the terms of the Restated Certificate of Designations. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Liquidation Preference <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Upon liquidation, including deemed liquidations pursuant to a merger, consolidation or a sale of all or substantially all of the Company’s assets, the holders of Series A Preferred Stock will be entitled to be paid first out of any proceeds in an amount per share equal to the price at which shares of Series A Preferred Stock were sold in the Series A Preferred Stock financing, plus all accrued but unpaid dividends on each share of Series A Preferred Stock, and prior to payment of any amounts on the Company’s common stock. Thereafter, the holders of Series A Preferred Stock will also share pro rata on an as converted to common stock basis in payments made to the holders the Company’s common stock. Accordingly, the holders of the Series A Preferred Stock will be entitled to receive the proceeds out of any sale or liquidation of the Company before any such proceeds are paid to holders of the Company’s common stock and then share in any proceeds paid to holders of the Company’s common stock. As a result, only the sale or liquidation proceeds in excess of the liquidation preference plus accrued but unpaid dividends would be available for distribution to holders of the Company’s common stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The commissions and issuance costs associated with the Series A Preferred Stock financing were deducted from the carrying value of the Series A Preferred Stock, resulting in the carrying value of the Series A Preferred Stock being reduced below its liquidation value. The Company accretes the carrying value of the Series A Preferred Stock over the period from the date of issuance to the earliest redemption date using the effective interest method. During the nine months ending September 30, 2015, the Company recorded one month of accretion, totaling $56,000, at which point the Company ceased accretion as the Series A Preferred stock was not probable of becoming redeemable. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Board of Directors <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Holders of Series A Preferred Stock will be entitled to nominate one director to the Board (the “Series A Director”). Subject to applicable law and stock exchange requirements, the Series A Director will be entitled to serve as a member of each committee of the Board. The rights to nominate a Series A Director will terminate if less than 20% of the shares of Series A Preferred Stock issued under the Securities Purchase Agreement dated May 12, 2015, as amended, by and between the Company and the Series A Holders are no longer outstanding. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Registration Rights <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company shall comply with all federal and state laws, rules and regulations and applicable rules and regulations of the Exchange on which shares of the common are then listed. If any shares of common to be reserved for the purpose of conversion of Series A Preferred Stock require registration with or approval of any Person or group (as such term is defined in Section 13(d)(3) of the Exchange Act) under any federal or state law or the rules and regulations of the Exchange on which shares of the common stock are then listed before such shares may be validly issued or delivered upon conversion, then the Company will, as expeditiously as reasonably practicable, use commercially reasonable efforts to secure such registration or approval, as the case may be. So long as any common stock into which the of Series A Preferred Stock are then convertible is then listed on an Exchange, the Company will list and keep listed on any such Exchange, upon official notice of issuance, all shares of such common stock issuable upon conversion. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As the holders of the Series A Preferred Stock are entitled to receive liquidation preferences that other equity holders are not entitled to, the Company determined that the preferred stock should be classified as temporary equity in the condensed consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company reviews the rights and preferences of its equity securities for any changes in terms, rights or preferences to determine if such change is a modification or an extinguishment. The Company evaluates amendments to equity securities using a qualitative method which considers the business purpose for the amendment and whether it adds, deletes or significantly changes a substantive contractual term or the nature of the equity securities. An amendment that changes a substantive contractual term or fundamentally changes the nature of the share of preferred stock is considered an extinguishment. If considered an extinguishment, the Company accounts for the removal of the carrying value of the old securities and recognizes the new securities at their current fair value. An amendment that does not meet these criteria is a modification. If considered a modification, the Company estimates the fair value of the equity security pre- and post- modification and recognizes the incremental fair value, if any, resulting from the modified terms. During the nine months ending September 30, 2015, the Company determined that all changes to the terms of the Series A Preferred Stock resulting from amendments made to the Certificates of Designations were not substantive and should be accounted for as a modification. The amendments did not result in a material change to the fair value of the Series A Preferred Stock. </div> 29.93 23.93 26.33

504000

456000

225000

<div> The table below sets forth a summary of changes in the fair value of the Company’s level 3 liability (preferred stock liability) for the three and nine months ending September 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Nine Months Ended September 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Loss on recognition of preferred stock liability </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Gain on revaluation of preferred stock liability </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(79</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

79000 79000

<div> The table below sets forth a summary of changes in the fair value of the Company’s secured convertible notes for the three and nine months ended September 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Nine Months Ended September 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">929</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Proceeds from secured convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Loss on fair value adjustment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Conversion of secured convertible notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(987</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(987</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

-487000

500000

987000

699513

1536929

0.20

0.08

41000

57000

2015-07-14

2018-12-31

240000

0.510

0.550

0.0003

0.00

P29D

0.738

0.180

153000

17.80

404000

30.01

162000

128000

114000

0.77

151000

-0.28

8604312

-2397000

1000

-2233000

695000

669000

-2397000

26000

165000

647000

1323000

2928000

234000

724000

695000

-0.27

9862802

-2627000

7000

-1026000

334000

274000

31000

-1023000

60000

4000

1507000

920000

56000

41000

1360000

103000

333000

31000

-58000

987000 0001407038 us-gaap:ConvertibleDebtMember 2015-07-01 2015-09-30 0001407038 bgmd:PreferredStockLiabilityMember 2015-07-01 2015-09-30 0001407038 2015-07-01 2015-09-30 0001407038 us-gaap:ScenarioPreviouslyReportedMember 2014-07-01 2014-09-30 0001407038 2014-07-01 2014-09-30 0001407038 2015-04-01 2015-06-30 0001407038 2014-09-12 2015-09-30 0001407038 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-12-31 0001407038 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0001407038 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0001407038 bgmd:CentersForMedicareAndMedicaidServicesMember 2014-01-01 2014-12-31 0001407038 2014-01-01 2014-12-31 0001407038 bgmd:CentersForMedicareAndMedicaidServicesMember 2013-01-01 2013-12-31 0001407038 us-gaap:OperatingExpenseMember 2015-06-01 2015-06-30 0001407038 us-gaap:ConvertibleDebtMember 2015-06-01 2015-06-30 0001407038 bgmd:PreferredStockLiabilityMember 2015-06-01 2015-06-30 0001407038 bgmd:FutureCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-06-01 2015-06-30 0001407038 bgmd:CurrentCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-06-01 2015-06-30 0001407038 2015-06-01 2015-06-30 0001407038 bgmd:TermLoansMember 2015-01-01 2015-09-30 0001407038 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001407038 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001407038 us-gaap:CumulativePreferredStockMember 2015-01-01 2015-09-30 0001407038 us-gaap:MinimumMember us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-09-30 0001407038 us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-09-30 0001407038 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001407038 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001407038 us-gaap:ConvertibleDebtMember 2015-01-01 2015-09-30 0001407038 bgmd:PreferredStockLiabilityMember 2015-01-01 2015-09-30 0001407038 us-gaap:EmployeeSeveranceMember 2015-01-01 2015-09-30 0001407038 us-gaap:PreferredStockMember 2015-01-01 2015-09-30 0001407038 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001407038 bgmd:CentersForMedicareAndMedicaidServicesMember stpr:WV 2015-01-01 2015-09-30 0001407038 bgmd:CentersForMedicareAndMedicaidServicesMember stpr:OH 2015-01-01 2015-09-30 0001407038 bgmd:CentersForMedicareAndMedicaidServicesMember 2015-01-01 2015-09-30 0001407038 2015-01-01 2015-09-30 0001407038 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001407038 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001407038 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001407038 us-gaap:ScenarioPreviouslyReportedMember 2014-01-01 2014-09-30 0001407038 2014-01-01 2014-09-30 0001407038 us-gaap:EmployeeSeveranceMember 2014-07-01 2014-12-31 0001407038 bgmd:PrincipalAmountOfNotesAndAccruedUnpaidInterestMember 2015-07-14 2015-07-14 0001407038 us-gaap:SeriesAPreferredStockMember 2015-07-14 2015-07-14 0001407038 us-gaap:ConvertibleDebtMember 2015-07-14 2015-07-14 0001407038 bgmd:PreferredStockLiabilityMember 2015-07-14 2015-07-14 0001407038 bgmd:CurrentCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-07-14 2015-07-14 0001407038 2015-07-08 2015-07-08 0001407038 bgmd:UnderwrittenPublicOfferingMember 2014-04-08 2014-04-08 0001407038 bgmd:SeriesAUnitsMember 2015-08-18 2015-08-18 0001407038 bgmd:SeriesBUnitsMember 2015-08-18 2015-08-18 0001407038 2015-08-18 2015-08-18 0001407038 bgmd:PreferredStockLiabilityMember 2015-05-12 2015-05-12 0001407038 2014-12-31 0001407038 2013-12-31 0001407038 bgmd:TermLoansMember 2015-09-30 0001407038 us-gaap:SeriesAPreferredStockMember 2015-09-30 0001407038 us-gaap:SeriesAPreferredStockMember us-gaap:ScenarioAdjustmentMember 2015-09-30 0001407038 2015-09-30 0001407038 us-gaap:ConvertibleDebtMember 2015-06-30 0001407038 bgmd:PreferredStockLiabilityMember 2015-06-30 0001407038 bgmd:FutureCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-06-30 0001407038 bgmd:CurrentCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-06-30 0001407038 2014-09-30 0001407038 us-gaap:SeriesAPreferredStockMember 2015-07-14 0001407038 us-gaap:ConvertibleDebtMember 2015-07-14 0001407038 bgmd:PreferredStockLiabilityMember 2015-07-14 0001407038 bgmd:CurrentCommonStockPriceMember us-gaap:ConvertibleDebtMember 2015-07-14 0001407038 bgmd:UnderwrittenPublicOfferingMember 2014-04-08 0001407038 2015-10-31 0001407038 bgmd:SeriesAUnitsMember 2015-08-18 0001407038 bgmd:SeriesBUnitsMember 2015-08-18 0001407038 bgmd:SeriesAUnitsMember us-gaap:WarrantMember 2015-08-18 0001407038 bgmd:SeriesBUnitsMember us-gaap:WarrantMember 2015-08-18 0001407038 bgmd:SeriesAUnitsMember us-gaap:CommonStockMember 2015-08-18 0001407038 bgmd:SeriesBUnitsMember us-gaap:CommonStockMember 2015-08-18 0001407038 2015-08-18 0001407038 us-gaap:SeriesAPreferredStockMember 2015-07-31 0001407038 bgmd:SecuredConvertiblePromissoryNotesMember 2015-05-12 0001407038 us-gaap:SeriesAPreferredStockMember 2015-05-12 0001407038 bgmd:PreferredStockLiabilityMember 2015-05-12 0001407038 bgmd:TermLoansMember 2012-02-10 iso4217:USD iso4217:USD shares shares pure iso4217:USD bgmd:Patient bgmd:Employee

EX-101.SCH 6 bgmd-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Description of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Term Loan link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Follow-on Public Offerings link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Convertible Promissory Notes and Series A Preferred Stock link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Reclassified Amounts of Historical Statement of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Common Shares Excluded From Computation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Changes in Fair Value of Company's Level 3 Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Changes in the Fair Value of Company's Secured Convertible Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Term Loan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Follow-on Public Offerings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Convertible Promissory Notes and Series A Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 bgmd-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 bgmd-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 bgmd-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable (net of allowances for doubtful accounts of $151 and $0, as of September 30, 2015 and December 31, 2014, respectively) Accrued Liabilities, Current Accrued expenses Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Preferred Stock Additional paid in capital, preferred stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Allowance for Doubtful Accounts Receivable, Current Allowances for doubtful accounts Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Antidilutive Securities [Axis] Antidilutive Securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets Cash Cash, end of period Cash, beginning of period Cash Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental schedule of non-cash financing activities Cash, Period Increase (Decrease) Net decrease in cash Centers for Medicare And Medicaid Services Member Centers for Medicare And Medicaid Services [Member] Centers for Medicare And Medicaid Services Class of Stock [Domain] Class of Stock [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Commitments and Contingencies Commitments and contingencies (Note 5) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Common Stock [Member] Common Stock Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock; $.001 par value; 100,000,000 shares authorized at September 30, 2015 and December 31, 2014; 11,126,579 and 8,632,810 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Conversion of Stock, Amount Converted Conversion of interest to preferred stock Convertible Debt [Member] Convertible Debt Instrument Convertible Preferred Stock, Terms of Conversion Convertible preferred stock, terms of conversion Convertible Preferred Stock, Voting Rights Threshold Convertible Preferred Stock, Voting Rights Threshold Convertible preferred stock voting rights threshold Convertible Promissory Notes And Series A Preferred Stock [Text Block] Convertible Promissory Notes And Series A Preferred Stock [Text Block] Convertible Promissory Notes and Series A Preferred Stock Cost of Goods and Services Sold Product and product fee costs Costs and Expenses Total costs and operating expenses Costs and Expenses [Abstract] Costs and operating expenses: Cumulative Preferred Stock [Member] Cumulative Preferred Stock Cumulative Undeclared Dividends Cumulative Undeclared Dividends Undeclared dividends Current Common Stock Price [Member] Current Common Stock Price [Member] Current Common Stock Price Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion, Converted Instrument, Amount Conversion of convertible notes payable to preferred stock Debt amount converted in to preferred shares Debt Conversion, Converted Instrument, Shares Issued Number of preferred shares issued upon debt conversion Debt Conversion [Line Items] Debt Conversion [Line Items] Debt Conversion [Table] Debt Conversion [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Face Amount Principal amount of secured convertible promissory notes issued and sold Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Loan facility, maturity date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Depreciation, Depletion and Amortization Depreciation and amortization Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items] Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items] Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items] Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table] Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table] Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share, Basic and Diluted Net loss per share attributable to common shareholders - basic and diluted Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Attributable to Common Shareholders Employee Severance [Member] Employee Severance Employee Stock Option [Member] Options to purchase common stock Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity Component [Domain] Equity Component [Domain] Equity [Line Items] Equity [Line Items] Equity [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Expected Annual Cost Savings Expected Annual Cost Savings Short term rental basis, expected annualized savings Fair Value Assumptions, Exercise Price Conversion price per share Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Fair Value Assumptions, Expected Term Expected term Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Liability Class [Axis] Liability Class [Axis] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value by Shareholders' Equity Class [Domain] Fair Value by Shareholders' Equity Class [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Inputs, Discount Rate Discount rate Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Changes in Fair Value of Company' Level 3 Liability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Convertible Notes To Common Stock Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Convertible Notes To Common Stock Conversion of secured convertible promissory notes Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Included In Earnings Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Included In Earnings Gain on revaluation of preferred stock liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Loss on fair value adjustment Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Loss Included In Earnings Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Loss Included In Earnings Loss on recognition of preferred stock liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Proceeds from secured convertible note Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Ending balance Beginning balance Preferred stock liability, fair value Future Common Stock Price [Member] Future Common Stock Price [Member] Future Common Stock Price Gain (Loss) on Fair value Adjustment of Debt Instrument Gain (Loss) on Fair value Adjustment of Debt Instrument Loss on fair value of secured convertible note Gain (Loss) on Disposition of Property Plant Equipment Loss on sale of property and equipment General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Deferred Revenue and Customer Advances and Deposits Deferred revenue and customer deposits Increase (Decrease) in Inventories Inventory Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Interest Expense Interest expense Interest Paid Cash paid for interest Inventory, Current [Table] Inventory, Current [Table] Inventory, Finished Goods, Net of Reserves Finished goods Inventory [Line Items] Inventory [Line Items] Inventory, Net Inventory Total inventories Inventory, Policy [Policy Text Block] Inventory Inventory, Raw Materials, Net of Reserves Raw materials Investment Income, Interest Interest income Investments and Other Noncurrent Assets Deposits and other assets Operating Leases, Rent Expense Sublease rental charges Lease Expiration Date Sublease expiration date Legal Entity [Axis] Legal Entity Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' (deficit) equity Liabilities and Equity [Abstract] Liabilities and Stockholders' (Deficit) Equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities Line of Credit Facility, Maximum Borrowing Capacity Loan facility amount borrowed Long-term Debt, Current Maturities Loan facility Term loan Long-term Debt [Text Block] Term Loan Loss Contingency Accrual Accrued other contingencies Minimum [Member] Minimum Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash flows provided by investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash flows used in operating activities Net cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Net Income (Loss) Attributable to Parent Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Net loss attributable to common shareholders OHIO Ohio Operating Expense [Member] Total costs and operating expenses Operating Income (Loss) Loss from operations Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Business and Basis of Presentation Other Liabilities, Current Other current liabilities Other Liabilities, Noncurrent Other liabilities Other Nonoperating Income Other income recorded upon remeasurement of preferred stock liability Other Nonoperating Income (Expense) Other (loss) income Other income (loss) Paid-in-Kind Interest Non-cash interest expense Payments for Restructuring Payment for severance payments and benefits continuation Payments of Stock Issuance Costs Costs related to issuance of stock Percentage Of Common Shares Outstanding Owned Percentage Of Common Shares Outstanding Owned Percentage of common shares outstanding owned Preferred Stock, Dividend Rate, Percentage Preferred stock, annual dividend rate, percentage Preferred Stock Dividends, Income Statement Impact Deemed dividend on beneficial conversion feature Deemed dividend on beneficial conversion feature Preferred Stock Liability [Member] Preferred Stock Liability [Member] Preferred Stock Liability Preferred Stock [Member] Preferred Stock Preferred Stock Shares Authorized for Future Issuance Value Preferred Stock Shares Authorized for Future Issuance Value Preferred stock approved to issue Preferred Stock Shares Sold, Value Preferred Stock Shares Sold, Value Preferred stock sold, value Preferred Stock, Voting Rights Preferred stock, voting rights Preferred Stock, Voting Rights Threshold, Percentage Preferred Stock, Voting Rights Threshold, Percentage Rights to nominate director will terminate if share of preferred stock fall bellow the threshold Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Principal Amount of Notes and Accrued Unpaid Interest [Member] Principal Amount of Notes and Accrued Unpaid Interest [Member] Aggregate principal amount of Notes, plus accrued unpaid interest Prior Period Adjustment [Abstract] Prior Period Adjustment [Abstract] Proceeds from Convertible Debt Proceeds from secured convertible note Proceeds from Issuance of Common Stock Gross proceeds offering Proceeds from public offering Proceeds from Issuance of Preferred Stock and Preference Stock Aggregate gross cash proceeds from issuance of preferred shares Proceeds from issuance of preferred stock Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from ESPP purchases Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of property and equipment Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Property, Plant and Equipment, Net Property and equipment, net Proportion Of Each Unit Of Shares Proportion Of Each Unit Of Shares Proportion of each unit of shares Provision for Doubtful Accounts Provision for doubtful accounts Public Offerings [Abstract] Public Offerings [Abstract] Public Offerings [Abstract] Public Offerings [Text Block] Public Offerings [Text Block] Follow-on Public Offerings Range [Axis] Range [Axis] Range [Domain] Range [Domain] Redeemable Preferred Stock Dividends Preferred stock dividend Reimbursed Medicare and Medicaid Services Price Per Test Reimbursed Medicare and Medicaid Services Price Per Test Reimbursed price per test Repayments of Long-term Debt Cash for payments on term loan facility Payments on term loan Research and Development Expense Research and development Research and Development Expense [Member] Research and development Restructuring and Related Cost Estimated Annual Savings in Employee Salaries and Benefits Restructuring and Related Cost Estimated Annual Savings in Employee Salaries and Benefits Savings in employee salaries and benefits Restructuring And Related Cost Expected Number Of Employees Remaining Restructuring And Related Cost Expected Number Of Employees Remaining Number of employees remaining after restructuring activities Restructuring and Related Cost, Number of Positions Eliminated Number of employees eliminated Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Reduction in workforce, percentage EX-101.PRE 10 bgmd-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`,Z)<$>CT2N4H`$``%43```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V874_",!2&_PK9K6&E5?$CP(UXJR3Z!^IVQAK:M6G+@']O.]#H,@TH M2\[-/GA/S_MNIWLNF+SN#+C!5LG*39/2>W-/B,M*4-REVD`5E$);Q7VXM4MB M>+;B2R!L-!J33%<>*C_TL4ZCK4 M12$RR'6V5F%)ZH,U7`0]&2RX]4]/XJ26\A?O`WS[?XVOA;TER/. MM;G^:>B-Z$ASZA$2)^5@2')<(LEQA23'-9(<8R0Y;I#DN$62XPY)#CK"$@0+ M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$KPT)6 MAH6L#`M9V2=92?-OVNP=4$L#!!0````(`,Z)<$=(=07NQ0```"L"```+```` M7W)E;',O+G)E;'.MDLMNPD`,17\EFGUQ2B46$6'%AAU"_(`[XSR4S'CD,2+] M^X[8@,)#K<32KWN/KKP.J:P.-*+V'%+7QU1,?@RIROW:=*JQ`DBV(X]IP9%" MGC8L'C67TD)$.V!+L"S+%4EK0VTPAGEN&;>5AD MZ3SXB?078VZ:WM*6[13@2=&AXD7U M(V8#$NTIO8+Z>@"%,;X[)9J4@B,WHX*[O]C\`E!+`P04````"`#.B7!'3C$_ M_V,!```1$@``&@```'AL+U]R96QS+W=OOI1#11>/>HCT74!@:?P__638 MMS[;/\/:15"OS/&YY4TUL^Z7MIAM>A<8\/PZ$K3 MV_QJ2S&<92OCIG/2X_[G[.1\.:3N?*$T>;&NE'!(WSIW]95(\&:\T6S88%B^ M]_*?[;NBJ',Y=?EK(VWXH\)\;9":>!#'@Q@2-(\'S2%!BWC0`A*TC`-`*$K2.!ZTA09MXT`82M(T';2%!E"DR9I@D#6N,UJ1P31BO20&;,&*30C9A MS"8%;<*H30K;A'&;%+@)(SK.C-&+U9T9M!9VWML(W1FQ6] M&:,W*WHS1F]6]&:,WJSHS1B]6=&;,7JSHC=C].:)WKZR3B[/P=5MZ1]=\VVX M^L4]P=N'^TT>GS).51LF6H=A)S'C]>%.CU,_0\ROOS_'#U!+`P04````"`#. MB7!'R#&[@JD"``#Q"```$````&1O8U!R;W!S+V%P<"YX;6R]5DUOVS`,_2M" M3MLA=9)U6Q&D!M*DQ0IT:[!DW9F5Z42H+!FBG#7[]:/LUG4Z9X5S6"^E*3Y^ M/%)B)H8&XX6S.3JOD,1CI@V-67G>VWB?CZ.(Y`8SH!,V,7R:6I>!YT^WCFR: M*HES*XL,C8]&@\&G"!\]F@23?EX[[<63$&6:YUI)\,J:^*N2SI)-O;A\E*@G MT6N#$L&>ER@+I_PN'E0V355ILY2@<<:QXA0T867UHBQM9C;+P>RBZNM&F0?Z MD:_L'#PV4?L'E?<-.$PXZ)[W6EG:?-EQG3I@9QLP:TR:MG\?/G-QAXY"I]95OA$29]0*4HWBR]>,M2F_=4YNV_M@N)5:&IM/=BO.CGK@'PB"> M][;@%!C?$Z1^\^>H5X6MM*6L<_(N_FG=`VT0/4VB6EF*3=NFK$[CT5EIP=*^ M9517%C_1ME=WT*R4UTBWZ0*<_T]4E#751)SU&M4_NQ!@$G%I/(^CN#95*&Y> MDY):FEF^%X8P$2R1U2KA,4O$!6@P$L41F`]=,$O/_SCG(S`?6S%S).E4'NH5 M-A47!2F#1"4E%T"MF*5:&\4]X*Z+J92V8.K,6BPXHN27HA5SQ4,@[D`7&,)< M*<.E*]#,-Y\662MFA2X3-Q8.59MERH?^5=ERS2$--(=SL%K;7WVN=%'<,-?,NN$W(2RR=W/TH/3[MS!A-Q0> MZM*`E#PX-&Q3/OX4UI8N>,V)*VYO,W6.&Z]W34/@?U M%1%],4T2%1@H(=4KUOWBB'['JU,&[GY_GI9(<^,T5\>K11'M_\")_P!02P,$ M%`````@`SHEP1]:&Z;$^`0``:0,``!$```!D;V-0'=WE<))@6!"C08#(2. M*,G*%[,SMC8%Z?5E$1U7/.#22K56(&^;ONQW*G9&\#JEH_/Z6QR90)R(R"J@F+8.%ADY\ZOT[O[U4-63L;T M.J621 MA'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_> MX%#BVR]*+41B1%G\@MNN01.+5)#3(3 M/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8: MXIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2 M/'K^!?F<-0HACA*FNVB M<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ? MJH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0] MH=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[ M9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X M&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90 M-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=< M7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9 MKF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E M.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J* M@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT M-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8- M-!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`,Z)<$>)3S)\ M:0(``$@,```-````>&PO?SOG.)^G81PDKM:'X M<8FQ`FM&>17!I5+E-\^KTB5FJ!J+$G,]DPO)D-*/LO"J4F*452:(46_B^S./ M(<)A'/*:S9FJ0"IJKB(X[2#@XN]$AB/X=/'Y3RW4[2?@QM&7T%#^J][Z)L`S=7& M#@)O3*#7'%P!#HC#ZAFL$-7^@7%/!142*%T@.H-%.&+8>=PA2A)) M#)@C1NC&P1,#V)IJ_!CA0MK<+L,PS]CO,\DBB:#?_-Z>+NG9[6"61RC=79X& MXK!$2F')Y_H!-/9B4^K%<<&Q$VG]7O$N)-H$D^E6@!UTWD3(#,LN^P[W.@?,Q9^Q# M8%2TIMZ(QNS+P&ZJM\WFN+=IKX[B!>N\2Z"C45G2S7=*"LZP$^N@N6B>7J,/ M]M#'(6I9P5)(\JS]32&D&L`2@A66BJ3;R%^)R@5>JZ:"O76^3^&Q2WY/3:?? MM5Z-+L&/WIZCDUOHOF8)EG/[V3MF3E'M-^>JS%QBSE;:_^Z:U[33K9Z]T[$[%"0UH8KP5@,R=ZQ[HYON M--.^6VO.;-TW:CNK4**O]3M9-%F&BXXB@KW] M"V>D9N[2V/]WB/\!4$L#!!0````(`,Z)<$=CO9X]:P,``'T*```/````>&PO M=V]R:V)O;VLN>&ULE9;;;MLX$$!_A=#3]B&UQ=A.8M0%DB;9#;#;!G60/M/2 M*!J4%X&DXK1?OT,IEW'#&LV31%V.9H:'U'P(RZWSWS?.?1X[Q1D8;^;N*:!BLX=U5OP,:)G$X7$P]:170VM-B%XI$6 M_H06.@^J#BU`-'J$&86V^/@A+!O4<`L^$%BHKONL#*R*!UT(K4*\J#%"O2IF M-'1;V+G@^^ZL1YT&\^F\F"384ZK77E2NAA%VTV+X]GBC$#4TJM?QAH)]^NZJ M*.5,RL7(2(_=(FP#!Z8+0E41[^%&;5;%M!"JC^X2=01_KB+\[5W?H;TC5B$: M]"&N4[K#DP8M&OR9XJ91:-WV'^?QI[-1Z77EG=;#6^G&\!)](3Q?H1@C5CL/ M1K7YFF9B52RF!+S'@!O4&'^LBN%<0\ID\DLJ0_E?SH0=BO,TQ4+96ES82!1Q M9@.0/-7X/.(50>NU18X1IQU@>T M$,)0^S,5&&C!0(O7H#7>6:05JFCB3JO*]31Q]DY<4VP5`@<=,=#1:]"E0B]N ME>XA!72)EFJ,2I,"(?K>,-`Q`QV_!MV`-^)?IWA93]@K)[FR&H,QR3=6@(J; ML@#[2PKEE)LWS21!"\-M#ZBHU_V&*B"^-`UX0NU0=OS-"WR?UAHM'W'MG<$0 MG/\A/KL(*3Z.X@:7&87W3D_)%2ZYPV5&XOVH&4=QB\N,QGOGNN0:E]SC\JTB MEPN.XB:7;U6Y/.(H[G*9D7G=&Z-HRBBBKU#1_R,0F!;JJ4G4'1FXS65&9X:Z M(BULI`V;-/CK'*)"_8ZCN.5E1G.&(N.[/JKGLJF`%=\8N>@R(WI:,?3JNE6> M@KEXJ'1?4WZ79&MB126W77+;9<;VYPU)'(C3FMH&*OI`&O]M',5MEQG;]VY4XH"CN.TR8_OO MMZHA3([BMLN,[7OW*WG,4=QV>?S8'+ST`]02T?*M4[<4AL]0NU&E%HH.XWXW MFR?-T_@_:JM61>I]J,WIM?Y$U[Y8JO/0(8SDIZ;IX_]02P,$%`````@`SHEP M1^HL>A]-`@``]`<``!@```!X;"]W;W)KFKKE>Z\4HMOY/B]*TF#^1#O2RC=7RAHLY)3=?-XQ@B_: MU-0^"H+$;W#5>GFF8\\LS^A=U%5+GAG@]Z;![-^1U+3?>]`;`B_5K10JX.>9 M/_HN54-:7M$6,'+=>P>X.\%(2;3B=T5Z/AD#5?R9TEX&J@=2D$"H% MEH\'.9&Z5IDD^:]-^LY4QNEXR/Y=MRO+/V-.3K3^4UU$*:L-/'`A5WROQ0OM M?Q#;0ZP2%K3F^A<4=RYH,U@\T.`W\ZQ:_>S-FPA:F]N`K`&-!I3,&D)K"$># M^72^J4SW]0T+G&>,]H!W6/W;<"?E3"61F0'7V61+7`'+W$X`\EQVI.WH:\#)*,)E0#@`PFD'H;9'R_9HL$=3>Z3M\M$;(T_FOE45K*B"Q@X&3HL,R0SD$&3KJ!`-\7N MRLW,7S)HHB`-PA6K"R(WRNQ/.+?`K`:M6&$P=%/,-D9PCF(U:`7%O=FAVF^%.6/'Z'C!'9`^I-_E>=;A&_F% MV:UJ.3A3(8]Z?2Y?*15$%A$\R9)*>06/DYI]/E_ M4$L#!!0````(`,Z)<$&PO=V]R:W-H965T&ULC9?!7+?>'F61UO?J M),OVG[VJBK1I'ZN#6Y\JF>[ZH")WF><%;I%FY6*SZMN>JLU*O35Y5LJGRJG? MBB*M_L4R5^?U`A9#PW-V.#9=@[M9N9>X75;(LLY4Z51ROUX\PD/"P@[IB=^9 M/->C>Z<3_Z+4:_?P<[=>>)T&F=YG:GO]2TL\^N\#Q_9#] M>U]N*_\EK66B\C_9KCFV:KV%LY/[]"UOGM7YAZ0:1)=PJ_*Z_W6V;W6CBB%D MX13I!UZSLK^>\9^E1V'Z`$8![!(`W!C@4X!_$^"BLKZN;VF3;E:5.COU*>U& M&QY:O.J2M)F=NL_6EE3WC8]=Z_N&\97[WN4AA(V0F)!I(B%"7!"W[5\K@@TB M_+$(AO'!?+P_Q/-QO(_QX;7$L$=*+(*0@+-I*$&(`_/GE7"M$H[=+*\[$6,E MB(!@TTQ"3,CG=0BM#H$Z(H,.0D:U?M6!#/>\>1V!5D?0)_`]@PY$P#=H38@1 M%N\CU.H(40<8=`R("`Q"$.)+`?-*EEHE2^S&,/HQ(L`-.@B!<%Y&I)41H0S# MX,>(1*9Y&M'86:Q\\+0Z^N96B*'8F)C(]$*(`1L3`=!+01L;%:.10HQOG"5$ M"39:@--J])X(:(J^33UZ5P2T,S\T*25?C`*+)0YZSP-T*]]D>L2`;YKX"5%! M9#.?],8':%DF-XF)$8%1"T*19S,`>O.#@.S3I(48P\M+B(&EA1*]_0'YELG_ MB('H=HN\UD*91&@SM?46".A>IGYB8LQKGAB+W1KT+@AH8/S&!J^^'(AAGA], M4\F0*0C9O!JF]T*&'L9O:AXS\<"(:2;YRDPKT5LA`ZK&\%[8\-476>S*;.+# M#TV.6VQC3&]RS)]=/S$Q`(;Q(\9B4C.]"S+T+FXR'F(@X`"F!7_A0`@+7V9Z M*V1D8.`L$]TY?@)PB>9S/%]9;(T,J$R8B(N0,6FE;_D$K83!Z]+;*0 M]FG3-`\G=OSKZ3-D^K+CNZ-3V2D]R%]I=Z4:V6;Q[ML" MC^W!^_*0RWW3W8;M?85'47QHU&DX65^.]YO_4$L#!!0````(`,Z)<$>@S^6& M00(``$0(```8````>&PO=V]R:W-H965T&ULC9;=CJ(P%(!? MA?``TD+YT2#)R&:R>[')9"YVKZM6(0.4::O,OOWV3Q,X*/.JAM@A"` M)&AQW?E%KL?>6)'3BVCJCKPQCU_:%K,_.]+08>M#_S;P7I\KH0:"(@_N<<>Z M)1VO:>TI^3^F'ZOPX;GV@'$A##D*EP/)R)25I M&I5)5OZT2?_55('C]BW[JYZNU-]C3DK:_*Z/HI*VP/>.Y(0OC7BGPW=BYQ"K MA`?:`-%L0&0#HO\"`F.F MY_4-"USDC`X>[['ZM>%&XDPED9D]KK/)*7$]^*)&KT4H-``)XNR"ERT@D"IY0>EE;AC)5E((1A$J?K&2M+9DD4 M9G")%'1+F;TPF5E].\LLD8(S4L%HO^_QF?S$[%QWW-M3(8\.O<^?*!5$)@(K MF;:21_J]TY"34,U4MIDYY$Q'T/YV9M__.!1_`5!+`P04````"`#.B7!'NDT' M12($``"($P``&````'AL+W=O_R*K M$FI]+BDN.F_^.11EEM3-97FTJTNI MDWUGE*6V8,RSL^2<+S;K;NQ[N5D7'W5ZSO7WTJH^LBPI_]OJM+B^+OBB'_AQ M/I[J=L#>K.W!;G_.=%Z=B]PJ]>%U\<97L9`MTA'_GO6UNOMMMN"M3GH5._JUD72?'WJ4*=IZZF)_!N=WF*VAO>_>^_?.KE-^N])I<,B_7G> MUZ!EZZ3Q;%6=MV;2JF[PK1W]W'C.VOYL_2`B[I`M(NXT$@'"!\)NXAN3 M$`M3!-&9B^D`(1">1^3PU$G\QF M(.XQC[LS]D%N[MP<6B5='\[H`60ZB+F9;XS9R6;FSZ'-JNHKH_,TB'OQE=H.A=SP^8![DQ4 M+D%?R(R<0A,V_9YB[K8"FINBNBTR2Y=ZGC5`T[F8FZ2`?J1&B_SA=0*9I?"$ M/XV%`_:E"A]>*GK,8XP(&@_8K"H4YDXIL">-)C%X4`?,DKV,U04/ZFZ8FL:B M&S9^S0P>U`W8G&XIS-U20%-25+=$)E">4(Q8C&'OS&..Y`08]1Z9ZP?4PT7< M>V1"27_\]F'?'3-DNCQV!SR5M2L^\AK>G(?1X1#I3;3'%*/Q+5^%W#`>\54, M1T0W]YOU)3GJ?Y+R>,XKZ[VHZR+K3C(.15'K)F?VTB@XZ60_7*3Z4+<__?9. MP$$17-3%I3_W&@[?-O\#4$L#!!0````(`,Z)<$?E56_(2P0``'`6```8```` M>&PO=V]R:W-H965T&ULE9A-MFIJ#KMG8LL?-8"\@./9?[]`-PY)VD)SL4%^N_MM0(^%5E=;_VR.QK3! MK[*HFL?%L6W/#V'8;(^FS)LO]FRJ[I>]K'Q=R,0[\.!V.;3\0KE?A+6YW M*DW5G&P5U&;_N'B2#QL=]9)!\??)7)O)<=";?['V9W_RY^YQ(7H/IC#;MD^1 M=U^O9F.*HL_45?Z7DK[5[`.GQV/VKT.[G?V7O#$;6_QSVK7'SJU8!#NSSR]% M^\->OQGJ87"XM44S?`;;2]/:<@Q9!&7^"[]/U?!]Q5^2,8P/``J`6X!T!R@* M4&\!>N@4G0U]_9&W^7I5VVO0G//^;LN'3E[W2;K,03-DZUIJAL&G?O1UG::K M\+7/0Q*82)Y1(F^*L$O.5H`%%PY#.-POL$%%',]74&,%->U!80_9?+P>X_4T M7F.\?&\Q&205-H&2I=9""B'N"S=12Q'45#ELPC/F8[BC'^0T?1 MM".4Q-FG=J:J#:KZGGV:25@S"9H!AQF4Q$JXW:!,IYF7FY1UDZ(;Y7"#DF3F MTJ!*QG[W.6/-9&A&.\R@1$;2JXP4;)UAN"L4.0J11J>)7R7)5T):9+&K$FH\ MKYP$=HI(I$:6>&10O%7D1I:ZK*)F*><>31+&D5]//(@DT@,RER/4R"29,40Z MX?G@1+PC(I'3$6KF_)`J];/#>.3R@R*(](RC>+RWV@\HDN>;3,8K[3(U M09S+4T*>_`SQB).$)N%"+HF6$$5SCS8I$Y%YHB'C9RRA3*CY%,!S#`2EE7B0`5`EC_4/\"0#12D2EUE%TT+,W&\29J#\YBKP M,(,10"Z^DF@)63HS6T>E4K'?8@1XHD%$MAQ(VY`(_`KQK`)BE71V1:SRK,0# M"`A`T@4@$GVX^_=+\6@!0HMTH85$('QK\8LC(%Y(UUIM%(DHGGE^4!C%D1_L M%4\@17"1+@*1:"EU^OEUX9VK-Z7G9%,\KA212+IP12(M8>9?B(1)XKGJ5,"; M(K))UV*01!!KF#%%KXG*$[?JSLLBL5)Z+!P53S9%9),NLJGQK7*F*Y1IY=D4 M_[ZH"&K2XQU8\;A2A"MP+:U(E'F^(RB>5XIX!2Y>D5@KQDCJQ,"+(JY#F`:0)0``>*23[M.AQ;>.QXM#\U-8TM<%U:4FTC,3G M__;WFR8D!.TW"S2_#-(TM4%[I-#\I=&_<6GX!8:.^$OS?C\)14O-/0SA9".O M-/5AV.!L@JV]5"WNLMU&;YNH3]!O!'X8?Y8/&]P*?4NS7IWS@_DKKP^GJ@E> M;-O:3PNS;_C#ICFO<$,63UI['_=W;)O/Z?U!+ M`P04````"`#.B7!'6LW7?94!``!P`P``&````'AL+W=OVRC`.,"CKM_ MOX`OM:I(?3$SPSEG#@/.![07UP)X\J&5<0?:>M_M&7-E"UJX.^S`A)T:K18^ MI+9AKK,@JD32BO$L>V!:2$.+/-6>;9%C[Y4T\&R)Z[46]M\)%`X'NJ%SX44V MK8\%5N1LX552@W$2#;%0'^AQLS]M(R(!7B4,;A63Z/V,>(G)G^I`LV@!%)0^ M*HBP7.$1E(I"H?'[I/G9,A+7\:S^*YTVN#\+!X^HWF3EVV`VHZ2"6O3*O^#P M&Z8C[*)@B06!^(Z$>]NLP]P&T6",G%)+3ATJ7B,U6NQX;N<7:/0A.$KS&G"+`@6U&^V MX/06G2GW:X?;VP[7F-.,>?C2A*U&HL$VZ>8=*;$W?IS(4ET>UY&G MD7["B[P3#?P5MI'&D3/Z<#%IBC6BA]`^N]M1TH;GOR0*:A_#'R&VXXL8$X_= M_+Z7GZSX#U!+`P04````"`#.B7!'M!9&_I4!``!P`P``&````'AL+W=O-9]I-I(0TM\E1[LD6.O5?2P),EKM=:V/1D0"_),PN%5,HO<+XDM, M_E1'FD4+H*#T44&$Y0H/H%04"HU?)\W/EI&XCF?UQW3:X/XB'#R@^B\KWP:S M&245U*)7_AF'WS`=81<%2U0N?4G9.X]ZIE"BQ=NX2I/68=S9\HEVF\`G`E$ M]UDR/C9*-G$+XKHO-$Y]_3MS/]Q]KA]K;#->8\8^Z_-&&K*]%@F_3RCI38 M&S_>R%)=ANN4WH!]PHN\$PW\%;:1QI$+^O`PZ19K1`^A?7:WHZ0-X[\D"FH? MPWV([3@18^*QF^=[^VRC`.,`7B=_'\"76-5*?3$SPSEG#@,N1K2OK@/PY%TKXPZT M\[[?,^:J#K1P-]B#"3L-6BU\2&W+7&]!U(FD%>-9=L>TD(:61:H]V[+`P2MI MX-D2-V@M[,<)%(X'NJ-+X46VG8\%5A9LY=52@W$2#;'0'.AQMS_E$9$`?R2, M;A.3Z/V,^!J3W_6!9M$"**A\5!!AN<`#*!6%0N.W6?.K921NXT7],9TVN#\+ M!P^H_LK:=\%L1DD-C1B4?\'Q%\Q'N(V"%2J7OJ0:G$>]4"C1XGU:I4GK..WD M=S/M.H'/!+X2OF?)^-0HV?PIO"@+BR-QO8AWM]L'N(TB09FXI!8K[0OVT=YM<=;C&G&9-G_S1A MFY%HL&VZ>4]_J3E9]02P,$%`````@`SHEP1P!SN9R2 M`0``<`,``!@```!X;"]W;W)KRN(H*49%5M'RI5?6B?'1C`BNVAM@G=OU_;7(JJJ'W!,\,Y9P[C(1_0 M7&P+X,B[DMKN:>M#+&]4MS\.X+$84]3.A>>1=.Z4&!%SA9>)11H*U`3`_6> M'M+=<1,0$?`B8+"KF`3O9\1+2!ZJ/4V"!9!0NJ#`_7&%$T@9A'SCMTGSHV4@ MKN-9_3Y^K7=_YA9.*%]%Y5IO-J&D@IKWTCWC\!>F3]@&P1*EC4]2]M:AFBF4 M*/X^GD+'$;")D"^%W)+"Q4;3YASM>Y`8'8CL>[B[=>;@)(EZ9V*CF M'=I8/(3JM4@W:^W&B2S59;D.61SI![S(.][`(S>-T):&ULA5/; M3L0@$/T5P@=(M_663;?)KL;H@XGQ09_9=MH2@:E`M_KW`KW8F$U\*3/#.6<. M`\T'-!^V!7#D2TEM=[1UKMLR9LL6%+<7V('V.S4:Q9U/3<-L9X!7D:0D2Y/D MFBDN-"WR6'LQ18Z]DT+#BR&V5XJ;[P-(''9T0^?"JVA:%PJLR-G"JX0";05J M8J#>T?UF>\@"(@+>!`QV%9/@_8CX$9*G:D>38`$DE"XH<+^>D M^=LR$-?QK/X03^O='[F%.Y3OHG*M-YM04D'->^E><7B$Z0A70;!$:>.7E+UU MJ&8*)8I_C:O0<1W&G2R9:.<)Z41(%\)M)+"Q4;1YSQTOK@) M(EZ9V*CF'=I8W(?JJ=AD6&PO=V]R:W-H965TV':P$\^=+*N`-MO>_VC+FR!2W<#79@PDZ-5@L?4MLP MUUD052)IQ7B6W3$MI*%%GFHOMLBQ]TH:>+'$]5H+^WT"A<.!;NA<>)5-ZV.! M%3E;>)748)Q$0RS4!WK<[$_;B$B`-PF#6\4D>C\C?L3D3W6@6;0`"DH?%418 M+O``2D6AT/ASTOQI&8GK>%9_2J<-[L_"P0.J=UGY-IC-**F@%KWRKSC\AND( MNRA8HG+I2\K>>=0SA1(MOL95FK0.XPZ_GVC7"7PB$7P*TO&QT;)YJ/PHL@M M#L1U(M[=9A_@-HH$9>*26G#H4O$8JY=BL]WE[!*%)@Q?84X39D&PH'ZU!:?7 MZ#S1^?_IVYE^NW:XO>YPC3G-F+M_FK#52#38)MV\(R7VQH\36:K+XSKR--(? M>)%WHH%G81MI'#FC#Q>3IE@C>@CMLYL=)6UX_DNBH/8QO`^Q'5_$F'CLYO>] M_&3%7U!+`P04````"`#.B7!'6%I,TI0!``!P`P``&0```'AL+W=OYZ9G:\=K(>S8=M`!SY4E+;/6V<:W>,V:(!Q>T5MJ#] M3H5&<>=34S/;&N!E)"G)TB2Y88H+3?,LUEY,GF'GI-#P8HCME.+F^P@2^SU= MT:GP*NK&A0++,S;S2J%`6X&:&*CV]+#:'=(1-$"Q0VO@E16<=JHE"B>)?PRIT7/MA9[,=:9<)Z4A(9\(VB<:' M1M'F/7<\SPSVQ+8\W-UJY^$FB'AE8J.:=VAC\1"JYWRUOLW8.0B-F'2!.8Z8 M&<&\^L46*;U$3R,]_9^^GNC72X?KRPZ7F..$V?YIPA8C46#J>/.6%-AI-TQD MKLZ/ZY#&D?["\ZSE-3QS4PMMR0F=OY@XQ0K1@6^?7&TH:?SSGQ,)E0OAK8_- M\"*&Q&$[O>_Y)\M_`%!+`P04````"`#.B7!'6RX;7+,!```Y!```&0```'AL M+W=O[H7'@6=6-]@>496WBE4-`:@2W14!WI:79YI'(CIN+^[W<'!M1=QRL0$-9?0A.+)5Z_Y;G^? ML:L7FC#Q"G.>,`N".?5-BYANT>-`C_]/W\_T9)UP/[HGT=$UYCSC/E$QF33 M)!DSWG_@D4P>GSA(NNF13@+[#TQF3/*/"5O=K0)=AQ8VI,"^M>/5+M7EE9SB MT!OO\#SK>`T_N*Y%:\@%K>NPT`X5H@5G']VDE#3N'2\+"97UTR]NKL?6'A<6 MN_FA+G^+_`U02P,$%`````@`SHEP1V+1SE_``0``GP0``!D```!X;"]W;W)K M&ULC53=CIP@%'X5P@,LZH[.=N*8S&S3M!=--GO1 M7C-Z5+(@%G#F-P.'[(Q[(1ZG>=`M@T+O@G3[BUIC^0(@N6Q!4 M/\@>.KM32R6HL4O5$-TKH)4G"4Z2*,J(H*S#1>YK+ZK(Y6`XZ^!%(3T(0=7O M,W`Y'G&,Y\(K:UKC"J3(R<*KF(!.,]DA!?41G^+#.7,(#_C!8-2K.7+9+U*^ MN<6WZH@C%P$XE,8I4#M-7"$=(G6`IN?9?5`[:2#%3,!+T?1I9Y\=QVME'@;9-2`(A M60A/GD`F(Q_S,S6TR)4ZI^W?QP<*5$['*2'LUFU#[XLE5KT6\2W-R=4(! MDZPPYX!9$,2J;UHD>(N>>'IRG_XXTW?KA(\A8?9WPC7F/&/V]TUVFR:[(/!T MPV3&_,=)TDV3-`A\NF$2,&ETWR3;-,F"0'S#9,;\>Q*RZB`!JO$71:-2#IV9 M&FBI+G?QE/@._(`7>4\;^$Y5PSJ-+M+8/O9-5TMIP-I'#RE&K7TME@6'VKCI MWL[5=(&FA9']_!PL;U+Q!U!+`P04````"`#.B7!'DT=32;WW"B;<`'"KK%:A;;O`,G'LAU_AWU/QHZ8GK>%;_&D[K MW%^I@6?%?[':=LYL@E$-#1VX?57C-XA'R+Q@I;@)7U0-QBHQ4S`2]'U:F0SK M..WD^TC;)J21D"Z$IR08GQH%FU^HI66AU8A,3_W=[8X.KKV(4T8FJ#F')A3/ MOGHK=]F^(#4/G-$S.![PL>MK"#ZI;)@VZ*NOF+PQ+HY0%USYYR##JW"M?$@Z-]>&C MB_4T^%-B53\_X^5?4OX%4$L#!!0````(`,Z)<$`8``)&PO=V]R:W-H965T(2Z*>_?>;2P\&[!DZ+W+QZ]OT=/\^TZ+:N/VY=Q\;;-TJ=&:+T:\R31 MXW6ZW`S/3YOO?F[/3_/WENML4RSSS6";/9\-?["3>^-JI"'^7F:?1>?]H';^(<]_UQ]F3V?# MI/8A6V6/9:TBK5X^LHMLM:HU59;_!:5?-FO![GNO_;H)MW+_(2VRBWSUS_*I M?*V\38:#I^PY?5^5O_+/:08QJ%KA8[XJFK^#Q_>BS-=>9#A8IW_:U^6F>?UL M_V,3$,,%.`CPG8`P40$!`H)J08*`W`EP%A50(*"^7(H+:!#05`L&!`S5@@4! MNQ.0/"K@0,!17:ISWF8NH=I@NV1_95L<$?'I9IU\N[B(3SC[RCB7<1&?H:'F2O/B#!S[1D99FX\H\+,U#,ZS,P(MN:> M,6'FUC,VS"P\$\G%'3`FDHM[SWSE8EQM"'Q7<+\K1'=7<-#`"1J$UR"[&@1H M.,ACE[GPC"18D:@5"1H.LEQ7>P5M6C,ME(RX(MA1J!W5J.`'"38=*U>`:%G- MU"3,7;><%DQ$N9N6DXS'N2G1[HQH=TZT>]MRQB@6Y1:X?^$$:#0!&A)]4*JJ MNV(MPYU.OGG4Y>8X%_;(H!X9\,B$+5VUS%^,&QE/=@LJ9:*>3V/Z]D(,Z]O+ M34!?>"DLNA2V46-99"4L6$J.;*MK`+EP1]8"0"F3[QNP"\X`U$82@W1HD*[- M=\(C/CEP7JGX%IP!:)+]*,,^L01UJOFZWH4VXA5`W-GXKID!*`2U,AC#O?(# MZ&"0=:&%ARS)$,<-P9R*;;V%APS%#C[,&$PJ&TG^`B#*D&'X-&,PSJR(9;.% MG(VW<8PJ`$??QL<%@;E@5-G8%$%_P')JW8^'43W80Y7*%XRV>0XMW@J)CU[_W MKYK\Y0C)#[SAPTW!NYU+"IX'P`C<>*=F4-G=C(6IZ;N2R*X MH(+W`3`2)][">:"%,]:Q=N>I474<%.%^>L_[]5..]U,.K=(=[#&WM_8`C608 MFE*@!0)%7,8[,X?.[#1!ATC0\A1)C_(4>#L5T$Y=Y+)O`A`73&E%"5K@S4]P M/$][O=M#%#.!6S6^]5$FI\!;G^C3^@3>^H2BK.WN0"HD:2_@[4=HRM)J^M+B MU2_:>C4D3RV^LK;/RN+5(WSUQ,XU'E*"UO`D?JZ1;949RAR5#`U9LAXA2[QV MI+\T%)&Q`9",W\*:>UV<>):1>)W)MLYHMSOQ,I-]RDSB9285OC)[!P>`CMR0 MFGM=C'B=(_%JE&VA&BS-OC]&"7! MCTBE3`"B#`D5>+C@C]24QJ`T'J[N$RX^K)2AA&OHX>)5IBR8(3V.<7BXKD>X M&A]4.L'#9;P;+U#)B.*MQFM,^QJC'`,T_D1.]WDDI_$!I`4I8M$G8KQRM*\< MRDU7K?"(59^(`X^-_%6<#7>W>X`4]4I/X^6C??DXB@[\L*?['/8T/EFTKPT= MCOD*H-@U]7%D\0V)/$3#B]!`$;(#,UUHNH,H7@Z9/#1J\ M!@W4(#NLP>XCZZFGW,C%N#EP(AD=SN\][M;X:3BB7.,9O*@-%#6CS"F#%[7I M4]0&+VJC24L(E!B1;NF9P%->*&I&:88&+VK3IZ@-7M3&D6(&2H_$8`A+\M\W?PHZ#G/RZQ24W7^X>`U2Y]V'U;9"@0YM&=:'BT(%X6DK/3ORT52E$)I+B)G^-Z;-QA2^2C5LVX!#'KE3.@3 M;HWICX3HJ@5.]9WL0=B36BI.C0U50W2O@%X]B3.21-&><-H)7.0^]ZB*7`Z& M=0(>%=(#YU3]N0JH93L=W7?96)/$^)S8^8/:[CR%E@,0+@E@#FRX2O%4AF5P<_E-B MPGQ>(IU+I.M&TZG$E\\%LED@6PMD7N!K]M[BP4-$:"-`XET<1=''L'(3%MR0 MU0PYJ,;?;8TJ.0@31KADE^=S3OP=>(,7>4\;^$E5TPF-+M+8F^3'7DMIP#J( M[G88M?:!+P&#VKCMP>Y5N/,A,+*?7_#R&RG^`E!+`P04````"`#.B7!'9P6C M1',"``"D"```&0```'AL+W=O)2DNG(\ MUXV<&I:-G:4R]DJR%%]853;HE5CT4M>0_-V@"GD: M0B%XP!65O];A0AFN>XIMU?!3/;,GC*Q72"7"&B:,;#0Y'=%Y%) MFWYOTQ\WRU<9//>Q0-`+!&.!0!E8W'J,):11K5`0+PZF,;F6B9)IS%9A`(C< M:=!.)P/AXG%%H;&B4%FYB*]WWS_<46QL:)8*SSQSUP8M_SB^2V? M&!TDQBU_TZ_$W*^;5B3_T0K@&IW(\/SRYAHSNW8[#3*8<49'<(W(65Y^U#K@ M2\/4H3)$APMV[8DC_"Z^`&UL MA93-;J,P%(5?Q>(!:C"05!%!:AE5G<5(51>=M1,N`=7&C.V$SMN/_V!HFC0; M_,,YQ]\UQL4HY+MJ`33ZX*Q7VZC5>MA@K/8M<*KNQ`"]>=,(R:DV0WG`:I!` M:V?B#),X7F%.NSXJ"S?W(LM"'#7K>GB12!TYI_+O(S`Q;J,DFB9>NT.K[00N M"SS[ZHY#KSK1(PG--GI(-E5N%4[PUL&H%GUDV7="O-O!SWH;Q18!&.RU3:"F M.4$%C-D@L_"?D/E_26M<]J?T)U>MH=]1!95@O[M:MP8VCE`-#3TR_2K&9P@E M.,*]8,H]T?ZHM."3)4*0R:ZXHJ M*/)9@@W`10HR4:1+"A(HTML!Z120+0/2$)!]AEP[3>_+\)HLORZIO&25W<;( M+F)D`>-LC7R)X37)^OZZIO*:-%W=!LDO@N0!9/7-?N1?-OWKAGA-%L=G('AQ MU@9Z@%]4'KI>H9W0YMBZ,]8(H<%DQ'>FM-;<)O.`0:-M=VWZTO]@?J#%,%T7 M\YU5_@-02P,$%`````@`SHEP1_MM9]NQ`@``I@D``!D```!X;"]W;W)K&ULE99-7`.MGWWUW49#2"VM?^9%2X;S75<.7[E&(T\+S^/9( M:\(?V8DV\I<]:VLBY&-[\/BII62GD^K*@P`@KR9EXV:ICCVU6R\-1J("7I5Z7MRMKVO"2-4Y+]TMWY2\V/E"()GZ5 M],)[]XXR_\+8JWKXL5NZ0'F@%=T*)4'DY8WFM*J4DJS\QXK>:JK$_OU5_9MN M5]I_(9SFK/I=[L11N@6NLZ-['GXA:3_Y"XJT2D$)PV,NH#N6`5H7$P7R`V!T(R'NR*;3R*3-H.KS:`_K,`."]\7"*\"85\@ MU`+8_^@QUDAC1F&0!Q_`8)K*+06#))ZF"DN%(9BIN+$4BL/P?E_1:%^1Z6LP M^ZC?5V2]^--,\9F9](%&?2#C(YCQ@>Q\(Q#/.!FC)KW$HUYBXR6<\6*0APC- M./G,3/K`HSZP\1'-K#EL5Q,:?@8^K#G\I35G*03`3,4-_I\UEXSVE=A_QF1F MP(9),((8S"S.W'`8@3#P9[C"ZH$H3A"8YC96#T`OS>IM03=N#WOZYLV7G1IC/:A?M MCA@KJ#:Q07SM+W)_)%ZH(XG>]&[R67HB!_J3M(>RXF[J&B>Z%N8_4&S#'"/`AVNIZ*NJ-9]@]02P,$%`````@`SHEP1V/D MUC?\`0``F@4``!D```!X;"]W;W)K&ULC53;CILP M$/T5BP]8[N0B@I2PJMJ'2JM]:)\=F`2T-F9M)VS_OKY!Z(IN\A+;PSEGSDSL MR0?&WT0#(-$')9W8>8V4_=;W1=4`Q>*)]="I+R?&*9;JR,^^Z#G@VI`H\:,@ MR'R*V\XKVZD#OA%[D^\NJ70 MB99UB,-IY^W#;;G6"`/XU<(@9GNDO1\9>].''_7."[0%(%!)K8#5*B&$[X0^>`C^;62!0Q2Z=M/=QBD[C9A_I-_,I?E!CR$Z- MFTR1]_@,/S$_MYU`1R;5BS3/Y\28!.4L>%(^&S4HIP.!D]3;E=IS.SOL0;)^ MG(33."[^`E!+`P04````"`#.B7!'9)_#Z-P!```3!0``&0```'AL+W=O!Y)DQ(O[> M`^7C(=@$4^&Q:UIE"CC/\,RK.@:]['B/!-2'X+C9%ZE!6,"O#D:YF".3_<3Y MDUG\J`Y!:"(`A5(9!:*'"Q1`J1'2QG^\YHNE(2[GD_HWVZU.?R(2"DY_=Y5J M==@P0!74Y$S5(Q^_@V\A,8(EI](^47F6BK.)$B!&GMW8]78"CT@.Q/SLS5[#A1'1RDA:-=V2M,6CJ5[R M*$XR?#%"'A,M,/<.DUZ!%`ZRF1%8!UA-$05K#I%+<<7@+>)#@W@RB)=MQK[- M]'.![22P70ILO<#N=<:=Q?2N"X>)_^,K)*L>B?>X_=BC<)C=W><>Z:I'ZCWN MKO3A,%\6C;S/X3'O@N#%)F0@&GLX)2KYN5=N#\[5^?P?([N)7^!Y-I`&?A+1 M=+U$)Z[T4;#[MN9<@;8/;Y(`M?J&FA<4:F6F.ST7[M"ZA>+#=`7-]V#^#U!+ M`P04````"`#.B7!'/A1S@O@!``"?!0``&0```'AL+W=O*JWVT)X=,@2T-J:V"=M_ M7S^`I1%)+F`/WVN,/&G/Q8>L`!3Z9+21>Z]2JMUA+(L*&)%/O(5&?RFY8$3I MK3ACV0H@)TMB%(>^O\:,U(V7I;;V)K*4=XK6#;P))#O&B/C[#)3W>R_PQL)[ M?:Z4*>`LQ1/O5#-H9,T;)*#<>X=@ER<&80&_:NCE;(U,]B/G'V;SX[3W?!,! M*!3**!#]ND`.E!HA;?QGT/RR-,3Y>E1_M=WJ]$?T=WU2E0[K>^@$)>FH M>N?]=QA:B(U@P:FT3U1T4G$V4CS$R*=[UXU]]^[+QA]HRX1P((038?)9)D0# M(;HB8)?,]O5"%,E2P7LD6V)^=K#3<&%$M#*25DVW)&WQ8*J7+%SY*;X8H0$3 MSC#/#K..;T-R!PDF!-8!%E.$WI)#Z%+<,;A&W#2(1H-HWF;DZ-'ZL%PVS#[6.3>-$D=J<8!+=-)??^QR7K19#W\\2N3>-Z) MP\2;VY#<05:;Y'&.9#%',N0([YRHPWS;;NX<>[X`-"S=`W$;Q=AR'TTS._@%02P,$%`````@`SHEP1]:\*WC>`@``S`P``!D` M``!X;"]W;W)K&ULE9??CJ(P&,5?A?``0%O^Z$1- M1LEF]V*3R5SL7E>M2@:H2ZO.OOVVT#*HI71O!.KO.STM[4E9W&CSP4Z$<.^S M*FNV]$^"^.)RX;PM4B[.OV145J5M#: M:\AAZ;^"EQPBB;3$KX+D^:WE'[(AQ_[I1])#Z0D.RXEL+AOM.U!@2*;BC M)6M_O=V%<5KI$M^K\&=W+>KV>NO^F46JS%P`50'L"T!L+4"J`'T59-:"6!7$ M#SV$W5#:B<@QQZM%0V\>.V.Y/,"+P!LI(I0]UJJ).6!MXZMLO:Y@C!;A50HI M!@Z8M6;B<6:CF6269&C6TDX$YW8!*I=2R3]<]!&PKX1D:-V...*"B*74(29"95T+V'RO!'"I@ M-KV9UQI*;;'20RXKVQPL0"5"FMB62P>!X-'R_7)14H'+W$!SND"UW5,7"6!\ M0Q"XOR$X&ULC9/;3N,P$(9?Q?(#X"0-=+=*(U$0VKU`0EPLUVXS:2QL3[#=!MY^ M?4A"6%5:TA]C_@:G-_-EF:A!9!P M<('`_7"&.Y`R@'SAMY'Y63(D+NV)_A!7Z[O?, MPR\8EW`=@`>4-O[)X60=JBF%$L7?TRAT'(-U97`@MN?A[/*-EYL`\61B(\UW:&/P-D3/=7'SHV+G`!HUQ4*SFS0_9PWS M_(M%BJE(N2Q2)$#V#.3F*+0E>W3^G.*FMH@./"B[NJ:D\Z]A=B2T+IAK;YMT09+CL)^N M^_SFZK]02P,$%`````@`SHEP1S)(5B6$`0``-P,``!D```!X;"]W;W)K&ULA9-=3\,@%(;_"N$'2$F%BO-!KMIZN M1.!48*O^>X%^6,T2;PKG\)[GO'RTZ-"^NP;`DT^MC-O2QOMVPY@[-*"%N\(6 M3%BIT6KA0VB/S+461)6*M&(\RZZ9%M+0LDBY9UL6>/)*&GBVQ)VT%O9K!PJ[ M+5W0,?$BCXV/"586;*JKI`;C)!IBH=[2F\5FET=%$KQ*Z-QL3J+W/>)[#!ZK M+WJ-YDY9M@-J.D M@EJ M&^\;)9MWPHNRL-@1UXIX=XM-D-L("63B$BTX="EY$[/GDJ]YPWC=!WFMK_8/O#8CL]T^E?*;U!+ M`P04````"`#.B7!'7?GB?NL"``#4#0``&0```'AL+W=O/)85:SY M.^>E.$U]XO<3+\5NK\Q$,)L$Y[A-4?%:%J+V&KZ=^D_D<45;2(OX5?"3'+Q[ M)OE7(=[,X,=FZH^8*7I6'2RG\LZ:>F"1R^]^S?VG)U^J], M\H4H?Q<;M=?9AKZWX5MV+-6+.'WGMH;8$*Y%*=M?;WV42E1]B.]5[*-[%G7[ M/'7_9*$-PP/`!L`Y@*:C`=0&4->`R`9$YP`@HP&Q#8B_!`1=[6WGEDRQV:01 M)T\>F-E/Y%'#&T.BF3W9LNFFR7;RRQZQZK>B,"70M:$'0%T2'!8$5R6X3T)X@&A)02Y!?9IFVF+KKB,6$ M87@=M+2@>`RTZD`Y4(=\(S3?J.M8/J(RMYC;$C$J$5L).$L"SL';,8*2G%N22*&Y98JV640>*"*\UNJ-6W"4DQFLE M<%%LAPH?8@`BV/`V3&`.P9ZQSCL0L`=`WBO+QI0Z4/Z_4#`X'1_8CO]DS:ZHI?H\T5N]@]02P,$%`````@` MSHEP1^PGSA4^!```VA8``!D```!X;"]W;W)K&UL ME9A=9M=UJ_A2_+O/YO MI8KJ=#^C,W/A^_YMU_87PN4B/-MM]J4Z-/OJ$-1J>S_[0N_6@O7(0/S8JU,S M.@YZ\2]5]:L_66_N9Z37H`KUVO8N\N[G0SVHHN@]=9%_@]._,7O#\;'Q_C2D MV\E_R1OU4!4_]YMVUZDELV"CMOE[T7ZO3L\*I@(#1-!F,D-&8W#:"891_FDY5%#U`EE M&OHGHL+)/8$JK[QB-*]8RY&18_EBN"U3MYH,YZR"$E10,CB)$L:.\EB9%`Z40*';DK)E4)EYQ*$$##9<_EM)5 M4\#0B'R^X2\464"[)HIK,DW6=6<`U,4B5T3AH%T4PT7ICBM=70&8*+ZB",/L M>O#^3:&!D\3#Q;F?7CQ#J&FH'AV9XKV2FK8D[??/,T#>&X"W+PH])Y4>+A(\ MX>2&A/$.0"5>F>.$5P!Y)XSW`*H+G(Z>=_8A@:`),^*?,,.+D9EB3!T[;"#? MIL?P&F-FJID,)92.5Q\;1]#]7O@N\ M7%`6\7QT883<#&Y^=.+5QR`YLP.90AD%X.W44Y!S&0O^^\F M(S4PJ\P=DC,$LJO!&RUGH"9V;,$9\I@PN.4EDX,+CV"%)Z#P*'=L_AGR*"F!EY2`:J&N=T.`!/)Y(AQ]7SOF;^K? MO'[;'YK@I6K;JAR^JVVKJE6=&S+ONO).Y9OS2:&V;7^8=,>U_O2J3]KJ:+XD MGS]G+_\'4$L#!!0````(`,Z)<$<<8EQT=4```!X2`0`4````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`8C:NTTOP,+E5UE\ M`M^L%V;:9`\F7^VW5_:F>("M])S7^\HLTFRFS><%@K6FVKMW_Q[(! M/%K_SOL*R&,%IXR3FK\NLP7>L$0#2+H+A`._RQ!B/%?O6]>`5776A*MI_T7LS], M1H<`.V:P$FB_"J@PU3@9'YTEI^?/Z8V+Y.SX*+D8_]/@V;EALUF&H`6<1L)U M`.1]FBXRP/&>N[B<+W/B#P*^_KM1[P3JSGVB7>PVQW9<;.]]BK?_WC09\.S] MK;G:Y096T\,#PHN9>,S9^&8'F;8=P6BR[=OEL$#0&=)__=9=F#4;CE_;N-O> MU_NWVOOJFGT.H,Q-`_]AV@T$YAVP6]KY]B+0\=9:14=`^F!`J%B:^KL>OC]; M3ANXQ_S"T/-;8P;?X6LV]/2JK*T4P%L&$F-Y[N!R\/5%\.DI3M+=5`VR\?2> MWI[!Y_.2I)8N9/*<"!N\-D^K3Z;I.;37IC`HEN-+Z6R>%23K(V$;X/=KMM4> M\6-9P_VNRKE]%TZ]1ZH"]`=U-BNF95>[<(_E&_VR!8_5>SE\L"-8_@32+3[8 M<"WU+'O(`'\["'9M`'MG[K&&*S$!H"'U)'B@^%#C5;XU:;.L>@4N0W<=T'\Z M+&WHIHPH0^]MMYL!;M54V639D`0/(Z=R6?&6"I$?'`N'P2]N,PMF6B>B&;H)=('Y(B@X+5S%ERW>*+6]$: M5(!`GR\?`UK3IR3I6WHGQ%2\-LC>>\71R]E?EK6(HP`T4*5*D$0!@H6%,/R* M?T]QR.*"59!LN M$U"AAXQ1>1NF3-<;7TXSX4T(]-J`2D`K\IA>E%T5WHZNTYS&+7HULUX=JWE+A#;@*'KR6JKS[>7 M?)L5($'NLN3%%_78"9 MSZ::9C5?%"+ZY:*7+<9#M[U3\2B4ZE+1ZUJ\9H>CV0;,.'QF@,T!%(BX]UB> M\/@2X)QW65'@;+@H,F#VOTB<=NB5F^5BD1.=!PX\R^HI$%T`$#%8NPM8A[,5 M]Z(2W70D=)8LKOT*6M-G2T;WPA+4;6!SY06$%O_'$W24`UG&AD.*9W+$?)N! MWH+9+Z96AI50F"O$FM[9O-S4.^&UJ:=5MK`"SXMEG16F9CKX`M@Z<>;W:(\! MN/8=SGBD-\ZA6G.H@1$*K=-F!J):`;3Y33$=Z;W_^,=_#W[]CW_\#PTX`)=3 MP0.Q!,./^P`(G9(@@U>6='"1;/`-&)""S%JK6[2^&Y(*\8('XKB(YSF(TM4* M%S7+TKL"P`TD""26)2M!3:D0#S,>/@6!'35ID-<+^!I-`R/O0=YOD,_FB.4X MKQR8`N0O*Q331NHCC'?K_V^U?O'ZK7X-!!HPLS@XUO_[?^%'`$>K$OX.W]9` MO."^(3KA0D@,G0+S(KR^JXP(5(]9PE*T!C8,<$K'IY"UK.KPQ8:[JJ&:*/69X#D7`0O:;#DG_%S`KO'W6M'; M]R!OPMNF(`V@6I05O45[J$H4+U'*QKLY);J4IQ-\!31C@S/`*W>@=#8$^L>R MRF75_J.W2#`-A/QX=[G_;AN.!@Z++<,@[IRP]7?WCS M\>751X2W_3_5B_=T!"A;T2&0;%RDRUG6,*$7\78:BK=";])457 MSE'C;![L-2#D(WU)2X!MY"LZEA7(J4A)$0/RYR_'U"X,CRIW#3&+TW[8QAI/$Y9O.I[H^^@A&K4*6BO$T*2M*:EIT6QA-&] M\\!6$GM,Y0((!M,\3S(2!20:KQ5<@ MOA#/4_4"!'5BL[#$:6`(`PP$F`(@'K)R6QNPU8,K(R!KB]F=%[FMYC$-%J9M9BK01# M0\8R$1LPQ0]T3`@>8$HLAXQS2,BRNG&DP1DT`P-`!&\>KN>P:+B#&5]8`N,= M,*4[6*4NEG3Z**F(I:%G@GYS?T)<3P`[6TZ9\J$B@PHW[KJDBU@#LUH#LQ%` MID)G0%D$1$F%X$H'W0&6UK1!I.1[L^S6NF8FIGDD/@>[BT^(-A:!13':L8#+ MVW"(OX2%1B(>4@CQX>4K%5IJ^D!JC<$.=B#S,\>R_,!^',Z*-]7%*92L!.:1 MU,+[)YL3:L&(*G#[@;_6B/4D+"'3+Z>P7IW>`D6@#\;HB(Q2`SK"\N!>&_I\ M_U6#AXP:BB@;:3SA81FR]TT-7TBX=60@`^$]A1-$;77N6",(&T7ET9Z9OEI(8W8*22'?OK;O!RL%#.@@JC!&X/CR0X0OB]-KTL MAYF2I;26F!8H%LW9I#Y,2"M24!S]SW+4TD%F9E`(A[53`V0FAFP>1%7MEU88 MPV$8G=I.M%,%+^&+>/*EF'%#*J\[SV^7*%G2K+2S&ED\#]DD,(4G7X/,E\]P MP1@%I5A8^LNR("3S@LWFB9Q,H7!YANRG!:*'%Z-"0G#)/)WC3H#WJE?`>?7X M\.!?.P`S/4['D;KL8Z8Q8[M/A7\V:*U'N#\[&IVI.8C5L+D$EAQ98^W=0<_O M(A$.XB0]H9` MLC\Y*T)H2E->P:<-\*CCT6%G%![EPEJ2`"7,9QR_S.I[Q!(/46TARI?4229T MAVHMR)2A,1"Y*FY%X0[\`KJK#,P0#J60"M;&('M6?(%BHILY\01P#RXYJ;DU MVRJ\PH:3(V*`4JD"I?(C&B#(3ETCY\*W@OOCAZ=6,<>#=#H2*$>O6VK@2`<. M(RRGPAIX='XX. MQV1^5,_&YZ.+0Y+N<"T$*7]'BU3X89Z!DBHZ&HL.>-+!J8>KQP]:<0T_=_1\ M])RC9=(%RHB`!M.*'#"`9S^/;D8)7"A4[!";WMUG);W["Z+7G[/J#G2G%,`% M^$;`8^IP="QSJF='9Z/CXSC8(Z$OK4;J)J,X"$>"QM&9A*:5;"YF1*)$M'Q[ M'6"NJOQ,D@1IR9!-C@^!S"6"XS5$T/5!X-&%[2T`)3X M,'*3/B#(3K6!#Y8K8^J8M#1E^0EH4(82I%D0X;"(RS"E+W?=NFS5_]R@21;> M4$1VJF7QF"*)A:<-T.Y%>,5#LUF>`F>]I\U:,XX2,V;==U>#TV:T(3.)&]IZ MS'+AMY"5]1BKF.!& M1P:W'$Z=I"J#-Z`022^&!?I7:A7Y[^',[M+"4E36%^?E`PH^(II:W9N=9"B9 M`-UGX0:U!;RLQ,39`XUA<23MHP,=E/L,T"TP/CKOE9JB'0=-DU6)!A%`FGJY M($DF,ES&H`?!M[1&V?;1D?RQ$LF;EF#G8Y7%;QEA7TLP`VCN$Y32P)HRQDD M?BV5!$J`(KB<(7'P1L/(7MBS,-S&A+@Q2TK$NUL6561^=$QY.C&T."L@(_"1 M<@&3MF;&4`5P"[3K(J!96V)MJ?*KZTN@_?8N@\8C-@MY'./3(Q(QY[=!)@P@ M0V\\4JFTJM#LQC()&W\(E98-X.A43IHX.+[.]@(5L]/H:UT:AS[P:D94F:)$ M0'<$*4*1,"#DDU#&+\? M2:^U_IRB`7;D8K<JCA1\4I6??$@BNQQKYW83"'<`H,L)DR\5'A&YHM%ZB#(J?K#BT!!Q MW!6ST'C3QT/6\(X3ICT*6->O"R+ M##V7)O4N%1Z@RL)XLA)Z-%C/@:?W:7Y+YP/PJRKA>I;2X1NJ=WR"A"GU+P*# M$:OJ&"@;D3.[/(7+8QZQE\$&QA"ZF MUP!6%5#L1_PAV-AMJ)_$D!06[B'_2.9SD:^$O[NI@]AH0*#RD:[GO*Q0$8(C M?3YZ_ORW?6I_B$&1)S4FWN*##TP-=EDC_1(//-JZ"IV.>+RW2UP5$*2#VR69 MD`=.V6&)^C(LZ1_/=$:&`/]F]DMP(:&VM3AEW]QGG15><_&#/8=.G^1/`''U MQ[6P08$<]QI8_1C\B?C29FR8HN">6L):K39O":UV454<_;[()5X&%]C[$66YU(R61X8+1-RTFC'E M##Y_%G@EU.!V)R"4%N$&$93O/EXI_B!9E>"??WHA>I@&J;\*2:N,K"FS6U%\ MV]OK$4:V?:20M-Q1P,ZUBSSE)&4,;AS>Q7L?,Q)A5DH,B,2C*8XTM&1"LA$9AQK,;7$QB+_.K!&ZFK M%*Z_$D]Z(MKYJDV-05J@$W(^+PP'$W?V!"1ZNX&$C&[`9\AN)O'FY@0A*=IY;%ZK:^%;>$I'@VN;P)_ M?$'L9`2^7#H0$+NB@FNAI5DV7@T#+'^/D,J<"#Z\/*DLZG9H8X0L%"/G[K0"1\Q@MET64`8X!,URJ=J/87R>TE=B606**02C%*T"&B;^`.`X+8&C<' M+*"$B5[;-\=IDLCF289:8(R.4!6>SU)FX2=PN7@_UBOE)B87BVIE)=;:0T-$ M"9L(TAHI*U620M-=+U^>@*5PUA&&DJ84Y=E543PI=.HB>7_O2K%A3$W%"4QH M`TQKN)-D$Y*8DEL$@8A)FX)OU>80D)Z83E"BEO/6TKOZ+>-EW]H]&[C2@ZPG^*/);;2X"A._A2%(C"?PFXJE?4O)F53$(;1TY=-VCIL/,5S` M-Q.\2\0HW1)PD($)T M\9:%.+^:E0I3&9IM\:53M.8F8!*7+B)8OP=LF/8D>1R-=/\(94',A&AG2*TFYOF.U*$`9_J95J3N\!&KA'A M#[T_S'_K[Q6IGBXY@4P>4QLL@U)95G\BR*/X@$\7>&`S&@<#V02'572LY7AJ M+`N8+%<81%3#??F,FGP%PH+$`@'.?"^*[\,^@#Y'E+('1($)*.;$K"8(W,@P(+Y$?9'"S M5<^98)@)'8HSO]MYHO6@D%L"944BPL&:UGY-$K>,.9BL#ERZH;-GJ6C-]7VV M(.=Z0TB%D)X=4#PIG?]("6;S28H!44H+->EG_#Z?N&6B7MZD2PW?@,L[1VL/ M!\<@%2DD_4H*&G"\3A!B9">D#WB[)6!L3V$:T0_#CS!=S0W*0,I_T7UO!:)F M1=G-8JV$N7(>&HC+E8D^;6.#T-+%X0%UK%K,,@H<]%&GA2^^%.7>*E][J>(( M)ZQB0Z^P/%`9(,&%31N(;)CP`>6EBQF)@((!+"@EHH#)#)7D`]!*6#F&J\ND M'=@(1J3,TP*Q0`R$A='G5L']@\$@*GWM[I/ZT5V](/'J#]<_2N00YR'4':DQ M)[MRXY-?Q<+8R69R]/.5,9ZH#MS$1;><@S,)R%VLE3@2 M((3Y`0-YDI5O_\__A&?+S_KF,E'X//B-7[K)<-Y:3I`BO_PIU@J/CF>6%WD4 MKO(R1RL/O4!3T[_Q,7E@;3`WK]\Z02J\2C95FW8/LC4G5;7,4I:!^[@.-B[0 M(,Z;M#'Z3ET)SYG*DX&0@9]N[JT@Y.,"`I`F%"3'$JOW<%D/3D9Q5"6%7B=\ M11C(1")#&`M1SEK2I,"Z0\6.IT)U"NB;)Q94+8$P'4EY:[>L3'^^RZ;DMDTY M4\/I+Z2EHP%9L7&HN_=`JG)!!&3_YG2BD7[K(IY4&'7FF35SJ$<)(G4F+(P#SL3::WI!*0E?0',]&>J!2'_:U$C_5`*GO0=&5M>] MP3F"9+PKQ9JUA"#9F=%$'B1BN=0EV1N=*8EU.<5#UR*7UB#-X2,IWK/_'?JP MW+8^4HC&^JCM$WW96N,.H^0[/VT.#N]^9IM!';E=/]-GST_Q?\^>P_\>)4?' MQ_3?\>E%/T_ZCW_\5WUT1O\Y/U5<1J<[&_VOGPW^JUQ)1/^7SES^C[C"D5E7 M;.)#FT@E2CTF)DEXI!/`(U$0#I"4)T<'BJL/T#U1-ZC\XM<+Y>MM#2;`Q]4MJ&TW*C*C"_@ MLJE$CHI*Y&2UU+-A+D:E@D*C5'L2YQ4*)Q'V]RBU=+2MI>/MSE%5G2A7R[)7 M)FBQ`,*1T4S.FL?R@"Z`XC.F#:7YE&K0$;OM5-[I@TG+KT6L5L+WAJH;)6U_ M:>']6Y'W+/805!Q<*P'&I+[9N"?:I7([$JREM/T"B-#MU,@@6VV,J MW6!0"L:)]4Z_PAW=&]/P1K?'L$/6L*GU(LWQ-2:61_@-< M6H`4FS8[6YB5AOE'!B4XC=-RT=@(/S02CB838C%U&%7.,V#Y-YH)(H M#3-+Q(#*_"HXQA!9"XHC8M^GO4X>DIQL3TH&:_"!$Y?@4B_G&!_W-[%L\>5Q MQJ$.#JJ>W5N4YR!`6O)6>6V2(/R=8B83EI:+*95J^/D$"@:5L/;.TJ.GY_SGR?)R>&8_SQ+SD].]+X: MJEP&+\.;Q&C<7VK7\F6XCM/#(F/Z>7)Q=I1<'!YAT=##D^1X?`2_'9Z>)\_/#N&W MPZ.+Y/C\6'U])35E/PEK/AS9/<%?%_:OLS/[UP5NZ')=K66?=^(OFO,!1LRF MYD!QP$N6ZEQEHM85#(B_:NUT8J8I9I\U6'R!8I`X!X1]01A;SU1KMK0V09NW M9J6U[]3`15+O%K8JR@!#.'O^/#D='X.D<)*<7SQ7OVQD(8#`QV?)\Z/G^FA\ M!D+:6=MV^PK+E_W9QJ:]^M]],Q#GM2J\F>G`D^+CI9F# M9%50`2Y1_M@E5&Z.9,6'`U"%*+=-LI&URXI@XM;ZTAP^Y`)T=U]^+JLID[1@ M,QPNP=B*(V*CIL@XG_[+5EC%:<;LE-"4ORF9\Y@`>(NN*V=&7.D]BL/)&IYR MWX9'^9ABE,%1%H\\J^)JLUS+?$F7^?&3.^I5X24B(.-R>O!P:DY!N3-T\_9'"L>X!J7["HJ)VAT MI*//"J`1DA(`%_2A+9`A0"ZD)'OI;:8 M@-=[?L35Z3$PLC\M2[:'D&F*2(TQ?J4D])YD?U+2M`911Q9"/E MPECI_@U8B!X#1'_NHJ9?H"2>\4)@;$,K545I;YPD"Z\$F>RPP.,G%"\JA:FB ME<5G_7'H43A%>*GI)A!Y%'K3=WV0``8WB(T#M1TL82"T>]J%RNH-FPA6T$]1 M%%$4&POS9>1#R9M]Y(,`Q4+5Q&!5OUJN$X;9BQI!G&7J"X/&>[#%5*+@"\:+ MD*BW1%B'1ZO]S9H&,J2N1-.K871T"M08E#>>!/9?&[K_3!^/]3,2EVW-5+%G M6F&M+7Z[M;/-Z;EZC39=&O?@SG#=.+UWC"K'WOESD#Q?QJ4B:"6RGH_WMKH( M&ZRSAN/U_.HH.L%5.8D6@()HY#:S14"F5,M9PDPM?]T+8K(DKG>7IXZ+`KN/\^"D2?7NB3BW,5%Z$ M\PM4:O@_V^-0_[>CS,06IJAM,$4/8TIH1J?%#-\*7`:M#W[)`*+(9%9S_XRQ=/I3\:`3K4QC^\,E$/Y]=)!1^<'"+*.HJCU:R M[,/1X=%O$U?^1SE;PRJC?"QX`QX_E%A&B0")R6@E*>/GQZ.+WR9!\HSAHC.* MICTZHHHX(D6N/Q@F+8(?MXK$M)4DN$:Y4WN8AK=`II^NI*?!/3\D=8H-RC&X2@5%0-"+*N2/I ME$*N'#2=+0:&(]$2C*9E:.>>8975P2DM@D\D+-@I"KA)`UC`BQ*'1P/]JFUV M;J!M)TITI_23D9CJV$V_8?EDAU!J84BFJ)*"K7L+"8$G-4`,6<47I^J(`C!MU^IN\F(%D'E^Q MT4)!8KR-CD2-SRIJ^)3^5D=.=PVM\T*LX@_6PE=$;[$#Y=1L,;E09/_+V-B([DH"$Y0G1D`*Z:)MOE*1%7YO#W% M9#>1_V*P7;:%4DBUB`ZTW^_TWGB_LR)E66&XM+VC?1=H%ED=0\YP?(9#E!UR MO(]ZMW1]DOT,CAV?!)]3>R?[\6;QK?'%"'G$WNF^IWCA1!X486PL1PRN6_GI MF.:E>,VS?;5A;MV:N[U%-?"14_@(\*@F0"J"N16)+-]2GF^UL8>/T2'8,**J M%J+V'S2+!*/CX]9!JPT'/1Z=GD1#CKN'I>2P"*@G&P^,('0V.OIM)SZ9VO_] MV-.?X`3PW3[#&KBOS*3BDF%\$X_69[0'=?]45*5.#,U!_3H;Y+.NJH)Z-CX, M:N2AG":)EX[VVY@EH;Z!W1/##%6/W-).1-;]BK&BG.^ M?L9$$\0IYZQ)VK(8^+FXRH
*8&9W(!#OX9XT`0.N#2FCLZ>G11V>L?!$8'45A2X4+VQWDFMQCH1/SD]4MW MR"^I5QZ%X[@*V1PAB;"^PH!5X,OZ15I\TFO@HH)B(6%2"`O342YTUG6/D,]% MN3(LWA#;*A`EL-S43/,J;*;9?OETI%OOJ^A]]8HMZ4"G& MBMDY$(U<27(RAVIPIDB&VP*5*8B!I(KO*2DJDL"B;`)+*]8%_8RUL86D;(=0 MZD0@0C:AW,S@`;`-S$N9%`YM!5^7Y4+N3ZKJZ:1X:O)#\4AT$?I+[U[Z*L$S MFD3Y19&EUK8*LO:FOOC'#,D:2LR\SEQ<6*$_RM5B]N5.BRAX40P+M`^QOOM, M"[_&D?JI=*["@)O'H"1?MRP\;7HB+!)QO55&$!.$403V4^GLI\=&C$?VJ9CW6] MMM][.]]/I2VD/U0BK#W1.8HEZ^=20W,A<>K:XC>6V5/=2F^N`IO_5&^]/=6; MWMY?;X]RJV1Y'!AE/_)&W&M7K#"QB+_X-8KS=9:OXBI]0:WPWDIPOB2?52#5 MAG)\VVB.AZ-3ISA:&-#ILY,]&V,C/=17J+8+!P-\JK$RXVSM^@ ML(B@F/W#`O`V,OMV$)'7UKJSNMS08-'J^DK@L97+Y1?Z@'^G]GB!T4,F.'O5 M^I8O(=GZ_4<[#RNWP*.DK#R;;$C/T^CL"%08;QE$S''M%R2>RP9@U:%8VTZJ ME4@$-I&W;[1;$ZXG="$V;#;V27P<[2PII.+P55P^VCD8)Z;:' M46WC8=1AHLYU6/X4H*3(+VS+$_0%$_00*;M4%;G,O2N+K2L.:#:]9RWHV!;` MY--3".J`MRB75!!F8F8('R!3V8-T1`F:G-3*IIB%@7KN$MUC2%S+`!=G*AN; MR]L*I%E$&81"X.NP2K6M,R/A!!;`\FJ$$A.#[5FLQ;Z6X[2N/65]!,X;$-FC MUJ"D_9;:&?UTC'YJ!_0;2J4;1#_U\T)\PACV$,I7:UA8B[QR0H5-**&\'$^_ M(ZTFI.`VAA%)W"!)<809@7@@+A(O'?@0`.5Z>83?^&==6M5?`G<;R'$I6-4J M!1M'DJPO!:MZ:I3NR)55Q*>R(E!EAUA-S&74=H56`WF(1@62RDC=B&EYHPSX M0?J?.2A2(#5#FEB>3)L$]XX%4:XO@R&6N?5ID]P0*AYGO<2X^CRLN+U,"?3-L!752*J@?TZ4+WPI;F,820U<@ MMO>WU9Y*P-$Q)ZNV8!8^[A'28N%<]1CN`PQL/6+AB>EC+/Z'^-%M;F1MX9+* M$(J,/99SO%S;5UI-=$LW#%_!.:F\Q9+MI-1A.^$J^M-E3X6YWL*KBD`_&JCB M[8ZT#:UNR<)P.;[A=Y3Z1M36ZQVJV=&YT#IM%&(45E5:60&&VEG:9`:L4;&- M6T>UW3IZ![>."MPZNNW6N;QSW/''V*>C7CN?SO:^''(;"?YVW3G:77AI$0IO M.4\?UGK=8J,YMJ&3>PH726V6N!P("%;;@*B-_?`6KE+N5$NE M#F^JK63UJY*:;AJ-PY/V-5`M/E$[8'AW=<]$O?[#CE_+4JD.GJ\I:]'"\^A& MJXTWVFX%RUMT=Z)V]N;M^OF6"Q$5<6\M]J8.>%:M+(_=1;X4O'(>SNXW^U&N M*1-QV%JBBAZ!!-GA/&O:6R<$[2YOB*E9?X@O&C+2/SL7=A@^%V`;S;Z]K!5+ M34D_6KG3]`?2I=XJ;L#'JETL/5G\"6U$+*6FO0RK3TKMD4QUV.O/7XZ=.Q!T M*P3'"[#R=%O8<-`>-/\E6YP(M3P@;]M2]*56>*275B/#L1VF>H8-KZ<+366A M&8G94FS)MS;N#XO8(#<1?KZBQ*E+O&%SXX6"-9?4R9*MH<2:UDM0J?2AZ+.V MV;YB)/%&)1IUY!&(<+$/[ZQYH(7E6&D10U>E(FP$-A=VU-8K6@J#VE[=ZU?+ MU("Q=)R,S\^2H[.C=LL,S)/+[HJ@:X;JE?@C*#?1]"SJ!VJ!BE/GO1V3W9%4 M'374WKMF?>^@C&ROZ;!R9GNJ4&[CVNXK=*$249@ZRI*RU"_1[3`.RD#V\1LM M"(M/JV4Z3[QRR#3ZZ/E%,KX8;Z/]]8+9NJ2MX2F&A1*:.-"NU>%);%L>)R?G M)\G)R;':3*]L/;6>^!%$/Z(BPOT]<"3X9S-[(ND>QW+<;!(&S4IM6%!=1$H"C;C:+/ MLKPK"94=;[474.$H*].`R$Y6_<8G:OA_7(-L\.B<Q7-OO< MU\"B;NE`FBBG507>Z^WE*K(KBW!&]EB6(OBX[K>%*`6O38P*P=JJ>$(+]6"@ M8LS%P:>,*DQ(55'*2*.0XS*TPT7^8[J8+TI,F$;THD1>U"1M;]H9%K'B0)]5 M\#T2.6B:LE*M!`[B=4-NA>`0\2AX>2Y),/1!:^^`(_H%Y/)6V;&&E9_PAD4$D/J0\\CZ."KK88 MC6*+9RF3[+P2++VN'J),QS[S::]P8@\Y>,#MHT][Z7R`Q[^\[G9I:Q_`<#\;!9>YC98F'K+@>+ M-4G0$1X$T9-#+OCAA$<[;U>/'D`,)6"0]^O`M1G& M+W2#]6`#T0G3[AK6(>X,80`1-2GQ3P6[$G=#Q`?JR4MH[DD_&6N>5*P$4^"7 MM&%-=-=J\9VOGX0OS-!)DE,U,B#MCQF+=LL%?1FJ\._6(&H8;=D%<'O-;45E&5(N>:_V85P.36L'<&GC01)#+J,[E5: M?.)4SD(0$/=>($>GA%(O_O4C(,LCKO]\3`7M:LQL"XWB>TL6Z*29<[`6FJYD M=\R=.&0KX,E4$MT37`E1KWN40W8X*VLB9T:`(/X^W`1_*=Q2C14:9"J21U0D MC[20S`KC]":*W5SLW6*^-(&8BGTG2"07WDB!?2[N* M+0HB#[J.U#J0!CG?(_(@NA05VX)N#;UQ9,8ZZD(=;+.HRN$[G4PDWQ_',[F( MJ;7"=$.N5D=LK$Y:@JD8WFP3;!7$.=A6TT$P9A#;>(D.+3Y*D`H.;`<8]%`U M1L9+G^V9[8PA7:D[5J:6K$8`=]:$%'D=HUV/5*7/D2]V5#;SA82B(H!$T]K M6B5G^\-P.$@I:BWQ7(5!: M8&,@!:-3JH[839$O+(UUD2B]>QT43$;2Q:WGZ_$VE8;N0/Z8R^5^;Q`T4>M MOZ4?//R%WB,E"4[%UEG=BG9T#GLGVJ'\JE@.$`?).C4()08K+F1%8-ZQUAV6 M,GM,69W8#HNCJ6\ME5-EO9VB*UI<>MA( MT*/G3D1!XQIS8C<3(9=U3[[<;,,.K.OM^*"I\7U=UDD"(EBRBQH=!IWH[!9: MNJYLR=I`HTAF-!MD+*M>B5F71>,P`@,]#38"HQ.STDV#`+J'60<['@79VGB5 M`&U,GDZ=72.PW0=E5KF1)MHYT-KNVG20H4V.PGY]W?4<88U;CB#-5YU%KST- MP2'58W853+"^%8]*C-NQNB4>9,OX)P;[W?';:"=PTW!I;*Y3&:]QN-.HN`;% M\,@('""T3*=:6QX$%A;4M]*0=,;`S_?M*KPT2,)J-WOPE@J(ZH`G*,!F5\8S M,E^KT-+:A';HLQBU8M\A:G<@'CP6020E&MLJHI0 M\D8(%,#OD#2FH0@>WG/8(/6H]#VP\=^W9D:!D7R:""`TQ@$Q6N;BV*S,'3E2 M+,T,T,"]I,.7!*`O+59@U%A+.@K,#E)WUS8#'^DWMVW+%RLO++-)BS1OB`5! M2BUW;H5&W9)\%?);##,(@R=QP2HZL^"X;%4"=%\9V<](W_!- MH5N')#OLIL&]VEPPTUH_LT`PRGKDWG:NASV+K_9@>OI)XWL43?')F$4T2B0_ M/Y9TW?)6S#O`,Z3$JMK,0;RWX^$L)W M3D$]B7G&$I]28UMMS3G%JJ)T4&;)XJ%I/#C:F6_FKG(S6U;D8U: MO04?,O,H?7D'R\E1QW,N&>/[UGC=/:@WBWIX8F_@A.R)CY,O>$8\ ML9P%S74KSB!'07&9U?>^SH]+<98.9\)J7(]?`4VP4A:Z4FQ)EF<-.\NE1PW? M#%L]L(X]49;F"@U6[CL$I,=[=J=EZ)7'+BE`14C`I(KDKK9=[B&4*J?V/["5 M$\D$J=E4=%+D'%+[2"/&T?!]=8T-O(ZA84*+8:#$]IN,)6E-C;KO>\349O MB[@I$L4LDJU-.FP19+=2Q2WI_0T/;2&!A:_NN%U)7<53#._$0.:V=IG;\^FHBJ6^.**1LL(3^H&%\QZ;=>L_^M=\>V6[RM^GY4_/NI^;=3\V[ MGYIW/S7O?FK>_=2\^ZEY]U/S[J?FW4_-NY^:=_OFW6T-XJF7]W:]O-MP^[+6 MWJU9].=Y_EV]2*?F]]\L1`[[Y@NG?NH:_M0U_*EK^%/7\*>NX4]=PY^ZAO]_ MTS5<[VQL_HB'VC4UW_B&DQ]">?;2-^G^@Y?P;T()_YV3\#M2TBX:A.[3(-1. M&H2.-0CUI$'\\S6(`'$"87[-6U?QY?1RZ[5<4R<`+ZP`O)7<_,2:GUCS$VO^ M2M;AJEECL$_`:ELW>>O[^\,3__^U^'^G80VZJ?]L0Q!>.6/?FZ"9XY`( M$);`O<:*V'[0.G+NPX7BCPNO_Q?7-M+54^YTC;M_ZH3]_VPG[&[,P4"5[/^4 M4\T%EX*>\.V>P.[1_F;>W8F!4;_N41^/Y:3MT85-Z,LUK>Y9+GNN7E/AK"+J M4+]NG-X[1B:^=_Y\IT.]-O6TREP"^HNP=L.+5/KYOF>C"B_B0%_ZS-LW!9JC MI/;5M6G2+.]0E\OEW<@5LOKYYEKO/=MG*OY,?ROTO#WFC\M\I`]ES-`KQ!P,'7N]; MX,OY(B]7QFPX'5NU$E%E064@+/-BF_ M__8C7N(W<-WK?V]_&'4?;.(7U"IHOV(+7/;V#C.VS6&JQP=P'0Y.R%78FM*& M'O14+^CSX$7,7P1`IP+3YV.':*^_,RP4R[1_R`,:N4"E%X6XN#L[Z6W@Z-=* MM1XTZ>WZ[P-G_6/8R;6#DT%AU7^A=(5I]T2NL+09-4&T011E$?2"'9K[0YB3 MCD$H,`7&IX-<.$7^HWOX$; M>M&9YAZN%>-'Q3%@K@:9-#QFESG7R&&`M.=XV6F"YCP_ZW;PWJ%6Q_D5%64I M'PLS:P^FOG7=P^;XTTWG@=$G0Z<1=_%;>P(VVO7GH@<';OH+K+$KN-T[<8@< MN.9Y_9^P*"`G!PO'J*[.\5C<=7>ALVE)&Z>`MZ^X,%8SIIW^7:\'T'M7I^=;,,HIW0\F$_Y%1L62*#^[R MH6P^P=;!,[F!:)B@0$&^B@/BVO8?A'G>W6?E5TWPR\N;C_K/;SZ\?O/3FPZQ MV21Q;503X(T!&3N2['?][CI)[U=Q=?1L`(X,F.='JQ%V*%-5`;BORJJR]:@0 M:]]3-8OWG(=^Z;1Y5VF8OKQV-\!6L'=U@I*Q%2`_B`"YG;%^][WX8*&U(G48 M@-.Q5$51.)V+VP[&^54<"CZBIG?'EO?AUG_F9K?KP7`SA0TL@2Z]BU?QSJ[B M,EC%2QMP@:L(S:IK8?A%!N8MC;BOMC'B]L*LGU5M,GAV3`*AH35(2E]K98[` MN!E^T3>"%++8:-PR&+O8&&IV_;Z!I]]4\#&`=%_ M]"D-B?X3ED"RF94AU5X'Z8[]J\MR=[.!M MFCI(QLRZ2'K5KBPW2`(^9/6G`^PHZPN^5#W"X^'H\*BCN\&/QYT?7UHEU/E0 M5YGIRK2'?98(-Y9APDM_*+$`0]]5.#\>7:R9!#7DSF?U"LABYQR/K#5]_!RK M,W>?]_]\+4V^>T$VONC;XKI[]G=]):E9D;KTON^$3\]&1]W93\=]W[P)H#F( M".L7]HJ[$&^QKM.^%;A>:KM;W%^9RPE5TQ8M^/7U%TG:*SC;#//OL:VL]YJA-WO:;ZU4,J31IVA.R1@;4\L3A4->LVU@MQ[/&P`,:'>8<,IPN(- M8R_C:LO:5UM.VEL>WL6VC;9:'8DWG:9OOE?RR6[T/0@I[C,<>@=-&R2NG!J> M.S6.][%M&[\HK1LX"Z/]]EDKD131[')#$Q;]*S1AT5_3A&6K7AL;FK#H MKVW"$KHPOZ0)B_Z:)BSZ5VC"HK^D"8O^ZB8L]-)7-6&)._CMW(3%@D'>W[D) MR_":FZV:L.BO:\*BO[X)B_X5FK#HKVC"HK^X"8O^%9JPV"U]:1,6_;5-6&QY MV2]MPM*>:9W4(D9O MVR)F4'O\NWZ;%=E\V3%Y?>A6ZIU%]8"C\KS=$GNRJ=N48(%V`Q>-VHND1[VF MO6"=E\,V8=\VL'5`&V52J1+AC(X5U209#H7J-<[]W-.KT+_S;5TW/_Q?4$L! M`A0#%`````@`SHEP1Z/1*Y2@`0``51,``!,``````````````(`!`````%M# M;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`#.B7!'2'4%[L4````K`@`` M"P``````````````@`'1`0``7W)E;',O+G)E;'-02P$"%`,4````"`#.B7!' M3C$__V,!```1$@``&@``````````````@`&_`@``>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"%`,4````"`#.B7!'R#&[@JD"``#Q"```$``````` M````````@`%:!```9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`,Z)<$?6 MANFQ/@$``&D#```1``````````````"``3$'``!D;V-097)PC$`8``)PG```3``````````````"``9X( M``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`SHEP1XE/,GQI`@`` M2`P```T``````````````(`!WPX``'AL+W-T>6QE/6L#``!]"@``#P``````````````@`%S$0``>&PO=V]R:V)O M;VLN>&UL4$L!`A0#%`````@`SHEP1^HL>A]-`@``]`<``!@````````````` M`(`!"Q4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`SHEP1[I-!T4B!```B!,``!@``````````````(`!I!T``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`SHEP1[061OZ5`0`` M<`,``!@``````````````(`!2"@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`SHEP1X^54.V2`0``<`,``!D````````````` M`(`!IRT``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`SHEP1ULN&URS`0``.00``!D``````````````(`!!S,``'AL+W=O M&PO=V]R:W-H965T31U-)MP$``%<$```9``````````````"``>@V M``!X;"]W;W)K&UL4$L!`A0#%`````@`SHEP1S-E MU:1X!@``ER@``!D``````````````(`!UC@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`SHEP1YIOVA''`0``OP0``!D` M`````````````(`!*D0``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`SHEP1V2?P^C<`0``$P4``!D``````````````(`! M0TL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`SHEP1]G`49Z4`0``?P,``!D``````````````(`!FE(``'AL+W=O&PO=V]R:W-H965T)^ZP(``-0-```9``````````````"``2!6``!X M;"]W;W)K&UL4$L!`A0#%`````@`SHEP1^PGSA4^ M!```VA8``!D``````````````(`!0ED``'AL+W=OIYEX>)CSD?I M^$)":/$5OU;#NY0D[9R0BZD_QC])S26500]J'1S?G.^`NQ/TFV:Y-!Z/`F2 MF63%L73#>^72#X'B3,?=G<(BNRAF$^B3)@A:L2P:+?MM[E3OD$>C;CSPH`--7DPR07MXTM%A MFJ.G()@L^SP&^4,YH/F#CJF$)WRD>6>?\DE7IR);(V)XNFC('X0-79RWTRZJ MA[6F16=3M6I:K#:-U^A1'"5_=36$C\47 MOW_],Y8X^?SKAU M00L+71>!*S0XKBHD(UUYG++V#5KA_!3H=1X0>C*(Z*V=?@ M+1I/QW::9>DK.!\GF,"38B:-TJ1@;\4-!\+2^/Z[IZM442A"6,4R^F^0([F_ MO7/OY7N`2&2"9?@18ZQIF+YAHA)5`0,0LE$T#F+0RJMO_ID4P8J.PGM=EA4# MZ_>V:RF^[\M(\10-*:JI(,LS5:1CW78UFQ#?-NXQ?-4]6.!I$E7#F5N7^U]N MW;//\+3\[Z>+76#6!73['&3L.RQSMB5\55;AUQ*^3'7S#5,9T---\"W/,75/ M)DC1/(/+P$>VI6G(4%U#52W%H="(:^P][H9_/V'9?-1TV]1 M\?Q+DC[P&"-XB-E5,ID6^0T#V7"%*@,=_BMX;M`F.\BC_$L4/)2Z5G[6\%)$ M=`\A"I>/;M;6SD%D41?W'1M/TBS(9M[_3*'%]R"[SFX+[L7+QM]95JKN[@*D MN@(&",N:H=4,4%M^IF7YT-%#)M4P"-%PD$4M'\F>JU"%NC;6K,K\T!Y**)]# MRW=1]L2Y5CA.D&4S$*HUYJ&E5119]#`M^"37/10\)<[*7!BB`5;IU^[(J_`&*ZJJFX,@7V^?U<:J$0%: M:T8J$7$58>'6R'6*MY]S5]4UXKDZ\E5L`G*B(%-U=&2ZIFD3<$[8]N^I+),: M\H4EQ8JNP(B$MF(53QVX$P=Y?OWX&QB3("FNL[)84//]RX?Y_&F.MQ:)@0T^ M[O4BT%S;T55PR9[K48AMB84,3!VDV([L^ZIKVYK!18#OC1[.!9^O:L%.,&M6 M(05Y@%(W#O47']6(EU-VF`@LBZ8FA<0529*N\*0R@8/6T0:2E<6EJ7 MPBPM@QC7L>!K6%/)(/#5IHT\2?B&08V#S+[&X>L=\.5S]80%,-S\Z\U(=!Z`&(>;1;-O/K\>8\BB2R\I>.2%C=DGWBS:[-=C3B>K0).2T>*Z7K(,FP?*5CW?8?H+M8AKKDO8Q>U MRUYA$"C$3S]=]$/1F-4@!O=6MBSEL6/&J,B*O)AC52:P_9U%)- MY!$?`GR;0(#O:3("J^\YGNP9CNSTK]EHYV1UC@7(#H(?(CNL5);+@.C[#5-8 MR2KA\B"J:H`\H)>Q6>=]A6+5DI%IN!#C^I@BRW$NJ\ MJFPKC].HWRR$>8CZ#:VYO5I^\+&UF^&+ATNQ#:YS6C.[$.DIQ(;L#02[R!_WMH!FU2N!QL=-M+`/.T!5PO!%<14-E9AU<."UWUJ M^9YOE%E!64F@PO*11L$>U_)G&.V!G*I&Y8]SJGTWAJAVM""C2Q[T(/)HI<=K M-LJV#C+V2"46$CC(_EB_L(KT2I>&]^X'AO[_9&MPHQ3W""V%(1+$1?BCMP8/ MJ("'""^%9?O_LPHHDF*'`GJ>#!U-#;F&YR'%H!ZR;4(0L3U%,1S%MGVO'9?6 M%-`DQ]ZRS?4T%+.G>N>JWAOH`/MYC;!KXOZH^BSK2TY`3,-NW$)A]^8OC3/'<`#%HL?;2A[!;%5+&A>NP6BO736 M<63/]*B.5+.,/+&*+&+[2(:X7=,M*D/\>K\F[%R=RSXHA'I[S`DE0GA$III( M8846=:#IV@./*5R`6!05=)$TRB(HA7.AT3)%6$(#4% M8Z.^$#=":4"/X_254P3]-'/3Z4/Q.(U!H3EYC"=(+"KSIQ.P16(AJ/6IW@I1 M71C7Q3/+5A3_&Z2+QT>.A4IN*C7DXN&W5W!4\#PYMY+PW9+M89QV7+XBMJOT MED>7211_.BO`K31/K-RP(H@2%GI!EL#(!4Q'Q2H,$!`F>ET[VR-?&\E^B>"?L*S4 M5+M,+-FATC>DKQ'NMA-5,=:%M)U0A/$!+,D3FV0A<$I58=#0":.7VZUO*@Z` M7&TA5RP3@'LFTBQ31XKOF!`,RCJR=-LQ??ZQA2 M_\4\?+7AB'8\Q+&23)3>^GLP.Y'@`PMM.J:TE0EU#'Y]G'$*"(6+O&';!&.O M`[Q*BB!YB@"_E>>LR+^QPGL;Q5->JOHY3^Q^GGCGV_ MYG@1UHT&\HTXZL`YQYAEQ>Q[',`:3T*^]"<\QH0^QYQJL0&OVZQUXV^8IU(5 M3F#-BOTR;OCEVI`%"GL3O'Z%L#.+8%0GHZ_">H6B=JNK$$77'![5X`J78BNJ MJ@:[-[-JV&A`&`QHCP,R(MYZ5EM)MP-&TD6P" ML:'W-F%)SA9]3L:>"),Y3,V&K=R(HSNB>Z^_P-H\`<2"72@>W7='=5T`!/;T MR'Y/&+$20KM-Y]+1E11/L)M%-AT54\Z0@"F^8651PDGSPLL+&![\8B7)-(AO M@Q=>N;A*O/$D3F>,W09QD%4IH,T2]A@-LI[;69SJ$ETV#16I)N'WA&@FLC7= M0UC6J2:KINW2]?P_$(:R>H1X6,P?N"=;'C3#5"\/FJFZMHX;3';+AM7F*@@.+9(^K&QKW%)3MG!0,Y=>4 MU^NKX]MWS]#[>95DZ<[EHWY)0A[Q13K[JE" M6OL,@N9B`\L>H@9QD&)8-K)`$9!AN<32'!O+5%M[YJ^QJ=Q"L7?$SVGU>&-` MT>LL15D,I4(@NM[8A6M'_<.1*)4VK)U9*J2;1+F)G_(Q],EA@?Z3T2<'!G_" M],F!D7;1)PV-$K!5)\">''CQ=K$G-RW>#^9-=B#>,:LC_VR\R8$UNXLWN5FS M#T^;'%BGNVB31R-,=F#;M2A!UA`F%;5QY^!'$2:'Q25@E`()T:&'-8"B=6[7M;^>#+D$N>."_=$R)##KM1U9$A(O^H& M]L/)D,-B%9^64/6MJ)`#LP&'12ED':B$"$.X/FS`(5A?P]H:H?)JIMJY/7AX MTM>P`(5SB4^#]#4H6O%9$=HDDQR?]=4/>2\6C?`R$$XUT>1387T-.M=BUA>N MF^*/H7T-BFT-4[-Y%.8#:5^#*JPP)]/:#)R#T[Z&-;G"M=ARGP/1OH;-+H6Z MA\FFR[2&IWT-.S/BE\F0MI4\,N]K4.1BWI?:Y,@>C_KS?M:/.FZC>@FRO_P,\8@-F(9:/\-?ZU@;YBXY]MLVK?OY"LVW7Y(^9C[(_PUC8.BO"/J,/.]#W"U8[YUNO&* ML2Y@K0A_Q%B8^UDZ7KQ.YOIQIT(P%KPGHX/:V>O.]#7G>%HLM(TP5EEG+!N! M:0R>WELT]XVO7Y-M=@E%R-OVKB?P6K"R7-^F:2Y(9CTA=-33JNU2M^3`PL=$ M:5AU_<9>RT=;!&FKL`_R9H"6J5LR.PR%*EJCXK81V5&D,=P[!%KO#%I>-L@/ M!-6N4#\5<1SRNOT63W6I'%KCXM]=Q#&T7>PAB0X[V5\0PLQM08+:VE8NI?=^ M5:X#3@5"AZP\ZU[%S"R\3NZR(,F#4?D>Z-.2BC`1,)M"V0KE%BOGAO'W?;.* MKS*)MSHK,;T3#?E4-6636I9&O/ONN[_E MTZPH MXX;W5E(I92DHZ?"Y%"7EUTL!))[E"#C#[C%*8`U&0Y&E7!5?&'RO%(1_G^:\79'"H\<8$)7?TH'D?-TN M56NN/BQVWOJE).U8NM?]O7Q+LC-W4K4-B62?6'KP]$GP>I$=LPAZ;T#Z)/]U M[]RINF[7C?*R>++7A`\]P=4[`3HF&!M=V7$;2?M-DM79A1QD,S_%P,+W=S&N M4A"W>*5@4PJ#O^BAE30N8T43`M05]NAV"/O$2/4#'E82OE^*LUM"N5%*'=6T M_D(2A@@]<\Q-<+=4J.KGV:U(YI;",%05BJMW)&8AEGJB@FR62^&7L=,2_,I/@&F-W8=!8#JL'FI M.027O5])0)Z4K0#9D85%^Y_GHW8*W5=)5`4,WX]:W62Q#% MU:'3E;QV'NR6'W.@Y=-7580$!J3IBM)A3[R7`H# M':0UJ72;L8A8(I62+S9FC[Q*UQ[N[Z*&U$??Y&Q/Y@'@]>/J.9GCSJKH;.&" M)E@C:G<#$"_.!9'PR-,HG$6L&L(5NAA[B^Y:3BT_57+MVAU,?O]V^6A'=#*59#>7'6/\2)>&!8^.> M4,5W8S?8^NV!UX']S!*8[IB##\?\`$K!)__E-(H1PH(,U@AP_8'FW?A'E^'H]/ M1>N^A2/'KN(0#E/%[)E$K\/7/.:!.$@Y?_4Z9(C.C$U<$!]`R;:!#)-?\6KJ+C)MVT'P%9@0 M5;5][-_3-9=(;U7>'[(J>AB@XKM]UP'MKI)^7]:)E[Q1OM)+M[X7:L70.&I5 MYM7/_==P2?Q;\XHCA392&3&LQA%("&=#OA\-0>TM?^-\&9Q5]PFPD-L![BBF M1>DGKA^;^_T5'V8/26&BZIQ`)^M:G>C211WS+,\QP'$CJOL^4HAJ(9NZ%'F> MH6N.K.B.JE6BZMJVUQ1%-U9>8#P(]!.5I@&1ZB#2)%R:7:QKPN^RT@XBS9!% MEVXZ*@E7=[/)]IY$]-Y'TU0U8@-$63,P^`[90J:%721SAZ)ZV%5\7)&N^:?^ M=-$S$DQVQ>T\`XZ6G'V& M_X.FZC(_]2<<7%L!JI#<`^>\%4]W&$T@O$(`!EDV$97K^E`;5\.%CIY9..7G M,3;0H^Y*)@S@L>-=2N4B<)H%R&Q;1]3P;03KV$:F3CR8)T677:RYKN-6:OZG MN/@QC%[^]%3\"`CX;Q,I+V8Q^W3VU;KY^>H;LJ_O[JZ_7DKRI/A1\J^_W:'; MJ[]YEQ)^_X-O?;WZ\M=+Z2X:0^+^C;U*-^DX2'Z4YA_QQ?/O+B7EW_^7O2M] M;MQ&]M]3-?\#RMG9M:LH1[>EN+)5/N3$6S/C6=M)WOOT"B)ABQF*Y!"D9>6O M?]T-\)1DR[(EZV"2JE@D#PU"2A M[3,9#8<<$4,EY0*8J?'`;(8^G8'"'`-+D1)J<<%1<7#SRQ>!3ENX\P(J'0X" M(>AS8(=@0R#T0#(!0H<%;X0?"CRR]4\^](]_?#RI'C>J*MN"RJ")_1F)\Y._ M"*7J^"`[]&HZ\K3%B?HU&50;+Z3\Z=7U>>^Z];OWC'N..?>_^LH2MGI=-K[3IG_+2$4P1Y\YS MTKSWY%"HW;P2/3/X0HFGR^K^:GV*5?Q'=;2>U?R02<^QK;T)"H/"@9;!@W91 MC3(-]/%OO#9"I-WX3+8I_=U#(Y7^G&ZKJ._]>=F_^33[`E9\K4A6"CJ>.Y]D M6L(QG$RW3$J?'7!SUP9<?CI3_@Z_>%GC7WA0XN'_&#E?*ME?'[5QH"21L!3GNTGIY^DE&QNPN?S M$.3990PL..ZA)0]6'#^>G?5Z%Q%*!1W$S7_12V1;:K/W`7&N-L_2MMJE&JV'&I7"40K'ZR*WCW/$ MU%<@=D5;K3!@&=C]2Q_7`>8W1DW'740.;K=Q]77P+I5W?A/7?Z\:X_=M$;:-:;6W]&,MM MHGD,50Q.R;A"IV0NP5/B,ESEWF:_RMS2H$-_VWD MZ)^_7=[V*C=?3\Y@&G>]`*103\RWUR=?;BZNKC_CK>WO>NTU5P/8]>!NE(9B?XW.ZP@N2LR#+QOHD*Y=/0^Z\#T\6]T,0B. M%3C'B'7LI.!B*(!)]3(;+:+R$V[%9E*YO0PBGQ:7K-/R?Z<[=%`ZY]+94J<7 M0R7]L3K_@[;1G1'B@_+3/$,HBKG&H]GK[6PI";5XZ=T02:JR3U;@D'*BXUO> MN.\[-MZ/AJG,(Z]B.EQB^:$(!QY=FP;FPXSPLC6ZYVUB.3^--MY=9ARX\VXP M+ID&<)JU.V\42Y`7/.)!P/'2-^B)'P7F0`%_96Z1PP9]#G6:MD]7!#"98$30 M6*&69&3QN&R\18X);?W`20!KIPX%`+&&,%P@"`]9&`B.%\Y!%5.;&..X!OP! M'Y&'0?U,JJ4Z/(15'MD2^S'R(L?*W%;'XSLK9BP)#MEOW@BOGJ.K^:8-Q/)` M=UPO9#;P4U]N-Y4C&0%59).YV_Y&G&[@X[H@`E%I:L!PS`%6D(H0"@AP3V*Z MC66HY'=AXSBS3,T*,*ADS$JFG^5H*K!Q;!IXMB6F227GO[5MVCX\@V4QL#Z= M@3.X55W*;#U[S^L%$`Q3!C$3A.$%E,L0XLW&74)`E$VO.03$A#;-<0)G>6&- MZ8G$J34K<2#>D6S;`06QA0*_%6@!;SWF38"$*/F\=GS>`ILRDY8E-$0)#?'R MY=62-Y:?"RJ4\!`;MZ.X"^?^2GB(U9_[FW>:?0]#5$)$E"E3"W5UHP[$E<*Q M-L*Q"]Y="1-1JM1NV]M2/M9(/K;/:RVA(DI5*DUM*1SK)1S;`A61V^I84;;Y M6[3Y>APVT,<_RG2WU7&B3(-:BS2HC5]'7OGHMLR& M4EGYVO"U,89VMVNT:DN.,*SAL)M-XZC3W8S`ROJ(_Y_/00EMG/S7C%:C;73K M2Q:%]1MXO=8V:HN?7UI$`R;6W_V`$1+3+WLGON^(BHW3%`B5>R\JKA@YMBOV MV$_)_#0!_O@,]%X>I^^"V\$?>`;QW)8F+!$C6**^/4I?MU[MGI^V6I739K=3 M:9ZUZY73[GF]TJI76YU.M0ZE3F:A].TVH$VM6OTXY[(K:P+CXLUT">>(NS#O M[#0.YW1UJ,:9U:`(,9(A#%Q"4486 M>"T]>-@]ENPNPQ4[Y0HJN+0E!IKPV#*7`X-QT_0B?!<(4]@/R`R%Q!:_^(#X M:F-\KA#_3)C^QACSXD-5$*J:4LF,.@AFC[H!$@[]"`27GDMOA`SM(0^%U"!Q M(&9W*&MT9MK`K8B0"!!&W>MQWD M\CY"+3[:H:KT`*'^5*P3?KL(_^=@%4-/AHQ;#^"B\7OA11+$)/@&UN_3T""8BDH.'ISS,TQ#HBB2+]:`_MORG8BY^C:'M]*0*E5+;K1P@D M";HUM-WBEU!)Y$Y\K=0VYAUP2IJ!W8?>\"P/!S8P'OR.,532Y]A/&AR"^#GB M03BDE:I"`_\<#6QSH*+@=@`=#T<>ZC;%OQ/MSO0%NXQ?@ZL3YGII*.D8\C'* M!E((ZIA*(]TF6I!<]'U-8MOKJ>F?D'FLECV8_M_(0\4F+5)HG29M(R@)EZ0H MF#<(<@XJ1>I"4+"IQMC;`Z^Y1*+7LT2_5)I+**XH\6[,&27^!*Z:T0D%@TK[ M[6`N0[!)R!0W_F4P&:$J2/8]QTQDG02SX/!`,P[*X6Y0RKCC0A';31B?]`2! M8)50'&.[GNZ+MCY3.HQ?F1R-):A_$'C@P7*-59Q^A#9.&5%$L5%]C?IHF'#G MS%'8Q'>1XX#)#(8Q5.R,893R]ZS\-;+R]_ODQ)`R4D:^VB9$A@%]0^(H5.1Z M,%AR\`7XO%.IEJ5OUNN@29H\ MN<0MFC:[HZ^6F=YA/O9&X'CKXNC*NV,E'L1D5'KY#)QF4D_RX/1S#?I,2RCELDOM5^>=4VV,IZXV ME>PTLIYZ(0TV8[K'!\]#1.-:(UGX,ECO0GE<\:Z)H[>9AQAV(X#VVE,,[05. M,=3:[W>,8?EME[OG\^PDSP6-K*+]/^G.Y2P-Q;&)GN/?=]I_9AOX-L! MX+!9AR7H;C%8#0;"]&`1&9]W+L+D)*N#E>K,3H""K-^IBZ,-.7*TSI/-KQQ6 MZ:17#TG$96WTZBV$9'_Q66G%"3^O'NGB^O#JY.X2#:A$8-EL*FZ?R]13`=#W M6$1LLV]=4NHM_:<-FS@:8'XL+^H[8H4V;_%&UW;JV#(ZED=17[*'&`@9.700 MT,:5/'=RJWK-;[OB6.[[ECN\:;EZ6.[[ECN]Z M"'NYXUON^#XI$!,AA@U+]=WU8,MFQ2^_!IXIA"45V-6L-<%*5:7D$A MXG;/BBIMG/#O=Q>7A4T[U+"LH6[AYM16[<>75%RG4PWK[-B4YQPVP`/:9DIM MX52R9?OS)1W+98!JICG-,,39QF@AO0T0YG7_@RO9AYX M)RX1ZRP6260FLN+4X>:WRHTY\!S")?`(RI:@4/"3H6<)AUAZQS[S,:O5LU!K MMI01X64AU_1!"*ACUOK4R!V8R:,M0>%_''6-:K5Z2`.Q55_5<9D,@!)W07H( MDXKPM[`E')M"U<)*ZH?01^Q$&-C?1.Y%NP,]L.6WRAV>N2!8241Z"'3GJX?5 M^D>#H;":H5!7NSP@[(_%QK9P""*N"A\\>`YTBTAZQ\W0H[NTCAJ'G8\*)RZN M@$!;/OR@JJ[7V5CP0&-//&`C3)XTA8M_IJ>U,K;!YV,O M"F/12F$686`PKMB\$GA30,!_L1!F+D:!"G"*U$:!^L0L@1)GNT+A!B;"!3J; M-F(H0D`5D4]$2ND$G]Y%(>+$4=&T[S+J_P6=SR)"HIW4L'7\&QUOHQNOE)W0 MH#5/#X(P,Z&6.\<;2<8?N.W$-V=-;U,--4.N!PV8F#"71J355:9?)#J<\!P? M"0Z=5^--Z8GWPX!`(2)GL4-9$L8`?/"Q"Y^;4`&MQ132CC(6PC43^,WL*%Z@ MY8_+TW)PC^<_A-?&NE9X"&\S[=Y2CBJ>ISBMZ&ZA/`7"$8C(J5"=%*(82)PC M%/)@#(6';^EOJ*6>H$UFSIO&'EU>/J7V\#3L65PP4?=`?(_L`EK97Y%U3QI) MTV\*/8L8=@/NW*FY&^C)[Q7`%DR4%M;O^5E/449#=1N"TO0L+!9^\4%#7T%A M?!K;R>QL8(E^UF)H[S/G`V$M9*[UR--[I]1(?\[._LI_26Z/,AC-^2Y">>%0 MM;54CIB"`#3`;9$$\DI^C3(5J<="(T.CE[2:&;:ZWVK(+1&O=FC,E2^Q#?O@AXT46Y4DQ-1&YV<*+BX:\^$YGO'+5 M#QN-`MMQ'$\SOG;8:N8*-289![5HUA&!F\^RCRC5/JQ_S$]LZC]Z-(&R_R1P M?AYC_QJLA!N)ZS0WH@#)_V8X^^>UZM'%Z?EIY;3>;5>:S=Y1I5L]Z55:S:.3 MLU:U<58[[\["V7]ROGHZ[%^8<`KS3?/CA&N=#8+1`<.O@6=%X"AI4A7AXN>> M5Y?4S[A[@>X>05WJ7!=4B-%`N`7%,6%)"7XP9P/^@&K1)\AH@?I@9_8S09)E MQ"7.>8)6BF;L[=*E(GJJ$8^V#"7V9-_.E@;#"B4#O`10)HLY$GIY&QJH6]F;?C3&B!8"R3_B`H2`:+6GCO[EL=(T M^R%3,:8-@-(ED-HRQ79'>XES!O3VA0O&)3'X-N-1(#%@+1`B"8CMN!()O.A^ M0+"H"(5^#VM_Y6<@OB:4!R<;`6YQ!1>B[T!AA>"!\'35O>+\WO7@A9F\!Z.E MKMKU`IE!#DDAD.I6A=9'))SK(3K: M9"GYUC%@5ZB5,7]$*B@]B"_[3`B7@.:2\S"T0SV_W^,"VD7Q0K#M");O`0&] M&@J67\VX<974Q(=\*ET\@V9!8A&PW\DU$U)@6WGA4$'::M(F.'H7`<45H$&P M/PQJFF<"Z&#'#? M)825/ZI#?)D%WDV`D3+0;/61Y`XI'T9:9'S50=P$6EUH0CMW@8VVW2(X7:T7 MZD96Y:0D=2"*MHLV!GN#,J-M[9U`K0#/:^0%WX`$J!N'[,JEA4%J=(_B8.!O M@CL@+>>)X8%:/B56R@#"F(?YF-!OYY]R$2%#VP<[-ZS<)$&6+[C'`&BBS7@K M`/3T]-?/[%=.ZSFWTB#^@_6?67S\(!Y8 M3_D!4`,^9;?0H@%S$4HCQQ"DYP"#,%G1%Z'*/D7V]+G[+8C\T,38KA<*=7\# MA7[9V8#[8)A8K<9TVH-@O[NT*7,3DO4Z34N?>5&0WA?1`V$"70':H@4W0^5Q M_F$']V"DN<&N@6K@NEKPP8.-/N\ABJ%#BD2A%)I'G=A]3DVG%D88D_I3Q@.) MA3$CBN@*MRC6G5Y[(3&48['O$0]"Q0F4!9*2*=?&U&JQK-P&8+^4P.!J/1$9 M-,HNM&?J928W8=DL$\PN$!A#A8M-I$\%N(-SG@K,\4A16VL!&^.%&XIAS'#84)^EL8H"T`$ON.E,%`)W5Z!PTU'B[KRU'BUB18<[QN!UMOO:$!K MG2=\]`LAUM5/G^$=::>"W0D1ST[*3[+#V#M"4Z;UQE$^7&+<$0B?@AP8%>5C MY??1+HBR)#2KV_I.HR!TBSX1J0"E6]'2&69/,.&.-<)I!Y:!N/U+EQFI6%(2 M@L+UKPCPSJ980`IN)SOIXY&"K%TG+R%GU-4W!;O>M[TX^-_K'D.IZ)'=G!C% M38(IGQ4JNK&Q/U+;#A,GKXSUH.G7/"ST2)>45=#%4'3X.+U"/2[#LQ)EX+PO MU75"P!0=]`(OP=>QS)1M=$L2=E*@-R4]1SMB=F"I:X1H*\2CV(RAW`#%/^T< M3^.;=LUM*]LG&3MXNLZ-6Z@;,F[@$]X$Z@,]9F4%C%6E"B[7L,?L4#P+F7^HG]>NZD"Q775]-E M3[V05%/(!!SCP%-7SZ!73(=NU!JD'PC^#?>\M/U[QI[.W2=G;J.@%,T6>^#Z9O,E)%VP0^PA+X!Q<9:1MKCP?V# M`,<%?56W]\3;>A-$!3IS``L[6=@I&:A3 M2EH;U""A$O!&<>8P<\WD$%22B_WL>+#$ZL2+I6".#GU)MD\OXQSB%^)U9+6L MC@]FJ?J;@%],:.U,Z(NYP2>Z]=>!3W2J+P>?:+P?]D39]/H`;A2D>0WA-GZL MTC]O`!MQ(A/CF9_0,T`1R<<%8(YA`61"Q"`33]+5]`>>62\X%^N(WO&6 M/$@[D)U72H9L@E+D@5=*%KRW3FPH/Q;+2RM.5: M8KRTNZVY"JY)HMEK1MK>*#2;5XRT;M0;C9T9:VW98!%O8\W6UG;-&;DO@7?6 M3F5>B[Y0;V_2B$LA>1''//Z%M=SGBXI6%*PI."RO,4) M\*?)7,=G$QCS^8Y?1'C&Y>"K/LU^.OY="NO2O5('BMS[$SS-16DI9YX+#S"1 M]"H];;1P,J0E3'O('?G+7J4QD1K9@>^JM8OS2OO\M%%IGM9:E6ZGUJ@<731. M+GH7G3:\_3_XM[W'_K^]=VUN&TG2A;\[0O^!K]?SAAU!J`D2O+5[',%KC\^V M+VNY=^)\7) M%=!(7_>BP*G#NW^>#5]_L.K-)BY,RI;[T9/>8CKT_)5,\+OOLM77B.CW:P[.UQJT!@,@HE>'56O9 MUK#3&#:;C4'/&71^-'[8W?Q5^P'<_D&%PA$L8.VTU4I7;PL])O%?M$3]09*_ M"#_`"U\9IX-^_#(;JZ2]LR2;,:T0WG_%;W?0Z?7'=LOJ-09#R^G6.U;?;@^M M0;?3[O=MI]/KCHLJ?E]VFRB[5OO;CKEY^L57O>ZD>7Z^F,5F&H!]FKF:%IT) M-&+A,$,134)OJ>IM^@AJ(2+.;$=QE3!0N@!N^FX)^K"BYF'"Q M_WOEDY@BD)[(JS?4_IS^>OB^PE4<1GQF\'ZM^A`AJ[!J6*N3P?SE"U&9J,H. MRLC&/3(+)BL--RM;:9-4T<,*:X7:H.17;)%0\1>66,@4=Z[&A@]J:##P[J5P ML4K0A0,D%+*JTW<5E%Y$FJ8$<-P&D);;2-*L)D6NY1>3VE2O`<>P0.#?*Q=,1-3A5.=`YS!2GC MNK"W^*"N3,;#GJ%(JCCP8&01#A45K\)(7E)(CW4G"9`:,E?RGZH$I4HP2X>Y M7(MJA5=AL!2P'/``3D6?QNA/8Q:E9MA-,ZS74W*Y'M5H9DHD05BF7*&B;5$- M6PMW)>)O@MB'5#0GSX:U"LS,5H0]Y=Y(!`=5?`QW#=S-?,ZX*[CK4RF1VN41 M200\G]8V(4)PN,32345)&,"1L\!=BB5/$]J+OE;=26,0%@F"+Z*`42TIE7@/ MQ223^UEO4(6WPW5`(/6J"!*&@5O&V[_>\79*0`_PL=ZW`4K6X+NIZ`ZQIW_/ M,%2"3WEAA+H3YZMV>\I.;>OAC-,AJK?0>TM0#"0D4BH0PH=TG*X/T7#(U8@; M]"'A,?@W*8DM$U@KJ2#5ZNK=^+'YCKIN$5PCSQ(]EZ?7)*JN!(2@==)6!M?D MA`M&`9WX(ATJ\].EN237WR2D.-EE6Y#SBWE,W> M?+Y:!#Q!0CW]#Z'@R2/K7!#XE*ZYI@E\D:O5D,.3\;40"CHB%_(JOUIX&6+1,U>HPINX=0E5'!6V!`5A M(@2*"3)/H)F8/''DFJX)L@R:/V5!=ACH*5#`I!08,Z(!^L;"!3& M1==@PS*06#M@(>17]C`@/DM=;ETXV[%N="D1JI61IT1)UL%7J+[HY-76SZ`U M^5P.AH/HM#4#L%/-,?_$;,;P;6[%MF!-+(<0"\)()-#\T=+W8@6FI6.AGE9Z M!=`,^E,G$A=7J]U?1V:WXIUP2YP#&KK,/I)#C&$V.)*256JT7B2GV-6 MT8Q0=@D%$85Z4;AK5,LP(%D(V+PQ(T,IX/.4@W1LP(?4?B;\F"A.%#4H&`G6 MG"#,FDN@!JC,L5L"S#;U1+@78%I=(`#M8D7MZ;%3)86>"H;`[B$2K1,N MU0[<:Q!_*G>C,)%9\8E4BNN8()W'S")]27#+%!\#4F8@W# MX"<-5A`2%:0^<C M@T;!,L&Y12L'>2473VX].Q-[M!$)I4 ML/':P-,DMGM:.5N=1P@7)[%D,O:+#B[#US':.Q*&6Y=T^'TD"@RB4ZTA57J< M+]!GQ#7#NQWE(74D2DP4#W2Y!UMIPKQ)+$/U';[$)R#:ZK/8C@:_AUMPW?O4 ML!.P>G@>WT'94+VQ=/MC_>\2OAT_0!1';*?R2]LN![IL1)?!RI_B[$/A3FF0 M=5>.!#'?,E1B&K-K%TY":A:"(I1>&7*5:X_-TF]T4%?H"!C#=DM99=>L_U[C M*@Q:R-32"-NDBWH;[>4L*I(TD&-,+4=)QG8$,,C<\WV0$(2F,\X:I:00@;,F MP43IN).-?:AADA\00M?,G4@XK?1X2?$)Z=A#J>(_(FZ41-26=U"T)!/W(3Y( M1]IEX*-NU44,\6&]"=N+;^S3AIK\:66H4*]P`ZVIB=W9!#[@K4M3%`#$X8825 M1VUW"#!-\3OAMHF^R%J+WIUP&A8;A4@0#,$@O&H2ZW/59ZIV*!Y'D1`N-SQ@ M755NR!V-`R^YBS#4*07M.1JI>2T)$8]AA.%]S3-+<4!<+8368"1U38=G(3.3 MDVS-53MZ7\GZ>Q&F5[9S4V!\$JN=09@UKS81,4$\>VY_LG:OR3T'N,_-20;K M,Y$O!-U#Y#0P#;S8`,XEX\E/PD1D_*>=:Q)`OX$*XOZ".3;G5QZXHKB'C,O M3F#]3,!A"ETMA,0=)R=/;';%R<#]W2I]H>S\])0V_D$Z/XW(T8$VY?_!_(=0 MFQ2:GANX))V)N#MMQY4HCN9-S]?A9&&Z$HQ8=;2E%CDGC> MR:8,AK=U\.DLDP^`9['ZL(V]ZZ!)'&90"&(=26C(9%>H<`U94*2$!F( MZC@(_B)[RD._C5B2":2.$I9)FD]J%LF>QI'L5DK`Z`R"3294N%I<8P05(PHQ MF*9+_3S6X[^^"U>Q2V*""G'"&+)95+3Q.-6CS+0+*:"DC9)Y@#T%'"&5)[#T MOV7BI:Q0BEQEVS))"(]7PDG+?9:;(B(=CO2<8+"CM012\@/+4;!Y%.66A-B6&O<@=AY"YX&1?FJ* M;L6=!BI3>5WXZ>IZ(WUC-`TU(OM=4$99+$+$NWS&>*:)[Y53383Q/1D/DBC M&TXNR<6]FGHBTC*>C&2GG,DA,>=T7>.+MKS>9?J(H/EOKI[OG@N?`;2G$N,[ M4JF0:;J4[K-+YJLFR1V69")4I.R)\;!7;KM-MITZ2BJN"F=)SIF;D7H')JU- M9,.L"`,6Y$?1^IPIA&G:?JL8M-]$[@VZZ^'C'$1*7)/J?#"^F`M[S>V)R,F# M`-[8M$9EMDKKA[99,JW$YT!R"5>C&8<6R(/@IMO,/+K?.#6'>K+@6V^Z'?JW M1!Y'NT`%49L<;$ZMKM/*%Z:$9YB,(Z>**H;MBC=VG4?EAM`)9=XBV7XRJ3VY M8N)+MJ->TE_!A7!5XD*B`=C7],9NU?/>4-+.$V#XQ1NQ5\/+%O$MQXA>VPIU&K+P9`*JNKTG61!DR4@J@#EX M]$3KMN:;^JF3FJ_2^<89'?($I=X!ZGV,ELAMCPQW0Z4^U0XI->8&C0FWQ$^N M=@7.20S0TYI=/7'HZPJVA$M'6B_)X5O+;%=/I<^8:41:Z#/7%)*)/'0VIJ[F M*GX=XU.)M<`M_:2E()N3U[LH@_)AQA9T:.;>!4[H66OP^98*\M>.UN5FKX9:FJ[ZR);@E MD&0-QQY3YLA-G$4)4CX]3+R<"8I-G''$_TWMM%:SBY(Y,OFNS$_9.4W-G_/Z M88DNA4]W-3.G!\]A&=E,&[YN7A:3OZ66W*PEJ=GY5NT8(3@";JTTJ9D3/=F3 M(9LJW21AFTZG5ODG!9%!4D)!/3IG6&2!U<+22*!H4B(ER1>PUPF>@V:S11G@ M3NX8A>':#LHM-MA4@J(%$?%'BB+ZE)/%W\-IK#41R]A)J2^&NW,:MJUL$-A@ M8TFSD_L'M]-%_85#E'&0AEU:;,A(V2#$_)_?5N:L$YGRN4@Y0N(?>8C2[I M6HL?#;F):M)@5@\&YAM,&PPEAP^`!P0((PX`TP]C@-6<]?SD]HBR*!Z3)K"9E*>1N3H3L!B-+) M*S4T>3NUL']P[GL7TKN0BGPR_5(L-FOTWNIB!?>?=9V.1ZXLF9.M6:]#[%&\ M`)L`6#[A+KS9@N%;328T!1`$!HT.X::8BOTD9I"(U`_0D0?:] MP5\O77]&6Q^D#]T29-0JVP2?.'F5/P*UTW;31[EY.F=CU#A0I*8(0^`DJ[)C MNDZ/W7&J#:>E'NTK:K`(T!,K'"\S2K3[AWDT5OX!W2,TH^N:NZ(EE,YT?YG) MW+3=;+(NUY1C)2^OTM1/!I=7PPEOW.":CH1Y$+)S#A:]>]KM_FVCHU_?AYDD M9]/^DH4'6J1!S?&T,D*1,'A!AW*:`(P",%OA).%4M&8K2I`ID(-$"FB,NTA2 MT0A\V,F7P%IGPYH816Z$S`31AR6??<=^5GA0_$2/<+XTT&?Y(PO*14A6$4Z[ MB1#3R&@8KZU)5>9J3CER):MJ(]F06/FBU1FN3EORH23&0I*JH;Z*\T?_X)I7 M(LD$*C7K70`3#*'$HY9R4'TO2O(W0Y?/M04.`D-][IT->_]3&*K?IHET!!Q1YU*QULN4"]#]HY!QV,@:=+!I)4E; M3$6;.86:FU"CF;7]XYI28^U.AC^!KFBE!6FGRS2HK4X!I8!V7!C#O<*&0LHL M(I'2#R\43@9''@R#XOR&IZ'.A+0:PUM<">QU&HA*Y')[&L-:A*]_5-]BP%\YG6-,FZQ-I&F=%^ M3FX515J5XGI@+5!@#DRN8"[#T&GHGSW8XAK/9@EHE,E)"R@TB&>D=[N4KY>L M@"L8AP0FRFLSFDKBIQ)=S(E060#1"N^L"$#`Q09XDNO9%1Q2!O'`BTN%6L%C MOG@V]50ER;-[CA6UOA'4!3?:F-#'"1XNBS+.DMKJXA]-.]U(%22YU4U$)$'B M)''NO,@2="YNT,.FD:2S#F4>DQW)M:#JMOB6#Y\1_\;""965S[MV&E2B@,^> MI-"RJKP,E&,EG;`X?/)FI'T)!KX"CK@7(EAE&V:KX-;ZN^G.G'J,#Y5Y-5O/ MJ3M?RZVTK1S\/``3=N*%D]6<`[Z@K?Q`3_+-U:G5"5NHF">Q2%RKE;62HIU6SU>+O3@49.POV/>%G+>EXXMV%>1AR&T[-+MS4 MI7VZ$OQ;MX)^9U^LYU=4I>L]]_.48"C#?'"Q,2K2M?;5,>;`7)"M+\.D<]A4 M>%+FIW1PJ3M=]=+#BH*"F$?)1QN/J6P(:1HIF(\DK\T`!U$Y-@8+4O;(VP9. M,.==.5LD@FY$.;-FK:290(2?BZKNPJ5J^(W^HO143GR=E-=]$/3<7'.74OKM1M)JO4;+NHF5!SJ-`-UP6 M,=H$=$0HUZR6.,\>-`[5B#CV%D)QUP-N6R;3]-1 MH9-%9[BF\&F;(F0/)7_%-S0%3LF7)<:[29!Y!/!_\E&7]XTYFP(.CQ!J[N:; MN*"\C47\&:$4]H5(VQ^VZH-1OVF-AKVVY72'(ZO7Z8\MQVZ/QX-Z>VBW>S_L M'PYB*=NO/R`*Y&CX$8Z04;7R\?/@E(&(\Z9H0O*>I49-+\&B(%QJ6+[]`^V. M@)QQMSNP@):.Y=2;;:L[['0LH*I=[[7:[=[0+H%V'QIHM[X?H%U-EBH]'=A$ MR5,)J[M7T*1;--,MV9>P[VOVZH8.Y)!!^3%V29B M-3$7\:]F(`6LA6CE1I3`IRKEZ>JD9V?R;3;"F9AABP0_ET*S$U4HBDXC+_J+ M#E9T6^!?EW@B3^40^AB2VD#6S ML.O>RYC*E38P*DNP'-3A3)5#TG3#,QP-JK"$=MC9QX%K%)&Y(ZWX*,E^(,?3 M31:"$ZU%!6!YDR1[1ZH.BVS#M*!"_7V*QSYBN`1)#<74`U%'+%9RV47D,%.I MVYC/G:EH2?9%I/8+>OTNR9B6$Y?;)XEU).ZRJE:"YB'*5(!W*B_VA;S!9.0: MRRQ)L),<.#62,2=V709P,T&+F^%(E)^"G*KR+>O\QE+_3G,7Z/ZES3RZ])94 MOQ(GN'Y3BU!3:,^4$KU!HN6YP]I`9M0L!"?>NC]Q<5AKJ$M[ZDBE:X$;\@UD MCH%JKIW%N\ABSNDF<#6]#$)9TJL5)ZLAZ1-Z,H^;0`T;5Q!VZ>F?X5N:+ZXX MWS#]:O+-F]/*.!38KTNF\,!H/K^L>8-#D?F\*B$NA69C%@.7;$5FP&'J$2Y( M"CNSP!R2X#I!U24OQ&R%L2&)I4174BH9!SW(#[%?)A1PVUTH1#LCYPD^`0.D MGIXI7:&E%F%G5E5&:N08H02JH]EP0(X.3+Y)P[T=JPN!M:A)9**,GMW65D&U M?PBL2Z\,$S4-H_R1Z/0\:/]_#/_(%M0R?EZTR5/J4^9:G`BJ2L/)`(P?'&L5 M:XRJ8&/X!-!V%?BP8FZ(ZGLI8D[\Q14[=Q=_A:ME/*&JJEBPUXL#@X-+=XFQ MM]-.W!UA,D&0ICD"^T-,TI"-P0DI)%?.B,_`;,'*.KO2A=^5%!/+Q M$2.[N.7)&T?VD9])24T+<%P^2/A=0SXUZ:3D02[0D/.7&;*R=(%]B5R[4!"3 MM97X?`]!TZ[)$#L#4Q1DP?$WB7@(@X,,556P$?ACP3*AT1`1&C3SFG,B%4B" M6K"E[R[8FX.!3E?E*H="K^C#@WF%J36R143BV0%)!0V?V!^,$<1Q&W*:XDG- M;)*@9+BUV)WDS>&\'W/,M2IU/JYLDN=M;`NT;A%0"B6><4U$DFO%JG5QXF#+E!\9=GHNH/#.^K[EQC(RPQTYN%\(JEI"?S"U+9X3&=F)-_)C$08X#YF9=$K MV:G0G\S.%9CXJT#_W.2`)&L5SR6^IDG^4DR,VQ!D$LR4(SVM+.9\%7H-1<>] M2=$ODT"M+E'4`R`2=)C&E^KH2NLLM66KGC"J"`>7TEH453;@$41"0`!]5;:C M).H[W\7RUDW>!+U,B,N,#S]%!!U0LB6$SB-!Z!0<16;XJCR2=FI()L"*7C!6 M@%;0*\\:9=&:>2^4*2@S765U6-X1%F&`EI-7C3!_@LWU'0/H6!%#1B9%A\,$ MEK4.3#.6^#SS_9BK%>C.Y,64&8B"TMU#P>:*[HI/"9TLH9 M9/RT\BE!N\";K(:':F0K+%R*^"JH&`;*YU.8H\=3E6"%'CV)DI:D(*(I[`3ZC.8 M>ZXAMB>`W9)86NKD4D<^:^GACRIOZ8]`(/`G>O?K<6S^>O[F?U"E67RTO.Q@ M;+>>AE,G9`CO&)J5[W=J?TM"I]LZ7:MW&L6O[.OWY:KV1&-,GMPOYF3ON.R*#:$@R-;X["W*53BNG?%$EV2'%QPE*F(4]8: MO[79:5R<;3'/6(@6_.H^259[%=R<=]_L9+W('\EE2*^UNLV=7EP$UZ&[_/MK M_M][S_8Q*&UU7PBE]6J]T7@QM-K-SF%IW9=&.V+]M6/H[9`RL&5][C#"NK"D M7@L\]PXUU0?=-K><^?K^:3TEBDLA>10A:1_81MA%PYK1F@(Z'X"763TM+P_D M9S5N#C_ES2%G`6ZK4P_]S0-?LTHNEEPLN7A47'Q1M_3OA-I8WM&/_S;W.'?_Z-&>VR4?'YNDDH_/F(_/LC3_P!4/'Q?8 MN3P(;S;8HD^3<0>J"I3LJE#K/$IHE$T%L#0H9+0^!*`*)4J2ECXX"&17NI.T MD-V`5*>N,9:WJ,I_!:NX\G;\6G+)#=DCS M7A0^09[D-AAY[(2999R1T$O"'P!U4*P,TD=2TIW]//X2O(??W.NDXB&ZDVG^ M")X6YZ6XSUK.80E]?CD?8VPA>8E]88-@^O`"?=\0M-T^<);/\9'<:!PX-^,9 M.DV?59"NY.)#A3I+^^H`YU%CXWG$05DO]:P\%1NK7G\I<3NG5BL/H)?MW2_Y M6$9)'BM*\EG$E3\0_?,K=MBC5FZ]F"'#5/N2`;<+HC_*_A_$WS*DL@VFPXV\ MB42&]5>QQ.8DK-6TD[.;X7;:+4OC-\9D$"!C)<&&IMZ5-]4;@&2'.4F;\>G# M2)RB:S*3,,!SQ4UKT]Y2^EO4I$)K6:BPD!@'P\2C!145X)Z]D M=(<(<_W)"AL-$#;2^2Z\66LJ2+A(^+K9"5WUS9;/9-Y8Z,T%C?:%9G.P4#!@ M$K9,E^"^JFO]J>PMEU"FZ")(6T2C6U!C'831FR3`47,@ER$^8NSU'3%D8=XG M;I"N2VK9JY"F$/]##4MC4+N0:^ZSQ8TJ4[P3]\KU?%."C(4_K?PCN!97$LXO MCY!I(!B`Q(/UE+TKDJ3GJ0K.W8DU=Y$J*41(PUY[RD"/O(I;45(7M]Y@=%N)\QOH,1@#+0 M6P9ZCQ`%IOYX@=[RTT\[O'WD,=M67LQ6ORQD<$0^9>`21@27D/Q8$/@VKP[/ M(-2]E6TFR,01<*T4^%V2%%YB8L9+1(\IU[G4*;GV1\)+V]FFXM]ZBW3P)'-- M2VD2/R>@V-.?Z;*4_@A/IS\L=>6?>7#JQN[]$N+NLG+'%KLK(X/WS53Y+&_N M:Q?*(PV3O;6KM;O'!-\]G-:X#XWU:J/;?N8T.E6G9C]S&EO5MG/GW+F--#Z_ ME+FOIO>>0QMB,7UPQ73?3+*WSE,0ZQ+,IMTP0U*7AZRM:N-FM/P51Z$5NJE(]2/EZ6U=J;3$*A(N,;DE$P M'T/OWPAS7CU!;=N\O:HMA>-8A.,9IGH_JRJ9DHLE%TLN/B"'/.\1.,'-VWO'FIIU9_"_?!^-#[_<%*K6JO=&8_AR=!8AI-V55;_+"YM MX9J6BK6>R?[D+N3=:J=5KW9J]9=VV>Q46S6GVK!?'.'=:JW9KG9;!RX6/C[" M.]5:O5-MM(\`V_C9&'+;J@_-FBM-89Z\>C25>=?#LW;Z[.T\(/'.N#U/AL36 M4_`RWH_$SD,8><^D+/X@!=N]".W$76H3JR8F;649Q&(1>ZY_8A9>1Y5K`6I6 M_)SXJRE8I;,PF.<55VI%T#!"1DF?BXF[BK"D4MQ4+MTIEAR[\#5ZR;L2JF9W MNB(=SA6^7`2;=*4.B>M/OY;ROJ"YW0UU>FLZK.PM_Q0* M(@Y7'H\KX^AU>U6F_:3 M0YR[-]F.4VUW#MRP^QFZF+=!"3TY^;>KS4:KVJT_N=[M]R6\;K>J]MWSE^ZR M`VYQ__YYN'O8\NM_:C6[_N/L^_!'O=WX@:93K=NH_8#;E#?]^VMO^J-=JSD=N_UCV.W9MMWH M6DZCU;2<9K=K]0>-L35NC%M]I^=T1]WF#QM>_("$2[IWN:%OUG"9MKOT(L25G;@^MPQ")L(@P:P2 M+$7HLIG@SG&]$!9,.D&HN8<756:>C[X3&)@=*5'EK8?`8FGGCUMZ+72>$&I6 MQIEP#Q?`+CPN]``<-9[1<[Z#O\Q/W^F^FY'F([SM_E>-_F\/U[Y>ZA47;2KT^PSHT3P#WT.(=MM'V:$+T%,`7MGG&J03T,^5PJ8P(:W*)7CL M/?%$U^-NSH'L47587]EF4WJSJR!A[=6;N!*+E=@$H'VD\>F7TS6^ MU7IR?I#C[1E_1+3:S0-WM]J/-CM:W346XK'UUXNHXCM"-^F!/:2ED#P#(6D? MV#YX+L6MZ77A@>K@[OW!`]^J2OZ5_"OY]XC\>S&W<&Z'6-[!C_^V]G(H?5EW M\(/3^MRLQ(=KT7C_+Q[G.5URL.1@R<%#68MKZ6PYN5OWR,,R,[I4<7^/:_L_ M4VG_EQEU)OV2-JJDOILP]E`65=TYEVLJ)M[<]2-*T@Y@\X/'.YU9;7P^.-<$O;Z0[?6;'=;M91%=R., MF3,5WJ_#8+)"QHV]:.+Z_U>XX1A^$^TMBZW;;;;J_6'#JK4Z-A!;ZUG=GCVT M:LB!YL@>.F/[A_VC\?H##O+;+QOF9*XH]I;U>,V!KD%`>7UB@5E]0WC/#Z)5 M*/:?E>>T>]UFO>=8_7ZG8SFC9M?J#H==H*?;&(X[PT:W91=EY3UNAIA=J_UM MQYPP_<*E7G?2_#)?S&(S_-P\S5R)BG01C5@XC+:FLF;<6-=-W[A/J>J!$B+' M5+$);U-I)?ROF18Y=V\JY]@Z\_Q?`MNF!L`D4&:P]WQQ0>6@RS"8"#'E_K`+ MT$:^Z\WAGZ$78?8C)4.*"BRHMW##&Y"(51C)UK?G*WA$1-%IJH^-GKM8X8E% MGA.=OSB'J8A%.,>^FUP,.A47V(TSF.%LSMUSSZ>>LS";T(7WZ`]!%!&"*16? M8A=/O:;5G4S"%=R=8;;8?G<&HB`AXY:+VQ?%.7FESO*&N MN3B@R@45N0-6O!E\#!YF)IXS1@&VPG4KOJ>(P+Q4ZH'K+28K`EY%LG!,SCN5 M'6=/9%7MQ$4H[$HHW"A8P(@WZ4QOV3#V8`FX2<)L*'SB(.$RZ"M,R`V2@2XF MW&XH6:[*#KWX"OS_(J@$BXN`:I93P5PG??T8OYVJ+DK%[FEURV=)?^61K(_& MS39(*Z/!8I`MD,%"H,-P_T=!<]!J.TZO9;7L<=MRAK6^U1W7QS#*J-,?=IO- M0?]N"=IEZ;PAAV7I?%DZ7Y;.EZ7S!TM@?X8%VV7I_+&L1%DZ7Y;.EZ7S9>E\ M63I?ELXORM+YB[)T_NF4SN_=]V+Z=OX(%A??13@?BO/X`.Z9;J_>;_<&5K?7 M[5E.'4;HUOMU:S!JM4:#5KO?&#H[>>JS=TSUC_>5&4S5FKESS[_Y=ZM^RWWP'1,[^;?]W9YJ;7WUQ3]\DPN&:5/P)WL0^' M_-P-+[R%!1_YE=Q+\F=6`+_6M%_AK'Y%_Z?)V8W+D%A/B\I8G(7C<164&2X4NY"JYIESZ&_]%.J7=BXM0 M7+@Q=O7R%A-OZ?JI4QE&>6/73FL5F+"/KJAKQ#%88:5=9;4,>`3TBJ*/BWW0 ME1@.O\BEV.1T`$?I$%!&"4XAS66 M:`LX@Y#=Y!,1QB[0@HM,-,I-?U/I83@`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`#@,)3\!/OCR%#,=>??/-O:Y@?DWH@7'[X/Z].U8J."^E_*1UYYX3A_1A'RLFPMA;>!'8\96+ M()@^O##?VUG=/C`"QO&1W&@\J(OZZ1<ZD;X*G84_7ZDTL1N*OE6#MPB\;G=N`\I]JXDH/[/71N55VXV:]N>N.39PE# M_F;_WO=^V^[TV^.&U1UWZY;3Z+:LOCUJ6,U:?=#J-UNU\6A8>M]+[WOI?2^] M[Z7WO?2^E][W\L98>M]+[WOI?2^][\/RE7R//A7VE+E=[WTOM> M>M]+W_&1'SG/B8.W]KX7^=%-;SNFQ0\">#2,O&#!_XK%].,BBD/"B.M158V] M#Z0^J['FB^_`C7>^8A*Y//AM:FR"ZFA@* M_M^/"RUP\K@[W*X7TFFWS2V^D8I,98_KBTB"RL-6>-RE+)18N]YN&11FIKUM M$67;;7AC(KPK"C@][EK:A90V:EN64(7:EYE>VO6X%-<+U[;> M[9C:J(B`8L']'5UJCRZ]Q6MJMVJ%TJOFGA5A+M;\BN6SCVM8.$5D=>R,I*93 MWK8?OX8""X.'8B80]5(>-+W%E$ZB'I6>/O(.+3X]M^G:78C;8%P]LA`7+K?E M.#6[V'3***'@QO7C&RGCCTM2X;G)^U)3/,:D38)^=[T%DOEE@9OWR^QKB,92 M?//5=Q M\C&*5EAG_66F6?Z/?&86GBCU9LT\4;92DCD\A>^#%0PZZ1,E&\&_CV)=VX4$ M=\QE+28@N\)2"Q,3AMZ5-Q6+:<1JZTRA-7]D'-7'%>G""SQ\IYU9[-V)6CMH M!FYT"=*"[TS[-W]&>/,?,X`U\',2PV@(K,,0R2OXG;PS(3S'X^Z&0O5FUYJM M[,%T#S*S6P7;&L!VHBR\O7AYI7@K\0\,=C M.-V*E7UMI]-M&WD9`X[Q@%`\IG/,Q8AQNU\=AZ^NT%]9[[;-K;V%C#6QN/+0 MRSL.PF&P.H]G*U^Y#QYW\3<<=G9VZ0M)*-X#.68M<.Q(S/1B[S0Y?_+%?@M% MNSK`OKHWZ#%"\>$6#'_(7A2/[]XLO'C6F\Z.+K%-U!4+BPR!8/^0(_"3%>Z, M329_A@23UN]BCH!GX0VC6"%KZ*3\'GP34_@;_OM_77\ETAY6CVP*%YX,&3OO M#I1E?:53(>8H,P4V]2,SHM`^<.R,RW0+'=G&51'U09&'QB-366C7@\2;.S\[ M[W6JOLS(GPK/G(GPRIN(Z"SP#^5!W9&^XD6L-];(RR<@0RC>;:CK7%85/K+= M7AR)LYV,M[B8ANRBJDCUEQG;>12=3L+6CQUV+U15[8]M MO!:KY59CBZ5R*RIW\MTP(N61^V[L8M]-8Q?/S8Y$9@_W2+CAY)(X>B7\@"SE MH[CO%5]_&G8V&+J!"*;W_&(^_?7KZMSW)E]F(%X(>WT`+&M8SKH];%O#VJ") ML)QUJV^W6I;3;?7[@V%WU!N-7AB6=6L_6-9CJKVU0+_S(L+[R3IN^L#1P5OW MEJ'GIQEZG:K6,DVA#".H--8^RXICI)KJF*]#+XX%(C(OB0F(&4TLP`IEN]JR M&U7,'I3-U220M([Y6\5Z:A<'2-Z$Z4P(=_A-Z[1>2QNK5:E#Y$5(W=;D+8H> M0TAL&$""8I\2?O)"Q/J(\NF0DB_60)1A$K-8($`O**_5!#562A[^,/4BZ7ZA M;IK8E3"*2#_CST+:M2>OTH:0!6#":DI5;C3G+F%J/ZD5I']3>=,UZ%C+K'P$ MT5A=P#FG86!W\L#"I7`$"/B]@UB\]=YI!:'5!@S7:CH5,)S1F]$C%1M5*\*= M7)XD->_RW6`A9)<]JKS7L*-Q(?"OEZX_PS^Z"HH:QM`[?Q2.P)*8/IB*H7U: MPW5!030FR2#2;SV='KOC5!M.2SW85]2`//B>6#&(>Y;431_6/\NC,;1V?!G@ ML_*E,*I<&[\@%H!N1?%S_#DU8Z2M.L(K($2)/2W`2:0,*,( MM"$S07A;/?L./GHE/G20)]-U)RI.G=2=*F:0Y6WDVY+-=N:+L/Y MYRBS>MJG8!.<^48S2+.4TN2'L>N%&??0EQGZS])J8_Z0#-S'N#4;<_ZEBM1FMD.7;7L3KM]L"R M6QV[WJZ-!_W>;F;EK3L_/?6^G8=LIM[>5S/U1,`JJ8152,1DYX[D/$D$K7*6 M]-*ZI^%;-C8&R^N3J[<>J>>979EV,VEW)1CAJSJFTE8?V*K$:%22KN':P^EC MP_?O4+\KG9][MJ>=:B*M[N(TCPP8BQHSKTWF(RA,;,4^X.XUQ@2J>.IB^#B6 M_9+3/AHP7K0Z_Q>8V>I/H.'8ZF'?B4N82]*@6:/XQ.CKH3-7-AO!(S!"5[0< M_6MJ;\GV/FR!)/MEF>Z7!>V77?OZU$Z;25N?->[0UC-X@M!0B8%G3!T&>M$:]R2=,!.+8B%1@S:)=I!CS_S78^LDD(U445ZX:RI M+-T0E1+,,>V?G=-3IU#=F&(BH;E@90(T95B4R%""\=3*:E!<2;\97P8<;S2> M:?*"&\K\\/H291]0,*CC$/?@`48+H;6022P9DL!+LL[/ M!36666$;(+*;0VI%E,Z>;4)%:`AB[48KO'C32IL3A`&2*>*L9F"#R*6`G_#R M)9N1DUU)+O\JZP$0C,4%K?"YP#^"K8FG&5N&V`N'S-VWV-'\'9J-P5RH7;!: MN"L06;5KIFA:4IB'RMD)7BU2B7!LT"=.PM/*#-+:[FC:)*4Y9S19ENV.2WH*9:"1]I/>2E9`,W-US5RY=@V&G@U2#*$]Q=\&9ZEU1TA#KK5#\>^6QIHT$Z%%4 M)5(]X#9(%/_%TF5`(3Y-WR/1,4-Y^MT&Y MJ:^A6KRM(LNH,6GN[*C("M08+DJ1(GLFF^$@EN^?2XZ71JOYW-6=0!N,U37K MQX>K;M)>+R8`C=3H,CS'NM$%PGDMA'*,%1[GB>6$I$F>ZA?0'^KZ[OO0FAB9P MINQP'>M.(O-,YY[*U4HFCI?[+'['Q]L-;&W4&3+SOXKS8X_AAAAI3DMMG!0M MW^DV$R;+Y.HFDO1I)I.406`*09X+LDI3YZH4EMOTI47&OH^)M:B>MGGVPF?IM6XL23I)GX#JW$>Q?)+>,/LX\X#/5[TDG\#OW# M3S*=S+-;9T,O\4JBLMVHLJZ9$7V#.*>_5'E[)E@;5)QWID"YE;/5.5W?58MU M))'*UB;P$0\(W(GIZWL0GD,RY#8OVN2Z9N&KSP$49+5X[R4RF=V#4NXU"R%* M&)6HG8UCXGF;M[.SO=B5OEW;8C#`SIO,4#-%NS]_.I)$$*<<"LG+=,N6]/>8 MB\D:"G:DZ51Z0`K^&MXH$^QV;@(IF&HOYGQWB\S&`<:S>!.HLP'3%ZIH-,V] M.,L4DO'UN1:?Y2';^AR9(4O_E#TD,M`E<],Y@I0N(7UA]XM@]OI6W:+HTU5: M/W0HER6J<(0%YUZ:@5M^6`2+0. M[,%HQJY6;&=S[:)>)0\3B;;R$J3QU5-)P0ZS49Z3K'&:".F&E(+J#J*,F9J/<$9LS'_*] M3K>ZFDAM.,:N2I4>JG=2J=O/B+P[;F84TPC;?#?A!(6B,#M8,K&0A,@0)LHJ M+(F9$EFTX?,VMPK59+0*?"R8@*Y&*8=[CU_`Y-,B'TG&]8%$[>P_S?=HHCV1 MGU=A5^UVJUIOU;5]OQ#7/D;N(^^"C1+^(EX$\GP7QAK$Q@?84Z$Y.$Y>:2X. M"JDGR0V<:CYQHTLC:K">YWBB)9\;:1ENL=K\H1H(*G,V>T:"=GD$[OJM)VJX^`R;C\FJG*/AF*.%TL])YE%DA2WM&93 M-I4:>XL-LX.M24X%9"OAIJ,P)Z@?D33&0?*O/%]@1#82,>Y%L/%E6.R;D-WW M!N@](`G@$A:_>B MH+B@(KW0G&'18>R&-S*#*I:?I;_%R1Q\]SI)`L]AJ91GC:7;7+ZH_G#BM$FC M6_83/%J1/US4AKN=J4+]3-[KTV?<073%/^1]8).BN(:#%#/=P';P8I]/+5G- M@+=M[)$)KV/E1%0!R687KL+_3NP?S<4X34`AE#]'[9X*_`^<=*OYRN>\FO11 M.D;YJ*U,8?`;+E.#_TA3/Y0[L?.W:I*K(V.U2X8SJ?Q[Y<(!&OHW5`R&5D00 MRM,^+NGX4`(-Q#(W%2YBKAW9'+)+IINQ` MLKR%]9>''C<$+_+.R06'JGON3K$:1J/$J(4I]\/FL[,?N"$9_D,/Q)S\R&!U M8/(PUJ+X+GEX,6TU60RZI1*'@Y!TO%ID67P$-GR2`UDQ4Q\U64=YY>%/7IF# M9P:4&31O'$J)E/D0(4K)Q%]-V?^,H2!94\1I""K)%DTK+,6D3)C4SG9C%B': M)R!]3(^RX9($N'\\ M'AG,_W.:.4R&XB1LP(8)FLMS$?H#GY[_&]"=]1N9+^4)>L@3]`IC/FAC2G^$ M=EJP+UESB7$=KQM9Z1WPW(T\+,G].0'%0D-@MD,@A[GU;.!TP5&NR"6GMF=> M\D2NJTX%$M=]?,6W#WFOBU;)J:FL=:0)+_9O-:^K2R%13!D-%I16FR)LR?L( MXH!P`),R/?$;T=+'DF#^06D5,@[.95`-SW]VIAK#D^J8<&Q2PE^^HX_\>P4; M1'[G;4\K,B:O<.HQ2(M9N%B4;YT#9^Z8"W-YV+JL7<%7D3Q4!X]JI?8 M1`:J:'85J+L^'@=O[%.G=DHW/CZ84"!,># M=WJ,T/U+J'`Z91"1[5:51SA]:SV*]6O%]V#(JO+D7&#,?YD,H>-E_YJSC.F9T$RM7\#=X8H74U) MVOL*(@7% MD6!-@3.=:K,;\E!5!Y)*].#C!=G]7B>%OZ83AC@6:C"RG]E7DEK0&<%;<^G0 M2X;SYCV'AI(]PO(G=TIIS^UDSZ5H::5-=PO^$:I%`DFRZ633"TW)+0\L4)>F M=4"4F/8BQ9.D"T'6\\"3FOM`N@K-O->5RC*02"Z;3KODD#M)$DMUS_IV#X>J MT-3.8#88U-FFFV:&*9:!V#%ML<@POJ)JQI\AP]KR$*"85EIL%.$9)D^JK,T" M-VQ,&60%`5:M-?7\E9I+ MD4%*,2,HST5''2;UFQ+*@$M=I5X*K-=32=<@(PSW(CD`Q[FV MUSF_<$TTV>670\**^#M]!2"-(,`G9@ M;4JM6(//H^N%RAMU(T*#R7%_%+@%V`_`R5B:^P3/F((19'80W0CF8/O3SDN< M)GJN&@Q2D`AB^'O*S;C39OQ#\\^E;7S*O;DSU('FX-3.=ZM\Q%?U/,-2?(K M%[YA:JHJ?"NN)SS)01:%2P&">-YZ?2CQ@R<-2X`9+&X2Z]/R/1.;7NI6BOUQ M?J9J\,PY'W)]U`QV.ATP"(-M?P@GQK]9HV'C6DDIRV2NR.0@*2LJ33<5-]X, M9BPA*9A1U^9S`:>-X.:[MS!W@!P9,T]- M'FQG9*67>AFJL([^C9Q4'KWZEL/3-4H^I#V5Y)+0\5^0;*SM@^L$E$Q/OZ)X M0)HAM,ZW'6@KCXW-)ET6I#>Y;$RPTP[J[P#[*XKI>N`HY[Z2J$!6F^P,4!ZI M7,>#W#S%L63#E7&7(1),)G;YG`NX.%'@UY17&LUT@$E_2E3L,MG$B^!*EK;) M@HR$!U-I)*;W.E4)(=S0][`^+NLN6B7Q*AGUO!)I,=UHETGSJ:9:5<[?PK'>-%LRA4L=ILO`8X!TC8$3]#E-TP%D7E3> M4K&.NR9TG*+$J#(MZK9&]7I&8&E0'S(W"A'G9!X.;J&IY+JR;W@YBM%SU2J9 MZ"=H`6I1JR5<2B>T-7SWFA&=&`+F)X/0J?0-Z>[..';5)W*G#W?B*\'N^KE0 M`?^D>0(<%'$LS&BY7C6@,X!`A#.?5,9CXL:J>+.*CP8$X6#4:PGL_TZ&N;RH MKY40X_,YY7A;D$%2((6J@B304-RRU8(Z1Y6LH%&V""I^`&L0ZF'+4E?MZ'&^ MD+UL2Y_SK+L,WH"."HQ2GE8^SK(9/BK^PU=^^"WJ MHS0-;;D*ET$DTQ,VUU8G6D(J0YQY*EW$&'1O:.7P.)6O,"0[/B["8+6$0=Y2 M#3W6XB((BA>!23M3,.!G')W7M$GC[?3=V\:[+&OHHAJ_DZH*/Z06!#TJ:CU4 M7E@1MZ5MI?%[$[>CI!)+XSDF9/+ME&B2+\Y=O+02H/_43PIK*56*`%%0R6;3 M9*L\K*X:4;>3'L4^'Q2S);`5BH&[P%80I1NZ%V):!`E6%>Q:GC`V*"&/4O(H M6;I!&.LP)#AIEM1T*;55K"KSE%T0M4G6-0_3<"5@S2MRG^$\QD2!WL8LY]/7F5 M7!ZJM,%3$:`!=LQU?BX'TV$B>=&M'$KD:TQ-*;Y,D3/)=)ZD9944%.3`AJ#F MQ>4*4IYR//98AN&>J<]SX$/;^9)C"?5-5E]V4MP8/(!B/,R*4KI MV?%,#L65)ZY9G*2ES*[<5!8"[F;'JW&2X"-YLJ:!%)=$F,:EPB!458T5A*98 M!92%(<4#36Q6"7QH>&3;!U..52D%BIX\=+&LO.B20)(R%`CT>;@$>J*P*T@O M2^G19LN."HPIH-_=B[E&BCT44L]2DZW$S9LD>ZO#71[VJ"(3M`UDU_4E9ZY[ M6(XUQ10\X9-S!L]0[V)!%"UB/^44);BK>,45YRGAX4,!`3S.5;4(IX_('9ZS M!J>5WD*;#2/*J8\4?>+D5?(1K##%UV/&`95OKG\ZB0(L-3-&*?&$;PQ=D%DP M-*:,!U!Y&(]D4$\FLE&7LJW@OF@"`^7[NS`.HBVW@JFF##=)DK@V!9BUDQ=6 MJ.G70D=QSV/L-!"1U'YS(>A=-!)@,%"][KH`KY&.+VI_SS2ZB6)"V^"YZOCT M^:O/S=5XOP91;)E[)X=\RK3BM3[1`>2KN!,I))TZ-!./(`^*NAQWMMZ>`KUA MM_;D94^'$P(R3P5O(VQUYEQ+9HO4X'PU#:"';K0`>+16\4#.8%Y3?;<4]"-) MNY&8Z_S=U`I@BWM3\A6FK08Q@9CD1%&KIF>L]!:'L7FP\7]R&LW=HW>:UH'M MF_#FYZL0SMQ/8#3#IL..T/Q/+VD`3Z@G<#GYCN[>._9=^V';M5;7:?^TZTZG M66_J_>D^?AZOM66SG=JPUAEWK+XS'%J.8]M6OP]?&;>ZM<:PVQ_VQS!FK5;_ M4=#S_<=2A#^^NE1V]OI#O7O:;4C.W9KF8^`7_MQNMEL_;=MV6DUG+_RK(__L MG?C7>$;\:[;:K;WPKX'\J^_$O]9IXY[\4PVYO\K0]9<9[>J/\B8VH(#9/;C5 M=CK(G5JSUG#VTCT2_ZM>P)W7'YHUL\_X)K(>E`%VK6.JI[LRH$[_U2EB@--L MW9,!XR#$#+!P!19?*!$-[TI\M]-MX.IWX9M)K=>LL"*KI6 MO]4>6<#`1JO6A*W1&//B%V@6V`WU9B[I68),LI/>HJJ#"1QQG[AUSO3+XAM: M3/A2'[,\_EP$Y^B^0\_#Q\5R!9,`YDS@+3K-[]U&]`?*2:/=_6DW:DVGO2XA M_>[`'G8'-:O3Z(XLI]/O6=WZ<&35ZDZW;;?L7G/0+&HKNO$BN[G-Z%K7>N,B MBNVS,W=/_<;(F?`,^=QE9&+]'F@8-B=)44=N5H0OKH1?:6C] MZ=YF'`8P0/+'=\G%@`M5T%3;9HB>,`SH+?&>=';6\1>9+ED[=`"[11?8M>4I M[`&[DOJV*O8PKY'Y[O<9E$$^02?A%/2MT1M_=[[AKTVE\HEV;_CS"0"<] M'%9^D9-;OU3NV`'XV3#M,RBXX^+9DQ?UPI5H;5R)MU0X'U\&JPA.GNC=(;F* MFAG6=ETOYZGM?C"]R:KM.YT\<$9<`#,"."3^:S`8C<;C@G7"_MIY9^E]S!!; MS#.N;0M^I3Y#]%+-WKGKNRH)?VDP\'`B@G]\LY,LR1_)#4ZO->R=WEL$UZ&[ M_/MK_M][3_;.>R%G'KL1GGEQG1&IN00JR=GK#'<;:P>]M<,6.98-\0?U7EPH M5Z\"/LC&VQ+C^4'WRY9%>A[RM'\5<\N9K[&DW7T*.^AX#YG?"34;]Q3'%H]J M3^U#0-[>_31Z][2VPMN[[X6-E.ZR!5[D-_\V&O!B^5B\_+5!JQ7_`Q+@[/V9XN.;5/N^F)'1H-4#W38'7NBP?4 M=W?_Z-$>&\^,CYN\6)J;BA_%W^;-^@$#7)M(3S)K#AEJU+(@DN'EF!C\_*<7 M7ZX-%9ECF1]6<[M!!\%'"83U<3%R0_2>W2<4G@EM;@R%U^RQW6L.F]:@U1E9 MSL"VK=ZHV[0:3A.^97?@6_"%XEAPNTNAX(?CR^'6`2^5Q[X.A?D8!UR'?+X< M=W"_WFQV*%?([M37>-T;CH;M;KUF]>S>V'+JPY[5[=='5FW<'_3M9M\9=OLO M*;C/!3)3HS!E84#B)V'\D[6,4NJ!EXUCE5'\,HI_T&\_^=!F&<4_3J:54?R# M^P_**/[Q!UB>;!2_6S]P:*UTIKW,,/Y7A5Q&=4Q%)O.#;I,R>/\H$V@9P.NVGL`&.1=P'!MI,H;/ER0G^V^[= MY>"I):D/)TOE>`V:,F_E"5@^SYE3S_`8>6;Y%B4?R[R5 M1\Q;6?O"_E(#]I^^8@;O-Z9-C$:U9JW5;5G#S@CK]!LCJ]^OUZUZ?^0XG8'3 M[X]'F](FX)6V@67P8`PZZ+JE1+4)A!A%@2!UP!8L7ADH;2R_V7F8;I M1$A.WX,!06DR%M91K4:C:#6ZROM5LFN$H>\-"H-QIT;!BVT1YC;E&S M9_4;PX8U&G7:K4'-:0^:+897T8&O&('U]8=6M]NT&^E>V`OI1\K-3J?1V0LW MZUFP&L5-N]EH=>O=@[+3P'$SX=K">:3DG)Q_]^!9H^T0O$^KTVJO,GSOH]^]L_?.?;U3B=U=O#(84\;#_QO@=Q@5_PC$L/[ZPUU;9%S!69'V$LK` M*QLRJ1J*66E#,6H@EG1U)+S0A6H*=>N93-PHINFD69*+E>IZD46ESP/3SJ#0 M;\31O!2(?-OG+\#XB-])'_7>5=XT3NLUVH=O/8^?F'"'6_GA M`K&AA-?0Y?Z'[HW>)COMH)>T8MHT2VK238#X50E?C$VOW]BG3NVT\C'M3EXU MQ]U=,*KJ^2*5&5=\@8*ZKCL+YTQX])IFK:*4DYH*+AA$F=!5D8^^A`:O)CM$ M-DQ(NRXH4%DDS?T+GH>MB,7;4@MJO2:KV(80/L-2AMW;+Z)?4_QS?&"*,*G^ M%4Z&>M"PYE\M32QH.F1F&%S.=GK#MT2B=O$7A;TK>18Z^CIMFO>,(,O3]1$L MEN<2BJ5P?34J]6C6UR_3X!5N@_),2"&&BUO`*J3I_@WVWQ).]7V6,;D3M$._^/#6[K'% M#V'>;X1*`.Q63*QT+\2^#GW\N5EOTL_M=LT`&EVOL]C)(F`06_TR!'(@7G^H M@?*6U]!;D;K)#AI*L?D&NVROS+&==L/>`S,:641DQ8M:IT@\\FG2!&6PFE,? MF"OQYX)WD)@.D_US`-K7,4=WI[W02^38J5MB(T7F^I^!U@X3'%;[7N1V)<1J ML]O8`\1J`V^MA6X826X!&8>F$?[1W+*D.]'H((U.H>.OO3N-0W$>?UP@MBS: ML9^P\0&<3T,\+>]!;JME`[EUT&C.^GUF;(_K]JC;L?K]4=]R.D!ASVYWK%'3 M&3NM;GLPZ/:4)^<#CFN!1-M.2E#QG$W:_L`^EZ.?2X_M`7S@%HO8J#%1+21J M?9E&PUYK[(RMX;CC6`Z,8/4&3L^J-6K#6LL9MIR1_4-1T+'LNM6P4PKR9J9I M%OB+P`:MO<5BY?JX;&?NU>V<_YG9;Y2XW4@I=/77G5JJ0@JG7N"6[X$5SRU5 M(_7J_P:H@]"O^>U68FB0C-C-'1"BGW;#KC>:]4W>WG5G+["C83=[-:O;&=J@ M5^T&L&0P``X-&LWVH#X<#226LY-SIL"T!T6V9`[`CIQ)X9W;D;:#OWA:[T[W(U0G/+#JX?"];X/W7GJH-WH[%$=<.!LZ$74N.:>+-BS M1EPS3A4+[$Z>S*^3DF/A]&`#4&WJS;:K"NTI$]C0PE4.K_@`7]6(B M]^>,V)`38M<[CTGD'KT1]6)OA&WOL+W5'XTV-W06^-CK%!_]3.[O+[.O0>2Q M4>![W+!^>@M>=!S-5;%M6]>'SF`XJCE6O=:'([T&QUVWV>S#<=>IMP;U5F,\ M=GZ8)]QHOO2#&R%0C:VAXKT0 M2CKHQ2]I/'K_+%D7@!U94L_+X>NT:G##JJ=,N!M=)F\^BQB#QG.!R<2]*]?S M,8_$2)J487\:9@],RDRF?(%XZ>?@T4`$D@A%3""M>NU34;'V8F74S1[T$PC1Z;K$(/1ZO5+21+S7R#.GIN']](HA^5HN(`EMEPU)RR28YROQ^%*BPDR&Z9VRDSZ^R]TO?9DOSDAG\) MU"7'0%V[<%,YV?!VT?Q-.G\7"U"5/CS7F\+EP0,KFE(=CH'8PH/=;M1-?;^% MBFP./=RPX5'YQ\=5*`56+O8@S[A!LM->)^K+C-0G=W0G#]@9&#./2EZA)ZO> M<-:HRY__VGU?N.'D$BU7;!(;+#';X1BDM56(E5PW2=U(PB',%&I7;3?:E%;7 M;76VT#L<`TDUN(YVND['3E7],%8CM071QMS[L-4?M@076[M!RQIVFU>GTFE;#[O;Z+9"SMMW: MY")I[.3?VJ,W8;^+5NQ-@$W6>!AOPEXI*C8*:P_E3=CO"A42Y#R&+V&OM!7Z M$K*1Z=T\"?EU(A$+[5GLQH3G\'&^=">/K"H+;VKPG78FDK8[30?UJ^R5`84F M7+=>N[M;Y;N88XUA>#/Z]\J+;WJ322@(&BCX)J:"4Q8Y@S$M$'Y4,2B4_Z9I MWMR!L*S/`JL+W;6B^CN411V"#X4^FDQ5T%8R]NMFVRN1A6XVNY$YF1[*S;97 M\HH3QFJ-QW>S[9740N7=R,0`=W"S'6-;-X-EA^CJML%(:VA5CX_9U>UXT.+6 M5F/?V%@;5L-JF@&`!\:*>R+P90^P0D\!O4SRBRB\![]H,!B.H&=NY$_P,Q[P M"!@APDHTN03:_O[Z,HZ7O_[RR_7U]6DD)J<7P=4O@X___?H#<,1VP([&ZI7T MM72H2%PD)I+\U<_ST)]ZOXJ?2]^;>/$G[F\U]>`Y9,#?7R=WD^G%[W^D`-?A`_P.+_]DCM\.J%?S!G]]HM!_&]+RJ74YA^[84QEM:H* M%[/2T]\F#X))I#W6M1HU''JJ/?3;+]K@O_TBU_"^"VH<&$>^H,FFZ=^DDH\H M(KRP.7@,R6,O<'4/OII/DSM%\;\CE_W$?W`V$0L7>&$J,_5;$/\K+UA%_LTW M@4A86/)R<,EW=EM;YZ'6]K@D_QBX8Z27'Q5W8,,[N^F%UJ&XDRE`."KVD%1@ MPO;CJBU?ACM:>^D'R0`RD,N,=?P/8>FK3.6HSV&5M\0@7N@ZFW781[[.R0KW)6;F&0^F7_(&U)(Y&@?AAH+NE[C8 M1V>\'`E[BE`IRKVPM[W0V&VQ&X=<[(U8+$>^UCN=;TGRW,,=:'3S>N0+VD9$ MH2-?UV/T0A_=@I9>Z&>\NILA$I_.:FNA.HJ^:>L]7L7P%RW.1FA"NRUWJ4P. M)V[KF*7/0MP&*]`MB[B4MT>7M^.ZJ0/O\MZ.M'OHK'[_,_YB4N??[/>Y7USAA'OLK)^M+]ZLN,3)V,"9+T MVS#O7"]\>?,[XASY_9)K=_DS^`*1W_=,/073S0??9XY8%Z2I?RL/Q5@<"2EOA"-7PO M5S:>CC/M&+U7Q[>B9>SE.2]OK=N1MWK[^)6Y@$S8WU4*)`(2L@_)>Z MNFVGTT)U7.L\H6P6+HW'JFKJB>? MT2HWV[1]FZWC3U!ZX&2T.TWM=Q%!G^^L__+45-B9K3:CX= MA?+T1.W+/UZVJ)6B]8P7^^BR'8Z$/4[I2ST"7^K.Y0:/(0^E+_51?:G'*!OE M'>]YKFJ)*O$\%_>XK)\C8(_-P`E:H6GI;'YH2)7#5=-)S)"V[>AYO!@G8Q_L5%GOB+>'*/L<.EU]F!)&&]>*32;@2TS\72[CC*8#FAT*-LIT=+C'\ MV`,L=)GJ\UQ7M@S>/Z_U+$/WSW=QRS*VYUW&=BSB5NLJW?:]>ZQ[SWRQA%\=B\75U#N-] MF8'>A6O0P]QLG!U6-WGL<*+?L3NZP5MOV:WFT6O6#08OK:VT=O]<>/$#A:@Z MEKW+7N7''FXU&ZW:$\JIV+B:_1>ZFD=W+!T)`BGL1S=9#+5-I[S^Y-2O!#Y^5 M%__QA:B,!952="N/PO%9-L[A+9LRF67/0LIQR`=8L*>DVHY/ESS8,I6FZ)-; ML]**>,Y6Q&&EJ,R%V/^B)2D.!]OZH*6/++#2M&":APVLE&D=>]`F',)^N$4J MLS6.>)&20D4L:BYWUIV^OKEL\J!%TLGN9WT?2Z=XGORN1SV*ILD^G*.H.TTF^VC][D4Y@@2 M(HR8:KZQKV$P]Z(H"&^H#/LAEHS3=Q]@RE MJ5NUNF7?*O"^`J.3UL6+`J=NMW_\>39,.#WG2,P'^;=?X6^__:)^R8/A^\4C M_8`/_XC021\E@TZ]*V!].G]\[S/P+'3CP+!PMWZ=:H/]!YP*'.^`QML6CCQ9FM<=FTXV:*X+P4M MT3:OE.@C)2>^7W]#2K9D1Y1I6UI*:;^T&YDOSS-\F^$,R?<_/?O466(N"`NN M6]VS\Y:#`Y=Y))A=M[X\M'L/MX-!ZZ.7\ZF** M.0JQ\XB>6<#\E7.+J!M1%$)ISCT)?I\@@?_AR/]Z#GSZ]69\[UR<=1UG'H:+ MJT[GZ>GIC'-O7>29R_R.TVZOJ_LE!G;EO#V[N#C[/O/+F$6!=^6\R7RZY3BN MV`-(5\[%>?=-N]MM=]\^7G2OSG^X.N_^.YN:+5:Y%^[)[]BR\UH^R MPO><43S&4T=AN`I7"WS=$L1?4-Q*OLTYGEZW)C/?DY)_<_[N\ESF_Z[/W,C' M`5#U/@0A"5>#8,JXKU"W'%GNE_%@"_YDUO:Q1UP28-6#PJ0[=F3B3F%YG5/1 MCB'G;P\A=#E9QW!Z1P)H(X+HB`DBJ[BE2`@R)=@[!KQAR5^3Q@AQ?%1#'%!\ M.,0!=8(E/9/*RO-(AWR(QOZ/L20P"CW#LAB="?EG> MR9#[1+B4B8CC/A8N)PO9IL/I320`C1"]P+M!@HCA=,1AVH2Q*'_O>9YJ>T1/ M'>'EU5ZB)![(+(`>[:(@[+DNK%*!`0,'1HL+HZ9/:!1B[S,.[YD0(\P?YC`YE\3HD!I+9`S5^BQ0Q8H/SRZ- M/.S=<>9OP:F"^"D55]+B[S$]/*>H`FAH#"5 MU>('U%@IX\@0!]=69O]D%)12 M%HRB">@LP^D4-CJ:&/(9"LC_5&6`68`BZ\6*>^!E]?C,W))F MS@[4Y_"&`HMCI/85T54MSD+KH"(A&=99#^KK#S9$L*F['J)X1#`Y6!%$4G/5 M8M@H)NE(K&H,%%=EE6@5S6Q28=6D[UDPD_I9'T_"BEHUOXJJB15H9Y4O>`?6 M7;4H=E2WBDAK:ZF^I0]5TBIK]N.!)$)R4Y^@=`EN"0O2XL"3KI'XJT13EFLG MKKVS4WWEF`P]-@H'(`%);=5.I7^.\>W^DU2NG'!3)";*$Q>)]@RA14?VJPZF MH5A_43VM?=Y-''+?)9]_2]9=,4(K.1'?1EQZ6M8U433!]+JU)W''(NXQ=C%9 M2C2?<6B&/C>+)0X\PMYZ@PN&S5X"FO16T&\LP!$BWB"X10L2(IIL:89JULFG ML3^C%3Y"X%#H,,<_VL.UIV=LI;&!4OH/->#43U8PZ=43'=2"'+88)&-"*=`% ML+>2V<`ZD$ON3"H%<6^$R35V:8`(/S+F/1%*-?B-LMKA%'O85H!(BSV3Q!9& ML>FSPW".^6<6N/%<4#BIF>2TP2BSP&F09U-81BA57CGPYHQZF(L/_XV4P#DI;2!6(\M8S+K4=4">3@^&X#,9;.`'*W0!.N:' MYP4.!%Y//+`Z\U-`YO)P-V\Q>2X]O$T?<7=<'_WRQT;(==)RDZ`@94B%+ M:Y,0^^O\4\[\%S;,E*R;U\#63,K)"7]P^L@;6`"I)S_V33..TMUEGJ\[Y!R MZ[XB;L5[G"GGBU?$>=OB3CE>OB*.1EII2OW[YE#/L=RSQ/-LH`W/;H.:>`_/ M(K,IY=O,=BW<[]`T=I9U@U2J8U@7[CFG4FB0KG6,%(ZP,%+9-$@E.T8V>:DV MY"\:I+_H=[2VIH&\[;IT<7OWVOCJ'.II_SY_A91U?NR4]:OKV-I=W91S@Q1S M\]5MVQ^9DFV056E&UB3`(:7?H(G,C+[)+FVZ;ATSJ=4U#FO[M+E]J"^/DUL) M11``16ZA)5%^2^)B\0"]2!N4H,U@)Y1"*)4\L;KU$2`[R6Q@_8@#S!$%&#W/ M)P$1(5?MGH#20-^7RU)0".98A,7(=U/9#:.(A]L:T][8B9WD-K!_Q@D*>4!8 M`W@[C764O24B-+8`,PMJLBBID]\F/`Q*L>(VCV\2"&9[6R4OI35'_V=8?K;Q M%`_;/9DL.?PS8>=]LB0>+,(B!K994@?^`KD%GG_S(NRXSSV,?:2B[W.A:KWG M^_+982,P**]S>=&#/._/E&NRN.,5Y['"@JT0#5=C0!-HPS1W$ED)54`4BP2` M4LWT82.Y26UC-H-K#2FF5&YS!MXGQ'_'*M1^ST!"CDJS:Q#KS8'OW0V\"-=)=9T)ZS_S"3:#>>YSX!K MI%/BR!V#K%QV!-?(:),2Q&!@,VH"4YHT,(Z3S6%[!II(EM76%LZ"3_"("WY,@OOWU$))`SU3"]-S9==H93&6R67BJZ@_:(`JPX@3<( MY2"6]Y1GCO%LSO#H?,%FF>TX6K<[^2#8"9F3'>9%1)G6#7M48?7BG9[O.)AE M)FL]./4373I93F0,-`PJT"MXSUO*ATJ$VDA?=K+X(#*MQ$B,6S'IN"&:ABO)4 M$?T1?,N^5*"+5#BET!K)(=XT+%D.IH762`X;4ZE,.9@6:CUDI[:!17%X[K]( MX.T)VLI):`?O*KXO>JHV7@9"1'(-4Q:V%GE!%DOW4+@8>R)^K6)S'Z34F[5Q M-?H7MAS?=W^?/5ALW-GN[J&'#Y@^/%PBGL+JP_O^$65+X&'.:6J5-I!UW915O6S:JA89JKT9\>,;<)0+K(K?W MY[/$9DGDRX]WC/=9-`FG$5V;07HB^BQV@MT6FXD\>S!.&^>F26XEN"FW=^L" MF_(3VPV`V+LQM^,X/$D%;*2GL101&5L+C3P47HJ(C`W+](!5L]SV)5C3.U<8 M[=/5&GFVOGQ)Z5<8S0'[FKOKOE9?.D9C;.39UVH%JE$S&WE,MEI)O3":3SM+ M^RIE=(@AV\@K-"H07^'>4BJDA@4OE;`;:Q(5V*30CO*E8N;Y;^2]<^4+2V<. M-S(&K'SQY.W)-_*,3`6B*=S(:N2!FO*$=$QTC^8XSA]N53.-&-(98:Y?0UI;$2Z:XU)_BLDPA$9S_.I/^1F&!S;RIKFO(;X#(_)..RCV]<._ MTX=&^UBXG"@\P^E-)""]D-SDB1:AMA`V+W#GOUYNG4'A>\AUQ2R[.5\-I[!F M;FY0BR]Z!:'_3(1<(-S,\Z'#::8'UP=^=C&S^=+8G3QV/^N")%*S`?%D0 M1;H_YY]OI^W!.$9/GZ!_:_0+BC=P5,R9>-,Z:=@0J M9SJ3FU)1O-C!8BC/=,I5GM`HQ!ZPE6;B"'.UB65_$DX)F0,%*W,NK4R[7"NNJCJ@?YS@'^`-V(;67\5:IA[[M M$\A@W5SEFFX*U55;DN[X>X;JJH`6O%Y04\1WC%+VQ()1-`$U>3@%6T==5EQ/ MM)EA!#:?3X20*Y4<4/&%4E+..Z[..A%12!_99KQM='HQY#,4)"XB("G`9O%0 MXC[*&EZ9P9IFS@Z/Y_"&2G]N[1@6VF:-Q[W^T%3\CW)GJ(;H-ZM4VL?KW%D* MX=95QMDPMQK+MF!M;<0$N+/"UACIX:NL`9GW'0ER@@2&/_X/4$L#!!0````( M`%N&<$>YN#W(K2H``$P(`P`5`!P`8F=M9"TR,#$U,#DS,%]D968N>&UL550) M``.^3TI6OD]*5G5X"P`!!"4.```$.0$``.T]:W/CN)'?4Y7_H'.JKNZJSF-[ M'IOLU$ZN9'N\<<4S\MF>W=Q]F:))2&:6(A6`](SVUQ\`4GQ(``A2H!JD>1\N MLS(>W4T`_>[^Z;^_+X/),\+$C\(/1V>O3H\F*'0CSP\7'XZ^W!]/[R^NKX_^ M^Z]__,-/_W9\/+F[FUQ&88B"`*TG_W!1@+`3H\F#\ST*H^5Z[/9+"M?[R0^O7K]^];;TE[LH";WWDW>EGRXP3UZ=F[X[.S MX[,?'EZ?O3_]\_O3L_\KCXY6:^POGN+)?[C_20>?OCNF,]Y,[E[=O2JA^.^3 M^R@D=/1RY83KR30()G=L%IG<(8+P,_)>98L&&;H32M"0?#@J8?C]$0>O(KPX MH=N\.=D,//KC'R;IX/??B5^9\.W-9OC9R3\^W=R[3VCI'/LAB9W0K4QDBXFF MGOWXXX\G_*_ET10.+\Z'E\%Z=Y+^,1U-_/>$[WD3N9RF&NA,I"/8?QUOAAVS MGX[/7A^_.7OUG7A'?V4;_H2C`-VA^81#_#Y>K]"'(^(O5P$ZRGY[PFC^X>AQ ML?38=WIW^N.;4S;_3Y>1FRQ12`GC?0QC/UY?A_,(+SG41Q.V[I>[ZPKXCXOC M)?)\UP\1/V]Q=G9/V.`3Y7HG^T)[1V=^O8_I`65[S.97?DB_J.\$MQ'AM^8B M<`CQYS[RV@"ON?(AT;AU,&KU(1HL'S^AV'>=P#QBU_0I7*)I$",O0\S%RXSU!WEUO;Y`O?>(&$4DPND3$Q?Z*?=/9_#PA M%!I"IJ%W[A"?S.:WF#ZR]"ZROT\]CW][)]CWAIO;W2`E[OU%2$^TZX3QU'4I M=XLI![Z-`HH%(AW@WF(_D]@FRZ6#U[/Y'7+SNSQ=,C`HX?_FDSC"[$:7SN%L MQ40-"@?9$_&]MNZ"!M?A,]V&[HI,H59>L0N(F3B4I!>#7AQZ6UQZ:R[]((F1 M]QG%-Q$AMPC?/]''V1!&378TB#'==AF%?%GR\;L;)![RKG"TK(#3!>+[;-S) M%W]RP@6B/.#*\?$O3I"@])M0H9C8,=.,7YX0@(0 M[I%+1WL7$;UJ./8?`_0YBHU=X):;&Z1#:==<_+JF"@CFTG$7'*G5C@8Q?D!X M>1,Y70@:ZJ4-OU=^G-(K9.>#<76JSWS>3YC`(JE$;A;?)(99;9?(XP MW;R3<]ED)Z/?,K_=M_3E]PF)\)K?\28^Y2*J!0<^A3?V`P0 M9M0D(Q(#G9UZ21Q.&U<6> MOSS)QIRP"1W"0[="(7-L'GMH[B1!W`RZW>F'@35:.G[8&M1T=I>0\AWHP5T^ M(MP0S,K4#F%\HDM@-WE$QSEEFD$J6B"#U\M=[\SS7H&97C(4>LRGF/[*EC+E M$^6;T^WI):[L&3#7<82%A.+H$>2^6D3/)Q[R*;'.WK)_L&?O[?'I6>8=_A/] MZ>N4;NVQ[:\"9[%9+G`>4?#A:/?O)YW#R/OBOY&!&#*QQX:3D8C/2B+D8>#L73LZ15#UY3KJ0`5 M#@>!EHO2>I"F0P\'97K:Y%=(/.YP\#W0915@\3]W#TWZ[%[0#3&SJWGH^]_1 M6@"6>-S!X$N=5DRN2SU7LR1F(4LLF$P.K&K2H2"_S&0;"8R79>&E>VBN_`#A M"WK.%U1\E@)5'74HV.[0PB?T=(7Q9VPY/(HB66*`L,_ M#P3#'#V"N;^<-\A M%_G/#)K/*-:#7C@%"`>J.'J;\%X?D5H$).-!H,_CWVX=W[L.+YR5'SM!Z5V5 MH5$_$00?0E"\;4_9^B,<7--')CBZTJ-1'00'9\T)KHP!AU*+J-MC(:!FN6D2 M(/F?0&"2A[[(0%7,@,(@>W%X<)8"[,JPH1CKVU/NFOG(%RS\);TCE)&FR3OT M@_X<1=XW/]BV`S>:"H-3FDNVIA!)82\-@8*1Y#=H%C\A_#D*W>R%4C$PG9G# MIJFU8$MGF8C+C5,6GLZ,&YJ MP<@2F7X7#'WJVR`GE0.0:P@N&`D!,7^)M8^);+0-D!?L1!/XT@0(^&\Q6E'] M\^/W%0H)VC!%'2U&9R8,1M$*X7A]&[!TDM!C#^"*L7RY1*.<`H'#'8JI4(N\ MCPX.>?:AZR;+)'!BY+&22ZXOPT1C(@0^N>5OQQR]!;]@("B\HE`ZR2`8.#5E M'DNDG,9RC662S`-:KB+LX'4*RX6#\9I>L[2>R#2.L?^8Q.PT/$1IJ2()6LW7 M.;Q#26UY8QZ(&FM2X3VRSZ^KCYR:G10XVN?8U<=1SY!1X&J?>[<)KAK&@QS5 MU_8Y>IO>RS(V]L6I:5FDRTBE1F";`WX:HZ3VXMD<`-08U:IYT>;(G\:H:6E2 M-@<"-3^W,MR@^`-L.`7$MVIJ-BQ_/I69JV`9]L7_FL!=9;8I<+5M-L"0IU MLZRR88/0]6<4(NP$E"93;TG?'/:)V5N0?70)7>MF`54KHN(?B=60;X^"K>^3 M/L$;F*0@2X:/'H^40)]11AG6-UY"Q.H8<"BGSXX?I)'I)4$I"UW@KY0.'AJK M@-0,H:*5P_(0:K^*:"18E9//5$RJPJ-^2FHF`54[*74CO/2??8\*BR0%+!?] MKIJP^>>@X, M%L\H3&HERIUA(+!&:R=@5?HY+#)(JX-`_.).@$@&`%=WY/5]A$.A8=8#%PQ2 M%`0L52ST/CGX-\2>;_6E4TP8HSP&&^7!LG$0K[@?,?ZQY,8;;GV=>O],4JE< MSWVMM1($QK\B?_%$E>'I,Q5C%NASPBQ_LSG7ETLV.SV%N^5B<,;,.IM(U:0I MMU7UP27:!-<:N:0/[M`FZ*K801_\H4UPK37Y],$SVO3>5FVT\/[0EU?*0Z8C M5*ZA4.;M0[4J'>RV-8\^U*UJ^M6V/A@0=QCCP\PZ0.E>'$4^RXM\!#*,R=SAKK>Q^*?.AANN6IZD-!#UT&46N4[T-)#SUD MFWE9P(M\=!5[J6<;&TX)C,8.7/!*&,90KXV^Z4,M;#U4VYI#P2MECQ&--!WPP*Z2V.&.?PSM=?J!9Y M'>9"^M2-*4_AI79J6A=VL15(9**-G0^SP\1*I])_ICI&:B/."G64R7?I$V8- M2#"JBZK<=UDH6M"WWX_HV:%,WR'H$J7_J\!2,@&X$L.G"H>0EU_(QL%`2P\% M9@\XY3L,EK2@:?HS939G4NCKYD%@PRM3YI#EP%R']#SSON8IE#*DM*?#X+:B M;,;G^4?TWP$7AYEC91GAV/^=_R[%2V/J&)^<5?:-J.81TH\M!%0]MI=0-ZYG M\KA8>AR:TQ_?G')8V"]??Z9K,3%@%EXY/MY2SF9S=KF*F[0%8(L%0"+8;O^9J9^; MV`;D,7,LU4G3PF*!(Y4QC"T/31N!^;/<#%P#_;H5P#%D9W#&8Q7(Q^\(NSZ1 MIK'5SP/"YMEG7C!!E4XY(O(I,)GBJUR$*/>ND\`O'0Z2PRJ\OQ+()8-!4$W$C2GT!M[4U.[H)!&Y&]!&GLS M6KL@3DN#+V\BEM_,3.H`)%>UE* M\Z`Y-8,5A87V(0_1-!TJ`93@:8@`!-"+32PH8R_C[.J*J"/&^U!?R31E&L9? MPY=J>GD%P\P&4VZ94.I<^^`EK&`)I(P,*FACKXVI.]K(/9@%7>RU(1WZ4K6) MM"CH:*^\?A@Z2F(6"@+9*^T?AD`[H64%:>Q5``Y]!^NCO`JJV:LU=$>U?;-7 M"NK9JUF8S3R0OE=U462%G:)W6]Z)Z$;($8W M?JV"IKV3[,TDCYT_]B+(HV%GSXT"-F+(HWUCCZT$=&LF*ZH!M>'WB'Z M6-K0*<04/MIQWL,I>[]_A`5XC7Q;JKK:B)BF@)>A^MIF7U?#)`Q18X"T9DVA M@^A=WD-7ZRTNV24B+O8Y-+/Y>4+H>,*BQTO2A*TU+[@"+7G59_Y$P3*@N$)'XWGEF MO5=$QU@^&*02L[JQK/)!!U*7N<[-O MX4[MLF9SS4!:"2Q-=[J/`H]GF`K!4TZ`KA`'6>512N%HQ8KI,#7UH^,^?0G] M>!-4+R:P8KP1B.Z0OWQ,,'VN%>9E;LJD9_%AMP9NRT7&6G5-82?(P>X3SV)[ M1D'$`W!UGF6=F89.4NGIY$)N0$5%CVFQ'TGL+YU*5WLT#G6F3:_Z3FZ@87<(::O[/(C`PL"G4T9Q!M(;UG>)<]Z"?RE M'SJQM%1GR\7Z@W<::9,Q=J-$J*X,3A$&+8>=4`:`%/:5NEE&[ND]NO0)B?#Z0;,!5"^=CMC#*X M^[G6[N?M=S?U]3)O&L^0EQE&MT>!U;#FFI4,R&(`:-7DC5,V>W2T:E4+YX!B M48YATL%@9_Q8+WQO+,K\2@>#G?$PT-,3\!0%'L(D):D4[)V!=L#+*NM@DF:8 MWZ\"7UI!7&,F&$;,M(>\2ZYII.I2:DO[C+[Q/\D/D]9DZ_#:(7TK!`6K6%#_ M_<+!>,T$/QX[-XUC[#\F,8O;>8AN'84GKODZ%F!+(9EA_J:EUG7Z??C'T<-1 M.MN(;,1$RH$N^TA(!2E&\SF%6N#4C^2C^\U]$#:718'K=2!JF,.XF_] M]1>1OY7^"EA(5AI17\F246F8?2B1JD93JK+VH;JM-FKG$M3@"PXH$O#ET?G; MU<'%<=G@N6H:7[`NJKST'37MRO#5)`QBOJ3"+[:H0" MD$A6/,["&AXE"7+.#`24V=Q[ MLC%O]EXQKC;WL(20[K:#2VSN50E`'WGRCLT-*FVZDVVB[6UN8@EP M".4576QN209`J!9.>9M[FAWZ&M>DW-GH<]GCFN\' MHHYFLAEXX7C;Z"4*Y,R(]&8DDE[V7$:OMR.]=&M`9!1[-U*L/K,QH]4/(ZTR M6BFKMV;4^O-(K?J\Y8Q6?[$Y"%]9PKFBQNQV-VC:.,5J_+9RIXH\$2B3I%YC M2HU2RQIWVYZT$:WL&)-(6]&D4N,@:]5R+F,M*RQ:W%K[#%FMD=6JW5?YX+6Q*6GL3WLK-.UX8YHA*JL.)O"X54H#]`U/51VQ,JX2 M_=8F=+7NJ:SBF.#PBIXJF_#5^;Q[H6O'O:UG+;7E="H'6=:3K6`Y>NH+7'M> MI0'1<$->NUK(#:OA$,_I9'>9RJV74?(8SY,@^Z"RVF[**6:*N[9N87G(=I3M M6DLV:1,YJN?-2[2T#")YR:53]HI44KP>X/5/]/QG`*$S@'Q[XP&\0RY3'2CB MR$NS:Z@:\3>?T->/25^Y]#:;ES+Y!\+"]^@"BW&$+R*,D3#`*IK^L$:;4C"L#/ M4>21STA:^E@T%!IF/7#!('51Z-!K_^4PZM>8K8P\E1AOE M=14CCX$C,4`9O#MZ"UF-S57U.B/%MG1@*)*0X>12$(2W0K!%>JA(>8ZI`\RL[J@ MT;[R=4.,=5;+5:4(B,>"0GW%HO/HS=Y(6]PCR&*B9)*^SDQ0C.J,5X*!H/#* MS1.5(:`PWCG?/M&G#OM.T.R0R"=:;04$XK'*M\1>&4*JC\OO9#4!0(CU@/7F MAG11W#YPAY5Y;%4MC@&' MIZV+$`'^(V'E;E,57+]"FFCS_#J6R M4'ILO^5BPY0M#Q7%:?*%*H(\]W\3!JA'=T-PB?AELXK=+2$T9`*;%?)NB=-, M*(17\*'HU(J5P[OYK7A\=+0JZ]OB=4:JMB*3]:WR.J-8K1$)O.V=9OZ#*4UI M`.D1Y?JQ'[^[04(7965X*Y2QQXXYI43V^,^*=PWD31BG@VR=VTX-&J/:8 M61M"^]L3\O.U>`%%P&Z7._:0@C(;D?'E[:'-;G-[+9Q+TP:$R]?7,,E9F[1Z M)M?-.$M19GW(QX^>'!L].86@LN<#HI=>8F03$.MGM;RGV*A9&0-;&.4`_+HL MM]<_>N!&4;V`6V6QXW@=E6:'K%QH89D.^BTG1S=X@7@L(@XH%M AD M`Q4]Q?^3.(S$O)QVJ59=G0%KCP5[@;]*06ZY&"C>)2`_(8<]!]XLO&-O&,_CD*73J+([%]EI7VL>[W-1(BEX.9P<;4AE_]^&D')%*% MJ8I`#M_/%+#K,&4KU^&&CXC"Z`ZSL8TT8@XC$!I)-@:]E0TQ(Q+4LM[VZIMH M=*_^&V0EI[T:AI-C+;0D:DP`M8YIB2YE0?D`W`)<+Y&:Q_87D82D;"AP#-CP MU1&!S;ZA?;`#F2'D(9D[O-FISU25B97@48W:-I[]U*\!&+GV)X`F4X>O=-/@ MIG6ME!8-TM52';R_8TR7WM@D'YZ0P"S)K:[(NXC"9X1CGQZ&SU&\3[F@]LI; M"0;6[EL98R`>.Y38FM$<^7+,D8I`]+GTQ("A%3 MRS)W^/T'0%U>=O0PA$RWZA/-1J.F=5&F3Q&.'Q!>,IF%M?52%>H6CK4":G6I M>,GHT>HX6AU'JZ.]A%1SV)=C9P20`\'-C;TVXC90;[[N'MNA*A"]Z> M.["`7_MC7I88]K+:R26^=(O]HDWSKO5-/6$T>>?G;TI(DI:I(1^_4R[C M$\0I56?JD,ZS!YL5/F0<&L"@I4EPWTL-#.`L4DT*H8)IC MUCI8+QQ>-76`.`&5P=C2RAB`#"B=AT`PPP(,1@>Y]0[R,5_'9+[.2$WEOM#O MZ@MQ\?+*\T*'$IRP;#N,.ISNK M#`NE`5:XZU]BD$'?("_S'9!"66-*VX"R`:THE]7\X*G,&$+Z*75KFPB@=WI, MXF_'$6@05Z!A)\DC"&I\*#G>9ST(^FF"MUH^+M`&BM$98_'`3U,_8O'L+7YG MEI!E5>$%1R+*';,O.*RPUJ_V;^(,D%?3&:&DPO.-.SQ<"E%S`T;R(GM":/@)&QR&]0 M.%<%`R'\DU4P=L1D)=`WH+%J55AJ6X=)A\/#K@JB$XT<2E:'+9$T9KXINPVS M^065;_SXRG%3V<;Y[B^3Y7F$3R*/#]H> M`LK#Y<]KF:W)GP9P_BWU@M4\Q'+TAN^_:D":9I>P#SZG.C:7JU<[5QGME&%: M(%@7T;0U)6&VQPU%J&E/NX__2G@!MN4J"ND+JCSDXK%&1-9T::7\O#T$N&`# M#\1YB@+ZU)*,,/JYKW73!XS;7NFYM@COLK1.^CC2B^$LTNX,[+%AI""S)":Q M$WJ4M\V^A07?K&1XZLZ%.!NW.'(1\@CK!WQ-2.*$;@&FH.:\_CQ#Z;31*L), M2&`=BMVG+U1NH)X\8E$5B> M8:NQQLM)&9:_REZ1V#@3%,PU6J3=6 MQ\!Y&>76B-P6*N(H\#&;!E$[EZ!F;_*94L.NQOGMF#&:QOA9C=_650-/\1:[ M("26B.(8BN7&H;H8%.1HRK3`W0DF<-7(R+(O.5@7.PTUW^9TWQ8?44?;MCF+ M5QME81J[?9FW6D^PVMQC<^JL[N=JZ<>Q.4-6[\MJ&U![E0"K:5'/R5"O78$G MO`XM#TLOU$!I-+0WOL`0ZR;0MD)_G9D5NI1H,Z4+9"U*J:GON&I,GJ7<978:OH3,%;*A:5: MP-(G),)KWB=P&GJ9\;.:PFY-+%D!R*WC>]?AA;/R8_H?%6@E%FB]N8`19WV+ MD&L#+U!A^2_7Z)6&1NJJT^T"4(8S4B M3U'#%4"^2K),`EZ,I`JA.@!1/'PL/>YH$5KV`\2P3LF`S;_OI^H^K5,EDH1I#H& M`LI9_(3P9ZK=K;C;+5Q&T6\#&%2]* MYFV_3F<8W%.=K!&HQ03XDU/6,+7.265"!S05JKS2>]IB`4,P^Z'KKYP@%0]_XY$ASA%Q6:UCN=E$E#NE-!:&SR%.D/N2*&O4ZW2$/I1T^TH8? M.=^0X-1F)0LPWE332479:1QC_S&)F97X(;IUL#:^&NM8@"V%9(;YZ4MUN9KD M7MW9%F!6=J;H85.986M2E18OS"-#7ML7^]X,S3J';8$I4$"QLNBLPI6V79YR MQW%D6;%9LSF,SAF?MA M;$YPVO\XZXB5-N=`F7C22BX&FW.>]O_85=FS#TE/NI]594^`SVXR^DW;^@KZ M4+BAM7"J"NOK0]D#DXAOQ?R!5T8P??QUP@WZ4,I#]VVKB<$M4!V$.*9RH!>H M]EH4:Q777N#>:R%,Y'$H4!N$T-4DQ:)`O=BV1M`JP*U/O0HDF2NM#CX@2:V&GX>NVO3=`05T4[*HNK$K3]H%7W M-W@Y`M-XED+K,MS>V9!_KBJUT/M.CX=H:&E'X02#30RU@\(*SFFW3J^%=;L0 MYX($4)K2P`HU:;Y,.W'*.R_M;@=.>(P4;Y`N0GUY;02!T&6,MG+9BFMDKRVE M-GBW(M1(8ZP+5*%,9IIEEEY:D9UV>-IQ'QM^4E&@J>CT"HZZ3;CJ?-76J+;Y ML(&%$_J_\VI(K`AN%/@>_X_4$4F8\8/]YVPN MF%S48WJ@`)X'S$HV9H1O`61#1KCQKUQ%L[-M0*/L=PR'LA#[&]`Z)3D8JA(E M6X-&'6._4%SY&1$:K(8?@*M'$///4'%$@%PRVL8_\34U9HZW1Z*X]Q//'TP/%WWR1@Y=4\Y M]>8'B%K)'QT<4IC()E6'P[*N8T1ULX92M:X]7:_#9WH`(KS6(ZAT^"@W94X, M1`F4H#OD1HOT%NL1MG[>*"V-TM(H+0U&6M)X*,`%)6/(RKE,'U*M]7"LE5#` M=W,NIL(?4:Y>L."QYJVAE-:6`>'Z0L"0K'H]&SQ(B'[^[04*/#LNT M9%UNDHU=>?NZUMJTS&\$2Z]MN,X=XKO3T+MDJ"&/'WI]HC1;#1ASC"-\$6&, M>#]7PGT.],U*NQ07\3?U=LY]EH2E0=S.&I-:X$!7-WI@`3F9$SP0E.C,KBM#.9M3XOXDN%%*;275]3D M$8LOZCFC#CM*KJ/D.DJN';+NFD<+7#0=N7`C+KRO)=9(SUV6'ZINZBH<.\8: ME/K*W_C.HQ_X@D;T,@E".`<4BPT\/DMO=MA!]6;A'=,*,!7ZF79$OH31(T'X MF1W;ZY`J!LS=1P]\X',-81LG96>/[O?M.36UA5&36_5?AM7J.9:?%U6C+M4$ MF(XH$8Y9P2[V"C_0W51=,H1CK8!:W>]',GK48P:DQS1BH$+QMSM>!:XR:>@* M!V/9DH)B.Z\GN/5O:'JS9HJWBB%4*UM*WF!X1#4T8S4#D92Y+&LUX&KQ:`;I MR`QB5,H&=W(9L)YHLE;P>V\05.&MN`-+;^2="CR&56Y)(\"."B]>AQVN:R%]%RZ:=1:].0 MU3!E20`H9"D`1LM:[>-\:@2AS"O5:)&AN*N&)6:,#'MDV"/#[H1A-WUD1TYN M'2>_31X#WYW-YXA9LX87O&D++Y.YC&7DK^ZO'CMRU9&KCERU]URUYD$8F:=U MS%/>O(.*0_?T"])_;/?":\5?)=QCG_T%#&:?Y4;==]1]1RX]GA' M1BYGY#^=L"T>'8+H?_P_4$L#!!0````(`%N&<$>WQ+<)"4@``,O8`P`5`!P` M8F=M9"TR,#$U,#DS,%]L86(N>&UL550)``.^3TI6OD]*5G5X"P`!!"4.```$ M.0$``.5]^W/D.'+F[X[P_X`;;YQ[(DK=1=9[UFN'^K566-/223VSOINXF*!( ME$1O%5DF6>K6_O6'!]\$0+"*1%)[CEB/6@(2^27S2[P3__)OW_<[](RCV`^# M/_U@O9W^@'#@AIX?//[IAU_N+R[O/UQ=_?!O__J/__`O_^/B`MW=H8]A$.#= M#K^@_W3Q#D=.@M%7YWL8A/L7=.T\X%V,KOW@KP].C">(_G\/A0'ZS_=WU\A^ M:R'TE"2'G]Z]^_;MV]LH\C)I;]UP_PY=7&0M_01;7Y"]M1:7%C6A;7\:EL_35<_3:W_4RX='EXB__$I06_< M'TGAZ>*"U)BAN[=W;TOP_B>Z#X.8E-X?G.`%7>YVZ([6BM$=CG'TC+VWJ=!= M"A<18P;QGWXH(?S^$.W>AM'C.]+,[%U6\(=__`?$"__T/?8K%;[-LN+6N__\ M^?K>?<)[Y\(/XL0)W$I%*DQ4U=IL-N_87WGIV/\I9E*N0Y=924-!)"U!_W61 M%;N@O[JP[(N9]?9[[/WPK[3!?XG"';[#6\1T^"EY.>`__1#[^\,._Y#^[BG" M6[$6NRAZ1^N_"_`C^98>;6%#6["6M(5_2G_-_.P'1$O^IE1KYG])?_W[INH0)"6'J;;CS71_'EP]Q$CEN MDK7&,/[I!XT*[W+]:94*@@C'X3%R<2>3\,_348O?=P^TTGY'JM#P@X.+7^Y_ M0+[WIQ]\[_?5=#I?6ZO?+^=5ZJT1>'W@0X0>$6.;M=^(V..F.T#2/DA<>'9'O<(2>K0\K\P5I8 MR`D\](?I!#GL5_>$&WC_@",T([^C?L8*?"0-\-]:[+?S"6DS/F`W\9_Q[N7' M,=!5Y?4BTDH_`A!UHR,9Y?K.@[_S$]+%MO)64MXL:<5*:(^55IN9E3.6RD(E M8?!D[0.=74:'OQ]P$.,8F"]J5ZN116$$$*9XGD\GPL[NUO&]J^"#<_`39T=F M^OLPN$]"]Z^R[]E>T21W6K71=K/U:C9/290+150J\@.4RIT@+ADQT4"$ZAFR M78-\(%(O"&27RP7EF+:35LBF9Z`1L>Z6-(%)//!.(%ZM+CSWJ@KI3V*L];J= M?KGP$3+P'.`B$J*"A!-TR('',N#`K!0[L08Q!7:#X>9_'>-D3SKE^&M(1K7$ M$#X;U%X%;KC'UV%,?O_!B9]NH_#9][#W_N67&!,8-P>Z`^`'CY=T',]Z][95 MR"&:,LK\_O77Y283*&=5&LPXAZN4F#4R:?+1QE M+2#ADAKL!'TX0]@50TB6T$##PBD>7N%[9^.=3N08NV\?P^=W'O8IA^?T!TK= M>8FZY%>_7Y+PX]$0]'GG/-8^>O/O!BC7:%3;BZS%)J-35A]1`6:9)[_NY(E\3OL7N,6%_XZ;N[.Y+N\C.!0D^C'!-VC.-F M^\F)`M)KQK9)OLI/I06'O0MYK9RY1MI791T3#*6D;4 MI5"I;;KID;6.2/.(M3]!7`.@CLV\\>R&\>+">+AB/+=J/)P9CXP#44S;!^T7 M^R1AI;_L[9N\PMCT_D4LX/*['P_CP\H67T\<4\'0[HOMQ6JMCFZ_47E0L_VQ M6*@9P@IIKS@DZ7"OQT#5^CU>8?BZ]@-\E>#]0+&J$/]Z`E.NL_Z,8+J>]CK& M0K]1)1#3XG7&KA.-J`I4O1OQE42Y!D5[#&G5SS2>^/7%V>./X=[Q@T[N6:H& M'F\*7;2G&_/53!U')HA*1;]QN:.*#*?"53%>`RXLAYMNVL[-FJ%`.!?'.)'V M^/R/)OG#6M0_Y#E;+5*6L(K#L"!,G)V2!2M9I]9%U9NW39!PKETRZ9JI8QQ MA^YZU-Z:S9=E?QYXPU,O')\$HA2575Y_--%9M4G9``SNV%HANUX6RM$[GYZ9 MK_))?M7A1Q+)S\+%`OJ'<7I_>WP708=@`ST#)/E&[$\&?9VVIS\X7C`^^)6/5B< M;7BH0'/+.HVKP(VP$^./F/]7X6*2"H:#@U@+_1[(7L\+VD\0%X>A-)E%X M'WOX^6E?$-EDE5Z%\-+J_$(1?*>K=KLZNQ2FZ,:;A\>]Q]@PW.;[;LYJ1R$UQ0T&2OW6A=_R;:?),F M.F-"6'85*@9X9_M<1'9'1,;Z9ZE#5?IE,7I`!OS%B2(G2&XBEI_RTW<8$83^X7[O\PNWI'?^$++\ MBCB@V15E;J*H89+*H^7V5_P]>;^3YZ#J*&1L[,XUZY*%VNI*;]H*8LV,F>`GVJ*=X:/G M9T1!A"FDZUT+>TTF MD3H!A(D=3^PX`:5.W!@0YKLCCB[#=W^T:0U82@A4T?;JY;S^;1)D@DB@NG.#Q>-F.SB8CTX=?J!7293 MS&$?".QG*G$DO&IS5`G3E/8!YAY3)+X\)D]AY/^M>)%._K4;-6"X5E=#V]G6 M=GXBN<(Q+A`5$L%Y=1Y$`9]B#M%10@3@EPA$65-+'LY6:PVK,1ZLIS9D[4UK?9H[&\E:G9IH_JTXDA(7>&#A,C%QX,A M;_#,GYU/C_?RE+O\UV22*#TZVUK/*+U;E.EP6]F:97S/9.8'MK/TUB@7#,7\ M7N':3;@^O0F!XX2^]3*BEZBTG;5*-1UKP7$O\1]V^"-^2%I6VD5EC7.LIH#^ MA,9:VV5>,3F("@)?=3\;EBV$=17$2<1V/.$9(W&Q)DM$=@!F1O6UN*\XVLSIE(FGSUY#N6_.;(5^)B/@IW-47'D^18/X$2A?U-/US M1D99RUEV'D5!4=Y(>J,*YA7L_CL/HA5XH!T_QY*4\%T4T8MD/Z\Q9C,I.*@2_!M[I?==*D MM`D4?Z@RG[X?XJ M]8C45B,%)9.6/U8HU6Z8?M9^\G9^"3SL[AS2T$?_V?=PX(GO52LK&%^_46FC M?\UVL^,Z>^2A?=*&9RQ1I?)45S/-=H4V'W85%=O$Y?:ZE]X;25J,$9+\&T4KL;S/(Z&CB3 M7V4Z?/9CU]G];^Q$GP+OHY/4CRDKBQH8)*O:UW^M89%G]$Q=A\M"5!CZ1,_- M$G%FF=$?,/L48$.S0L?%*!]:S0`QH:1'O8JC(OF1R.+L&C\K*3L$K%W=X"13 M5R?M2=C*REY>9N?Z"MF3XAQPZ;1?=D@89N(Y#'K!"6&WM%47L/VY@_-"[.[2<<#B7P> MM=@X#I">YOR=^-TT*CS+KR79$=M*@_'VNF-Z/.*5,VLN)"A@$L!>L=FG8(/A M51< M@$U?1W713F`O*6R8#6=D8I\M%F5"C"CS?!_`[.[`3#)#+V6\PA!0_"C-XK[[ MJL%4K:!A7E1;UW:=Y3*[QUV[C$E#RX]JNP'KG]P=MGB')G1Q]@] MTOE\>49KV:NIK*L9 MQ6S];&SB7F=$LW6%N\FI,H[9>J'/STYRC/SD1;`UK5$!C"]E+?0']JN9+>F+ M,GD`&]5]`V2\N0Z=`&T=U]\1&1.TS^!Y0-O5^LXGIT[#)/#L^>+LL?(]9&EQ M,.84.F@OGFZ6V9G'!F^H-.`GDON!)^IM-.#!\*;I=G+6U`P"SYFV]>%Z23"F M=%I,G2[GLW2B<^\^8>^X8T_V7H?!XP5-`5//S@3T0DIO2.U^D,+P1[F:+#(+ M#&L.$79]=GB7_+S#](?+P",3+3*9_)OH4&^GJD9YU:Z/]J5(:UZ,X@JQ$Y0+ M9I/ILF@HBO4-VJZ#9DB=%J3F**;OKU7.:=JIEQ/['W'L1OXA87D9WQ]C,AV+ MX_=.[,7I3^[C?.]'+S?;>?PS\K>\Z07+ING29PP\>;\.=W_IL MXH"MF;XK,!P4W9LIUGQJIQFM2LJ@FRW*U$%,'_J;LD8\TPG7B?ZMI!4JU$*9 M7H`O/([%QM;KM['ZQL18#&V#&]K([8WA@VY^]6/@+SO./DCZVN9`+;WZOJ?3 MA&R$WD"8[?,QFPE3'?A9!!U=_J:Q_JLH9N-4L5T+\T8%FK&I_2Z[]<&F+BS%]K[@F9?0HR$_>:6]TLN]BL M-H1I/M";U7IL*$J"<"%OOL-;!_9"S`1V$7X4/#@1E9`%:E3F.=!P+3$#JB8P MY_^E'DFV'-Y:W#`31#IHA\_Y?+JLT:$RT@!;W.P7H7TR0I,,43E?G292FX!P M1;1LIRP*QY%N%\O(O'2MX@?$:DQ_P!2T@%L&T7$Q!1OZ..K0E0E\O"9/BR0N M9Y@#E<:UP^=BE2]K9GZ2#JSADB'U@,CNBLBDUPO=J>[R3?#F_/TK$:OX+NS/ MAKV;MJD_)K#6]5$/K0_GR=VUM[6T-^FU9:>H.VN.#^+XV2TF(X^^."9:]L]%6R^"ALQ95]"^CS*QT[IM)I)&/9Z>9L.T3ES\-S>7" M'#;K%2S/3(,3M`OC&!T(6):2!CE)$OD/QR3+M^6F[WC3/](WM(B2Z`(]Y!;Q MY!8Q=2A-TXO+Y]%T3#D&0K(]I!?9VV&ZM0`)65.E0RZ7[$JIB)!<*OHM_2_8 M.U:#H,Z9>4V9F:-&ES5F9IE;2\P<$PLEKJMBHG(>/,857CUF^4:+HDQ/C?!P(_2Y( MJ_,)F2,TRO"K`GPO_P.9YD7.[BKP\/?_P"^"R:ZXG*%U`F'C'=:,YNG^>7H< M(Q6$F"1$1)E?.^@!D=T5D8GU!*4[90L+^^PX\^ M/93+,V](/TNMF%'_KK:MGUUH-JM&YT(.2Y0"Y>'GP+&[P3'GXV(WJCJY`#C( MFL]_'_DPZ!`&9&JAS(D@/Z)T>4BVPMD9I:(?4`N"0(9T&P3$)0 M7W,Z"X?=`8>1JTL2W\]O*8G0@G1&411&'$HPBY;J+X,O-O(#R-^\.O2^Z]C MG+"L5'>83-*)JK@]6^QY,DUV;NB`/8N@^#H[#Z$<7+O/-/3!\*X M+BULO+.7::+;UVQLTM^DW7XJ"W%AB$I#J3C#_7\_J"P05"U#@GZ@\=R+3V&4 M()9PD3[N2L#1@W?Q!.$,L\-:\?]&GY230S8S>F@C6#&.4)H(8D3QV?&C7YW= M$5_&\7'/M[\_?<>1Z\>8/2LMZ5_:ZQD<&;0JT^&$Z"9=YJ0R$1.*2E(G*),K M?S)\^,Z]9[SUEV@/[,GW_&0L9)^L[9[E?E?//.-A&X$'_UGW\.!=R?/5:]= M'9Q[39TZ;*EFSZW+*9CV`9E\=`>6UWX8^':E>_FR^PV5"L)J=SQ<:\[VBKG$@FJ,3"M[(RZ#,OM M,39F_1KNR!20/N1Q8L=7$S`2ME6UTG^1;FU9FKPK6AAI]W>.":ID9&=OTV'I M[0N4056&PME[_SXKY\CC*\"XAJ5Q/2":I28`9]#-V MZ`/2=#."9;O5XY"P%@R+1*IT2)8X3<^]E<2D>9-'PJ3S\=E=\0&P2>6&$CY) M#0/,J/+-[/34$B6\\NR<=G48CBEUTE_<6\Z:RRH/+Y6K[/^,LF-J/.*#GKP; MQ@)V;Q8`X*F6O-5FKJ@K!6(4^^OGPELOF M_*[TO;WRZBV3%+J.L"<.B&?TF+:0BKPU%$] M`JWS*MRBSW[@!*[/DA?D;_6.C5G*'%'M]@'EUE5P.)*^D^A&.U&=K0!!#0A> M-=70WYJ:SJ<-5G%Y$Y1)',,*_[D8>2;1#-!HEO+E/BL\=)`#P+A2-=!RPYWN=<;*2=+#4Y0N-''ZQ,]Q(J2HNFZGG<3W&'W&$5^\,CVCWX)PH<81\]488:._)F8EM1B0.H; MN'HKPX.U"Q&!A@+3XN613WOUL,^F7F=\Z[R$9]GV>E4/:9611;8/Y2$RELB5X6_IT$ M2+VEU[X_5"_W^7/M2MNS?_&3IX8F<565JMY%J,XO?MYL^<^)3R1\"1,0I+D"_[QC[US^3.=!5X.Z.'O:N@NSE M'P/4D#3\RGM.,2K=%#/3V6HZ&[B;I!JB3$7R`\J4?-4=8A]V'[;W,V1WF'ZN M%_.S3HV9B1@RPL]$/6Y4TKL=2$C$493?MMU!3OC,Q^&A^B_%=P-=$^L/'7VL MK[5_,]\^Q.K9T*"T%WO($%:PI%8.M]_TPNVDN=Z6ZSGA$?<-U?7'(O#Z<(%W M[!^$Q5_VN"6)N5OZ99Y9/^CDJ2!'L;IF*C8(E]R,?+(QSA.TXJC!AE_Y/.$\ MPJ[MZ7HZ\#R!!8*_NWE"'W8?=IY@UN[JG*DC-+Y=[J0BTNICX/]_,TEH[[`, M?[:_@TG"O;/#AN8#O*G7._1G^NO2U9[E;T(,.LIG2@'OF(.9ET7#VRAT,?9B M1`./?)#7%.=B"1HFJV=/5K?U"B*=$H`V%Z?SYE7\ MDT)=K(IU7.X@H>[`WGSX%`RR;M&CC>?\R3CZO"MZ<$B-@7*<$*%7: M)F?Y[W_&^P<L-H*S'"K3]H$*Q8-FBS1B^EZNN%AHKRI%:;GHODV3=$,70NC#9622YB-'0,:P1J-$31/ M6@QI"]F.G>0X(-0RP.F\SV-3=RM"3-D++>G2PTUK/TX'\JD3E?529*A<(L*_2*U*XC=2HR0;FFYY(5DFF89H3L M$L[PN]4=#],Z31>MZ6*UMG7Y!C0W'A#XZZ5?<]+DK@//IH[YZNWEVFKE$V@.I!YQMG%J!+F+M%Q2@U?`.8.(5A%V8OP1\_]> M!9#[#GBVE.4M8`>I,U M]2.]*)2UAM+F^$R--UC.``3&X,&MPZB=F^'`Y4Z0D]H`\QE.S`P3)D\XRL]: M2,QBD/!G,*46"4XU\[A"Q!UVL?^L2+6J5744]"_TT>ZIUJOE7(_LA7"H#8#;R-\<'POZ\33W5;28]_0A8A+]HFT/49+&"BS=3343_B2'_J1L#QM M+3^(0%V=-81X2^/I90>PRSR]1,0L(%CCA]\W?R5U'HZI1BK?KHW^H=#W/-W`SL2E5)XA(1F]R MV2@3_B-4=]TW;KN&VTEQ!QCT[&P77ZU24M-`0`3$Q"T2]3G9>BFSM"HWK>]) MJUF^0,PE#'/JM4M?=PZ2>04*ED,Q2`>1Y]0\OX$8TLEO23_8\G%8$0#WINWJ M#VOFRW7-MVE]L/A_(@(^(7/B)\1&9MLP(D-5+FP,CEWV%I%7YX!A7#I=3?IP M)*.Z(%&]N2@N:]3)!0KHOQ$\GRXS;T_E3%`J"?8MQ!YPV=UQF>.!PL6JA)"9 M`909G^G9[2?LT3$6'73=;.\P39*@6&5OKPG!&KDZ^G=EIE.[P:%,+IM!I/.* M<(LRX<"49<4!""3]>=G[->;-;U M+F@$[WB?"\CN!L@X0QKN)"3$-?@#V;DJA(YMGXH6@?!YTFZ'@P7S::.S^")> M?#'HY9TAV*W;KN=K'R;.;ACMEU3[KU0^F14IM\.-$[/DYT)*9EA!R7@;[GSW MI>TM56EQ")+6=-"?22Q7LP9AN3#T6_I?\/=(^T'9SFGC;)`XFI`9(NR@++ES MOOWLD&_G.[MN[G3J"7)ZGIV?T1[9&1UM-Q7336TA".9=TQ-"1*L[HHJS M4Q\!$)5[#2!?#BP"N3R%*T!P,=#M"E40_8&''NCP\[=OHO8H*0 M^^1$C["+!DH?*Q-%;@,P:A`E_(A?%">#2DOU\>I%31.CUK[V0O!RD5W%8&)0 M(0=108!T.`M1E0VX`.5)0!FE@\2O&FP0F>!T,L38??L8/K_SL$]Y,*<_4/>? ME]R?_(HT_4CX%R1^\B+(EB,J8<#9!U!T\H6='?Y.6'PSNXD.*7N+5O$'M]8L.9/$EJ4\8^#`/H]4[T"*"&Z)T]> M+)=R8HRI[SD+(;\D,W:6:'8B(DO`L";`-]L/$?;\Y+/CLK<0?W:^^_OC_GT8 M1>$WGBF!_$4QM^H@PBBS]/7J\!;GRLJX%K"G;7@#*&MA@M(V4-X(REJ!XM]0 M=N#CO]"A3W1QN.:XV=VUJVSM:#<0_H;!XU<<[>D[82WC M/D%)DVQL-J^_7#;-'MND4BZ(Q^_9"WA%'_>SDQPCP)2U9Z-K4FD0(,\X>@@' MAF(Q+%0$VA%`H"%`SHX*TR60H0G==F1;7!:(U-V/,2^6\[F(UN@W\"/:/0`K M6'`](A8H#V?+4<,P(8X_A`$]H((#]X6EHG9VE\D')XI>R"\K;X,WOI].7:-, MT5"H0YQ=YLR)8U02C%+)4+3I'666J)VE9>C97Q0%BMIBEATOK`#]"=@<(NH8!T?J&7E)V\B1'"F;_@ MA"96N8W"9]_#WON77V+L706?_<`A\2-XO'03_YDOR3!"'LGOTH.182`[*7&F M4(-T.4]3_?LS]CP]5$IO!K%,-EF3Z.$%O:&M(C_X$>4-HZ+E"2K:1D7C,"OZ M)@VVS`SF4H-M=^&WF+Z4G)MMFQO+R5N%I'P_7"K'B!ZL_?J"2LN^1$_"7TV0 MZ9[#>+-<]!ULP'=)(&Q8I!WCL8>R_>\LZ*BV8WHT^8B"$+]FT_/(1E.8ENA\N]ZI2&;,AH6A8_SF'S;PTJ.("T!LJXD=TF221_W!,:%)X ME(3HUAGNXHH&64]%EX^`=J0JV/#F5.V7;=H;C`I-YZ^1NP82G*.7SXZ_H^[[ M-?P0[O=A4+X(]]Z)?5?G@VE(@>)YNVH=[G=9\DB0-4/#`&^H+D$-$P M9[&?:'BS2N&-_N[WFW^O??[LMP;"3]J4MN?,EXOT!-O-OU_=F(T,)^G*F'[S MY(<0WEO[O-0;RR`@.M)\4)XF=%,>KY04-M@MBC70/U^P6BWK60:S)W=ACU[V M`UD7,FZKW:T5)Z]105!*"(2=,1=;VM$&/RA`1 M9MAS-J1E?B>AO!(CV1@P3@7U?$L&'H0$T:,3^']CMOM`S!?N?(_]XS+P;LFG MIYE!Z3]OMNEI)6=W3WZ#>79=]>IL/[)-$JT/A3NL*\[3YP_*[;)%UZ)E%O#+ M;=.;X'GKJ&@>?%46P'BV(>,9BQ]]DK$2<7K[-J\N1GWT8Y=,?X\1;KODVGLS MKR5R"737[HQG,VO58Q`K5!G!W5Q8HZ9I^6,W\@^9S=X?8S_`,9\&T#6,F/ZV MK,NK#5\*GO86R63?!"2HT1NFVKG49*5-AABQ"OJ)7!:K+%*PR[7FEP*KK4[`#&&*)'6%UC4'U(06G37&FJH.](B^QP:?Y*4UA;Z0(DR;G` M2@SA3YZA"+MA1(]O'0]D3!B1@8U#!S3LO3"V/C@H*&@P+S=;U M\TDLL@0W5,B%'UQ0,=$A`TQ7)!]P@+?T$5&>..T(OB+9YHQ5#BE,!YQ MG^U4G*.8II/9B_7,FOT^8US*1:.;;7XDG$E')?&(R1^DTQ(%C@%16^-`+>VJ M!X1NUZ"3*%(^]$WB:0EZ*(,^='PYB<8TT'2W'$@WGJW(L2CXT:<7Z`+OCH3X M0G59_Z)3U62WKJ&/_@F>V2HC9[YFR>1.4"894=$35`@'&D3W#MNNPHXY;"<@ M0^8=\C+T$4-_4*(WUOEW\.+*($#7=N.A9LR7DO)C`U?[@_R,8R<1X%05ZZ6_ M5C*=;824S1D;3[+EX+P-Q!L9$W7[,$-Z/(?4]PK&DIZ5SX'9N29"*S)-CNG9 MG2VF[X;T'+\Z3%2&\X9Y7W:`C61JTK='-(4M^YGF5%K-]IQ?A'=[-"H8G]"H MM-'TN-ET,5]ELYA:_,DE#GOG1SYUZ0^?,+X:PMD/I*T$"3<+T6%9,?5H MM0?\H$9Y^4]8%&R0TO%^W'1M+\1D@;WV=SXH$3G&TV/*[_=)D0_0`_))_N4Q M>0HC_V_8^QQ&GX]T:)$M,XH>[3E=#FQ_J:>D=@2>KRQ)-YJNB!4ML=T>WE:Q MYLY:@^Q?A["',))`VZ-+?SR$443K%,@YT`3+Q08%R&C^[)`@Z<4[6'&PJ'8? M[KQ.X:NH,(8XE6O394AH*P,2%3D92]PY$9\JP`R-KWL<.1&D,&#$#-VS#!U8 MJ&CP3!D3JA:!']G_&M)C;W?^XY/\.("\`M@HOZR%?IZ7U5R\\$A(P^0A+G`, M(_[3`8IW!9XYP$@*$&8:('(_^62@890!.L]R&U])O9CF>I+NL9T@`+9S;=%. M-TY;]FPY%W:V-2ZAO)'!=^`TN]]>+:`130Q:H$L'W:L96,Q)X9+Q?!#N_A=]0\H3)_U+E1M+K:P8( MR2A`Q^Q`HX*#XWOIR??+P&-'XR_C&"]P[:+L,.LL/QM.&52XG.ZP)X/&$KN/6!A9:%NMIA.$'KG]P M=I?[\!@D-]LO88)CTFCZ4/0OP8$=O>>'[E6[<2?(,3_>Z*YDA^GA/)_CI\T@ MW@[M2EA+S$NS%[AY8_F]$K!]O:%-8HW4)&TCDJ'MPI]C?WR,V.D&,M;(+.14 M+31!A]V1V"FUT9';R%=<1S(T\C@]<)0&("=:&68& M6:&+L1=_)N`^L+-4B?^PPQ_Q@YQ7\AI&62550WM0:\_7RXQ37!K/^%F2AZA` M*#[UA-!N(HPQ&:N3+LTM(0U(!P#+J%97K/));1YH-F6;>OG5@42>'K"]'A"S MA,KH)Z]:KVT1OZY*5\_*#T?`\ZP'O(QM?XYH^N!#ACK<;O%@%W4UDCST_4D% M$>5P?-CYKA(I1"!1LE`63N0F&D]0J2X@\@R%Y!>8_+%[I&D5!AY^VC34/UF^ MS%ZMD\>D^DYZFF(T;6]\L:I?X]1FQX\LE+'D%8>*QUR!KF?G M$40_B2W@3U>>$SK:PZ.68<<3,_EABU\"#T=7`=U;\9_I(B_[]7LGQAX)]W3E MEZUBWA)?D!]^Z$D\>%SMKK/^W&-:W#B01=KTC-*1MH]R!5C`97^Z>*`ZH+(2 MB&DQ09^^N[LCNUW,@_3-`?#Q9ACC"@+1I_O;6S(6B]PG!_CMEKXIV!Z-3C0W M='RZ=W8LE-)T8\D+U2LA6G_Z[Z-_V*LV6/4E`$69%K7T?7VV$DXCJ7P^7.,M M3%AH2"8L?.3-P`>$7NT@X#P]#Q&GMCBDK3`;8)4-(.*`IJO+J*YC2'`VT\XH M[8L^?<>1Z\>-!#'Z]:"8*U)&VT_GRYEPBE7IIU$N=P0$/1^NA)8XE98G64*A M?)@"PDB5NTIY*+47$/O$\>`+5G2>\BIF.2?50W]2:L^MG&[ECK#:#TX0$0K& MM9Y@VF68U3YN@@(Q/H.T:O7#&J/45NGIE%%X""/^;,DGQWWZ)?"3;*@L/GVA M*&_^U)!<&=UT5;,Y?4)CECD.%T7 MKDL/!RF6P>15S':C4CWT^Y?-M!BUAM%18#38 MC[8Z8JT?55NFGWZ4[6_>I-N;LN=)E46-]YYB/;3C[GJS7*0=)]_[527!:9QURX3&V/PYI#?>+NBN5PWD6,@L?%&SW0P0(]P[8G5\ M^=V7#6>+OQL\+%V,-X M[SSLL"3'J>P3M=8SZ?%MRNAOY2ZSP4LALW'L,!<+E=JW;[QS40:?++$O*(%T MO;-"*RWK]#)ONS+K\RG8:7:#&1\<\B>=KL/@\2N.]HI+ MB-+B1D<#8AWTW[_;+.89%0^E9\BHL`N:%@?P\F$_X!BQ/M"K`W27H<`8L*P_ M:!6UW':'10*-+A;-DRFR^G\E@779*8)1^""A.]H;0;*+U"(BR'--RP M2J0VHXR.3>KU)8V:8V%6M]60;].NBD6N30-U--\O/2( M+VGQCC^K2I\?_10G_I[^XY*]N';O/-/-CZO@T_ZP"U\POG=V3N2S3#OOTR>- MQ3.>7ELP/Y/O4_TNB>7M;)I?4H"Y=ZH">]47Y4H@K@5*U4!^@#)%4*8)JY[I M8GH=`,Z.UNNS8]LJ`IPQ6;@M&0=GQHG+QGE0&,?0DL,0@:VT'M'[%Q@\GI,> MQ"4_?SG2+N1FF^D3WV&Z[U-Z\%W7U=H%CBE:MVJK.^Q8;S:KI2@X7S:"2MHF MXHVRT\Q9LRAO=SR!N&<3">+NF$QT>HSMV4XLI*;XZ6GP''^4R4/.EFB+HFH? MYB;^LY_X@(?%>PDW6D%5S^1`TU&9UIFVMV'L\SMF.Y^G")==I#Q1F-E)ZPD: M:D_IEM/E2F?`-D$%8?+V4-$@V.1V<.-(HP56@C$WAXPS+I6MG'FF3WJ`AT[EO M8?37;4A$3>BVL>(UCW''$R&MS@\N35.#1QJJ,=,_QM&S\E!P2RVH"-%417_] M=UU:]"ZQ_RO1&O8T<9\`[%40N81V/OD1`&[LN.ZQ_V1 MQ82/>.N[OKQS;JUHE%EMVFAW$,3W\J53+A1E4M&;DER4"OX1BFK](N9)(TOP M/"X%EF>ZSEFEFI9E8-CVC(,COL-N^!BP3O8VW/GNB^P>FWX]HUQK448_S&_L M_'`$DXE*0LG0E(E%OZ7_!;L3-A#P[!HW'86B5#;HO6UM[ZRR3</CB[)*75!_9EZD6 M,NG?E9;U<]3/INDE_U1`%AZ!//L,%)4@O\4816,(]$*OJ3AX$S*$>_-\D>Q2 MSHA<:@:&8`-:@O$ON\)>Y+\/,,LYQ=)6?XM\]JZOY\<\Y\P$N>%^ M[\K2IS(A27L2%\J<[FYE8,IG]UI87JUVUZD6AR%R10?MZ/QXV$,5W'Y+)9]-("8(223 M)#PT#0$5">)T!/+G,/1B>3I885'#$:#>OO[RVS0[J\G$9&/="6*2`+.^GH^J M,OH=P\A7Y5-U,@BA0Q-!CP.`[M_%1];+S;RRBC$29^^,@?GYUS!Q=DHO/Q\% M;6(P%$L]%!!DQRT)*WYXC'9 M+OIG&3?9A>""-H50E$D="7_Z@6NWPAT#M=J\4T0QI7T@J?9+$!^PZV]][/'\ M9BT?NED>@%P-)?3WD-;K39U5)6G`:>IZPF>?AL\TCZ2N)R*0V"0PS'G"WI&N M@5P&B>_YNR-]?NZ>OK/.+IOPYPJQQY\KWQ^._#H6?0"`GS/)%DR^THQB4D_H MM1&C'.U3O]SKCG@MQ]<&:.A51KZNY\0(4[,LH\-Q%?Y<';2! MRUM3Z7O&2E-^I!K2J[LX0=?T;?6#:H/N]84]U7&_@;Y5+TD`"MTJ+;]W8M^E M667X9RLIPK\Y4^?:#_!5@O?"7"[]"#:=%*`7K77S<-K+Y6+#DP/DH>IF6V$. M^2=KFUV&SSA4"4ME#J+?J`Z(*6'X90L`PUFOR7#J!`(`UK,-6L](?H%>(UF> M9Z"_+P,>KD5S[)Z$OJ8PW6GF9R_MU:+?$#W@]'F0Z'R"O7J-S!#+#1!&ZS4@ MPZTH]!NF>HG#8UDQJ`_G:\HS-?67!;I)`YG[=U)1?WML-K6:$_SF7'V24L8I M469\T_1'T8\(TQQPHCFMW#(_)#\J+?_>;)@F-[_ M1&WU;Q&L9Z*!`&T6E=IE71QK.4O<5#IR5VI\+#N;9NS6V,T)IY-./)BW502*'6B?]K?+U2G`6(1<^0:GX$4:"/BU09WTF&R@=]:D> M+*:LAJ'Z64*@YP5HUDG27I3X[`76D-ZX)TU_"1,<"^\%=*IJ?)E!3R]=9YLO M%JML/YU+1B71J)"-F/!AKPO(UR*&`&V-`W3+@L40R.TR$_%`@#ZAPN,6, M;L0MEC6&]6^PK3-[$G M-B]1+H^GR`.G4T\@[3)(6/*T^EN5-VH#]+1:R!KY)?`3Y<)@HY3Y-<"Z"MI' M6*SE(CMGE+DZ$P.VL'<>$LLTDK;5NO/@V$TX@$MP,C:45MN$<'LDXWLM,KZ' M)^/[$[[Y;#G-'KI-O_G[$9#Q="26:20Z9#P=CMV$`TQ&$1MJ9&S`A1E,/N/( M(8CH`U2Q)1W45$L9'316FNZ0ZGN9]SFI!/;\H>%'ZGN!85=A')P7ONI=?EZ> M;@Z1.5L-S=<%'I4=8C8-`:(\Z='Y.DNU)Y.[40]1TMADU00:J#M2O/I M*EN.H((N'J@D5!8%1(T>8!6YME-8;@LL8VQ0NEB%%'(S@''C*=QYY//Q\^F8#=Q;P=[IT&/`B=HSQ/0$W6>2*P%?FCB MU`_`,/Q"7ZK9O="%]I@GVWF1PS'*UHJK-\A9`.YG]8&E9[K95A<<[TD$$,XT MY:6-KT9(5=&=_"[FJ]D\797@2:INMHWE<"K0\.)$3\`L(&`M:Q4]H4L?PL@P MQ?QYGYC#C278S*Q@M#*J6,E0&P.FLPVCY"N.]A_Q0_*5M*8H=CDE5TX^`R@;+/J/@;_U72=(+EWVM",9 M/K/7J7T<7RL3/NK5-#Z(U%)+^\[!=+:QT@%E(1@5DE$F&C(7XP"0K5%`;AEX M#H#;[@.WF4%I)^86`U1]HPT?8.1I<=IKC2JP=$K(L+;72ULSJ(!DS^D9J5XL M@8;Z:Z)`2_D#X` M=!U"@LX'.GEO97J@;RT06F:I/-X?8S*RB./L>J)J!4I9QR0)58IT>-MMOJK? M,(5!$?J@S#ZJ4A6!=60']\9$UR_,4\^KCF/N<#L;6!&.<(2)G$E*B@1V4 M`\H'2N`>&SGI`0QK-IU/&_,;T,<_SL!1G]:,X#&.]HAM)LH/;SU M77\@/&'B[(;$LZ1XOM)6^-67'-6;%-:/"#.QL%27,:A*=Z$IQD'YUNF5M`)H M".@\GY^N9^O.H6`$TZI^@`NBP[AYI)XV*8TR#E[=T1PF,>;WW0X[7Y]@S9J@ M3&NHTV'9>3.34VZ"4LG9=4TJ>RPL.Q,THUL&CW5?*);!@^.8U$759!/;!HQU M5W%\Q-['8T3/^K%WHOBETR_X&_N3?,U"J[)I[K5JI+^*MEJ4![^(2T9<=/H> MVX2_!E+'PMJE:AS2_E?ZSA<""WG2,5#[7'OST8)G)K&>- M$7L8<;0$EONY-I,EE@.A]/$A)K,&>GSKF1W::IE$RHJ;)*E$ARZKC=D]T%P4 MXK+@IXF]@+-/`6>,72TN5Z&1RAPP?#D<=FS%U]EEN^Y7P3:,]H[.%K=F;:-L MTE*IPZ95?B^D)+DX;8%*PD?`M@'`VPWPGA^[NS`^1NS55)>:8DM-X1=-P1*R MDT]7^:EO0`BZ?L7[0Q@YT4NZNN2Z$::*?0WOL$?^1G_^U=D===]5>3M.S*WDK^F1RU+$YFS2#>SF14.]8# MFR2=Z$NI_T?TA[?3J84.3L1I_T>TF$RG4_H_EOE^FB5+=([)4QCY?R,UG03= M$P:S-Q70;#I!U*=9Z8_837]KL=_.)XC4/6`W\9_Q[N6/R)K,5_/)?#ZK"O?Y MH@S]77A,XH3\P)XV.[VA"M]/&04]^X$O[T#Y`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`\H[!**F)YDS#>@R[=T(?M%H?^4^\(F>A`WQ_[C4X*]RV<<.8_XRY%J<[-E M2WVEE;[W3NR[EX'WT=\=$^G6T(G"3!+G)`WU#PQL['1#*6L(I2TAWA1[LJ*Q M!CY!K$%^OI,W"<1(`^:Q*^9Q4O,$N7G29?,+])#;Q!O0)AK'2HPX3<4L%YE9 MLFC6V$I`QYA8SP]HB<.1/;YU(/9C!9'#CGYJV]!82#PKUE1BY^E?Y/REI#@Y M1#3`6NPG&EBM4F"EO_O]+[_67"G[K8%0ES:E[7Z+9?9ZPU\^W7]%OU[=_?GJ MR]6EV0!TDM*VEM)#>W?M@U,W+:/A7SQ5[)J4(/\F_R(_$&YB\H__!U!+`P04 M````"`!;AG!'4.%3NWTL``!J?@,`%0`<`&)G;60M,C`Q-3`Y,S!?<')E+GAM M;%54"0`#OD]*5KY/2E9U>`L``00E#@``!#D!``#M76ESXSAZ_IZJ_`>E4Y5* MJN)VNX]-NFLF*?F:5:W;[T___;KR)R\`$XB"G]^2O+O`!=D(P>71>48!6F\D=!@0$H1/2 MX28W,/C]R2'@WR?L_WL3^M-?S^]O)N_?GDTFSV&X_G)Z^N/'C[<8>^F8;UVT M.IV'E*I_EPFC9\\X__,$D:?WDEL-3AQX>T^=GI7[_>/+C/8.6%W//G_^?!K_-6E-X!<2CW*#W!@E!0(GPA;LOT[29B?LIY.S]REBN/(?_IW>!!#-RP)\N]D[1.(!+@.ZHUTG"*>N2]^KD+ZJ=\BGJP"DA[4WF*_+U4:K ME8,W\\4]<+.S/%TQ,BCP?X8D1)B=Z,(^G*\9^T#I("T7WFKJ/C"8!2]T&CHK MZ&IIQ1'[H)@Q.%%R,.C!H:?%I:?F$OI1"+Q;$-X@0NX`?GBFEW-'*ZHS8X73_R@'>-T:I$3A\+;S-Q+U_\V0F6@+X!UP[$OSI^!))O0ME< M<@->@/_A!CI/T*<,4U=?O,:,O:[X\1EP2'@`+FWM72!ZU'`(GWQPB\+.#G## MR3O$H3!KQG[-J$B!8^ZXCQ>IT8P=KO@1X-4-H/5N7^Q/YE"E%P5WT1'F6^6(!,)V\EWU99Z9.OV5VNN_HS0\)07@3 MGW,*]@-@C_N4LJB4''H5/(3(_;V73]P-$=V(.?'$CRB['C(>C0%*<'3HY:`%B.W,?<.0,2;Y2>SK#,BGTKK0/CZSRH1]+_H&!4O&GUV" MI["GK\J?HN^%2;BSWA^\FG/W#<4.Z];3HH6S]/^EZS)IO7WVYH1L05H7V"%F M$RRA11N#P&.VD>171DY7MIUX>DH`):8TI\],8`B7/]%VRMC.18#[=HE>3CT` M3^E7^\C^P3[?QY-W9ULKUS_3G[Y/Z=0>F_[:=Y;I<+[S!/R?W^S__;1W>BXB MS&PGU_0\.O[_`@=?!=XE_9(7(NZ:_$0Z0XK:'II-]134J\Y:'H['P)>DE`&;T?I$1RFVN MA=J8:5&C-&EZ."J3W28^Y/QVAZ/OD0XK(2O^<__4)#?)!9T0,PV&!U[_`C8< MLOCM#D9?8AY@+VAB(YA'(7/W8*XX8F)EG0Y%^25:.3`0TKC]\Z&HN88^P!=T MGR\IHR(DJMSJ4+3=@R5DCU@0WCHKWLG@-NN?NANP=/QD[NDKY%W+NRWZI^D1 M.VP7/VQ63\CG4%3^>T9/D=F@_]SC-LHO3ML7I.G9'.7&?H9\Q MJ0O*"=?A6%(J4,7+,4'8`SCVPZ/_]V:R3AGKFV3=0F)C2D.`"8A;LIX084K- MSV_>OYE$A"X4K1,5KA:H5!F!7822!R1'Y6S4J.R(&SDL[T<-BX`;RN'Y8.'A M"0DY0!\M0'QI+X?HTZ@AVGF,5SE>JT#K=9?CK=M9/U;SU3#5O:3@E#-OH9$Q?>34XF6>_2O]%BDHTU20?[ M]TEAN,:JHX5#GF*((W*R=)PUTQ]].@5^2-)?8E-409&T_?G[UN.$W#D;=ARV M3^^.5JFB<7.55WNZ[X$+X`NCYA:$:M1SNVA:`X[HB=FZ=D-`*A<@:*^%^LSW M\LA!(2[&MZ=/^JC2V`;%C321V?%#BZUT4ZE M$JB[;750S>(2!43&?])"D]CM242JI(>N%6QOG-@Q3T)VJ9DIYL/FR,V87]&2 MN3XE9X0^I$G@%OV@OR#D_8#^KF6J5E<]:TKB"#>4(B'MA2:Z:"39"9J'SP#? MHL#=WE"R!TREIUGFU.8H%Q@L`9K%%IHI9,Z&[&IZ1CX5R,C5WZ,X++&*;'ZW M(:ZEXI%6[JYY;7+&:"`\_3X9ZN@/@4\J.I]7`,YIJ8/B^"96WB:BUD.@/']. M%(DO=-!!_QT&:RI_7KVN04!`^BBJ2#$J/?6L"*T!#C=WOI.XW=`+<,V>?#%' M(^VB8PWW(*1,+?"N'!S$D:>N&ZTBWPF!=PD6T(6BE2ATU+&>3/VW9Z[8H9_3 M4"N]',5GQ5N@U%7KFG@.RX)&>NA4Y.,&PKG5YM4&QIT]@M4:80=O$EHN'(PW M].I(\N-,PQ##IRADN^$1):FW!,NJ/XX."X]+$MSW7NHB$039PT4.OXQ("$0N(N` M)&8`4UTO:\,AMP&;ZHI9&Z:R8MM4'\S:L"C)_Z:Z9-8_:R)#U-7.%_>,3)NAT@9M,LYKC9E;L3L?[K0A4DQB>X=Y070`E==W( M@3.3O6P#7`.-40ZGF6QH&SAEK7/`*9K#Z,+`JV&0W80 MS0W\5'?FV-4@E$,G3$U%U`P?E>`X4[,4-4-,Q?'/U,1%S1"3ROV-,A?581V' M&Y5=+I.H(\:0U5!AY4BO$;Y$T5.XB/Q]6W5%I&2M,31'SU'$YSC^.%[\&N1E MP;AK4^FI>45)RI!I%#[34_!'OF'%*]GK,8@5S`B)U*G?MAX$Y>(DKTI=3(G1 M-"NRSGK#6V_XAM[9-Y#^3U)(*JFJ`%B];S[U2ET'L*::[Z9J[P&L3/']K.HU MF)5(WU%9C\&LH/H]K>QF';(&(2,J*<_KB2#F*V]40%.^G5MI;H["=-P(L/U+ MWWR%36.8TA?%U%S3'4#$S]AI:-1#(YP$3+'IH0]J6"DIJ$P/AZ@-E>P2-S,& MHB%$^Q>XF>&,#>$1I%LVG"FWO@C6%\$D7P3-5KY90/\,ICZE.:!SO>08;3,N MO_]X)L^XG(R@PPIX@0A=`0M[WQ:$?8$N(`_(%YMCA!WT6&1('!ZR#9`4)_7< M:38$6BMT\\+F.FA/'1Y2GO3<(="EQ%U"/PJ%.L>J7J;8OYKC^@L(`'9\BLG4 M6\$@+D3#KI#M1Q?@6M5+3]9/=H=EUUK%YA:UUI0GELJD))1COMM*;V;5!+^4 M)B')@N;6TIL`=`NVR-P@(GHZRFVT4SE]<:"?!.\5I)FM@U5\OZJL0V$4+=D: MUX!=9,&R\JOP6FK++WE+^<(R/?*KI**3ICR3"7<>;X1+^`(]RAV3G6MZMEJ+ MK_1:0^C)VN@!L&*[7D"J8&'5_?2LA@`JQ#TS=@J\`!_%.;[D&T_>1\\J7D`0 M5?+">\VTT(HVCL_J!<:TB"@M-]+B.^/X@&P)B`4U<695;E/=-*N1JXU2X/LL MFC[POCKX=\"N;_FADW2PWFW&>H*Q$%P0%W!#[/U8Q1JKV*PS]?X6)5RYFHN+ MTD@Z5OP;@,MG*L9/7R@;LP2WT>H)X/DBEO0+BG4U54'#P70J1JOT.67+@UC/ M9KI?2QV<*K@:TZ.1ZD`E>XA,=VFI@U.EBLUTYY:Z]U19G][.I67XLLQ M&D*M.^O.'A%)J:7-P96Z3,^/K(+,KMS<+E.R&9CLR;OM4DT._YI5<]#9A\YZ M"0:_UMY@;X.8$EH&Q3N&U[Y,!4F;9:I=PS M*+YDQXC<+L&>*;>.@JVM68H]\\Y9/=-KL[1[YJ'62-W>+#N?>>#5]BAIEZ;/ ME$NMT@G2].)C:C`UM0NU*DUV7`R%C2R0PR';<".*+&"EM*Y]](,R`Q[$H*!* MVD86?&+:(EED`1MA$@^A)<=8]O82]BZ[*'!A7/\J?WWHHT-)O,.(L3W>^>8; M`=XLR.3YJ1M2ABA.)"OW$.IE*BU1`G'Y-.X:XS\-D*;O[[51Q;8VJSQ#_YDH M.A*+Z#:^K?A1+R%Q?40B#*KB+MH.JPL+RI9`1':_MN/943F"K!".(1_Q+\+UZ70U48P;8L, M(2J.!_1C9:'K,-9TN17.MJ9=5LJ-'BK*DN.I]\*2?Y'8UV_-$A&H?]1Z MHPX#B;3$;9W-6^PSC%5D\M(V6WQUH*?J`,-8WUU2<3?=8-S*N\IK51I,9\PK M2_PO7$VAB8T8S33G/"4"1S!,"E9&]+?MAD>!),2TS:#'AT/%G='1X`/")536P9V&K=6%(\)B/$7I5"RB5=;(3^(=8H501SF^JA&;D`>.0: MH]56^0FI],WT14+2Q3UTKR#=Y_-%J0I8Y3KX_8:SFO)VH0)8GHFV_A(K!QO. MNI,TE]\"#V!ZS.GIAB],_$S=5X#'E+%4)DVR\_J.D,?H;'C=V'#4G\RQOD)] M6F<$[2MD>W`>.S*0JU>`74B$8=?5_32MY@4R:Q*G,(!X(>(N>C*;K#,6HEC: M74"_L+F6G`O<\RN@7-!8:ZZ('4,3X6B4U/K8#!VUZD]E#DOJ=:?VN]@L(Q(Z MH_7:CVEP_!2Y6;!`>.6HE/M2[#WB_"D:W"#[])(K.E.J^4*8G@7]4&B+WM!6 M85,67YEJJ67LE<56C?]N%KAE44Y1;N*O9'[8UZ'VMJH7E?FQ8H="O(X/2;M` ML^'?+5WYK)?Y.E7_W0S=#V862>H#705?[QQ6,Q,I]`%KPZCGCV8*)7T@W"Y" M^J.9THG46UU0*BRU0^;'W,SBCLK8\,VT.3QF/MWU76'E3!#/V;M9`/DQ,9U= MHUARJFX603YF^-2\G7-J6-FCJRI&<+Z0U;L?I*C:JHJ^=#701,GN_PKF"E, M'N8;"%S=-W,.JYGIS0Y];U0[)>>(FYH2K3_,VX9JYM@WT>H/ M/^=AMR%ZPANZRMTZ5QN.2C;I`.:VL:8Y\F:)QQ7X-(PQ5$GY_,%,MZ/^@.S' M!2'_'F8Z*/6ZL5N%)^?(-RFE-?PW4RG`H)0RF&]3,UTAIYR&NI-];'H!Q59H MUF8T3*^QV`K-VG*)Z948%>L72=*3MBN_>$1O1B5"+8LMKF.`Z70X-`61[^]; M5@!+,+D*!JZQ5D-$.?C+%@7KQJFN706Q(\)1$KDYQ@*H\JC0JGH-[\<'AZ)\ ME)5NL`CIJFBA"9=Z8$MB?, MN8D5S2&QY2C_A)X'$\H+B.JH]M%MY0I!GN\+P/8#N4;X*\.1[CR*2O)/Z#T` M_`)=0+B9HVIWUU)9P'=(Z@TC3:7.::B1WM\HM7*P1MZ(<)E`!?T.J<;./'! MIE+>'?+IDPO(GKA8?!IZG&V8:/!2W?0YDY;J)*NUCS8`/`!6C#!P@?2^%K6V M55X&4N6%Q:>XK+1D$$14DD`D?'!>6$E.WC86-]92O04$=$_Y+!+$6\$`,HF' M.8IN0VZD^U*MKZ;Z"<5XW1LV$[L9Q$R&K,>`5B#=X?(^.E9QPVPI='_YZ$:\PH/(O_Q2@[*U#&?OL^__,.+>FO.C#*OI_*4REHK(5NO'2" M;5X]NN$(98:]E&\NLM'SQ=84EF(%DID>D._%&3RXY$D[ MZ,Y1K3//O!!AM&:),-FAN7+SY"_!1'-F@\EBI].QH)Q6NSICU]UD8)Y.) MKT@(5TXF)F]%Y%F0Z4(=3"@IKTIHCBE](YE2X@#*'VXHLQ"*"P6T'"PXUEWXJ*X?=@[!:$\ MLG9$&+4Q[80^`$"BK:GJUWU4._[R3G\ZN#?@:J46-E-SUKB5[!& M$2Q9CXY.9CP!8VVEAW"O58>SGRO-?MY\]JZ^WM9F%".BHKV&MO*^FT7D7QM5)9P5Y[/=33'?", M?`]@DD`J)'NOX3#H97G:,$F263RL?2@N!U3=4]N*F,H)>)WKCWH&RV0,\H`J@I=.!AO&.,7>XA-PQ##IRADWBF/Z,Z1V,WJ MCS.`U5)*YCB^TQ*M+_T^\<=16Z.P=R>\'=/8W2`GD#!VNTVT($HGF"]*4K!4 M.A*WUT']UEM6*D.4VQS$NOC;KSSK(OU5:PIVH>=U*7Q#)J.9GB!<#I%08#0] MI[PR+.<"6)K$/0\?%K';^6[Q$K[#L>G!A56NUH7-HZ@>;9=]Q2#$]I@+4PO? M',A-OAS`J"#EF9I#1!?>=60U4S..:,!^-RF'6=>J!D"YCJJMDIY8?.67<\O\ M*19>E;R/AJ59T8-L-XD'#&=6G<,#@MS4K]/4JNQ:]G<'KF&F M5G$_FN]A;K'WP]]&K;QD3:T&KX-[WW4A:E;UW6++P58<=M2LT+L%NIN+?8Q: M%;>UFWM'<<[-E&%J@5M=`.\G4&E5W-4BG-W/DL1-S:J\6H@K^;QR]L%F95\M MS'5-\@6W<%-KO.J`O!"S9&IUU\/SS+*$%Z86>]7A1M(L27*KXJ_V"U37WRVE MGFE5[M6**\5[13FIDJFU7P^0K[>J",E_FN8V?2!,%8.0C:UD4$"*;;& M>?[KVL+R8CS&E2LZ,,R5B752H#]8H+O9S_O1_"G$'RW$K2"6IO-.0?YD0>YF M'^]G!DDA_I.%N!'$O8LZYI=JDU9Z*&DU]HL@':XZV\"QV0F\ST-]S;(B*3T; MRJ_,6`)_E2I.%/$2)4#/CYM9BO#&0"EEXLT/H]U>BCD4<\C,,M$VADRQF$^. MFUD&0$EEE%0O>54J:&7ZE3[OLM1#?XSL2,IV*Z8Z+GFUB?,\F8X6-TUQM@=K MU=O-&1*S_-&4Q;2\T9#0DT.:O$Z)W+$HK_5 M2!4-K:T<9277C]%I';OSO1SAIN);XH=H5=?,9J9ZVGO@,AF7H@.\)$2665!(RT%7!P_2?Y+ M"?@%(8_<`F%M'5Y3W32KD:N-4A<$#MV5=QB\0!01GWYK%BG'\O7)JO%5==.Y MEF\!60,W?F[DY1V%[?50_PR\R`?SA>HM7;BD>2)?AP-K+6B6?B:58F:EMEK= MY[IXO4O:7>XU:&H"]-Y@W'WU3$UX?I!]N+,%K>./D1)Q+;:WM%4Z>-%,![62 M9RD#6L6LY7`9ZI72&9-4I=@R+E2P'P@KN#5C8X?[1;/EJVU^Y(Y4..!=F9S[ M]7!/RT#TL+.`M07\8ZN'T8VZVM85D&@!^6ZU47[-(`GIUIJ)L M[+W#O)9%(KY*3ZTKJM*]LERPUT4KCO?/C*[WH,73\>IM$W''01HS! M.EU4W#JF2VG2RW9T)G)E5&1WI/D\JOAEX&(CN>M,]45IB)2,=S!=(5X3JAT- M;1,=-PH=?YB8#%A#.Q")CP5,1&DX)HNF=%FX./0C5N@(A*RT8Y;$?K0280L7 M'0>SPE`9ACL(BYQP*GJ9(MN:Y?2S4P^5^V7+;;13.7UQH)]482DDL-F6S(UW MGKQA!:7+2`!\"*82\@5>2U5=FO MFR"$3/V<*UUTA0ZY(6]+AP-K7*([#:#VHCMVX4PV'OL48,,(?$=MOJY@! MBNOBY/8)P?YL,I*.%?\&6'YRX$U9H.`2I*4AX^]0R/"L]NPW'&SXNJ&NSHFI MZI(!BRDZ0BNZ?#24"M:;I3/I%T0%CJ.9AN5S`FQ`ST&X;3LR:.LQK,UT-A;E M1DQ*,Q=&"W9M:3,'VJPLCOW"W)0-S=$V*T5MOVA7*O5R6`VL5=29O#LZJVCW M\'6YS\<3=EPLPW3UZOH1'935PBK!9VT@G=%/2?$8FO`%/`"75>&$$N!W;]>T M.#M_J9V,?82HG&_X`TA"X/J<\0@1%.F7.Q]^.-C<.BL@C7>M[*;%AIIF8V/2 MPCQ^2*21Q^+VUFXZ1+MISK^T/')J(,%6$ M."#W4/P\U<^)!;P>LU&-;FT&V51[1EV>AIO)=9]W,-T/M`EZ/<9I5HV]TE_=H(E(+/@VH$X-L4FJFTGV)`; M5LGLPPUTGJ!/EV*30&88G6\R5.*"$1)-H+R/UE7DVZ%*RRWMHG4-LX">;)(B M2\_]_T0.VR9Q4;1"SOPJ#62+`8]B_3)]3W;[XZWQ MG7P+T!,+1&/$QBNC?T:!2WO%B]@]CU)E;?_S=N(?G9&YI8TYU/P&P^<]DDB9 MIO(",OI^H83-@N0=G07IP\GSH3[,Q$/$B%DLM6`DF%CKJ:RY,B)86CQ6U4GL M="Z+6H.YOK\WP*XBN"7*_J'9NKD&`84..B4P):ZU*%`=X)$U7!IO^N@!R0:WBOFIO0ZF%,R>RPKIT%3OD`'; M\H=F3GM\!AR+6FR>!-X%"EX`#B'=@[SKRVYKBX6LM:=:2 M=DR6M,/8-9(S3V*7B=W[JA13?`!3ASHMQZ3'E\C.2D:EP\]O`+IQP:3#`)E, M=4R8#<:R9%$;K3VNHSBG9X3#1X!7C%]]I+/)RA5RVPZ":GG!3$'K08CBUNYE MNAK9VKT.^2GD[(RU=&G\!C*&W1J\]!DA:TBPSV2UBZI M8DT3"`?6'FGMD:::QS3%_LFD<.F)'"U"XGAQ@<'N<#6F]9I8"];4:Q@XE*=P M_%E`0AS%I7>GG@<3:@NWSACLJ@)KT+8(7('+OLLQ\:GAE]H98"CKNX?D]VL,*/M(GR=`PIJKXW:WT>(=K*(@[,?BN]HZ MN+T&XJW#1)(DI9-B^*^LZT#6=.P>2(PL!JO*L>?T&,`*K`_5X'VH;#:"+K,1 M6/^+)EXK(C^^*,SSIBL(;M+VQ^\/S@L*U;^R;*\]P)W#U%S/9XJ M=&:9V%MH,`A/&NO_8W,-&*I#5I30N*A+1:'1`*<@$&9."A6*U0RS,S,SW3;" M3,[2Y)`9[KQD?2)-=V$Q-_2SGX]09"-;>9.^`/R$QH6=@D'*NH6V!91OBVCF MU6EQK;(UFEJ0]/"X[MH&32T^>GAD$PNRJ55'>WKFA9JN',?/]M&OLS-YMK)< MD+("0'W'Z8]6;K*.TP=SG):GQ+(R?!TD^5K/%$L;$&'=^0U-+W;6M\NWC9\8 M5G2`C9_H+W[BK&^%K=[X"0;2#7*"P01*L(^0DU?AM"AHK,-(STC)`T\D?@6< MAOKIW9,NI43?:'4K+--265!=V%P_[3)_1UY+4\)MAN)$ULTW9:=AOKB@CP,, MKQTWX<>\),YW?$CX\8FC&5#J]X[(H@U3O-IMOUJ][:3#;=NT],K^TM>>D3!,\A@$+#M\2-\>$+BL2OA0Q'4)C./PTO'(PW]$=9 MQ)I:7YT/7Z,;(O>KKSP&ILHNM>^IDA2CMJ5,%5]JW:!5[/KH=M8>.C6VHF53 M1\>F7B/?1S]0MZEFYS?MA.1)1E:*C_M-M&$1$[@ MYF1RBEJI]^LHN05:(\R>T?GBRG&?OP4PI,]5C!\7:UG[;BC:>?+Y>AYI4\TI M-B@?2R`]OVG&>`!?F/O>(WT1"26/L2S\;UYOC/$D$A'LE`?W&7@1FR&Y*(4Z M+'[#;FB@6P^0*3L&$K,WIU6'LY\KS7[>?/8.$[GLOVS2="GB'C85#8<^*I;% MONE%J4.&K["]5NIWV$GI#I'VT;,*BB%[L(%W&;%GZ2ZI/A2_D+?@1_PG\7*4 M.G=R=WRC@CK^@6%(1?;R0RJ^22K[Z$!\*VM*);QR&ZVJ:Z'F(-.*\=X44QWQ M:\-R+H#%S+0#4BF\['*^I^HXG+OYP+'9N2!,S9LDTY>4(C@47RBC#3DJ."F$ MDH]S!RGH-$S-!]-@\ZBH`TQ-\Z(,%S<[DUFI6:JP4-#'F9I;176;-#1CF9I" M16U'*6O66V5(&3!,38TT&835HK*I^5`&[*"@X:A5F"9R296OF#8:&ZDR?G0) M<=0@4=*,&QO%4!,CL6[;V%0V#1'BZ\^-35*CAA*?5S+7M;"&U4V0ZZB"1S+U M-5,VIG$$DY+Z>C0`R>QU19`$"MNQ^+06LL)0*7\%"4%XCQ-O<0,5T6.!TH1)]^SO1.Q? M5&.`CN+-!//]BIBC?Z*?>:1#$/;,\`S.-4?0\E6B5>3'6>O*%,H]CN6=.JK+ MG,[!]!>N3R_T+`DV/Q!1VD%7:IM\4VXW`_`*@=YQ,1"1I[IR]T&N+5'3)8:Z MQBLL#Z)_G7MZ2NF";K0GA4\?`;XEDH;Z]B\'"QG`95`1+>4J/6` M*&>E#P)2["5:CU'4X:R()V)G4/UNMQ>DW:@W10Y76 MA.V91N$SPO`/X%TCG%2&2]U5>/D/FH_3VPH>J%13B]2\@_Z=4Y31E/9)J4,/ MF'*%1N$Y;3!`1S3#P(5KQT^8F_DBU1'%&1>`]RU8QXJ4I$R4K`QQ@W&&$R*W MHPH+O.0'0/]8/VZN:FM%JJC)P+^'C$[X$ML_9,G MYA,VUT'[(UBM$7;P)C%-,L8(Q.5KT#WP0%*.+ZG.E[T9@F4U&6D`*TYS=R4L MXC0,,7R*0J:_?$1WL058;;T*XPQ@M922.8Y/3B(C542OJ_8>P,J*:GZUU91Z M##?R3^DESSP(WIL5/5$/HBI#9(Z2F>[=%88F<4;DHMW!U*"W&B"U4*>9&AC7 M8(LI/SVF1LHUP$QHSC`U/*X[C#+#B:G1<^V/H`JOVRK`[BB*1+=Y``K6"%-# MZMIOLS(K;GI,G>IVDJF53`V>:["7FII"3$\/4Y.W5_,9;)4@Q93+OJD[HJE9 M5!H=6A4?$--3%:F^!!5NR3E,HV?U9=X4.4RC9?,;A1CDN)F50:/!]N+F7#D; M/3M?)\HFAVVTW'TSI\%<%SUZEE\QMBY';/0S7\(C,81L#FU\K M:10R)\ MXLS/XB(.[!1?-\601--SD2C7E%=V=,X9'W/5=4J(-0M'R>$S2Z%@$R+N[*.] M():]1VQO2YB,1#FXH(C%3D1Q?D#,5$16!KB4>$%A)$\.DYEZ;IME3!4@7E`$ M;P]Q-ISQ&%6$8(B9Z(-GIM61@BUF6![1-0PJF=1CJ?FNK;AJOC,SP# MNI4*15R;U)#7_<66XVJFE91_7519JHQ5'(OAD&W$0ZJ+A\7O/L!E0"4CUPG" M_8O<P(.2*VSY3@MQVDY3LMQBGU>%2\ART=:/M+RD2WYR/2' M\?*3S>F_0)BHC95;%)5+U,XX^:XS@)F(4%XHP:HL+GEZK=&;T`! MBL`]WO+REI<7\O(*5\]HV'@I4.(WS_1L5VKX5/): MIJ>ULM*@E09[EP9C,$OKA_1 MK<_2ZK#ZHU%J5]Z]^BOM$-U/I!>O7;K.'0+=:>!=LJ4!+SZTZJ#4&TWSRC%& M^`+1"]IEGXC$/@?TWJ6T0^3EGLC5MJDV0^K%(.,,+R*,TP=/?;T5W:T$;R5X M*\%;"5YLC6MU&5OAOMYE;H7]5JS/:)0`BO!UQVF;G@';JE>L>J6%>N7:@3A. M9Y1[/'?AJSDL?41S#IH'3X5^1]IE*&NH$L/D?:QFR,J#A[C,54Z?E0BM1*C( M7E980I8TS&&$>?/@GFE",`R63)M$O@7HB0#\PH[>+%A' M(7-6HH?6A_'-L/M=I!6@^Y_WR-%4%IBZG.KXY2Q!'>ARGN!LOXCK@,L[Z*F= MC7#(LK:SE^21SB:KI\QM.PBJY77A!:VMK&VPK"WC`;C25']/E>EBJ]5O*.+3 M-SX3RX=:/E21#ZU[DUL&U3*HED$5,JAWT9,/W?F"KI9%0AH7PS44 MYD7DT2:"OSR_O*UEHWIFHPY(9_95*T2N_7:6AQG2\\/E82J.O&55+*LR*%9% M#R["*W`84N*P^#=QT7@J'3W0*X;^H^R=V)#%$S`P;>;G\#AMAK/Z-JMOLXRB M912/XI%38!1;7:V6E[2\I.4ECY*7_.F44?CD$$#_X_\!4$L#!!0````(`%N& M<$=\'U7>-0P``"QP```1`!P`8F=M9"TR,#$U,#DS,"YXY(I(>DDGA^_9Y#74Q;LB+93N-@]1+(XKGR?+P=4LSQ M;X]A0.Z9TER*DU:OL](1-CID?= M[L/#0TUVJN!+;,H1>=?9W^^\=4KZ,A+^$3ET7ITK1@U0$Q^, M."+[>[W#=J_7[KV[V^\=[?URM-?[CTLMIS/%QQ-#WG@_`?'>81LX#DB_T^\X M7OV=#*300!U.J9B1TR`@?>32I,\T4_?,[R1"M7660`T*?=)R_'LXZ$@U[H** M7O?KQ^NX4EH__D!BVJ/'H0KX`@>^27D.NEQH0X7''):`BS]*.+`8Z]Q5DF-) MS.J]?_^^:TL=ZDBWQY1.,_H1U4-+G11T;>7N]=H'O44N,YLR7%\PB`KGVWA_L.3P"(A2%Q77@&]5%=5T@:@,54]QS69_FR_$@ MC6\R-K>Z#[MQH4/M`3B-FBV2:^9UQO*^FQ2B4P>YJO`BI:#%K6)-2I'W;8[7 M9[R8#0J*.=BC-REFP9+B8'%QS[0IYHK+BCT3E'NZF,T6(5DH]5AV%T->%3)A+J<(+-J)1`%7R9T0#/N+,;Q%J MC.+#R+`%@DC,27Y%*<=4"&ELKV5_XYOIE(N13'[""VR:1TH&[`Z@2?#A<_^J MU%"3]+]=).Y>2"]"4ZGP/PC#S>P*Q*O0*FT1#BVOE"(S)#7%9R,NN#6YM]T%:@`66U#=C"ZY@!Z?T^!6:FO.>4"U3K"%(>L#P[>*#.41 M/("P98((CHO"9P+':WC2,N`XFOKDC`8X!I'!A#&CFT!N'LA;"GVYF3##H7YJ M1]5R/Q':M^N$EKQ9,.RG)M050WT%$^60G0:&*0%NW+/BF.;)RH-X6"V(&8DF M!?-!7PN>*>:8X?'FR\O"]6R=\J(18+4WXRL+W M21JF[V363!_68?F%0T_3H5_ZSCK]+%SY@NNO4#J2+$[]FC.`NG] MX8#A.RHMA]8O..'*N/`'TY[B4[L&!A2=11JJ36L[&3NCFEMLN88TZ%H/70,^ M%C`*>U284\^NY[@8WT*X/0X8)H+M:R8/S`0L[HM?7WYY>`X MR#?[3!69ZR)6F>T'8G7DE&0*B=788.AC6X3$(G`UL7+%:S_!-8N M6PT#EZ8TNONY1*(374=*$ZYUPX7G0*-T%P\'6`\&]PL>1(;YGYBYEEK?,C68 M4,56AK..C/)PY[*(3K@=+79F@'KLM"#11$`505T$E!&KK8%%35A@TE8*6W?Z MPZ,71#[S+Y4,%R)<#1V;B"H'22XA&:N*0ZY)JHR@MF74-%AYABYD0L68Z2N1 M+1'C+H&*F;YF]RPXN.9TR`-N9JN[D!HRRM&1RTBZ74BLA7"QM/9,5/U#$ZN, M')!,78.+C7%Q-V$%81TP#ZA])V%LDP]/0Z2>N'*TY+.3A6@Q$[82,8GBA2@4GQK\Y>'/)=]+#VTT,!@:QV]/4$@Q=*)A&H=?!W> M\O#GLHNK3S8TL=]>%U#W+$+%GF$[8LL1DTLVKGW4>4A?_FWOMVIDE.,!-/=5&PJ(,>]^'&Q!>A2_256I1(F M$+R3%G[6VTX_FOP&')W',$A)##>HY7PNAZ`@_3.A0=#J[J[GBV&LX#@P%#A^ MD8EY)7X'=,B"BBX#;8'+URCAE7B[W,PK.`TL!4XO[+T6^'[<=3_XA5^+'P0? M@^M2&2(*OU!><4\`B:\BN):>%53"@K_:*5\;7[5[^^V#7N=1^XF)=2R8UW0] M"U*^NA:4WB^PR@:KO_!"@RX+C,YDM>>RZE='X14$E6K%Y?P4,V*UO,=JZ;W; MQ)+UK%C/A,(+$JJB(F5`I8>U@;!\/\4&.,`W=6'PU%T/I>84\:4_VG,A:QA2 M<'-$-4MRZFOBU+UU%4,B/EP8>-E"]?;%%)>\9DGS9"1/Z*C$H6.&S) M\T9PR-VX4E0Q(>?!A,^5+5X%4TYXRV:<5^I-[0:P! M,+V%1Z;TI50?<;%'%8/E5?S(<9EUSSVF/[)PR%2\0L,IQ;=:7/$4*;X.Y\B7 M(>7BRK`0EP\M0H?:*.J9DY91$4Z`\*JA(Y@8<>G?648_4LD"4?`@P,.#*:V. M@)F;"$M_5S*:GK1B=@[B5[B[.M\$4Q^&=FG7STKDL8.Q:O`&2';1/WONLIIO M">EW]LLW1Q/@5%XTM#6[RD,G+^`N_[](=""^^NH.IK]Z(@-_P=]ZC`EL`;/3 M9!N[R/L1#72A^_&3')20N,P"W,;%F^^RVGVZ4.M_"X M<=%98X!@NC%<>NJTJ)M^3B4[U+EOW&Y%.SD0)+>!'9:<*?8:6*46S>5 MR'<(+1_^C,#*HN:2*]DEJQ^GS#/,/X7.BP;G4IL!O<<-&]?^U31;[,_CLF%\ M]=1)RX.!@V]G.,^.-'QD%+<=L.C?W$P^"SG$&SM1_)681D;WF2=A1A9P:U,? M#Z9@=&R3S`XTQ>.ZMHUV^;3,G70&":<*7\Z$YXN0SX:[&:#?<0`6\2'&*_&! M*K$$Z.^D[_^Q<>"9T.]9]ZOTO0K81V9^SG?U[+.<;)J`DQO'@1S5\S5 M61;6RLCS:1TA;"Q> M5WI:E7UC4&<)D&?$=(%G`QGX56K`H=N>JUOWJ3`W-6^7*WU\DF^G6BR'875* M@_B#OIM1FI."]23(]#^+*>4PF!H&?IB"AKP.^VZU;XE;`G;V_(%Z,/7@X$8, MTP5'R\A<$/O,XR$-7@[#2T?Y\JOIE10[M!0MOYNIR(T=SI?V&0^'D=+,+]FQ ML1,YZ"7NH*$X7J[!&[N?'E1`MQ"M+^D^3M<\&.<@3F!]GP5XJRWF#CZ`K)!F MZ80DE0!S]W`:R!EC`QBX;&Y<^&=,L!$W>J%NMBOX-0R[93XGJ9E/$7:ST$\E MOL+B";M8H*]8=Q7DN%7%H7L?,_5R`,/_F>)'`2O_>#9=#T([<2;413FZ+YT$X^6$]5;D+63.>FY7W&.=K7?"^6[Z4ON^[VE7 MBCS*%^Z>\6=EQI_MKO%Q,F*TM+I;W/4O(UIH-I;NQ6;,M;<\7^'V9:VMR%>[ MK9A^L9AO3[F276I,>#I"/2AN#%OZ$BOGQ].D+^C8<3<^*`>/_P-02P$"'@,4 M````"`!;AG!'Y2TC1L",``#S$04`$0`8```````!````I($`````8F=M9"TR M,#$U,#DS,"YX;6Q55`4``[Y/2E9U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!;AG!'I6`H^B`-```CHP``%0`8```````!````I($+C0``8F=M9"TR,#$U M,#DS,%]C86PN>&UL550%``.^3TI6=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`6X9P1[FX/IH``&)G;60M,C`Q M-3`Y,S!?9&5F+GAM;%54!0`#OD]*5G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`%N&<$>WQ+<)"4@``,O8`P`5`!@```````$```"D@7;%``!B9VUD+3(P M,34P.3,P7VQA8BYX;6Q55`4``[Y/2E9U>`L``00E#@``!#D!``!02P$"'@,4 M````"`!;AG!'4.%3NWTL``!J?@,`%0`8```````!````I('.#0$`8F=M9"TR M,#$U,#DS,%]P&UL550%``.^3TI6=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`6X9P1WP?5=XU#```+'```!$`&````````0```*2!FCH!`&)G;60M M,C`Q-3`Y,S`N>'-D550%``.^3TI6=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``!I'`0`````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Term Loan - Additional Information (Detail)

Feb. 10, 2012

USD ($)

Term loans

Debt Instrument [Line Items]

Loan facility amount borrowed $ 10,000,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=bgmd_TermLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Term Loan
9 Months Ended

Sep. 30, 2015

Term Loan

4. Term Loan

On February 10, 2012, the Company entered into a secured term loan facility, and a term loan in the aggregate principal amount of $10.0 million was funded upon the closing of the transaction. On July 14, 2015, the Company paid off all of its outstanding obligations under that certain Loan and Security Agreement by and among the Company, General Electric Capital Corporation (“GECC”) as agent and the lenders and the guarantors thereto dated as of February 10, 2012, as amended (the “GECC Agreement”), and terminated the GECC Agreement. The security interest granted by the Company to GECC in its assets in connection with the GECC Agreement was also terminated at the time of the payoff. Notwithstanding the payoff, the warrants to purchase the Company’s common stock that the Company previously issued to GECC’s affiliate, GE Capital Equity Investments, Inc., and Comerica Bank in connection with the GECC Agreement, continue to remain outstanding in accordance with their terms and are not affected by the payoff.

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Promissory Notes and Series A Preferred Stock - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Jul. 14, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Jul. 31, 2015

May. 12, 2015

Dec. 31, 2014

Debt Conversion [Line Items]

Preferred stock issues and sold, purchase price $ 0.001 $ 0.001 $ 0.001

Other income recorded upon remeasurement of preferred stock liability $ 31,000

Other (loss) income 7,000 $ 1,000 $ (514,000) $ 2,000

Preferred stock issued, value $ 2,594,000 $ 2,594,000

Preferred stock, shares issued 1,474,443 1,474,443 0

Aggregate gross cash proceeds from issuance of preferred shares $ 2,000,000

Debt amount converted in to preferred shares 987,000

Deemed dividend on beneficial conversion feature $ 1,507,000 1,507,000

Additional paid in capital, preferred stock 1,500,000 1,500,000

Accretion of convertible preferred stock to liquidation value 56,000 56,000

Secured convertible promissory notes

Debt Conversion [Line Items]

Principal amount of secured convertible promissory notes issued and sold $ 500,000

Aggregate principal amount of Notes, plus accrued unpaid interest

Debt Conversion [Line Items]

Debt amount converted in to preferred shares $ 500,000

Series A

Debt Conversion [Line Items]

Preferred stock approved to issue $ 2,000,000

Preferred stock issues and sold, purchase price $ 1.7003 $ 0.001

Preferred stock issued, value 2,000,000 2,000,000 $ 2,000,000

Preferred stock sold, value $ 2,000,000 $ 2,000,000 $ 2,000,000

Preferred stock, shares issued 1,176,262 1,474,443

Preferred stock, shares sold 1,176,262

Aggregate gross cash proceeds from issuance of preferred shares $ 2,000,000

Number of preferred shares issued upon debt conversion 298,181

Preferred stock, voting rights Holders of Series A Preferred Stock will be entitled to vote with the holders of the common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of the common stock on the trading day immediately prior to the date its Series A Preferred Stock is issued, which was $1.40. In addition, prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of capital stock of the Company, with certain exceptions; increasing or decreasing the size of the Board of Directors of the Company (the “Board”); and certain other actions.

Convertible preferred stock voting rights threshold $ 3.20 $ 3.20

Purchase price 1.40 $ 1.40

Convertible preferred stock, terms of conversion Each share of Series A Preferred Stock is convertible into one share of common stock at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. The conversion price will be subject to adjustment in connection with stock splits, combinations, dividends and other corporate transactions affecting the common stock.

Series A | Minimum

Debt Conversion [Line Items]

Rights to nominate director will terminate if share of preferred stock fall bellow the threshold 20.00%

Series A | Adjustment

Debt Conversion [Line Items]

Preferred stock issues and sold, purchase price $ 1.00 $ 1.00

Cumulative Preferred Stock

Debt Conversion [Line Items]

Preferred stock, annual dividend rate, percentage 8.00%

Undeclared dividends $ 41,000

X

- Definition
Convertible Preferred Stock, Voting Rights Threshold
+ References
No definition available.
+ Details

Name: bgmd_ConvertiblePreferredStockVotingRightsThreshold

Namespace Prefix: bgmd_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Cumulative Undeclared Dividends
+ References
No definition available.
+ Details

Name: bgmd_CumulativeUndeclaredDividends

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred Stock Shares Authorized for Future Issuance Value
+ References
No definition available.
+ Details

Name: bgmd_PreferredStockSharesAuthorizedForFutureIssuanceValue

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Preferred Stock Shares Sold, Value
+ References
No definition available.
+ Details

Name: bgmd_PreferredStockSharesSoldValue

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Preferred Stock, Voting Rights Threshold, Percentage
+ References
No definition available.
+ Details

Name: bgmd_PreferredStockVotingRightsThresholdPercentage

Namespace Prefix: bgmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares Of Preferred Stock Sold
+ References
No definition available.
+ Details

Name: bgmd_SharesOfPreferredStockSold

Namespace Prefix: bgmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value received from shareholders in nonredeemable preferred stock related transactions that are in excess of par value, value contributed to an entity and value received from other stock related transactions. Examples of other stock related transactions include, amongst other, certain costs incurred in issuing equity securities, certain dividends and certain tax-based consequences of share-based payments compensation awards. Includes only nonredeemable preferred stock transactions or transactions related to preferred stock that are redeemable solely at the option of the issuer. May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1),(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingently Convertible Instruments

-URI http://asc.fasb.org/extlink&oid=6508575

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_ConvertiblePreferredStockTermsOfConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtConversionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=bgmd_SecuredConvertiblePromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=bgmd_PrincipalAmountOfNotesAndAccruedUnpaidInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CumulativePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value of Financial Instruments
9 Months Ended

Sep. 30, 2015

Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

At September 30, 2015, the Company’s financial instruments consisted of cash, accounts receivable, and accounts payable. The carrying amounts of accounts receivable and accounts payable are considered reasonable estimates of their fair value, due to the short maturity of these instruments.

In accordance with U.S. generally accepted accounting standards, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The table below sets forth a summary of changes in the fair value of the Company’s level 3 liability (preferred stock liability) for the three and nine months ending September 30, 2015:

 Three Months Ended
September 30, 2015 Nine Months Ended
September 30, 2015

 (in thousands)

Beginning balance
 $ 31 $ —

Loss on recognition of preferred stock liability
 — 79

Gain on revaluation of preferred stock liability
 (31 ) (79 )





Ending balance
 $ — $ —





The resulting initial recognition and subsequent revaluation were recorded as other income (expense) in the unaudited condensed consolidated statements of operations

The table below sets forth a summary of changes in the fair value of the Company’s secured convertible notes for the three and nine months ended September 30, 2015:

 Three Months Ended
September 30, 2015 Nine Months Ended
September 30, 2015

 (in thousands)

Beginning balance
 $ 929 $ —

Proceeds from secured convertible note
 — 500

Loss on fair value adjustment
 58 487

Conversion of secured convertible notes
 (987 ) (987 )





Ending balance
 $ — $ —





The resulting fair value adjustment was recorded as other income (expense) in the unaudited condensed consolidated statements of operations.

The preferred stock liability was valued using the Black-Scholes option pricing model as of May 12, 2015, the issuance date of the secured convertible note, resulting in a fair value of $79,000. This valuation considered an underlying security price of $2.12, strike price of $2.68, risk-free interest rate of 0.02%, expected dividend yield of 0%, volatility factor of 73.8%, and expected term of 0.22 years. The preferred stock liability was revalued as of June 30, 2015 resulting in a fair value of $31,000. This valuation considered an underlying security price of $2.00, strike price of $2.68, risk-free interest rate of 0.03%, expected dividend yield of 0%, volatility factor of 73.8%, and expected term of 0.08 years. As of July 14, 2015, the mandatory conversion of the preferred stock occurred, resulting in a remaining term of zero and thereby a fair value of zero.

The secured convertible promissory notes valuation analysis was based on the probability-weighted expected return method (“PWERM”) utilizing various scenarios for the expected payout of the instrument covering the full range of the potential outcomes. The PWERM determines the value of an instrument, based upon an analysis of future values for the subject instruments, which takes into consideration the full range of the potential cash flows available to the subject instrument. The instrument value is based upon the present value of the probability of each future outcome becoming available to the instrument, and the economic rights and preferences of the instrument.

Due to the lack of relevant and market reflective Level 1 and Level 2 inputs, the Company valued the instruments using Level 3 inputs, which require significant judgment and estimates on behalf of management in developing model assumptions. The fair value model used in valuing the convertible debt instrument as of June 30, 2015 utilized the following inputs: conversion price per share, current and future stock prices, discount rate, and volatility. The following assumptions were made in the model: (1) conversion price of $2.68 per share, (2) current common stock price of $2.36 per share, (3) simulated future common stock price of $2.14 per share, (4) discount rate of 18.0%, (5) expected stock price volatility related to the current common stock price of 51.0%, and (6) expected stock price volatility related to the simulated future common stock price of 55.0%. At the conversion date of July 14, 2015, the following inputs were utilized in valuing the convertible debt instrument: (1) conversion price of $3.33 per share, (2) current common stock price of $1.54 per share, (3) discount rate of 18.0%, and (4) expected stock price volatility of 56.2%.

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current assets

Cash $ 2,642 $ 4,123

Accounts receivable (net of allowances for doubtful accounts of $151 and $0, as of September 30, 2015 and December 31, 2014, respectively) 152 174

Inventory 223 400

Prepaid expenses and other current assets 139 154

Total current assets 3,156 4,851

Property and equipment, net 14 117

Intangible assets, net 92 135

Deposits and other assets 94 126

Total assets 3,356 5,229

Current liabilities

Term loan 2,960

Accounts payable 1,332 695

Accrued expenses 562 906

Other current liabilities 48 18

Total current liabilities 1,942 4,579

Other liabilities 94 93

Total liabilities $ 2,036 $ 4,672

Commitments and contingencies (Note 5)

Convertible preferred stock; $.001 par value; 5,000,000 and 0 shares authorized at September 30, 2015 and December 31, 2014, respectively; 1,474,443 and 0 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively; liquidation preference of $2,548 at September 30, 2015 $ 2,594

Stockholders' (deficit) equity

Common stock; $.001 par value; 100,000,000 shares authorized at September 30, 2015 and December 31, 2014; 11,126,579 and 8,632,810 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 11 $ 9

Additional paid-in capital 164,118 161,550

Accumulated deficit (165,403) (161,002)

Total stockholders' (deficit) equity (1,274) 557

Total liabilities and stockholders' (deficit) equity $ 3,356 $ 5,229

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of investments and other noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsAndOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Description of Business and Basis of Presentation
9 Months Ended

Sep. 30, 2015

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

BG Medicine, Inc. (“BG Medicine” or the “Company”) is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders.

The Company’s BGM Galectin-3^® Test is an in vitro diagnostic device that employs a manual micro-titer platform to quantitatively measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The BGM Galectin-3^® Test is cleared by the U.S. Food and Drug Administration (the “FDA”), is CE-marked and is currently available as a blood test in the United States and the European Union (“EU”).

The Company has entered into licensing agreements with leading diagnostic instrument manufacturers to develop and commercialize galectin-3 assays that will be performed on automated platforms that have been incorporated into routine practice in laboratories throughout the world. On December 23, 2014, the FDA granted 510(k) clearance for the ARCHITECT ^® Galectin-3 assay, the first FDA cleared automated blood test for Galectin-3, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure in conjunction with clinical evaluation. On July 6, 2015, the Company announced that the ARCHITECT ^® Galectin-3 assay is now available in the United States. This is the first automated test for galectin-3 to be introduced for commercial use in the United States. The ARCHITECT ^® Galectin-3 assay is performed using the Abbott ARCHITECT ^® automated immunoassay analyzer and is being commercialized through an agreement between the Company and Abbott.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. The interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position at September 30, 2015 and results of operations and cash flows for the interim periods ended September 30, 2015 and 2014.

On July 8, 2015, the Company effected a 1-for-4 reverse stock split of its common stock. All previously reported common stock share amounts in the accompanying financial statements and related notes have been retroactively adjusted to reflect the reverse stock split. As a result of the reverse stock split, the stated capital on the Company’s balance sheet attributable to its common stock, which consists of the par value per share of its common stock multiplied by the aggregate number of shares of its common stock issued and outstanding, has been reduced in proportion to the size of the reverse stock split. Correspondingly, the Company’s additional paid-in capital account, which consists of the difference between its stated capital and the aggregate amount paid to the Company upon issuance of all currently outstanding shares of its common stock, has been credited with the amount by which the stated capital is reduced.

The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates and to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these financial statements. The results for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other interim period or for any other future year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

At September 30, 2015, the Company had cash totaling $2.6 million, an outstanding balance of $0 under its secured term loan facility, which the Company repaid and which was terminated in July 2015, and stockholders’ deficit of $1.3 million. During the nine months ended September 30, 2015, the Company incurred a net loss of $4.4 million, used $2.6 million of cash in operating activities and used $3.0 million of cash for payments to extinguish the term loan facility. The Company expects to continue to incur losses and use cash in operating activities for the foreseeable future.

The Company is in the early stages of commercializing its BGM Galectin-3 Test and assisting with the commercialization of the ARCHITECT® Galectin-3 assay. Interest in the testing for galectin-3 is increasing as a result of the Company’s market development activities, although it has not yet translated into significant revenue. In order to achieve profitability, the Company will need to generate significant product revenues.

Effective January 1, 2014, the payment rate at which testing for galectin-3 is reimbursed by the Centers for Medicare and Medicaid Services (“CMS”), was increased to $30.01 from $17.80 per test. In 2015, the national limitation amount for testing for galectin-3 was reduced to $29.93 and applies across the U.S., except in Ohio and West Virginia where rates of $23.93 and $26.33, respectively, apply.

Since September 11, 2014, the Company has implemented a reduction of approximately 77% of its workforce, or 17 people (the “Restructuring”), leaving 5 employees. The Company took this step in order to reduce its operating expenses and extend its cash runway in anticipation of the commercial launch of automated versions of the Company’s galectin-3 test. The automated galectin-3 tests are being developed and commercialized by the Company’s diagnostic instrument manufacturing partners and will be performed on the partners’ automated platforms.

The Restructuring primarily eliminated the Company’s sales and marketing organization and removed certain positions in other functional areas, while preserving some senior management and other critical roles to support the clinical and commercial adoption of galectin-3 testing by providing support to the marketing and selling efforts of its automated partners, clinical research studies that have incorporated galectin-3 testing and by expanding the BGM Galectin-3 Test’s labeling indications for use through additional clinical studies and clearances by the FDA.

Employees affected by the Restructuring were provided with severance arrangements including outplacement assistance. As a result of the Restructuring, the Company has recorded total charges with respect to severance payments and benefits continuation of approximately $404,000 and $98,000 during 2014 and 2015, respectively. Of the total $404,000 charges in 2014, $128,000 was recorded in research and development, $114,000 was recorded in sales and marketing, and $162,000 was recorded in general and administrative expense. Of the $98,000 charges in 2015, $41,000 was recorded in research and development and $57,000 was recorded in sales and marketing expense. The Company paid approximately $277,000 of such expenses during the third and fourth quarters of 2014 and $225,000 during the first three quarters of 2015. As a result of the Restructuring, the Company estimates it will generate annualized expense savings of approximately $2.4 million primarily from savings in employee salaries and benefits.

In May 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Company’s principal stockholders, Pursuant to the terms and subject to the conditions contained in the Purchase Agreement, the Company issued and sold to the purchasers (the “Purchasers”) secured convertible promissory notes in an aggregate principal amount of $500,000. In addition and pursuant to the terms of the Purchase Agreement, and as approved by the Company’s stockholders at the Company’s 2015 annual meeting of stockholders (the “2015 Annual Meeting”) and the satisfaction or waiver of other closing conditions, the Company issued and sold to the purchasers $2,000,000 of shares of newly created Series A Preferred Stock, $0.001 par value per share of the Company at the second closing that was held on July 14, 2015 following the Company’s 2015 Annual Meeting.

In June 2015, the Company entered into a sublease agreement with a third party for the 880 Winter Street office space. The term of the sublease is from June 1, 2015 through December 31, 2018 covering the balance of the underlying lease term. The Company has recorded in operating costs total charges of $153,000 with respect to the net present value of the net costs that will continue to be incurred under the lease for its remaining term and the real estate brokerage commissions on the sublease. The Company has obtained office space on a short term rental basis and expects to generate annualized savings of approximately $240,000.

As further described in Note 4, the Company had a term loan facility that was secured by substantially all of the Company’s assets. On July 14, 2015 the Company paid off all of its outstanding obligations under the term loan.

In August 2015, the Company closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million.

The Company’s common stock had been listed for trading on The NASDAQ Capital Market until September 15, 2015, when it was suspended for failure to comply with The NASDAQ Capital Market continued listing standards. On September 16, 2015, the Company’s common stock began trading on the OTC Markets’ OTCQB market tier under the trading symbol “BGMD.” The delisting of the Company’s common stock from The NASDAQ Capital Market could substantially further reduce the liquidity of the Company’s common stock and result in a corresponding material reduction in the price of the Company’s common stock. In addition, the delisting could negatively affect the Company by reducing the number of investors willing to hold or acquire the Company’s common stock, which could negatively affect the Company’s ability to raise capital, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

The Company believes that its existing cash will be sufficient to fund its operations into July 2016. For the foreseeable future and until the Company generates significant product revenues to reach cash breakeven, the Company will need to raise additional funds to finance its operations beyond July 2016. The Company may not be able to obtain adequate financing to do so when necessary, and the terms of any financings may not be advantageous to the Company and any financings may result in dilution to the Company’s stockholders.

The above circumstances along with the Company’s history, the near term forecast of incurring net losses and negative operating cash flows, the Company’s dependence on near-term revenues generated from product fees due from a single automated partner, the Company’s limited experience with the amount and timing of sales made by its automated partners and its inability to predict the timing of the market introduction of automated tests and product fees generated by the sale of automated tests by its other automated partners raise substantial doubt regarding the Company’s ability to continue as a going concern for a reasonable period of time. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Changes in Fair Value of Company's Level 3 Liability (Detail) - Preferred Stock Liability - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Beginning balance $ 31

Loss on recognition of preferred stock liability $ 79

Gain on revaluation of preferred stock liability $ (31) $ (79)

X

- Definition
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Included In Earnings
+ References
No definition available.
+ Details

Name: bgmd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainIncludedInEarnings

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Loss Included In Earnings
+ References
No definition available.
+ Details

Name: bgmd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossIncludedInEarnings

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=bgmd_PreferredStockLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended

Jul. 14, 2015

May. 12, 2015

Jun. 30, 2015

Preferred Stock Liability

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Preferred stock liability, fair value $ 0 $ 79 $ 31

Underlying security price $ 2.12 $ 2.00

Conversion price per share $ 2.68 $ 2.68

Risk-free interest rate 0.02% 0.03%

Expected dividend yield 0.00% 0.00%

Expected stock price volatility 73.80% 73.80%

Expected term 0 years 2 months 19 days 29 days

Convertible Debt Instrument

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Preferred stock liability, fair value $ 929

Conversion price per share $ 3.33 $ 2.68

Discount rate 18.00% 18.00%

Convertible Debt Instrument | Current Common Stock Price

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Expected stock price volatility 56.20% 51.00%

Stock price per share $ 1.54 $ 2.36

Convertible Debt Instrument | Future Common Stock Price

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Expected stock price volatility 55.00%

Stock price per share $ 2.14

X

- Definition
Agreed upon price for the exchange of the underlying asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=bgmd_PreferredStockLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=bgmd_CurrentCommonStockPriceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=bgmd_FutureCommonStockPriceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 23 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Significant Accounting Policies

2. Significant Accounting Policies

Product Revenues

Product revenues are recognized when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

The Company sells its products through supply agreements with laboratory testing services and diagnostic testing distributors and directly to hospitals and clinics. The Company recognizes revenue when products are received by customers, at which time both title and risk of loss have passed to the customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.

Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Freight costs billed to customers are recorded as revenue.

In the past the Company did not provide an allowance for doubtful accounts or a reserve for sales returns as the Company has not experienced any credit losses, and returns are only allowed for defects in workmanship. On June 7, 2015, Health Diagnostic Laboratory, Inc. (“HDL”), which is the Company’s largest customer of its BGM Galectin-3 ^® Test, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. In light of this filing the Company provided a provision for doubtful accounts of $151,000 in the second quarter of 2015. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016.

Product Fee Revenues

The Company recognizes product fee revenue when it receives quarterly test sales reporting and payments thereunder from its partners. The Company has entered into worldwide license, development and commercialization agreements with Abbott Laboratories, (“Abbott”), bioMérieux SA, (“bioMérieux”), Siemens Healthcare Diagnostics Inc., (“Siemens”), and Alere Inc., (“Alere”). As consideration for the rights and licenses granted by the Company to its partners, the licensees pay to the Company a product fee, as set forth in the respective agreements, for tests sold to third parties. To date, only Abbott and bioMérieux have paid product fees to the Company.

Product Fee Reclassification

Beginning in the third quarter of 2015, the Company began disclosing product fee revenue separately from product revenue. To maintain comparability, all previously reported product revenue figures in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to break out the product fee revenue recognized during those periods. Management evaluated the amount and nature of the change and concluded that it was not material to either the previously reported annual or quarterly financial statement results of operations. Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):

 As reported
Three months ended
September 30, 2014 As reclassified
Three months ended
September 30, 2014 As reported
Nine months ended
September 30, 2014 As reclassified
Nine months ended
September 30, 2014

Product Revenues
 $ 695 $ 669 $ 2,233 $ 2,158

Product Fee Revenues
 — 26 — 75









Total Revenues
 $ 695 $ 695 $ 2,233 $ 2,233









Inventory

Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following:

(in thousands) September 30, 2015 December 31, 2014

Raw materials
 $ 45 $ 64

Finished goods
 178 336





Total inventories
 $ 223 $ 400





Net Loss Per Share Attributable to Common Shareholders

Basic and diluted net loss per share attributable to common shareholders is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. The Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as its convertible preferred stock, common stock, and warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common shareholders. However, the two-class method does not impact the net loss per share of common stock as the Company was in a loss position for each of the periods presented, and neither preferred shareholders nor warrant holders participate in losses.

The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:

 Three Months Ended September 30, Nine Months Ended September 30,

 2015 2014 2015 2014

 (in thousands, except share and per share data)

Net loss
 $ (1,023 ) $ (2,397 ) $ (4,401 ) $ (6,744 )

Preferred stock dividend
 (41 ) — (41 ) —

Deemed dividend on beneficial conversion feature
 (1,507 ) — (1,507 ) —

Accretion of convertible preferred stock to liquidation value
 (56 ) — (56 ) —









Net loss attributable to common shareholders
 $ (2,627 ) $ (2,397 ) $ (6,005 ) $ (6,744 )

Weighted average number of shares - basic and diluted
 9,862,802 8,604,312 9,057,960 8,028,373

Net loss per share attributable to common shareholders - basic and diluted
 $ (0.27 ) $ (0.28 ) $ (0.66 ) $ (0.84 )

As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported:

 September 30,

 2015 2014

Options to purchase common stock
 699,513 644,789

Warrants to purchase common stock
 1,536,929 216,156

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Allowances for doubtful accounts $ 151 $ 0

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 5,000,000 0

Preferred stock, shares issued 1,474,443 0

Preferred stock, shares outstanding 1,474,443 0

Preferred stock, liquidation preference $ 2,548

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 11,126,579 8,632,810

Common stock, shares outstanding 11,126,579 8,632,810

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Significant Accounting Policies - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Jun. 30, 2015

Sep. 30, 2015

Significant Accounting Policies [Line Items]

Provision for doubtful accounts $ 151,000 $ 151,000

X

- Definition
Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: bgmd_SignificantAccountingPoliciesLineItems

Namespace Prefix: bgmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 26 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 31, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Trading Symbol BGMD

Entity Registrant Name BG MEDICINE, INC.

Entity Central Index Key 0001407038

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 11,126,579

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Reclassified Amounts of Historical Statement of Operations (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product revenues $ 274 $ 669 $ 1,160 $ 2,158

Product fee revenues 60 26 116 75

Total revenues $ 334 695 $ 1,276 2,233

Scenario, Previously Reported

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product revenues 695 2,233

Total revenues $ 695 $ 2,233

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Revenues:

Product revenues $ 274 $ 669 $ 1,160 $ 2,158

Product fee revenues 60 26 116 75

Total revenues 334 695 1,276 2,233

Costs and operating expenses:

Product and product fee costs 103 234 423 764

Research and development 333 724 1,314 1,855

Selling and marketing 4 647 289 2,069

General and administrative 920 1,323 2,978 3,696

Total costs and operating expenses 1,360 2,928 5,004 8,384

Loss from operations (1,026) (2,233) (3,728) (6,151)

Interest income 2

Interest expense (4) (165) (159) (597)

Other income (loss) 7 1 (514) 2

Net loss (1,023) (2,397) (4,401) (6,744)

Preferred stock dividend (41) (41)

Deemed dividend on beneficial conversion feature (1,507) (1,507)

Accretion of convertible preferred stock to liquidation value (56) (56)

Net loss attributable to common shareholders $ (2,627) $ (2,397) $ (6,005) $ (6,744)

Net loss per share attributable to common shareholders - basic and diluted $ (0.27) $ (0.28) $ (0.66) $ (0.84)

Weighted-average common shares outstanding used in computing per share amounts - basic and diluted 9,862,802 8,604,312 9,057,960 8,028,373

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RedeemablePreferredStockDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 29 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Promissory Notes and Series A Preferred Stock
9 Months Ended

Sep. 30, 2015

Convertible Promissory Notes and Series A Preferred Stock

7. Convertible Promissory Notes and Series A Preferred Stock

On May 12, 2015, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with the Company’s principal stockholders. On May 12, 2015 (the “Initial Closing”), pursuant to the terms and subject to the conditions contained in the Series A Purchase Agreement, the Company issued and sold to the Purchasers secured convertible promissory notes in the aggregate principal amount of $0.5 million (the “Notes”). In addition, the Company agreed to issue to the Purchasers, and the Purchasers agreed to purchase from the Company, an aggregate of $2.0 million of shares of Series A Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”), at the second closing. The Company determined that the liability to issue the Series A Preferred Stock (the “Preferred Stock Liability”) at a future date was a freestanding instrument and should be accounted for as a liability. The Company remeasures the Preferred Stock Liability at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations. During the three month period ending September 30, 2015, the Company recorded other income of $31,000 upon remeasurement of the Preferred Stock Liability.

The Notes contained a compound embedded derivative that requires separate accounting from the host debt instrument. The Company elected the fair value option for the Notes as management believes recording the Notes at fair value better reflects the underlying economics of the transaction. The Company remeasures the Notes at fair value at each reporting period, with changes being recorded within other (loss) income in the unaudited condensed consolidated statements of operations.

Upon consummation of the Series A Purchase Agreement, the Company allocated the total principal proceeds of $0.5 million between the Preferred Stock Liability and the fair-valued Notes and recorded a loss of $0.5 million in other (loss) income in the unaudited condensed consolidated statements of operations.

Pursuant to the terms of the Series A Purchase Agreement, and as approved by the Company’s stockholders at the Company’s 2015 Annual Meeting, the Company issued and sold to the Purchasers $2.0 million in shares of Series A Preferred Stock at the second closing that was held on July 14, 2015 (the “Second Closing”).

Secured Convertible Promissory Notes and Related Agreements

At the Second Closing, the Notes were automatically converted pursuant to their terms into that number of shares of Series A Preferred Stock equal to the principal amount of the Notes plus all accrued but unpaid interest thereon divided by the purchase price of the Series A Preferred Stock of $1.7003 per share (the “Purchase Price”).

Contemporaneously with the execution and delivery of the Series A Purchase Agreement and the issuance of the Notes by the Company to the Purchasers, the Company and the Purchasers entered into a Security Agreement (the “Security Agreement”), dated May 12, 2015, pursuant to which the Company granted to the Purchasers a security interest in substantially all of the Company’s assets, other than the Company’s intellectual property, to secure the Company’s obligations under the Notes. Pursuant to the terms of the Security Agreement, the Company’s intellectual property would have become subject to the security interest granted by the Company to the Purchasers upon repayment of all amounts owed under that certain Loan and Security Agreement by and among the Company, General Electric Capital Corporation (“GECC”) as Agent, the Lenders and the Guarantors dated as of February 10, 2012, as amended (“the “GECC Agreement”) referred as the “Term Loan” (See Note 4). Pursuant to a Subordination and Intercreditor Agreement by and among the Company, the Purchasers and GECC, dated May 12, 2015, entered into contemporaneously with the execution and delivery of the Series A Purchase Agreement, the Company’s payment obligations under the Notes were subordinated to the Company’s payment obligations under the GECC Agreement and the security interest granted by the Company to the Purchasers to secure the Company’s obligations under the Notes was subordinated to the security interest granted by the Company to GECC to secure the Company’s obligations under the GECC Agreement. In connection with the entry into the Series A Purchase Agreement, the Company and GECC amended the GECC Agreement, dated May 12, 2015, to, among other things, permit the Company to enter into the Series A Purchase Agreement and related agreements. Upon the conversion of the Notes into shares of Series A Preferred Stock at the Second Closing, the security interest granted under the Security Agreement was terminated.

The Second Closing was subject to the approval of the Company’s stockholders at the 2015 Annual Meeting in July 2015 and the satisfaction or waiver of other closing conditions. The Company’s stockholders approved the issuance of shares of Series A Preferred Stock, shares of Series A Preferred Stock issuable upon conversion of the Notes and common stock issuable upon conversion of Series A Preferred Stock, at the 2015 Annual Meeting held on July 7, 2015.

On July 14, 2015, the Company and the Purchasers entered into the First Amendment to the Series A Purchase Agreement (the “First Amendment”) pursuant to which the Company and the Purchasers agreed to extend the period of time following the Company’s 2015 Annual Meeting for the Second Closing to occur until July 14, 2015. At the Second Closing, pursuant to the terms of the Series A Purchase Agreement, the Company issued and sold to the Purchasers 1,176,262 shares of newly designated Series A Preferred Stock of the Company at the Purchase Price of $1.7003 per share for aggregate gross cash proceeds of approximately $2.0 million. In addition, at the Second Closing, the $500,000 in aggregate principal amount of Notes, plus accrued but unpaid interest, that the Company had issued to the Purchasers in the Initial Closing, converted into 298,181 shares of Series A Preferred Stock at the Purchase Price. Following the Second Closing in July 2015, the Company had issued an aggregate of 1,474,443 shares of Series A Preferred Stock, which remain outstanding and held by the Purchasers.

The shares of Series A Preferred Stock have the rights, preferences and privileges set forth in the Restated Certificate of Designations to the Company’s Restated Certificate of Incorporation (the “Certificate of Designations”) that was filed by the Company on August 18, 2015 with the Secretary of State of the State of Delaware. The rights, preferences and privileges of the Series A Preferred Stock are as follows:

Dividends

Holders of Series A Preferred Stock will be entitled to receive, out of funds legally available for the payment of dividends under Delaware law, cumulative dividends that accrue daily at an annual rate of 8%, compounded and payable quarterly in cash or in additional shares of Series A Preferred Stock at the election of each holder. The holders of Series A Preferred Stock will also be entitled to participate in cash dividends and in-kind distributions made on shares of common stock.

The Board of Directors has not declared any dividends on common or preferred stock. At September 30, 2015, the cumulative undeclared dividends on preferred stock total $41,000, and are included as a deduction in determining net loss per share attributable to common shareholders. The carrying value of the Series A Preferred Stock was not adjusted for the cumulative undeclared dividends as the Series A Preferred Stock is not probable of becoming redeemable.

Voting Rights

Holders of Series A Preferred Stock will be entitled to vote with the holders of the common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of the common stock on the trading day immediately prior to the date its Series A Preferred Stock is issued, which was $1.40. In addition, prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of capital stock of the Company, with certain exceptions; increasing or decreasing the size of the Board of Directors of the Company (the “Board”); and certain other actions.

Conversion Rights

Each share of Series A Preferred Stock is convertible into one share of common stock at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. The conversion price will be subject to adjustment in connection with stock splits, combinations, dividends and other corporate transactions affecting the common stock. All other anti-dilution protections that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing.

A contingent beneficial conversion feature was recognized during the three months ending September 30, 2015 as a result of the conversion price being adjusted from $1.7003 to $1.00 at the time of the Second Closing. The Company recorded $1.5 million relating to the contingent beneficial conversion as a deemed dividend. The $1.5 million was included within additional paid-in capital in the condensed consolidated financial statements, and reduced the carrying value of the Series A Preferred Stock. Since the Series A Preferred Stock has no stated redemption date and is immediately convertible, the $1.5 million deemed dividend was immediately accreted, resulting in an increase in the carrying value of the Series A Preferred Stock. The deemed dividend was included as a deduction in determining net loss per share attributable to common shareholders. The conversion price adjustment feature expired following the Second Closing.

Redemption Rights

All redemption rights that had been provided to the Series A Preferred Stock upon issuance terminated following the Second Closing.

Ranking

The Series A Preferred Stock will rank senior in preference and priority to the Company’s common stock and each other class or series of capital stock of the Company, except for any class or series of capital stock issued in compliance with the terms of the Restated Certificate of Designations.

Liquidation Preference

Upon liquidation, including deemed liquidations pursuant to a merger, consolidation or a sale of all or substantially all of the Company’s assets, the holders of Series A Preferred Stock will be entitled to be paid first out of any proceeds in an amount per share equal to the price at which shares of Series A Preferred Stock were sold in the Series A Preferred Stock financing, plus all accrued but unpaid dividends on each share of Series A Preferred Stock, and prior to payment of any amounts on the Company’s common stock. Thereafter, the holders of Series A Preferred Stock will also share pro rata on an as converted to common stock basis in payments made to the holders the Company’s common stock. Accordingly, the holders of the Series A Preferred Stock will be entitled to receive the proceeds out of any sale or liquidation of the Company before any such proceeds are paid to holders of the Company’s common stock and then share in any proceeds paid to holders of the Company’s common stock. As a result, only the sale or liquidation proceeds in excess of the liquidation preference plus accrued but unpaid dividends would be available for distribution to holders of the Company’s common stock.

The commissions and issuance costs associated with the Series A Preferred Stock financing were deducted from the carrying value of the Series A Preferred Stock, resulting in the carrying value of the Series A Preferred Stock being reduced below its liquidation value. The Company accretes the carrying value of the Series A Preferred Stock over the period from the date of issuance to the earliest redemption date using the effective interest method. During the nine months ending September 30, 2015, the Company recorded one month of accretion, totaling $56,000, at which point the Company ceased accretion as the Series A Preferred stock was not probable of becoming redeemable.

Board of Directors

Holders of Series A Preferred Stock will be entitled to nominate one director to the Board (the “Series A Director”). Subject to applicable law and stock exchange requirements, the Series A Director will be entitled to serve as a member of each committee of the Board. The rights to nominate a Series A Director will terminate if less than 20% of the shares of Series A Preferred Stock issued under the Securities Purchase Agreement dated May 12, 2015, as amended, by and between the Company and the Series A Holders are no longer outstanding.

Registration Rights

The Company shall comply with all federal and state laws, rules and regulations and applicable rules and regulations of the Exchange on which shares of the common are then listed. If any shares of common to be reserved for the purpose of conversion of Series A Preferred Stock require registration with or approval of any Person or group (as such term is defined in Section 13(d)(3) of the Exchange Act) under any federal or state law or the rules and regulations of the Exchange on which shares of the common stock are then listed before such shares may be validly issued or delivered upon conversion, then the Company will, as expeditiously as reasonably practicable, use commercially reasonable efforts to secure such registration or approval, as the case may be. So long as any common stock into which the of Series A Preferred Stock are then convertible is then listed on an Exchange, the Company will list and keep listed on any such Exchange, upon official notice of issuance, all shares of such common stock issuable upon conversion.

As the holders of the Series A Preferred Stock are entitled to receive liquidation preferences that other equity holders are not entitled to, the Company determined that the preferred stock should be classified as temporary equity in the condensed consolidated financial statements.

The Company reviews the rights and preferences of its equity securities for any changes in terms, rights or preferences to determine if such change is a modification or an extinguishment. The Company evaluates amendments to equity securities using a qualitative method which considers the business purpose for the amendment and whether it adds, deletes or significantly changes a substantive contractual term or the nature of the equity securities. An amendment that changes a substantive contractual term or fundamentally changes the nature of the share of preferred stock is considered an extinguishment. If considered an extinguishment, the Company accounts for the removal of the carrying value of the old securities and recognizes the new securities at their current fair value. An amendment that does not meet these criteria is a modification. If considered a modification, the Company estimates the fair value of the equity security pre- and post- modification and recognizes the incremental fair value, if any, resulting from the modified terms. During the nine months ending September 30, 2015, the Company determined that all changes to the terms of the Series A Preferred Stock resulting from amendments made to the Certificates of Designations were not substantive and should be accounted for as a modification. The amendments did not result in a material change to the fair value of the Series A Preferred Stock.

X

- Definition
Convertible Promissory Notes And Series A Preferred Stock [Text Block]
+ References
No definition available.
+ Details

Name: bgmd_ConvertiblePromissoryNotesAndSeriesAPreferredStockTextBlock

Namespace Prefix: bgmd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Follow-on Public Offerings
9 Months Ended

Sep. 30, 2015

Follow-on Public Offerings

6. Follow-on Public Offerings

On April 8, 2014, the Company closed a follow-on underwritten public offering of 1,613,000 shares of its common stock, at an offering price of $6.20 per share, for gross proceeds of $10.0 million. The net offering proceeds received by the Company, after deducting underwriting discounts and commissions and expenses incurred in connection with the offering, were approximately $9.0 million.

On August 18, 2015, the Company closed on an underwritten public offering of (i) 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit, and (ii) 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) have an exercise price of $1.00 per share. The net offering proceeds received by the Company, after deducting discounts and commissions and expenses incurred with the offering were approximately $2.0 million.

X

- Definition
Public Offerings [Text Block]
+ References
No definition available.
+ Details

Name: bgmd_PublicOfferingsTextBlock

Namespace Prefix: bgmd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Changes in the Fair Value of Company's Secured Convertible Notes (Detail) - Convertible Debt Instrument - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Beginning balance $ 929

Proceeds from secured convertible note $ 500

Loss on fair value adjustment 58 487

Conversion of secured convertible promissory notes $ (987) $ (987)

X

- Definition
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Convertible Notes To Common Stock
+ References
No definition available.
+ Details

Name: bgmd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfConvertibleNotesToCommonStock

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Inventories (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Inventory [Line Items]

Raw materials $ 45 $ 64

Finished goods 178 336

Total inventories $ 223 $ 400

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 33 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value of Financial Instruments (Tables)
9 Months Ended

Sep. 30, 2015

Convertible Debt Instrument

Summary of Changes in Fair Value of Company' Level 3 Liability

The table below sets forth a summary of changes in the fair value of the Company’s secured convertible notes for the three and nine months ended September 30, 2015:

 Three Months Ended
September 30, 2015 Nine Months Ended
September 30, 2015

 (in thousands)

Beginning balance
 $ 929 $ —

Proceeds from secured convertible note
 — 500

Loss on fair value adjustment
 58 487

Conversion of secured convertible notes
 (987 ) (987 )





Ending balance
 $ — $ —





Preferred Stock Liability

Summary of Changes in Fair Value of Company' Level 3 Liability

The table below sets forth a summary of changes in the fair value of the Company’s level 3 liability (preferred stock liability) for the three and nine months ending September 30, 2015:

 Three Months Ended
September 30, 2015 Nine Months Ended
September 30, 2015

 (in thousands)

Beginning balance
 $ 31 $ —

Loss on recognition of preferred stock liability
 — 79

Gain on revaluation of preferred stock liability
 (31 ) (79 )





Ending balance
 $ — $ —





X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=bgmd_PreferredStockLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Product Revenues

Product Revenues

Product revenues are recognized when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

The Company sells its products through supply agreements with laboratory testing services and diagnostic testing distributors and directly to hospitals and clinics. The Company recognizes revenue when products are received by customers, at which time both title and risk of loss have passed to the customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.

Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Freight costs billed to customers are recorded as revenue.

In the past the Company did not provide an allowance for doubtful accounts or a reserve for sales returns as the Company has not experienced any credit losses, and returns are only allowed for defects in workmanship. On June 7, 2015, Health Diagnostic Laboratory, Inc. (“HDL”), which is the Company’s largest customer of its BGM Galectin-3 ^® Test, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. In light of this filing the Company provided a provision for doubtful accounts of $151,000 in the second quarter of 2015. On September 11, 2015, True Health Diagnostics announced the acquisition of HDL, in a court-supervised auction has not yet filed a plan of liquidation or reorganization. Thus, it is uncertain what distribution will be made on account of allowed claims. Further, the court approved HDL’s request to extend the exclusive deadline by which HDL may file a plan of liquidation or reorganization until early 2016.

Product Fee Revenues

The Company recognizes product fee revenue when it receives quarterly test sales reporting and payments thereunder from its partners. The Company has entered into worldwide license, development and commercialization agreements with Abbott Laboratories, (“Abbott”), bioMérieux SA, (“bioMérieux”), Siemens Healthcare Diagnostics Inc., (“Siemens”), and Alere Inc., (“Alere”). As consideration for the rights and licenses granted by the Company to its partners, the licensees pay to the Company a product fee, as set forth in the respective agreements, for tests sold to third parties. To date, only Abbott and bioMérieux have paid product fees to the Company.

Product Fee Reclassification

Beginning in the third quarter of 2015, the Company began disclosing product fee revenue separately from product revenue. To maintain comparability, all previously reported product revenue figures in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to break out the product fee revenue recognized during those periods. Management evaluated the amount and nature of the change and concluded that it was not material to either the previously reported annual or quarterly financial statement results of operations. Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):

 As reported
Three months ended
September 30, 2014 As reclassified
Three months ended
September 30, 2014 As reported
Nine months ended
September 30, 2014 As reclassified
Nine months ended
September 30, 2014

Product Revenues
 $ 695 $ 669 $ 2,233 $ 2,158

Product Fee Revenues
 — 26 — 75









Total Revenues
 $ 695 $ 695 $ 2,233 $ 2,233









Inventory

Inventory

Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following:

(in thousands) September 30, 2015 December 31, 2014

Raw materials
 $ 45 $ 64

Finished goods
 178 336





Total inventories
 $ 223 $ 400





Net Loss Per Share Attributable to Common Shareholders

Net Loss Per Share Attributable to Common Shareholders

Basic and diluted net loss per share attributable to common shareholders is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. The Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as its convertible preferred stock, common stock, and warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common shareholders. However, the two-class method does not impact the net loss per share of common stock as the Company was in a loss position for each of the periods presented, and neither preferred shareholders nor warrant holders participate in losses.

The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:

 Three Months Ended September 30, Nine Months Ended September 30,

 2015 2014 2015 2014

 (in thousands, except share and per share data)

Net loss
 $ (1,023 ) $ (2,397 ) $ (4,401 ) $ (6,744 )

Preferred stock dividend
 (41 ) — (41 ) —

Deemed dividend on beneficial conversion feature
 (1,507 ) — (1,507 ) —

Accretion of convertible preferred stock to liquidation value
 (56 ) — (56 ) —









Net loss attributable to common shareholders
 $ (2,627 ) $ (2,397 ) $ (6,005 ) $ (6,744 )

Weighted average number of shares - basic and diluted
 9,862,802 8,604,312 9,057,960 8,028,373

Net loss per share attributable to common shareholders - basic and diluted
 $ (0.27 ) $ (0.28 ) $ (0.66 ) $ (0.84 )

As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported:

 September 30,

 2015 2014

Options to purchase common stock
 699,513 644,789

Warrants to purchase common stock
 1,536,929 216,156

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2015

Summary of Reclassified Amounts of Historical Statement of Operations

Nonetheless, the Company has reclassified the historical statement of operations amounts included in this filing as follows (in thousands):

 As reported
Three months ended
September 30, 2014 As reclassified
Three months ended
September 30, 2014 As reported
Nine months ended
September 30, 2014 As reclassified
Nine months ended
September 30, 2014

Product Revenues
 $ 695 $ 669 $ 2,233 $ 2,158

Product Fee Revenues
 — 26 — 75









Total Revenues
 $ 695 $ 695 $ 2,233 $ 2,233









Summary of Inventories

Inventory

Inventory is stated at the lower of cost or market. Costs are determined under the first-in, first-out (FIFO) method. Inventories consisted of the following:

(in thousands) September 30, 2015 December 31, 2014

Raw materials
 $ 45 $ 64

Finished goods
 178 336





Total inventories
 $ 223 $ 400





Summary of Computation of Basic and Diluted Net Loss per Share

The following table summarizes the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:

 Three Months Ended September 30, Nine Months Ended September 30,

 2015 2014 2015 2014

 (in thousands, except share and per share data)

Net loss
 $ (1,023 ) $ (2,397 ) $ (4,401 ) $ (6,744 )

Preferred stock dividend
 (41 ) — (41 ) —

Deemed dividend on beneficial conversion feature
 (1,507 ) — (1,507 ) —

Accretion of convertible preferred stock to liquidation value
 (56 ) — (56 ) —









Net loss attributable to common shareholders
 $ (2,627 ) $ (2,397 ) $ (6,005 ) $ (6,744 )

Weighted average number of shares - basic and diluted
 9,862,802 8,604,312 9,057,960 8,028,373

Net loss per share attributable to common shareholders - basic and diluted
 $ (0.27 ) $ (0.28 ) $ (0.66 ) $ (0.84 )

Common Shares Excluded from Computation of Diluted Net Loss per Share

As of September 30, 2015 and 2014, the following potential common shares were excluded from the computation of diluted net loss per share because they had an antidilutive impact due to the losses reported:

 September 30,

 2015 2014

Options to purchase common stock
 699,513 644,789

Warrants to purchase common stock
 1,536,929 216,156

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22663-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22658-107794

+ Details

Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Description of Business and Basis of Presentation - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 13 Months Ended

Aug. 18, 2015

USD ($)

shares

$ / shares

Jul. 08, 2015

shares

Jun. 30, 2015

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

$ / shares

Sep. 30, 2015

USD ($)

$ / shares

$ / Patient

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

$ / shares

$ / Patient

Dec. 31, 2013

USD ($)

$ / Patient

Sep. 30, 2015

USD ($)

Employee

$ / shares

Jul. 14, 2015

$ / shares

May. 12, 2015

USD ($)

$ / shares

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Reverse stock split On July 8, 2015, the Company effected a 1-for-4 reverse stock split of its common stock. All previously reported common stock share amounts in the accompanying financial statements and related notes have been retroactively adjusted to reflect the reverse stock split.

Common stock splits ratio | shares 0.25

Cash $ 2,642,000 $ 6,313,000 $ 4,123,000 $ 2,642,000 $ 6,313,000 $ 4,123,000 $ 7,751,000 $ 2,642,000

Loan facility 2,960,000 2,960,000

Stockholders' deficit (1,274,000) $ 557,000 (1,274,000) 557,000 $ (1,274,000)

Net loss (1,023,000) $ (2,397,000) (4,401,000) (6,744,000)

Net cash flows used in operating activities (2,550,000) (7,097,000)

Cash for payments on term loan facility 2,984,000 3,360,000

Reduction in workforce, percentage 77.00%

Number of employees eliminated | Employee 17

Number of employees remaining after restructuring activities | Employee 5

Severance payments and benefits continuation 98,000 $ 404,000

Savings in employee salaries and benefits 2,400,000 2,400,000 $ 2,400,000

Preferred stock issued, value $ 2,594,000 $ 2,594,000 $ 2,594,000

Preferred stock, par value | $ / shares $ 0.001 $ 0.001 $ 0.001 $ 0.001 $ 0.001

Sublease expiration date Dec. 31, 2018

Short term rental basis, expected annualized savings $ 240,000

Exercise price of warrants | $ / shares $ 1.00

Proceeds from public offering $ 2,000,000 $ 2,500,000 $ 9,238,000

Percentage of common shares outstanding owned 9.99%

Series A

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Preferred stock issued, value $ 2,000,000 2,000,000 $ 2,000,000 $ 2,000,000

Preferred stock sold, value $ 2,000,000 $ 2,000,000 $ 2,000,000 $ 2,000,000

Preferred stock, par value | $ / shares $ 1.7003 $ 0.001

Purchase price | $ / shares $ 1.40 $ 1.40 $ 1.40

Series A Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Shares of common stock under public offering | shares 2,315,654

Purchase price | $ / shares $ 1.00

Series B Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Shares of common stock under public offering | shares 184,346

Purchase price | $ / shares $ 1.00

Total costs and operating expenses

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Sublease rental charges $ 153,000

Research and development

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Severance payments and benefits continuation $ 41,000 $ 128,000

Selling and marketing

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Severance payments and benefits continuation 57,000 114,000

General and administrative

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Severance payments and benefits continuation $ 162,000

Employee Severance

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Payment for severance payments and benefits continuation $ 277,000 225,000

Common Stock | Series A Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Proportion of each unit of shares | shares 1

Common Stock | Series B Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Proportion of each unit of shares | shares 1

Warrants to purchase common stock | Series A Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Proportion of each unit of shares | shares 0.5

Warrants to purchase common stock | Series B Units

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Proportion of each unit of shares | shares 0.5

Secured convertible promissory notes

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Principal amount of secured convertible promissory notes issued and sold $ 500,000

Term loans

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Loan facility $ 0 $ 0 $ 0

Loan facility, maturity date Jul. 14, 2015

Centers for Medicare And Medicaid Services

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Reimbursed price per test | $ / Patient 29.93 30.01 17.80

Centers for Medicare And Medicaid Services | Ohio

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Reimbursed price per test | $ / Patient 23.93

Centers for Medicare And Medicaid Services | WEST VIRGINIA

Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

Reimbursed price per test | $ / Patient 26.33

X

- Definition
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: bgmd_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: bgmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected Annual Cost Savings
+ References
No definition available.
+ Details

Name: bgmd_ExpectedAnnualCostSavings

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage Of Common Shares Outstanding Owned
+ References
No definition available.
+ Details

Name: bgmd_PercentageOfCommonSharesOutstandingOwned

Namespace Prefix: bgmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred Stock Shares Sold, Value
+ References
No definition available.
+ Details

Name: bgmd_PreferredStockSharesSoldValue

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Proportion Of Each Unit Of Shares
+ References
No definition available.
+ Details

Name: bgmd_ProportionOfEachUnitOfShares

Namespace Prefix: bgmd_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Reimbursed Medicare and Medicaid Services Price Per Test
+ References
No definition available.
+ Details

Name: bgmd_ReimbursedMedicareAndMedicaidServicesPricePerTest

Namespace Prefix: bgmd_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: duration

X

- Definition
Restructuring and Related Cost Estimated Annual Savings in Employee Salaries and Benefits
+ References
No definition available.
+ Details

Name: bgmd_RestructuringAndRelatedCostEstimatedAnnualSavingsInEmployeeSalariesAndBenefits

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Restructuring And Related Cost Expected Number Of Employees Remaining
+ References
No definition available.
+ Details

Name: bgmd_RestructuringAndRelatedCostExpectedNumberOfEmployeesRemaining

Namespace Prefix: bgmd_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of positions eliminated during the period as a result of restructuring activities.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(10)

-URI http://asc.fasb.org/extlink&oid=58740216&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reduction in the number of shares during the period as a result of a reverse stock split.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bgmd_SeriesAUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bgmd_SeriesBUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=bgmd_SecuredConvertiblePromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=bgmd_TermLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=bgmd_CentersForMedicareAndMedicaidServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=stpr_OH

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=stpr_WV

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Common Shares Excluded From Computation of Diluted Net Loss Per Share (Detail) - shares
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Options to purchase common stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share 699,513 644,789

Warrants to purchase common stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share 1,536,929 216,156

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies - Additional Information (Detail)

Sep. 30, 2015

USD ($)

Commitments and Contingencies [Line Items]

Accrued other contingencies $ 0

X

- Definition
Commitments and Contingencies [Line Items]
+ References
No definition available.
+ Details

Name: bgmd_CommitmentsAndContingenciesLineItems

Namespace Prefix: bgmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss contingency liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities

Net loss $ (4,401,000) $ (6,744,000)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization 69,000 100,000

Stock-based compensation 630,000 489,000

Non-cash interest expense 79,000 164,000

Provision for doubtful accounts 151,000

Loss on fair value of secured convertible note 487,000

Loss on sale of property and equipment 64,000

Changes in operating assets and liabilities

Accounts receivable (130,000) 65,000

Inventory 177,000 101,000

Prepaid expenses and other assets 7,000 78,000

Accounts payable, accrued expenses and other liabilities 254,000 (1,349,000)

Deferred revenue and customer deposits 63,000 (1,000)

Net cash flows used in operating activities (2,550,000) (7,097,000)

Cash flows from investing activities

Proceeds from the sale of property and equipment 13,000

Net cash flows provided by investing activities 13,000

Cash flows from financing activities

Proceeds from public offering 2,500,000 9,238,000

Payments on term loan (2,984,000) (3,360,000)

Proceeds from ESPP purchases 2,000

Proceeds from the exercise of stock options 22,000

Proceeds from secured convertible note 500,000

Proceeds from issuance of preferred stock 2,000,000

Net cash flows provided by financing activities 1,056,000 5,659,000

Net decrease in cash (1,481,000) (1,438,000)

Cash, beginning of period 4,123,000 7,751,000

Cash, end of period 2,642,000 6,313,000

Supplemental disclosure of cash flow information

Cash paid for interest 81,000 433,000

Supplemental schedule of non-cash financing activities

Conversion of convertible notes payable to preferred stock 987,000

Conversion of interest to preferred stock 7,000

Deemed dividend on beneficial conversion feature 1,507,000

Accretion of convertible preferred stock to liquidation value 56,000

Common Stock

Cash flows from financing activities

Costs related to issuance of stock (504,000) $ (243,000)

Preferred Stock

Cash flows from financing activities

Costs related to issuance of stock $ (456,000)

X

- Definition
Gain (Loss) on Fair value Adjustment of Debt Instrument
+ References
No definition available.
+ Details

Name: bgmd_GainLossOnFairValueAdjustmentOfDebtInstrument

Namespace Prefix: bgmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c).
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies

5. Commitments and Contingencies

From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

No amounts related to contingencies are accrued at September 30, 2015, as there are no ongoing proceedings.

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Follow-on Public Offerings - Additional Information (Detail)
$ / shares in Units, $ in Thousands
9 Months Ended

Aug. 18, 2015

USD ($)

shares

$ / shares

Apr. 08, 2014

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Equity [Line Items]

Gross proceeds offering | $ $ 2,000 $ 2,500 $ 9,238

Exercise price of warrants | $ / shares $ 1.00

Percentage of common shares outstanding owned 9.99%

Series A Units

Equity [Line Items]

Shares of common stock under public offering 2,315,654

Purchase price | $ / shares $ 1.00

Series A Units | Common Stock

Equity [Line Items]

Proportion of each unit of shares 1

Series A Units | Warrants to purchase common stock

Equity [Line Items]

Proportion of each unit of shares 0.5

Series B Units

Equity [Line Items]

Shares of common stock under public offering 184,346

Purchase price | $ / shares $ 1.00

Series B Units | Common Stock

Equity [Line Items]

Proportion of each unit of shares 1

Series B Units | Warrants to purchase common stock

Equity [Line Items]

Proportion of each unit of shares 0.5

Underwritten Public Offering

Equity [Line Items]

Shares of common stock under public offering 1,613,000

Common stock offering price | $ / shares $ 6.20

Gross proceeds offering | $ $ 10,000

Offering proceeds net of underwriting discounts, commissions and expenses | $ $ 9,000

X

- Definition
Equity [Line Items]
+ References
No definition available.
+ Details

Name: bgmd_EquityLineItems

Namespace Prefix: bgmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage Of Common Shares Outstanding Owned
+ References
No definition available.
+ Details

Name: bgmd_PercentageOfCommonSharesOutstandingOwned

Namespace Prefix: bgmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Proportion Of Each Unit Of Shares
+ References
No definition available.
+ Details

Name: bgmd_ProportionOfEachUnitOfShares

Namespace Prefix: bgmd_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bgmd_SeriesAUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bgmd_SeriesBUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=bgmd_UnderwrittenPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 82 154 1 false 28 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.bg-medicine.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bg-medicine.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bg-medicine.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.bg-medicine.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bg-medicine.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Description of Business and Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Significant Accounting Policies Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies Notes 7 false false R8.htm 109 - Disclosure - Fair Value of Financial Instruments Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments Notes 8 false false R9.htm 110 - Disclosure - Term Loan Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Term Loan Notes 9 false false R10.htm 111 - Disclosure - Commitments and Contingencies Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 10 false false R11.htm 112 - Disclosure - Follow-on Public Offerings Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsPublicOfferingsTextBlock Follow-on Public Offerings Notes 11 false false R12.htm 113 - Disclosure - Convertible Promissory Notes and Series A Preferred Stock Notes http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsConvertiblePromissoryNotesAndSeriesAPreferredStockTextBlock Convertible Promissory Notes and Series A Preferred Stock Notes 12 false false R13.htm 114 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) Policies http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 13 false false R14.htm 115 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Significant Accounting Policies (Tables) Tables http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 14 false false R15.htm 116 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) Tables http://www.bg-medicine.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 15 false false R16.htm 117 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformation Description of Business and Basis of Presentation - Additional Information (Detail) Details 16 false false R17.htm 118 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Detail) Details 17 false false R18.htm 119 - Disclosure - Summary of Reclassified Amounts of Historical Statement of Operations (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureSummaryOfReclassifiedAmountsOfHistoricalStatementOfOperations Summary of Reclassified Amounts of Historical Statement of Operations (Detail) Details 18 false false R19.htm 120 - Disclosure - Summary of Inventories (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureSummaryOfInventories Summary of Inventories (Detail) Details 19 false false R20.htm 121 - Disclosure - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureSummaryOfComputationOfBasicAndDilutedNetLossPerShare Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) Details 20 false false R21.htm 122 - Disclosure - Common Shares Excluded From Computation of Diluted Net Loss Per Share (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureCommonSharesExcludedFromComputationOfDilutedNetLossPerShare Common Shares Excluded From Computation of Diluted Net Loss Per Share (Detail) Details 21 false false R22.htm 123 - Disclosure - Summary of Changes in Fair Value of Company's Level 3 Liability (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureSummaryOfChangesInFairValueOfCompanysLevel3Liability Summary of Changes in Fair Value of Company's Level 3 Liability (Detail) Details 22 false false R23.htm 124 - Disclosure - Summary of Changes in the Fair Value of Company's Secured Convertible Notes (Detail) Notes http://www.bg-medicine.com/taxonomy/role/DisclosureSummaryOfChangesInTheFairValueOfCompanysSecuredConvertibleNotes Summary of Changes in the Fair Value of Company's Secured Convertible Notes (Detail) Details 23 false false R24.htm 125 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Term Loan - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureTermLoanAdditionalInformation Term Loan - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Follow-on Public Offerings - Additional Information (Detail) Sheet http://www.bg-medicine.com/taxonomy/role/DisclosureFollowonPublicOfferingsAdditionalInformation Follow-on Public Offerings - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Convertible Promissory Notes and Series A Preferred Stock - Additional Information (Detail) Notes http://www.bg-medicine.com/taxonomy/role/DisclosureConvertiblePromissoryNotesAndSeriesAPreferredStockAdditionalInformation Convertible Promissory Notes and Series A Preferred Stock - Additional Information (Detail) Details 28 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2, 3, 4 are contained in other reports, so were removed by flow through suppression. bgmd-20150930.xml bgmd-20150930_cal.xml bgmd-20150930_def.xml bgmd-20150930_lab.xml bgmd-20150930_pre.xml bgmd-20150930.xsd true true XML 43 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Schedule Of Computation Of Basic And Diluted Earnings Per Common Share [Line Items]

Net loss $ (1,023) $ (2,397) $ (4,401) $ (6,744)

Preferred stock dividend (41) (41)

Deemed dividend on beneficial conversion feature (1,507) (1,507)

Accretion of convertible preferred stock to liquidation value (56) (56)

Net loss attributable to common shareholders $ (2,627) $ (2,397) $ (6,005) $ (6,744)

Weighted average number of shares - basic and diluted 9,862,802 8,604,312 9,057,960 8,028,373

Net loss per share attributable to common shareholders - basic and diluted $ (0.27) $ (0.28) $ (0.66) $ (0.84)

X

- Definition
Schedule Of Computation Of Basic And Diluted Earnings Per Common Share [Line Items]
+ References
No definition available.
+ Details

Name: bgmd_ScheduleOfComputationOfBasicAndDilutedEarningsPerCommonShareLineItems

Namespace Prefix: bgmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RedeemablePreferredStockDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Term Loan - Additional Information (Detail)	Feb. 10, 2012 USD ($)
Term loans
Debt Instrument [Line Items]
Loan facility amount borrowed	$ 10,000,000

Convertible Promissory Notes and Series A Preferred Stock - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 14, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jul. 31, 2015	May. 12, 2015	Dec. 31, 2014
Debt Conversion [Line Items]
Preferred stock issues and sold, purchase price		$ 0.001		$ 0.001				$ 0.001
Other income recorded upon remeasurement of preferred stock liability		$ 31,000
Other (loss) income		7,000	$ 1,000	$ (514,000)	$ 2,000
Preferred stock issued, value		$ 2,594,000		$ 2,594,000
Preferred stock, shares issued		1,474,443		1,474,443				0
Aggregate gross cash proceeds from issuance of preferred shares				$ 2,000,000
Debt amount converted in to preferred shares				987,000
Deemed dividend on beneficial conversion feature		$ 1,507,000		1,507,000
Additional paid in capital, preferred stock		1,500,000		1,500,000
Accretion of convertible preferred stock to liquidation value		56,000		56,000
Secured convertible promissory notes
Debt Conversion [Line Items]
Principal amount of secured convertible promissory notes issued and sold							$ 500,000
Aggregate principal amount of Notes, plus accrued unpaid interest
Debt Conversion [Line Items]
Debt amount converted in to preferred shares	$ 500,000
Series A
Debt Conversion [Line Items]
Preferred stock approved to issue							$ 2,000,000
Preferred stock issues and sold, purchase price	$ 1.7003						$ 0.001
Preferred stock issued, value		2,000,000		2,000,000			$ 2,000,000
Preferred stock sold, value		$ 2,000,000		$ 2,000,000			$ 2,000,000
Preferred stock, shares issued	1,176,262					1,474,443
Preferred stock, shares sold	1,176,262
Aggregate gross cash proceeds from issuance of preferred shares	$ 2,000,000
Number of preferred shares issued upon debt conversion	298,181
Preferred stock, voting rights				Holders of Series A Preferred Stock will be entitled to vote with the holders of the common stock on an as-converted basis, except that no holder of Series A Preferred Stock will be entitled to cast votes for the number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by such holder that exceeds (subject to a proportionate adjustment in the event of a stock split, stock dividend, combination or other proportionate recapitalization) the quotient of (A) the aggregate purchase price paid by such holder for its Series A Preferred Stock, divided by (B) the greater of (i) $3.20 and (ii) the closing price of the common stock on the trading day immediately prior to the date its Series A Preferred Stock is issued, which was $1.40. In addition, prior to the conversion of the Series A Preferred Stock, the consent of the holders of at least a majority of the Series A Preferred Stock then outstanding, voting together as a single class, will be required for the Company to take certain actions, including, among other things: liquidating, dissolving or winding up the business and affairs of the Company or effecting any merger, consolidation or other liquidation event; amending, altering or repealing any provision of the Certificate of Incorporation, the Certificate of Designations or the Bylaws of the Company; creating or authorizing any class or series of capital stock ranking senior to or on parity with the Series A Preferred Stock or increasing the number of authorized shares of Series A Preferred Stock; purchasing, redeeming, paying or declaring dividends on any shares of capital stock of the Company, with certain exceptions; increasing or decreasing the size of the Board of Directors of the Company (the “Board”); and certain other actions.
Convertible preferred stock voting rights threshold		$ 3.20		$ 3.20
Purchase price		1.40		$ 1.40
Convertible preferred stock, terms of conversion				Each share of Series A Preferred Stock is convertible into one share of common stock at any time at the option of each holder and automatically upon the written consent of the holders of a majority of the outstanding shares of Series A Preferred Stock. The conversion price will be subject to adjustment in connection with stock splits, combinations, dividends and other corporate transactions affecting the common stock.
Series A \| Minimum
Debt Conversion [Line Items]
Rights to nominate director will terminate if share of preferred stock fall bellow the threshold				20.00%
Series A \| Adjustment
Debt Conversion [Line Items]
Preferred stock issues and sold, purchase price		$ 1.00		$ 1.00
Cumulative Preferred Stock
Debt Conversion [Line Items]
Preferred stock, annual dividend rate, percentage				8.00%
Undeclared dividends				$ 41,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash	$ 2,642	$ 4,123
Accounts receivable (net of allowances for doubtful accounts of $151 and $0, as of September 30, 2015 and December 31, 2014, respectively)	152	174
Inventory	223	400
Prepaid expenses and other current assets	139	154
Total current assets	3,156	4,851
Property and equipment, net	14	117
Intangible assets, net	92	135
Deposits and other assets	94	126
Total assets	3,356	5,229
Current liabilities
Term loan		2,960
Accounts payable	1,332	695
Accrued expenses	562	906
Other current liabilities	48	18
Total current liabilities	1,942	4,579
Other liabilities	94	93
Total liabilities	$ 2,036	$ 4,672
Commitments and contingencies (Note 5)
Convertible preferred stock; $.001 par value; 5,000,000 and 0 shares authorized at September 30, 2015 and December 31, 2014, respectively; 1,474,443 and 0 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively; liquidation preference of $2,548 at September 30, 2015	$ 2,594
Stockholders' (deficit) equity
Common stock; $.001 par value; 100,000,000 shares authorized at September 30, 2015 and December 31, 2014; 11,126,579 and 8,632,810 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	11	$ 9
Additional paid-in capital	164,118	161,550
Accumulated deficit	(165,403)	(161,002)
Total stockholders' (deficit) equity	(1,274)	557
Total liabilities and stockholders' (deficit) equity	$ 3,356	$ 5,229

Summary of Changes in Fair Value of Company's Level 3 Liability (Detail) - Preferred Stock Liability - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Beginning balance	$ 31
Loss on recognition of preferred stock liability		$ 79
Gain on revaluation of preferred stock liability	$ (31)	$ (79)

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended
	Jul. 14, 2015	May. 12, 2015	Jun. 30, 2015
Preferred Stock Liability
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock liability, fair value	$ 0	$ 79	$ 31
Underlying security price		$ 2.12	$ 2.00
Conversion price per share		$ 2.68	$ 2.68
Risk-free interest rate		0.02%	0.03%
Expected dividend yield		0.00%	0.00%
Expected stock price volatility		73.80%	73.80%
Expected term	0 years	2 months 19 days	29 days
Convertible Debt Instrument
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock liability, fair value			$ 929
Conversion price per share	$ 3.33		$ 2.68
Discount rate	18.00%		18.00%
Convertible Debt Instrument \| Current Common Stock Price
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected stock price volatility	56.20%		51.00%
Stock price per share	$ 1.54		$ 2.36
Convertible Debt Instrument \| Future Common Stock Price
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected stock price volatility			55.00%
Stock price per share			$ 2.14

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Allowances for doubtful accounts	$ 151	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	0
Preferred stock, shares issued	1,474,443	0
Preferred stock, shares outstanding	1,474,443	0
Preferred stock, liquidation preference	$ 2,548
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,126,579	8,632,810
Common stock, shares outstanding	11,126,579	8,632,810

Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015
Significant Accounting Policies [Line Items]
Provision for doubtful accounts	$ 151,000	$ 151,000

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 31, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	BGMD
Entity Registrant Name	BG MEDICINE, INC.
Entity Central Index Key	0001407038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,126,579

Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 45	$ 64
Finished goods	178	336
Total inventories	$ 223	$ 400

Description of Business and Basis of Presentation - Additional Information (Detail)			1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended		13 Months Ended
	Aug. 18, 2015 USD ($) shares $ / shares	Jul. 08, 2015 shares	Jun. 30, 2015 USD ($)	Sep. 30, 2015 USD ($) $ / shares	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($) $ / shares	Sep. 30, 2015 USD ($) $ / shares $ / Patient	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($) $ / shares $ / Patient	Dec. 31, 2013 USD ($) $ / Patient	Sep. 30, 2015 USD ($) Employee $ / shares	Jul. 14, 2015 $ / shares	May. 12, 2015 USD ($) $ / shares
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reverse stock split		On July 8, 2015, the Company effected a 1-for-4 reverse stock split of its common stock. All previously reported common stock share amounts in the accompanying financial statements and related notes have been retroactively adjusted to reflect the reverse stock split.
Common stock splits ratio \| shares		0.25
Cash				$ 2,642,000	$ 6,313,000	$ 4,123,000	$ 2,642,000	$ 6,313,000	$ 4,123,000	$ 7,751,000	$ 2,642,000
Loan facility						2,960,000			2,960,000
Stockholders' deficit				(1,274,000)		$ 557,000	(1,274,000)		557,000		$ (1,274,000)
Net loss				(1,023,000)	$ (2,397,000)		(4,401,000)	(6,744,000)
Net cash flows used in operating activities							(2,550,000)	(7,097,000)
Cash for payments on term loan facility							2,984,000	3,360,000
Reduction in workforce, percentage											77.00%
Number of employees eliminated \| Employee											17
Number of employees remaining after restructuring activities \| Employee											5
Severance payments and benefits continuation							98,000		$ 404,000
Savings in employee salaries and benefits				2,400,000			2,400,000				$ 2,400,000
Preferred stock issued, value				$ 2,594,000			$ 2,594,000				$ 2,594,000
Preferred stock, par value \| $ / shares				$ 0.001		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Sublease expiration date			Dec. 31, 2018
Short term rental basis, expected annualized savings			$ 240,000
Exercise price of warrants \| $ / shares	$ 1.00
Proceeds from public offering	$ 2,000,000						$ 2,500,000	$ 9,238,000
Percentage of common shares outstanding owned	9.99%
Series A
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Preferred stock issued, value				$ 2,000,000			2,000,000				$ 2,000,000		$ 2,000,000
Preferred stock sold, value				$ 2,000,000			$ 2,000,000				$ 2,000,000		$ 2,000,000
Preferred stock, par value \| $ / shares												$ 1.7003	$ 0.001
Purchase price \| $ / shares				$ 1.40			$ 1.40				$ 1.40
Series A Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares of common stock under public offering \| shares	2,315,654
Purchase price \| $ / shares	$ 1.00
Series B Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares of common stock under public offering \| shares	184,346
Purchase price \| $ / shares	$ 1.00
Total costs and operating expenses
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Sublease rental charges			$ 153,000
Research and development
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Severance payments and benefits continuation							$ 41,000		$ 128,000
Selling and marketing
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Severance payments and benefits continuation							57,000		114,000
General and administrative
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Severance payments and benefits continuation									$ 162,000
Employee Severance
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Payment for severance payments and benefits continuation						$ 277,000	225,000
Common Stock \| Series A Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proportion of each unit of shares \| shares	1
Common Stock \| Series B Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proportion of each unit of shares \| shares	1
Warrants to purchase common stock \| Series A Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proportion of each unit of shares \| shares	0.5
Warrants to purchase common stock \| Series B Units
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proportion of each unit of shares \| shares	0.5
Secured convertible promissory notes
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Principal amount of secured convertible promissory notes issued and sold													$ 500,000
Term loans
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Loan facility				$ 0			$ 0				$ 0
Loan facility, maturity date							Jul. 14, 2015
Centers for Medicare And Medicaid Services
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reimbursed price per test \| $ / Patient							29.93		30.01	17.80
Centers for Medicare And Medicaid Services \| Ohio
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reimbursed price per test \| $ / Patient							23.93
Centers for Medicare And Medicaid Services \| WEST VIRGINIA
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reimbursed price per test \| $ / Patient							26.33

Commitments and Contingencies - Additional Information (Detail)	Sep. 30, 2015 USD ($)
Commitments and Contingencies [Line Items]
Accrued other contingencies	$ 0

Follow-on Public Offerings - Additional Information (Detail) $ / shares in Units, $ in Thousands			9 Months Ended
	Aug. 18, 2015 USD ($) shares $ / shares	Apr. 08, 2014 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)
Equity [Line Items]
Gross proceeds offering \| $	$ 2,000		$ 2,500	$ 9,238
Exercise price of warrants \| $ / shares	$ 1.00
Percentage of common shares outstanding owned	9.99%
Series A Units
Equity [Line Items]
Shares of common stock under public offering	2,315,654
Purchase price \| $ / shares	$ 1.00
Series A Units \| Common Stock
Equity [Line Items]
Proportion of each unit of shares	1
Series A Units \| Warrants to purchase common stock
Equity [Line Items]
Proportion of each unit of shares	0.5
Series B Units
Equity [Line Items]
Shares of common stock under public offering	184,346
Purchase price \| $ / shares	$ 1.00
Series B Units \| Common Stock
Equity [Line Items]
Proportion of each unit of shares	1
Series B Units \| Warrants to purchase common stock
Equity [Line Items]
Proportion of each unit of shares	0.5
Underwritten Public Offering
Equity [Line Items]
Shares of common stock under public offering		1,613,000
Common stock offering price \| $ / shares		$ 6.20
Gross proceeds offering \| $		$ 10,000
Offering proceeds net of underwriting discounts, commissions and expenses \| $		$ 9,000